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AIMS OF THE RESEARCH 
	  
The aim of this research is to develop a wide range of biophysical assays in order 
to investigate the biological activity of metallodrugs. In particular, this thesis 
focuses on: 
A detail analysis of DNA cleavage profiles using plasmid dsDNA by copper-
phenanthroline derivatised complexes. 
 
A unique experimental design in order to identify the site-specific oxidative 
cleavage of dsDNA by inorganic materials using type II endonucleases. 
 
Synthesis and characterisation of Cu2+-Phen complexes containing sterically 
functionalized pendant carboxylates along with detailed DNA binding analysis.  
 
The oxidative chemical nuclease examination of copper complexes containing 
oxazine and/or diimine N,N´- ligands. 
 
The design of a microfluidic “on chip” method employed to quantify and 
visualise double stranded DNA damage.  
 
The study of site-specific trinuclear platinum (II) (Triplatin) complexes on 
binding affinity, and the condensation effect on both DNA and tRNA, along with 
endonuclease enzyme recognition. 
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THESIS OUTLINE 
 
A detailed overview of each chapter is given below: 
 
Chapter I  
This chapter gives an overview of the topics common to most of the chapters in 
the context of literature review. Important topics include: biological importance 
of copper, DNA as molecular target, oxidative damage of DNA and the 
mechanism of oxidative DNA damage are discussed in order to introduce 
concepts that will be further used in the experimental chapters (Chapters II to 
VI). 
 
Chapter II 
This chapter describes in detail the oxidative DNA damage of [Cu(µ-
terephthalate)(Phen)4]2+ (phen = 1,10-phenanthroline) that was previously shown 
to damage DNA in the absence of oxidant and reductant. This chapter highlights 
a unique experimental design employed to detect site-specific damage on 
plasmid DNA, and that the “self-cleavage” DNA damage is oxidatively linked is 
also described. 
 
Chapter III 
This chapter introduces a novel series of copper-oxazine (Cu-PDT) complexes, 
where PDT is a ligand formed between amino acid L-tyrosine methyl ester and 
1,10-phenanthroline-5,6-dione. In order to establish how these complexes 
interact with DNA, a high-throughput fluorescence DNA binding assay was 
developed using 96 well plates. In this chapter, the viscosity and DNA cleavage 
experiments are also described.  
 
 
	  ix	  
Chapter IV 
This chapter describes the synthesis and characterisation of a novel class of 
small-molecules containing a carboxylate group coordinate to the copper(II)-bis-
1,10-phenanthroline molecule. The interaction of this new class of inorganic 
molecule with macromolecules (DNA and bovine serum albumin) is described in 
detail. The artificial metallonuclease activity of these compounds is detected 
using plasmid DNA; the in vitro cytotoxicity is examined on a wide range of 
cancerous cell line along with the detection of double strand breaks on ovarian 
cancer cell line using the immunodetection of γ-H2AX foci is also described in 
detail.     
 
Chapter V 
This chapter describes the synthesis and characterisation of a new class of 
copper-phenanthroline complexes containing fused diimine N,N´-ligands along 
with their interaction with a variety of synthetic and natural dsDNA. Also, this 
chapter describes a novel assay using microfluidic on-chip method employed to 
quantify and visualize double strand breaks in linear plasmid DNA. Furthermore, 
the in vitro cytotoxicity studies on ovarian cancer cell line are also shown.  
 
Chapter VI 
This chapter describes the effect of trinuclear platinum(II) complexes on dsDNA 
and tRNA binding affinity, and also detailed analysis - using microfluidic chip 
assay used to describe type II endonuclease enzyme recognition. Base-specific 
interaction studies using 2D NMR spectra on adenine-thymine rich and guanine-
cytosine rich duplexes are reported	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ABSTRACT  
Metallodrugs as Inducers And Inhibitors of Chemical Nuclease Activity 
By Andreea Prisecaru 
Manipulation of DNA is both an intrinsic and essential component of molecular 
biology and biotechnology. Reagents capable of cutting DNA are applied within 
these fields as probes for DNA structure and function, with the ultimate aim 
being the design of target-specific—customised endonucleases—capable of 
modifying genomic DNA. Thus, DNA cleaving reagents are essential tools for 
both sequence analysis and genome engineering. Furthermore, the discovery of 
new molecular mechanisms by which small molecules modify DNA structure, 
reactivity, and biological repair contributes significantly to potential drug 
development.  
 
The chemical nuclease of [Cu(Phen)2]2+ (where Phen = 1,10-phenanthroline), is a 
well studied reagent which randomly cleaves nucleic acids in the presence of 
molecular oxygen (or hydrogen peroxide) upon reduction to Cu+. In addition, 
compounds based on this chemotype have found application in the biological 
field as antimicrobial and anticancer agents, DNA intercalators, and as 
nucleoside constituents for incorporation into the DNA backbone. [Cu(Phen)2]+ 
oxidises duplex DNA without specificity, predominately at the minor groove 
with C-H bonds at C1′, C4′, and C5′ being the main targets of hydrogen atom 
abstraction. 
 
The aim of this research was to extend structure-activity relationships of Cu2+-
Phen complexes containing sterically functionalized pendant carboxylates and to 
investigate how synthetic extension of the ligated phenazine ligand within this 
complex model influences DNA recognition and oxidative degradation. These 
compounds have shown an enhanced DNA recognition relative to the well-
studied chemical nuclease, [Cu(Phen)2]+. Furthermore, the effects of nuclearity 
on DNA oxidation were elucidated using the [Cu(µ-terephthalate)(Phen)4]2+ 
cation with results showing potent DNA oxidation in the absence of exogenous 
reductant. Many compounds developed in this work constitute a series of novel 
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anticancer leads capable of intracellular DNA oxidation leading to genomic 
double strand breaks. In addition to the application of developmental 
metallodrugs as inducers of chemical nuclease activity, the effects of cytotoxic 
trinuclear platinum(II) complexes as high-affinity DNA binders that inhibit—or 
block—endonuclease enzyme recognition and excision are reported through a 
wide variety of biophysical and molecular biological methods. 
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CHAPTER I 
DNA oxidation by copper 1,10-
phenanthroline complexes 
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I.1 Copper in biological systems  
I.1.1 Biological importance of copper 
Copper (Cu) plays a fundamental role in biological systems, and its essentiality 
in mammals was first remarked in 1928 when rats exposed to a copper-deficient 
diet developed anemia.1 Copper is an essential transition metal found in most 
human organs and tissues, in concentrations varying from few ppm to several 
hundred ppm, with the liver representing the main storage organ.2–4 As a 
transition metal, copper is biologically converted between facile redox states, 
namely oxidized cupric (Cu(II)) and reduced cuprous (Cu(I)) forms.4 With this 
attractive attribute, copper has been exploited for catalysis by a plethora of 
enzymes whose activities are critical to a broad range of cellular biochemical and 
regulatory functions.5 
 
I.1.2 An overview of copper proteins 
Copper is absorbed in the body from the stomach and once in the intestinal 
epithelial cells, it is incorporated into Cu-dependent proteins and transported 
across the basolateral membrane into the peripheral circulation, where binds 
strongly to serum albumin. Once in the liver, copper is distributed to 
metabolically active sites by ceruloplasmin which accounts for about 90-95% of 
the total plasma copper, by albumin and other less quantitatively important 
copper binders.5–7 Free copper is a potent oxidant, and in order the avoid cellular 
toxicity, it is incorporated into chaperons and proteins.7 These cupro-proteins are 
needed for diverse metabolic processes, such as mitochondrial respiration, 
melanin biosynthesis, dopamine metabolism, iron homeostasis, antioxidants 
defence, connective tissue formation and peptide amidation.8 Copper also forms 
a vital part of a number of oxidase enzymes, sometimes in combination with 
other metal ions (Table I.1). Cytochrome c oxidase—a large protein found in the 
mitochondrial inner membrane—contains both copper and haem-iron and its 
specific function is to activate oxygen, the terminal electron acceptor of the 
mitochondrial respiratory chain.9,10 CuZn-superoxide dismutase (CuZnSOD) is a 
prototypical dinuclear metalloprotein containing one copper and one zinc 
subunit. The imidazole ring of His61, which bridged Cu and Zn together, 
coordinates both metals.  Copper is coordinated by four histidines residues and a 
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water molecule in a distorted square pyramidal geometry and zinc is coordinated 
by three histidines residues and an aspartate molecule in a distorted tetrahedral 
geometry.11 CuZnSOD is considered the defence system against the cytotoxic 
superoxide free radical (O2−), catalysing the disproportion of superoxide, which 
involves the cyclic reduction (Eq. 1) and oxidation (Eq. 2) of copper to generate 
hydrogen peroxide and oxygen (Eq. 3).12–17  
 
Cu��ZnSOD +	  O�∙� 	  → 	  Cu�ZnSOD +	  O�    (1) 
Cu�ZnSOD +	  O�∙� 	  +	  2H� → 	  Cu��ZnSOD	   +	  H�O�  (2) 
 
 Net reaction: O�∙� 	  +	  O�∙� 	  +	  2H� 	  → 	  H�O� +	  O�   (3)  
 
Tyrosinase contains a binuclear copper active site and is the key enzyme in 
melanin synthesis.18,19  Ceruloplasmin, copper containing glycoprotein produced 
in the liver, is responsible for binding 95% of the copper found in plasma.20 The 
enzyme is a multicopper oxidase protein that utilizes copper to couple substrate 
oxidation with the four-electron reduction of oxygen to water.5,21,22 Another 
copper containing enzyme essential for stabilisation of extracellular matrix is 
lysyl oxidase, involved in the maturation tissue, especially the enzymatic 
crosslinking of collagen and elastin.23,24 Dopamine β-hydroxylase is an 
oxygenase enzyme critically involved in the biosynthesis of catecholamine and 
consequently plays an important role in the regulation of noradrenergic and 
adrenergic neurotransmission.25,26 Finally, peptidylglycine α-amidating 
monooxygenase (PAM) is a copper dependent enzyme that catalyses the 
carboxyl-terminal amidation of glycine-extended peptide precursors, a 
modification essential for the bioactivity of numerous hormones and 
neuropeptides.27,28  
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       Table I.1 Selected copper containing enzymes and their function 
Enzymes	   Function	  
Cytochrome	  c	  oxidase	   Mitochondrial	  respiration,	  electron	  transport	  chain	  
CuZn-­‐SOD	   Antioxidant,	  free	  radical	  defence	  
Tyrosinase	   Formation	  of	  melanin	  
Lysyl	  oxidase	   Maturation	  of	  connective	  tissue	  (collagen	  and	  elastin)	  
Ceruloplasmin	   Copper	  and	  iron	  transport	  
Dopamine	  β-­‐monoxygenase	   Biosynthesis	  of	  catecholamine	  
Peptidylglycine	  α-­‐amidating	  mono-­‐
oxygenase	  (PAM)	  
Neuropeptide	  processing	  
I.1.3 Entry of copper into mammalian cells 
As described in Fig. I.2, copper is transported into the human cell through the 
high-affinity copper uptake transport protein (CTR1) (Fig. I.1a.). CTR1 is a 32 
kDa membrane protein consisting of 190 amino acids and is encoded by the 
SLC31A1 human gene.29–31 After crossing the plasma membrane, copper binds 
to cytosolic copper chaperons, which direct subcellular copper delivery to 
specific proteins, overcoming a high copper chelation capacity of the cytoplasm. 
Copper is mediated to the Golgi apparatus via the ATOX1 protein (Fig. I.1d.). 
The ATOX1 gene encodes a copper chaperone that plays a role in copper 
homeostasis by binding and transporting cytosolic copper to the ATPase protein 
(cP) in the trans-Golgi apparatus for incorporation with ceruloplasmin. Recently, 
ATOX1 was also identified as a copper-dependent suppressor of oxidative 
damage in yeast lacking of superoxide dismutase.32,33  Once inside the Golgi, 
copper is released and then binds to target proteins, ATP7A and ATP7B which 
normally reside in the trans-Golgi membrane, and form part of the secretory 
pathway including extracellular SOD (EC-SOD). COX17 (Fig. I.1b.) found in 
cytoplasm and also in the mitochondrial intermembrane space, delivers copper to 
mitochondrial cytochrome c oxidase via the chaperons COX11, Sco1 (Fig. I.1c.) 
and Sco2.34–37 Indeed, copper chaperons for superoxide dismutase (CCS) (Fig. 
I.1e.), play a fundamental role in delivering copper to pro-form of SOD (apo-
SOD) with CCS containing three binding domains; domain I contains Cu-
binding sites, domain II is homologous to SOD, and domain III contains cysteine 
residues essential to the transfer of Cu to apo-SOD.38,39 
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Figure I.1 Copper delivering proteins (Protein Data Bank, PDB, codes indicated) a. First 
transmembrane domain from human copper transporter 1 CTR1 (PDB, 2LS2), b. COX17 (PDB, 
2RNB) delivers copper to mitochondrial cytochrome c oxidase c. Copper chaperons, Sco1 (PDB, 
2GQM) play a fundamental role in delivery of copper to the mitochondria, d. ATOX1 (PDB, 
1TL4) mediates copper transport to the Golgi apparatus, and e. 1st domain of copper chaperons 
for superoxide dismutase, CCS (PDB, 2RSQ) play a fundamental role in delivering copper to the 
pro-form of SOD. 
	  
Metallothioneins (MT) are small molecular weight—cysteine-rich thiol 
containing proteins—important in the transport and storage of copper ions. Since 
copper is reactive, well know to produce reactive oxygen species (ROS), copper 
binding is an important detoxification mechanism for Cu-associated toxicities. 
Thus, metallothioneins have a critical role to protect the intracellular proteins 
from copper toxicity.38,40,41 
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Figure I.2 Simplified scheme showing intracellular distribution of copper into the human cell. 
Copper enters into the human cell through high affinity copper uptake protein (CTR1). Once 
inside the cell, copper is passed onto the specific enzymes, ATOX1, CCS, COX, which escort 
copper ions to its specific destination (Golgi apparatus, SOD1 and mitochondria, respectively). 
Upon reaching its destination, copper is either incorporated into Golgi network and released 
using a P-type ATPase (cP), inserted into apo-SOD1 or incorporated into cytochrome c oxidase 
located in mitochondria. 
 
 
I.1.4 Copper diseases 
Although copper is an essential metal ion, it can become toxic to cells when at 
elevated concentrations. The disruption of copper transport can cause both 
accumulation of excess copper (Wilson’s disease) or copper deficiency (Menkes’ 
syndrome) (Fig. I.3). However, these two diseases affect different tissues.42  
 
Wilson’s disease, firstly described in 1912 by Samuel Wilson, is a autosomal 
recessive disorder characterised by toxic accumulation of copper in liver and 
brain resulting in cirrhosis and neuronal deterioration.43 In patients with Wilson’s 
disease more than 190 mutations have been located in the ATP7B gene, which 
results in abnormal function of the ATP-dependent P-type copper transporting 
ATPase.44 The function of ATP7B gene is to encode a copper-transport proteins 
located at the trans-Golgi network and to transfer copper into the secretory 
EC-SOD
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pathway into ceruloplasmin and excretion into the bile.20 Hence, disruption of 
protein function reduces or prevents the incorporation of copper into 
ceruloplasmin and in the transport of copper out of the cell.44,45  
 
Menkes’ syndrome is an X-linked recessive disorder caused by mutation in 
ATP7A gene, which is expressed in most tissues except the liver. ATP7A is an 
ATP-dependent P-type copper transporting ATPase, localised in the trans-Golgi 
network.46–48 ATP7A contains several domains required for ATPase function and 
copper binding. In Menkes’s syndrome, mutations in the ATP7A gene result in 
poor distribution of copper throughout the human body; copper accumulates in 
some tissues, such as the small intestine and kidneys, while the brain and other 
tissues have unusually low levels. The decrease supply of copper can reduce the 
activity of numerous copper-containing enzymes that are necessary for the 
structure and function of bone, skin, blood vessels and the nervous system.20,49   
 
 	  
Figure I.3 Simplified scheme of the disruption of copper transport in Wilson's and Menkes's 
disease. 50 
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I.2 DNA as a molecular target  
I.2.1 DNA: structure and function  
Deoxyribonucleic acid (DNA) is an important biomolecule that can be targeted 
by metal complexes. DNA is a nucleic acid polymer that contains all the genetic 
material of all living cells that make up the body, and along side proteins and 
carbohydrates forms the three macromolecules essential for all known forms of 
life. DNA consists of two polynucleotide chains held together by hydrogen 
bonds. Each nucleotide is composed of a purine or pyrimidine base (adenine (A), 
thiamine (T), cysteine (C) and guanine (G)), and a deoxyribose sugar attached to 
a single phosphate group (Fig. I.4a.).   
 
     	  
Figure I.4 a. The 5ʹ′-phosphate nucleotide of DNA. Each nucleotide contains a phosphate group, 
a deoxyribose sugar molecule and a nitrogen base. DNA contains four types of nitrogen bases, 
adenine (A), cytosine (C), guanine (G), and thymine (T). b. Connectivity in a strand of DNA. The 
3ʹ′-ATCG-5ʹ′ sequence is shown. 
 
Nucleotides are held together by covalent bonds in a chain, which form the “back 
bone” of alternating sugar-phosphate-sugar-phosphate (Fig. I.4b.). The way in 
which nucleotides are linked together gives the DNA double helix chemical 
polarity. The two ends of chain are easily distinguishable; the 5ʹ′ end having a 
terminal phosphate group with the 3ʹ′ end having a terminal hydroxyl group. 
Because both strands are held together by hydrogen bonding between 
complementary bases, the sugar-phosphate backbones lie on the outside with 
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bases residing at the interior (Fig. I.5). In canonical DNA, the two-ring 
heterocyclic base purine is paired with a single-ring heterocyclic base 
pyrimidine; A is always paired with T and G is always paired with C and this is 
know as complementary base pairing.51  
	  
Figure I.5 The building blocks of DNA.  DNA is made up of molecules called nucleotides. Each 
nucleotide contains a phosphate group, a sugar group, and a base that are linked covalently into a 
polynucleotide chain. Nucleotides are attached together to form strands that spiral around one 
another to create a structure called a double helix. The two strands are held together by hydrogen 
bonds, two hydrogen bonds formed between A and T, and three hydrogen bonds formed between 
G and C. 
 
To maximize the efficiency of base pair packing, the two sugar-phosphate 
backbones wind around each other to form a double helix, with one complete 
turn every ten base pairs in B-DNA. A more detailed analysis of DNA structure 
reveals that the junction of the two strands coiling around each other creates two 
grooves, each with a different width. The wider groove is called the major 
groove with the smaller being called the minor groove.  
 
The B-DNA double helix is held together by two main forces: Watson-Crick 
hydrogen bonds between purine and complementary pyrimidine base pairs inside 
the helix, and Van der Waals base-stacking interactions between parallel 
nucleotides.52 It is important to note that three hydrogen bonds form between G 
and C complementary bases and only two hydrogen bonds are found between A 
and T complementary base pairs. For this reason DNA strands containing high 
G-C content are more stable and more difficult to separate, thermodynamically, 
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than DNA strands that contain A-T base pairs.53,54 H-bonds between the two 
complementary bases facilitate interstrand stabilization and allow base 
recognition due to the enhanced structure directionality property from their 
pronounced electrostatic nature. Base stacking interactions between parallel 
bases A//T and G//C are primarily electrostatic in nature being coordinated by 
London dispersion forces followed by π-π-electrostatic interactions. Depending 
on the type of nucleotide involved in base pairing, the energetic contribution of 
H-bond between complementary base pairs can vary between 15.4 - 28.8 kcal 
mol-1 while the energetic contribution to the parallel base stacking interaction are 
11.6 - 16.9 kcal mol-1.55 However, studies performed by Kamenetski et al. 
showed that thermal stability of DNA is mainly determined by base-stacking 
interactions. Additionally, stacking effects are probably the major influence of 
base pair stability and are the major forces holding the double helix together. It is 
interestingly to note that canonical DNA bases, overall, stack weakly to 
moderately, and researchers have demonstrated many artificial bases that stack 
more strongly than natural ones. 54   
 
I.2.2 Metal binding sites on DNA 
The interaction of DNA with copper complexes has stimulated interest in relation 
to the function of nucleic acids, DNA replication, transcription of genetic codes, 
and various other enzyme reactions with DNA. This macromolecules targets for 
therapeutic interventions and the development of diagnostic probes of nucleic 
acid structure.56 DNA has two sites for accommodating direct metal ion binding; 
at the phosphate group—through the negatively charged oxygen atoms of the 
phosphodiester linkage—and at the nitrogenous bases (e.g. N7 of guanine).57 
Copper complexes, however, interact with DNA in two primarily modes of 
binding: metallo-DNA binding and non-covalent binding (groove binding and 
intercalation).  
 
I.2.2.1  Nucleobase modification of duplex DNA 
Chemical modification of nucleic acid constituents has become an important tool 
in medicinal chemistry and in biological investigation. The incorporating of 
copper complexes into oligonucleotides is a key design target for the 
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functionalization of DNA with novel catalytic and electronic properties by 
alternating bases that are biologically important. Shionoya et al. used a 
pioneering approach whereby a metal complex was incorporated into 
oligonucleotide by changing the DNA base itself into a chelator-containing base. 
A hydrogen-bonded base-pairing was replaced with a metal-assisted base-pairing 
creating a novel binding motif in duplex DNA (Fig. I.6i.).58  
	  
Figure I.6 Schematic of chelator containing nucleotides i. Cu2+ phenylenediamine β-C-
nucleoside and ii. H-Cu-H nucleotide, iii. Cu-salen complex, and iV pyrazole-Cu-pyrazole self 
base pair system. 
 
Based on this principle the same group designed and synthesized a novel 
hydroxypiridone nucleobase (H)59–63  (Fig. I.6ii.) as a planar bidenate ligand 
containing the Cu2+ metal ion. The base pair (H-H) was introduced into a 15-
nucleosides natural type DNA duplex, between two hydrogen-bonded base pairs 
d(5’-CACATTAHTGTTGTA-3’)d(3’-GTGTAATHACAACAT-5’). In the 
presence of equimolar Cu2+ ions duplex containing H-H base pairs had a high 
thermal stabilization of 13 °C in comparison with duplex containing A-T bases in 
place of H-H pair.59,64  
 
Carell et al. then reported a copper-salen-base-pair complex in DNA with a high 
duplex thermal stabilization. This salen complex (Fig. I.6iii.) contains a covalent 
cross-link of both DNA single strands through metal complexation. Here, the 
diamine molecule is necessary to form the ligand and the coordinated metal 
prevents hydrolysis of the formed imines.65–67 In a more recent study, same 
group designed a pyrazole (Pz) base pairs having copper as a metal coordination 
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geometry (ligandosides) (Fig. I.6iV). They showed that, this system stabilize 
double helix structure in a cooperative manner through the combination of Pz 
and the Cu2+ salen liganosides.68  
Overall, these modified oligonucleotides readily bind to their respective 
complementary nucleotide and can potentially find use as probes in genetic 
testing, research and forensics providing powerful tools for programming 
molecular arrays in a pre-designed manner.  
I.2.2.2  Non-covalent DNA binding  
The specific, non-covalent interaction of molecules with duplex DNA is the 
molecular basis of many antitumor, antiprotozoal, antiviral, and antibacterial 
drugs. Compounds that bind to DNA with high specificity can influence gene 
expression and hence effect cell proliferation and differentiation.69 Most of the 
research into the non-covalent DNA binding complexes focuses on the 
development of anti-cancer agents. Copper complexes can interact with DNA 
non-covalently (Fig. I.7) by binding at either groove (Fig. I.7A.) (both minor and 
major groove) or through intercalation (Fig. I.7B.).70 
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Figure I.7 Non-covalent binding. A. Minor groove binding. B. Binding through intercalation. 
i.Netropsin structure and 3′-AATT dsDNA sequence. B. Ethidium bromide (EtBr) structure and 
DNA 3′-TAGC dsDNA sequence.  
 
Groove binding. Each turn in the B-DNA helix is made up of 10.4 nucleotide 
pairs, and the centre-to-centre distance between adjacent nucleotides is 3.4 nm. 
The coiling of the strands around each other creates two grooves; a wider groove 
of 22 Å called the major groove, and a smaller groove of 12 Å called the minor 
groove. These grooves are formed due to hydrogen bonding between 
complementary bases of DNA that cause sugar groups to project at 120° angle 
from each other.69 Most proteins that are essential to the normal function of the 
cell, bind to specific sequences in double-stranded DNA (dsDNA) usually through 
the amino-acid side chain and hydrogen bond donor and acceptor interactions of 
individual bases at the major groove. This binding is due to the unique binding-
signature present in the major groove, but absent in the minor grove.71–73 
However, most ligands smaller than 1000 Da are known to bind DNA at the minor 
groove.70 Minor groove binding agents can be divided into two functional classes: 
a) those that can induce permanent damage through the covalent interactions with 
minor groove
binding
major groove
bindingmajor 
groove
minor 
groove
2nm
intercalation
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A. B.
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nucleophilic minor groove component such as N3 of adenine or the 2-amino group 
of guanine, b) compounds that reversibly inhibit DNA function, via non-covalent 
interaction (electrostatic, hydrogen bonding, and Van der Waals forces).69,74 
Structurally, minor groove binding agents have certain characteristics that 
distinguish them from other DNA binding agents. Their shape is rather annular, 
containing aromatic rings, which matches the curvature of the minor of DNA (Fig. 
I.7i.). As a rule, members of this group are cations, providing affinity for the 
tunnel of negative potential in the groove and in addition many ligands possess H-
bonds atoms. These agents tend to bind in minor groove with relatively no 
distortion of the phosphate backbone, stabilizing the regular B-DNA structure.74 
Several organic and synthetic compounds, many used clinically as anticancer 
agents, have been reported to bind DNA at the minor groove, mostly at the A-T 
rich regions (Fig. I.8).  
 
Distamycin and Netropsin interact with A-T-rich regions of DNA in the minor 
groove by forming hydrogen bonding and hydrophobic interactions. The crescent 
shape and the presence of amide group facing towards the base of the minor 
groove along with the positively charged amidine group enables the molecule to 
bind non-covalently in the minor groove for interactions with A-T-rich sequence.75 
 
Tallimustine is an A-T specific alkylating antitumor derivative of distamycin. The 
distamycin portion can form hydrogen bonds with the bases in the minor groove 
conferring A-T specific sequence recognition, and the nitrogen mustard can 
alkylate DNA bases. Because of the binding through minor groove, tallimustine 
alkylates N3 position of adenine residues, unlike conventional nitrogen mustards 
which, alkylates N7 positions of guanine residues in the minor groove. 75,76An 
interesting group of minor groove binding agents is represented by the synthetic 
bis(benzimidazole) derivatives - Hoechst 33258 - which becomes fluorescent upon 
binding to dsDNA. The dye binds strongly in the minor groove of DNA sequences 
that are rich in A-T. The molecule is crescent shape and consists of flat 
hydrophobic aromatic ring creating a fit in the minor groove. Hoechst 33258 is 
positively charged molecule, which match the strongly electronegative potential at 
the minor groove of A-T rich, which is more negative than region with high G-C 
content. Hoechst 33258 has shown to display antitumor and antibiotic properties, 
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but due to the fluorescent properties it is used as chromosomal stain and DNA 
quantification.77  
 
1-methyl-4-[4-[4-[4-(1-methylquinolinium)aminobenzamide]aniline]-pyridinium 
dichloride (SN6999) is a synthetic compound that belongs to a family of 
quinolone-containing DNA binders, which have been shown to possess potent 
antitumor and antiviral properties. SN6999 has a curved shaped that fits in the 
minor groove and it forms hydrogen bonds with the bases of DNA sequence, as 
well as possible electrostatic interactions with the phosphate backbone in an 
intercalation complex; however, binding in the minor groove is much favourable 
energetically than intercalation.78   
 
Brostallicin, a bromoacrylamido tetra-pyrrole structurally related to distamycin, 
showed potent in vivo cytotoxic activity against tumour cells with an IC50 present 
in low nanomolar range. Brostallicin, interacts reversibly with the DNA minor 
groove AT-rich sequence, but appears unreactive in classical in vitro DNA 
alkylating assays.79 
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Figure I.8 Selection of the clinically use minor groove binders. These crescent shaped molecules 
alters DNA conformation by binding to A-T-rich domains in DNA. 
 
Intercalation. This binding mode involves the insertion of a planar aromatic 
molecule (Fig. I.9) between two successive DNA base pairs (Fig. I.7ii.) with 
concomitant winding and lengthening of the DNA.80 The degree of unwinding 
varies depending on the ligand used, for example, ethidium bromide unwinds 
DNA by about 26° 81,82 while proflavine (diaminoacridine) unwinds DNA by 
about 17°. This unwinding causes the base pairs to separate creating an opening 
by about 3.4 Å, hence inducing local structural changes to the DNA strand such 
as lengthening of the DNA or twisting of the base pairs.83 These structural 
changes can lead to functional changes of the DNA, such as inhibition of 
transcription and replication and DNA repair mechanism. Thus, intercalators are 
potent mutagens.84 Classical intercalators such as ethidium bromide81 and 
proflavin are fused aromatic molecules with positive charge on an attached side 
chain or ring system itself that interact with DNA without interfering with 
hydrogen bonding of the base pairs. In threading intercalation, however, the 
aromatic system is inserted between the base pairs, while one cationic substituent 
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interacts with the minor groove. Naphthalene diimide interacts with DNA duplex 
in this way.84,85 Another example is provided by 4',6-diamidino-2-phenylindole 
(DAPI), which is a non-classical intercalator. The binding of DAPI is dependent 
of DNA sequence. In this regard DAPI binds very strongly to three to four 
consecutive A-T base pairs in a minor groove complex. However, when fewer 
consecutive A-T base pairs are present, DAPI binds in the G-C-rich region by 
intercalation.86,87  
 
  	  
Figure I.9 Chemical structure of several DNA intercalators. Classical intercalators: ethidium 
bromide and diaminoacridine; threading intercalators: DAPI; non-classical intercalators: 
naphthalene diimide. 
 
I.2.3 Copper functionalised groove binders  
Henichart et al. investigated the DNA binding properties of a minor groove 
binder –intercalator compound that in the presence of copper ions, and reductant, 
showed sequence specificity and high affinities towards dsDNA binding. This 
molecule (Fig. I.10) consists of an intercalating acridine derivatives an 
oligopyrrolecarboxamide moiety of netropsin, and Cu-tripeptide molecule. This 
Cu-tripeptide molecule was first reported by Dervan et al. and was shown that, 
the natural occurring tripeptide, H-gly-gly-his-OH which, when bound to Cu(II) 
in the presence of ascorbate has chemical-nuclease like activity.88 The 
attachment of two well known anticancer agents, (netropsin a well known minor 
groove binder, and acridine an intercalating fluorescent DNA probe), in the 
presence of a reduced copper-tripeptide molecule, are capable of inducing 
dsDNA damage at a specific recognised position in the minor groove.89 
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Figure I.10 Structure of minor-groove binder-intercalator. Cu(II)-tripeptide glycylhistidyllysine 
(colour green), oligopyrrolecarboxamide part of netropsin (coloured blue) which is covalently  
linked to an intercalating 9-(4-glycylanilino)-acridine derivative (coloured purple). 
 
1.2.3.1 Copper complexes with intercalative properties on B-DNA 
The binding activity of Cu-bis-phen (phen = 1,10-phenanthroline, table. I.2b.) on 
B-DNA is known to be via intercalation in the minor grove by one of the phen 
molecules, while the other phen ligand makes favourable secondary non-covalent 
contact within the groove.90 Cu-bis-phen cleaves B-DNA in the presence of both 
oxidant and reductant via one electron oxidation reaction at the sugar moiety of 
DNA through a Fenton-type reaction91 (Section 1.4.1), however, binds dsDNA 
with moderate affinity with a binding constant (Kb) on calf thymus DNA 
(ctDNA) of 2.7 x 103 M-1.92 Copper complexes, containing modified diimine N’N 
ligands, are known to modulate binding and cleaving dsDNA under oxidative 
conditions (Table I.2). The extension of aromatic ring of phen ligand in the Cu-
bis-phenanthroline species was shown to enhance the intercalative binding 
properties in comparison to bis-phen analogues with a Kb value of 4.5 x 104 M-1 
for Cu-bis-dpq (dpq = dipyrido[3,2-d:2´,3´-f]quinoxaline, Table I.2d.) and 2.0 x 
104 M-1 for Cu-bis-dppz (dppz = dipyrido[3,2-a:2´,3´-c]phenazine, Table I.2e.)	  
under similar experimental conditions.92 Studies by Chakravarty, Yan, 
Hadadzadeh, and Palaniandavar et al. on copper complexes containing at least 
one diimine N,N´-ligand (Table I.3, except complex 9), revealed that complexes 
containing 2,2´-bipyridine (bpy, Table I.2a.), phen, 3,4,7,8-tetramethyl-1,10-
phenanthroline (tmp, Table I.3c.) and dipyrido[3,2-d:2´,3´-f]quinoxaline (dpq) 
ligands prefer intercalation through the minor groove, while complexes 
containing dipyrido[3,2-a:2´,3´-c]phenazine) (dppz) and 11,12-
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dimethyldipyrido[3,2-a:2´,3´-c]phenazine (dmdppz, table. I.2f.) ligands bind B-
DNA predominantly through the major groove.92–104  
 
In contrast to previously described copper complexes containing N,N´-ligands 
with intercalative binding properties, complex 9 (Table I.3) shows preferential 
binding towards A-T rich region with a Kb of 1.8 x106 M-1 IHJIFS>f>0
CH
=IGJ;LCMIHNI=N *;H>JIF>#f>QCNB;Kb 7.0 x105 M-1 and 3.4x x105 M-
1, respectively. This preferential binding might be due to the crescent-shape like 
structure and also the presence of guanidinium end group similar to that of 
netropsin.100 
 
Table I.2 Chemical structure of dipyridophenazine ligands 
 
	   Diimine	  N-­‐N	  ligand	  
	  
Chemical	  name	  and	  abbreviation	  
a.	  	  
	  
2,2´-­‐bipyridine	  (bpy)	  
b.	  	  
	  
1,10-­‐phenanthroline	  (phen)	  
c.	  
	  
3,4,7,8-­‐tetramethyl-­‐1,10-­‐phenanthroline	  (tmp)	  
d.	  
	  
dipyrido[3,2-­‐d:2´,3´-­‐f]quinoxaline	  (dpq)	  
e.	  
	  
dipyrido[3,2-­‐a:2´,3´-­‐c]phenazine)	  (dppz)	  
f.	  
	  
11,12-­‐dimethyldipyrido[3,2-­‐a:2´,3´-­‐c]phenazine	  (dmdppz)	  
N
N
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N N
N N
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Table I.3 Selected Cu-complexes containing N,N´-donor heterocyclic bases such as bpy, phen, 
tmp,   DPQ, DPPZ, and dmdppz ligands with potential intercalative properties on B-DNA.  
Complex	  
no.	  
Chemical	  structure	   Diimine	  N-­‐N	  
ligand	  
Reference	  
1.	  
	  
bpy,	  phen,	  dpq,	  
dppz	  
93	  
2.	  
	  
bpy,	  phen,	  dpq,	  
dppz	  
93	  
3.	  
	  
dpq,	  dppz	  	  
X=	  Cl	  (dppz	  only),	  
(NO3)2	  (dpq,	  dppz)	  	  
	  
92,	  94	  
4.	  
	  
phen,	  dpq,	  dppz	  
R	  =	  ph,	  MeOH	  
(phen	  only)	  
95	  
5.	  
	  
bpy,	  phen,	  dpq,	  
dppz	  
X	  =	  H2O,	  MeOH	  
(phen	  only)	  
97,	  105	  
6.	  
	  
dpq,	  dppz	   98	  
7.	  
	  
dpq,	  dppz	   98	  
8.	  
	  
bpy,	  phen,	  tmp,	  
dppz	  
99	  
9.	  
	  
	   100	  
	  
O
N
N
N
N
+
Cu
N
NN
N
O
O
O
O OH2
OH2
CuCu
N
NXN
N
+
Cu
+
N
N
SN
N
O
CH3
HN R
Cu
H2
N
SCH3
O
O
X +
N
N
Cu
O
N
N
N
+OH
Cu
+
N
N
SN
O
CH3
Cu
N
N
O
N NH
HO
+
Cu
N
H2
NH
HN
H2N
O
O
N
H2
HN
NH
NH2
O
O
Cu
	  21	  
8.	  
	  
bpy,	  phen,	  dpq,	  
dppz	  
100	  
	  
10.	  
	  
phen,	  dpq,	  dppz	   101	  
11.	  
	  
dpq,	  dppz	   102	  
12.	  
	  
dppz	   103	  
13.	  
	  
bpy,	  phen,	  dpq,	  
dppz,	  dmdppz	  
104	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I.3 Oxidative cleavage of DNA 
I.3.1 Reactive oxygen Species (ROS) 
In eukaryotic cells reactive oxygen species (ROS) are generated as a by-product 
of normal aerobic metabolism or during metabolism of xenobiotics. During times 
of environmental stress such as exposure to high variation in temperature or 
radiation, ROS levels can elevate dramatically. The generations of ROS involves 
the transport of hydrogen ions across the inner mitochondrial membrane in form 
of electron transport chain. Free radical damage is linked to formation of many 
degenerative diseases as outlined in scheme I.1.C. Usually there is a equilibrium 
between free radical formation and antioxidant defence mechanisms (Scheme I.1 
A.), hence an imbalance between the body’s natural oxidant defence mechanism 
and the production of ROS leads to oxidative stress (Scheme I.1 B.)—and 
therefore to cell damage and ultimately cellular death.106–108  
Cleavage of DNA (Scheme I.2) is an important process of normal 
functionalization of living cell. Many enzymes such as topoisomerase solve 
problems associated with DNA replication, transcription, recombination and 
chromatin remodelling by introducing temporarily single or double stranded 
breaks in DNA.109 Other enzymes such as restriction endonucleases protect the 
cell against foreign DNA (viral infections) by cleaving the affected DNA 
sequence.110 The activities of many anticancer drugs rely on the ability to 
introduce extended damage to the DNA structure, which can trigger apoptosis111 
leading to cell death.112,113 In general, three types of DNA cleavage can be 
distinguished: oxidative damage, DNA hydrolysis and photochemical damage, 
however, only oxidative damage will be described in detail here.  
Reactive oxygen species (ROS) such as hydroxyl radicals (OH), the superoxide 
anion radical (O2−), and hydrogen peroxide (H2O2) can damage either directly or 
indirectly, most of cell components, including DNA. Further, disruption of 
essential enzyme pathways and structural proteins and also can provoke 
uncontrolled chain reactions such as lipid peroxidation or autoxidation 
reactions.106,114,115 
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Scheme I.1 A. The physiological balance between the ROS production and antioxidative 
defences prevents the accumulation of ROS.108 B. Oxidative stress due to severe disturbance 
between ROS formation and antioxidative defences C. Potential toxicity associated with ROS. 
                
Scheme I.2 Schematic showing the oxidative damage of DNA.  
  
I.3.2 Oxidative damaged to nucleobases  
The OH radical, produced through the Fenton116 reaction, has a redox potential 
of 2.32 V117 (Fig. I.11) and is a highly diffusible oxidant properties, capable of 
inducing DNA damage either at the base or sugar moiety.118 OH generation can 
be driven by the reduction of Cu2+ by superoxide (Eq. 4) under oxidative stress 
conditions (e.g. in the presence of H2O2) that promotes the Fenton reaction 
(Eq.5). Overall these reactions couple to produce the copper (or iron) – catalysed 
Haber-Weiss processes (Eq. 6) and are known promoters of oxygen radicals 
under aerobic conditions. The damage at the sugar molecule of the nucleoside is 
initiated in two ways: a.) by hydrogen atom abstraction from one of the 
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deoxyribose carbons resulting in strand breakage, base release, and 
cyclonucleoside formation or, b.) β to α inversion at the C-1ʹ′ position that 
disrupts B-DNA strand conformation. Radical attack at the nucleobase is 
characterized by the addition of an -OH group to the electron-rich double bond to 
give adduct radicals and bases, particularly the purine N-7-C-8. An abstraction of 
the H atom by OH from the methyl-group of thymine is also known to occur.119 
In general, radical attack on the DNA base does not give rise to chemically 
altered sugar moieties or strand breaks, except when base modifications labialise 
the N-glycosyl bond, allowing the formation of abasic sites that are subject to β–
elimination.107,114,120–122 Among all DNA bases, purine bases – guanine and 
adenine – has the lowest redox potential with the best electron donor which 
makes these bases particularly vulnerable to ROS and leads to a plethora of 
oxidised products.123 In the case of guanine, the hydroxyl radical adds to C4, C5 
and C8-position and also to C2 but to a lesser extent. C4-OH radical adducts and 
C8-OH radical adducts are formed with high yields up to 70%, whereas C5-OH 
radical adducts appear to be less than 10%. In the presence of O2, the C8-OH 
radical adducts undergoes one-electron oxidation mechanism with the formation 
of 7,8-dihydro-8-oxoguanine (8-oxo-dG). In contrast, in the absence of O2, C8-
OH radical adducts undergoes one-electron reduction step and 2,6-diamino-4-
hydroxy-5-formaminodopyrimidine (Fapy-G) is formed (Scheme I.3).122,124–128 
The introduction of an “oxo” group on the C8 position and an hydrogen atom on 
the nitrogen at position N7, facilitate the ability to mimic thymine functionally in 
syn conformation forming a stable 8-oxo-G(syn)A(anti) base pair. If this 
mutation is not recognised and restored by DNA repair enzymes, DNA 
subsequently replicated will contain a point mutation.129 
 
	  
Figure I.11 Potential diagram for O2 at pH 7. Successive one-electron reduction yields the O2f−. 
H2O2 produce the fOH and H2O 
 
 
 
 
O2 O2 H2O2 H2O + HO 2H2O
- 0.33 V + 0.89 V + 0.38 V + 2.32 V
+ 0.281 V + 1.349 V
+ 0.815 V
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                  Cu�� +	  O�∙�	   	  → 	   Cu� +	  O�      (4)  
                  Cu� +	  H�O� 	  → 	  HO∙ + 	  HO� +	  Cu��    (5) 
                   O�∙� + 	  H�O� 	  
��������	  
	  O� + 	  HO∙ + 	  HO�	               (6) 
 
            
	  
Scheme I.3 Reaction of fOH with guanine.128  
	  
The redox potential of adenine is slightly higher than that of guanine, hence is 
not as easily oxidisable. Similar to guanine, OH reacts with adenine at C4 and 
C8 forming C4-OH, C8-OH radical adducts up to 50% yields and to a lesser 
extent at C5 and C2 forming C5-OH and C2-OH radical adducts up to 5% yields. 
A one-electron oxidation reaction in the presence of oxygen undergoes at C8-
OH–radical adducts with the formation of the keto form of adenine, 8-
hydroxyadenine (8-OH-dA), however, in the absence of O2 adenine undergoes 
ring opening in one-electron reduction reaction with the formation of 4,6-
diamino-5-formamidopyrimidine (Fapy-A) (Scheme I.4). Other oxidation 
products can form at adenine base, with a much lesser extend.122,126  
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Scheme I.4	  Reaction of OH with adenine.126 
 
Purine bases, exposed to reactive oxygen species (OH) generated from γ-
radiation, under hypoxic conditions form an internal cyclization between C5ʹ′ of 
deoxyribose and C8-position of purine with formation of cyclopurine 
deoxynucleoside. A covalent bond is formed between the C8-position of the 
purine with the C-5ʹ′ residue of the adjacent deoxyribose, with 
cyclodeoxyadenosine being formed slightly more frequently than 
cyclodeoxyguanosine. The proposed mechanism for the cyclization of purine 
nucleosides is by free radical abstraction of hydrogen from the carbohydrate 
moiety, leading to (5ʹ′R) and (5ʹ′S) diastereoisomers of 5ʹ′8-cyclo-2ʹ′-
deoxyadenosine (Fig. I.12. A) and 5ʹ′8-cyclo-2ʹ′-deoxyguanosine (Fig. I.12. 
B).126,130–132 
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Figure I.12 Structure of diastereoisomers: A. (5ʹ′R) and (5ʹ′S) of 5ʹ′8-cyclo-2ʹ′-deoxyadenosine and 
B. (5ʹ′R) and (5ʹ′S) of 5ʹ′8-cyclo-2ʹ′-deoxyguanosine. 
	  
I.3.3 Copper-binding (ATCUN) motif 
Most copper complexes in vivo are not able to generate OH in free solution, 
however, when copper ions bound to specific targets such as DNA, RNA, 
enzymes, cause damage by generating OH inducing site-specific damage.133 
Studies performed by Kasprak et al. showed that Cu(II) and Ni(II) form a stable 
complex with the N-terminal amino-acid sequence motifs of human protamine 
(HP2). This group showed that Cu(II) and Ni(II) binds with high affinity the N-
terminal peptide model,134 and in the presence of H2O2, Cu(II)/Ni(II)-HP2 
complex can mediate single and double strand oxidative DNA damage.135,136 
Pauling et al. then synthesised a tripeptide glycil-glycil-histidine complex (Gly-
Gly-His) designed to mimic the specific Cu(II) transport site of the albumin 
molecule (Fig. I.13). This group showed that Cu(II) bound to the Gly-Gly-His 
sequence had antitumor activity.137 The chemical structure of this tripeptide 
motif shows an NH2-terminus, a histidine residue in the third position and two 
intervening nitrogens. This structural feature is defined as the amino terminal 
Cu(II)-and Ni(II)-binding (ATCUN).138 The ATCUN motif occurs naturally in 
human serum albumin and other proteins, but synthetic ATCUN and can bind 
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Cu(II) and Ni(II) with high affinity inducing oxidative DNA damage, cross-link-
proteins, and damage cancer cells in the presence of H2O2.139–141 In a recent 
study, Cowan et al. designed a novel class of copper-acridine-ATCUN 
(CuGGHK-Acr) complex in K+ solution, that targets G-guadruplex telomeric 
DNA.142 G-guadruplex DNA are guanine-rich sequences of nucleic acids capable 
of forming a four-stranded helix. G-guadruplex DNA – stabilised by monovalent 
cations (Na+, K+), are formed by the coplanar arrangement of four-guanine bases 
and held together by Hoogsten bonds – are involved in telomere replication.143 In 
this study, Cu-GGHK-Acr selectively binds to G-guadruplex telomeric DNA, 
inducing irreversible damage, with moderate anticancer activity. 142  
	  
Figure I.13 Structure of the copper – GGH complex. GGH mimics the specific copper transport 
site of albumin and has the required planar geometry needed to bind copper. 137    
I.4 Mechanisms of oxidative DNA damage 
I.4.1 [Cu(1,10-phenanthroline)2]2+ 
Metal ions such as Fe2+ and Cu2+ can react with H2O2 via Fenton chemistry to 
produce ROS, resulting in DNA damage. The first chemical nuclease was 
reported by Sigman et al. and is the [Cu(1,10-phenanthroline)2]2+ ([Cu(phen)2]2+, 
Fig. I.15A.) complex. This species was discovered in 1979 during investigations 
into the inhibition by 1,10-phenanthroline –cuprous complex on poly(dA-dT) 
direct polymerization catalysed by E. coli-DNA polymerase I in an oxygen-
dependent reaction.144 The proposed mechanism of DNA cleavage reaction by 
copper(II) bis-1,10-phenanthroline, in the presence of H2O2, consists of one 
electron transfer reaction from [Cu(phen)2]+ with the formation of reactive 
oxygen species and copper-oxo–species (Fig. I.14), which are directly 
responsible for DNA strand breaks.119,144  
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Figure I.14	  Proposed formation of reactive copper-oxo species via Fenton chemistry90,145 
 
The actual DNA scission is initiated by hydrogen atom abstraction from 
deoxyribose residue and the reaction requires exogenous agents along with Cu+. 
[Cu(phen)2]+ binds to the surface of DNA within the minor groove, since the 
hydrogen atom abstraction occurs at the C1ʹ′ along with varying amounts of 
oxidation at the C4ʹ′ and or C5ʹ′-positions of the sugar (Fig I.15B.).145–147 A novel 
aspect of copper-phenanthroline chemistry is C1ʹ′–oxidation, a process that gives 
rise to the alkali-labile 2ʹ′-deoxyribonolactone lesion, which was then proposed as 
a mediator of direct strand scission.90  
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Figure I.15 A. Structure of Sigman’s reagent [Cu(1,10-phenanthroline)2]2+ ([Cu(phen)2]2+ B. 
Proposed mechanism for scission of DNA by [Cu(phen)2]+. Cu-oxo species are formed by the 
oxidation of DNA bound to [Cu-(phen)2]+ in the presence of H2O2 a. C1ʹ′ radical formation by 
hydrogen atom abstraction followed by carbocation (b.) stabilized by partial double bond to 
furanose oxygen, species c. is formed by by deprotonation at C2ʹ′ followed by elimination of 3ʹ′-
phosphate resulting in strand scission (d.). Attack by H2O on species d. leads to elimination of 
purine/pyrimidine base resulting in species e. followed by the formation of abasic site 5-
methyllenefuranone (5-MF) and 3ʹ′-and 5ʹ′-phosphorylated ends.90,148 
In order to improve the binding specificity of Cu-1,10-phenanthroline  reagent 
and its conjugates, a variety of molecules that damage duplex DNA via oxidative 
mechanism have since been analysed as artificial nucleases.149–166 [Cu(1,10-
phenanthroline)2]2+ cleaves DNA only in the presence of added oxidant or 
reductant, in order to generate DNA-reactive cupric species. Kellett et al. have 
developed a series of ‘self-activating’ copper bis-phenanthroline complexes 
containing phthalates isomers167 or an octanedioate168 ligand that oxidatively 
cleave DNA in the absence of added exogenous reductant. These compounds 
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showed significant in vitro cytotoxicity against a wide range of human-derived 
cancer cell lines.167,168 The self-cleaving mechanism by which these Cu2+ 
complexes damage DNA is thought to be via the formation of π carboxylate 
radicals, which leads to the formation of the reduced Cu+ species.168 
 
I.4.2 Bleomycin 
Bleomycines, firstly isolated from Streptomyces verticillus in 1966, belongs to a 
family of glycopeptides antitumor antibiotic. As a chemotherapeutic agent, 
Bleomycin is now routinely used in testicular cancer and certain types of 
lymphomas as Bleonaxane (Bristol Myer Squibb) and it is composed of two 
forms of Bleomycin A2 and B2 (Fig I.16a.).169 Bleomycin induces sequence 
specific single and double strand breaks through multiple binding modeswith the 
latter being responsible for its antinumor effect.170 In the presence of several 
metal ions (Fe(II), Co(III) and Cu(I)) and oxygen, ROS are being generated, and 
through a one-electron reductant mechanism,  highly reactive Metal-Bleomycin 
complex is generated.171–173 The chemical structure of Bleomycin can be divided 
into several functional domains. The metal-binding region, where transition 
metal form an octahedral complex with the nitrogen atoms of the ligands, the 
peptide linker region, which, together with the metal binding domain bind within 
minor groove of DNA and defined the basis for its specificity of DNA 
cleavage.174,175 The highly charged bithiazole tail, are involved in the DNA 
binding either by intercalation or intercalation at minor group (Fig I.16b.).176 The 
role of disaccharide region remains unknown, however DNA cleavage studies 
done in the absence of the sugar ligand showed a reduce affinity of bleomycin 
towards DNA binding and also is less effective producing dsDNA breaks.177 The 
DNA cleavage sequence specificity of bleomycin is mediated by the binding of 
N2- and N3- of guanine in the 5ʹ′ direction (G-5ʹ′) to the pyrimidine (Py) cleavage 
site. One single molecule of metal - bleomycin complex in the presence of 
oxygen or reductant is sufficient to mediate dsDNA breaks. The flexibility of 
bithiazole tail allows intercalation of the bleomycin molecule at the site directly 
3ʹ′ to the 5ʹ′-GT and GC recognition site 172,178 and therefore cleavage of the 
second strand of DNA at higher concentration.179 The bases facing opposite 
direction TG and CG are not being cleaved.172 The ratio of single-strand DNA to 
dsDNA damage is 6:1,180 but sometimes up to 20:1 depending on the DNA 
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sequence.177 The mechanism of DNA cleavage by an “activated” bleomycin, 
outline in Fig I.17, involves in a primary step, a H atom abstraction of C-4ʹ′ from 
the DNA deoxyribose resulting a C-4ʹ′ deoxyribose radical. In presence of O2 C-
4ʹ′ hydroperoxy complex occur followed by rapid scission of the C-3ʹ′-C-4ʹ′ bond 
of the sugar with the formation of base propenals and oligonucleotide 3ʹ′-
phosphoroglycolates. When oxygen is limited an alkali liable lesion occur at C-4ʹ′ 
known as C-4ʹ′ hydroxylated apurinic acids.176,181  
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Figure I.16	   a. Structure of bleomycin and functional domains. The metal binding region is 
colored in blue and the nitrogenous atoms that coordinates metal are colored in black. The linker 
region is in purple and the bithiazole tail is colored in green. The disaccharide (R) is colored in 
brown and the positively charged tail from the bithiazole tail (R’) is colored in red. b. Crystal 
structure of Co(III)-Bleomycin A(2) bound to d(GGAAGCTTCC)2 (PDB, 1MXK) C – green, H 
– black, O – red, N – blue S – yellow, and Co(III) in pink. 
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Figure I.17 Formation of activated bleomycin and cleavage of DNA. The activated bleomycin is 
formed in the presence of O2 and reductant. The initial step in DNA damages is the removal of 
hydrogen atom from C-4ʹ′ from deoxyribose sugar. In the presence of O2, 4ʹ′-peroxy radical is 
formed which is further reduced to 4ʹ′-hydroperoxyde. The later undergoes a series of chemical 
transformations with the formation of base propenals and oligonucleotide 3ʹ′-phosphoroglycolates 
(pathway to right).177,182 When O2 is limited, oxidant is added and alkali liable lesion occurs at C-
4ʹ′ known as C-4ʹ′ hydroxylated apurinic acids (pathway to the left).177 
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CHAPTER II 
Potent Oxidative DNA Cleavage by the Di-
Copper Cytotoxin: 
 [Cu2(µ-terephthalate)(1,10-phen)4]2+ 
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II.1 Abstract 
The di-copper(II) cation, [Cu2(µ-terephthalate)(1,10-phen)4]2+,  is a powerful, non-
sequence-specific, minor-groove oxidizer of duplex DNA which, unlike copper(II) 
bis-1,10-phenanthroline chloride, operates independently of exogenous reagents. 
The agent displays excellent in vitro cytoxicity towards cisplatin-resistant ovarian 
cancer cells, producing intracellular reactive oxygen species upon nano-molar 
exposure.  
 
II.2 Introduction 
Manipulation of DNA is both an intrinsic and essential component of molecular 
biology and biotechnology. Reagents capable of cutting DNA are applied within 
these fields as probes for DNA structure and function, with the ultimate aim 
being the design of target-specific, customized endonucleases, capable of 
modifying genomic DNA.1 Thus, DNA cleaving reagents are essential tools for 
both sequence analysis and genome engineering.2 Additionally, through these 
manipulations, tremendous therapeutic potential has been offered in the 
treatment of gene-specific disease and malfunction.3 
 
DNA cleavage reagents operate using one of two distinct mechanisms; (i) 
oxidative scission of deoxyribose residues through redox chemistry,4 and (ii) 
hydrolysis of the phosphodiester sugar backbone.5 Since the discovery of the first 
synthetic, oxidative chemical nuclease, [Cu(1,10-phen)2]2+ (1,10-phen = 1,10-
phenanthroline),6 metal complexes which facilitate catalytic transformations of 
DNA have been intensively investigated.7 In addition to their application within 
site-specific gene-manipulation, oxidative DNA cutters have found clinical 
application in cancer chemotherapy, as demonstrated by the natural antitumor 
antibiotic, bleomycin (Blenoxane®).8 The cleaving limitations of [Cu(phen)2]2+ 
include a reliance on exogenous reductant (e.g. ascorbate) or oxidant (e.g. H2O2) 
which are essentially required to generate DNA-reactive cupric or metal-oxo 
species.4a The design of “self-active” Cu(II) 1,10-phen chemical nucleases 
represents an important goal, as both the in vitro and in vivo application of such 
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agents should not be limited by the establishment of a local oxidizing or reducing 
environment. 
   
Recently, we have shown that the di-copper(II), bis-1,10-phen complex, [Cu2(µ-
terph)(1,10-phen)2](terph) (S1) [terephthalic acid = terphH2], containing the 
active cation, [Cu2(µ-terph)(1,10-phen)2]2+,  (Fig. II.1), is capable of inducing 
single-stranded DNA scission in the absence of exogenous reductant or oxidant.9 
This agent, along with a di-copper(II), µ-octanedioate derivative,10 have shown 
significant potential toward DNA manipulation and offer promise as cytotoxic 
agents. Herein, we present a detailed analysis of the DNA cleavage profile of S1 
using pBR322 plasmid DNA. Direct comparisons are made with the activity of 
Sigman’s reagent, Cu(1,10-phen)2Cl2 (S2).† Additionally, we employ unique 
experimental design to identify site-specific cleavage of S1 along with evidence 
showing that the “self-active” cleavage mechanism by S1 is oxidatively linked. 
Finally, in vitro cytotoxicities of S1 against the platinum-resistant, human-
derived ovarian cancer, SK-OV-3, and non-tumorigenic human-derived ovarian 
cells, HS-832, is presented, with activity being compared to the clinical, type II 
topoisomerase inhibitor, mitoxantrone. Direct evidence of intracellular ROS 
generation, within human cancer cells, by S1 is also revealed.    
 
a.  
 
b.  
         
Figure II.18	   a.Two perspective, space-filling views of the cation in S1, the copper ions are 
bridged by the terephthalate group. Colour scheme: copper, green; oxygen, red; nitrogen, blue, 
carbon, grey. b. X-Ray structure of the cation in [{Cu(phen)2}2(terph)](terph)183  
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II.3 Results and discussion 
 
	  
Figure II.19	   DNA cleavage reactions using 400 ng of pBR322 plasmid DNA were carried out at 
37 ºC using [Cu2(µ-terph)(1,10-phen)4](terph) (S1) and the positive control agent Cu(1,10-
phen)2Cl2 (S2) in 80 mM HEPES at pH 7.2 with 25 mM NaCl then analysed using agarose gel 
electrophoresis.† A. Time-dependant study using 30 µM of S1, S2 and CuCl2 exposed to the 
plasmid for 0.5, 1.0, 2.5, 5.0 and 10 h, B. 0.5 h incubation using 20 µM of S1, S2 and CuCl2 in 
the presence of 1 mM added oxidant or reductant, C. Cleavage reactions, after 0.5 h incubation, 
using 0.5, 1.0 and 10.0 µM of S1 in the presence of 1 mM added oxidant and/or reductant. 
 
The ability of S1 and S2 (see section II.5.1.1 for preparation†) to cleave DNA 
was studied using agarose gel electrophoresis with supercoiled pBR322 plasmid 
DNA (Form I) and is shown in Fig. II.2.† Efficient, time-dependent DNA 
scission, in the absence of exogenous reagents occurred using 30 µM of S1 with 
complete conversion to nicked (Form II) in 2.5 h being followed by partial 
linearization (Form III) across the 10 h period (Fig. II.2 A). In comparison, S2 
and CuCl2 did not cleave DNA to any significant extent under identical 
conditions. Following 30 min of incubation at 37 °C in the presence of either 1 
mM of exogenous oxidant (H2O2) or reductant (Na-L-ascorbate), 20 µM of S1 
was found to completely digest the plasmid, as evidenced by the absence of a 
detectable band in Fig. II.2 B. In the cleavage reaction using 1 mM of added 
reductant, S2, as anticipated, was found to be active with a large proportion of 
plasmid being digested. In the presence of oxidant, however, S2 was found only 
to predominantly nick super helical DNA (FI→FII). Additionally, the simple 
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CuCl2 salt was found not to affect any change on the plasmid under these same 
conditions. In order to probe further the activity of S1, reactions were preformed 
using 0.5, 1.0 and 10.0 µM concentrations under conditions of added reductant, 
oxidant and with an admixture of both (Fig. II.2 C). At the lowest S1 tested 
concentration (0.5 µM), the presence of H2O2 was found to induce complete 
relaxation of the plasmid to FII while no similar relaxation with Na-L-ascorbate 
was witnessed. Reactions with 1.0 µM of S1 resulted in an overall cleavage 
enhancement with complete relaxation to Form II in the reductant reaction, and 
linearization beginning (FII→FIII) in the peroxide reaction. A further increase in 
concentration of S1 to 10.0 µM afforded almost complete digestion of the 
plasmid with each exogenous reagent or the admixture of both. Overall, it 
appears that the presence of H2O2 is more important in the DNA cleavage 
reaction at lower S1 concentrations, while at higher concentrations the presence 
of reductant becomes more significant.    
 
	  
Figure II.20	   Experimental design for identifying sequence-specific DNA cleavage. A. The 
unknown double-stranded scission mode, specific (¢) or random (¢), of plasmid DNA occurs 
by S1, B. Introduction of a site-specific restriction enzyme (¢) (e.g. EcoRI or EcoRV) 
hydrolyses the S1 linearized DNA exactly once, C. Gel electrophoresis of the resulting cleavage 
reaction reveals either random cutting (laddering) or site-specific cutting (precise fragmentation). 
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Figure II.21 A. Cleavage reactions of pBR322 by the restriction enzyme EcoRV (lane 2), S1 
(lane 3), S1 followed by exposure of EcoRV or EcoRI (lanes 4 and 5).† B. Reaction of pBR322 
by the restriction enzyme EcoRV (lane 1), cleaved plasmid DNA by S1 and EcoRI extracted and 
purified from gel A (using a Qiagen QIAquick gel extraction kit) were subsequently incubated 
with T4 ligase (lanes 2 and 3), control DNA and a 1 kb ladder (lanes 5 and 6).† (Note all 
reactions performed without exogenous agents) 
 
A novel experimental strategy to identify site-selective DNA cleaving capability 
for S1 was devised and is described in detail within Fig II.3. The use of two type 
II endonuclease restriction enzymes, EcoRI, which cuts pBR322 exclusively 
once at the major groove producing a 5’ overhang (sticky end) cleavage 
fragment,11 and EcoRV, which also cuts pBR322 exclusively once requiring a 
conformational DNA change, or kinking, at the minor-groove prior to producing 
a “blunt end” cleavage fragment,12 were utilized in this experiment. Control 
cleavage reactions with pBR322 using EcoRI and EcoRV produced complete 
linearization (FI→FIII) corresponding to site-specific, double-stranded 
hydrolysis (lanes A2 and B1, Fig. II.4) while S1 exposed to the plasmid produced 
a mixture of FII (majority) and FIII scission products (lane A3, Fig. II.4). 
Cleavage reaction products induced by S1 were then subsequently exposed to 
EcoRI or EcoRV (lanes A4 and A5, Fig. II.4). Double-stranded DNA cleavage by 
S1 does not appear to occur with sequence-specificity as evidenced by the 
laddering pattern in the S1 + EcoRV and S1 + EcoRI lanes. Additionally, S1 
appears to favour the minor groove as DNA nicked by this agent and 
subsequently treated with the endonuclease (EcoRV), is not completely relaxed 
to FIII. Thus, the remaining or protected FII in the S1 + EcoRV lane must arise 
from S1 nicking either the EcoRV recognition sequence (GATATC, Fig. II.4) or 
the minor groove sequence required for conformational modification prior to its 
cutting. Conversely, no protection of nicked FII DNA is observed in the S1 + 
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EcoRI lane, indicating that DNA cleavage by S1 does not occur on the exculsive 
EcoRI major groove recognition site (GAATTC. Fig II.4) within pBR322.  
In order to identify the mode of DNA cleavage (oxidative or hydrolytic), DNA 
from the agarose gel in Fig II.4 A was isolated and purified using the Qiagen 
QIAquick Gel Extraction method, and then incubated with T4 ligase. Plasmid 
cleaved by EcoRI was utilized as “sticky end” religation is generally more 
successful with ligases such as T4. Plasmid treated with T4, post EcoRI 
exposure, was successfully religated to the open circular form (FII), with a 
typical banding pattern corresponding to successful ligation of larger linear 
concatamers also being evident (lane B3, Fig. II.4). Isolated plasmid DNA 
treated with T4, post exposure to S1, produced an identical FII and FIII banding 
pattern as S1 alone (lanes B2 and A3, Fig. II.4) indicating non-occurrence of 
religation. Such behaviour is typical of oxidatively damaged DNA. 
	  
	  
Tested compound IC50 (µM) 24 h 
 SK-OV-3 HS-832 
S1 6.7 ± 0.4 4.5 ± 0.2 
Mitoxantrone 54.5 ± 2.6 25.9 ± 4.3 
 
 
	  
Figure II.22 A. In vitro cytotoxicity of S1 and mitoxantrone against cisplatin-resistant ovarian 
cancer SK-OV-3 and non-tumorigenic ovarian HS-832 cell lines,† B. Generation of endogenous 
ROS within epithelial lung cancer cells (A549) following exposure to S1.†  
 
B. 
A. 
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The in vitro chemotherapeutic potential of S1 was assessed, over 24 h, using a 
platinum-resistant, human-derived ovarian cancer cell line (SK-OV-3) and a non-
tumorigenic human ovarian cell line (HS-832).† Results were compared with the 
clinical type II topoisomerase inhibitor, mitoxantrone, which is also known to 
function as a DNA intercalator. S1 is a potent cytotoxin toward both platinum-
resistant and non-tumorigenic ovarian cells and was found to be approximately 8 
times more active, under these conditions, than mitoxantrone against SK-OV-3 
cancer cells, with the clinical agent also being poorly cytoselectivity toward the 
non-tumorigenic cell line. Of course the potential utility of this agent as a 
therapeutic will require extensive toxicity profiling in various cell culture and 
animal models. In order to identify the role of oxidative stress in the cytotoxic 
mechanism, S1 was added, between 2000 to 2.0 nM, to human-derived lung 
cancer cells (A549) pre-treated with the intracellular ROS indicator, 2′,7′-
dichlorodihydrofluorescin diacetate (DCFH-DA).13† In the presence of 
endogenously generated ROS, DCFH-DA gets oxidised and releases the 
fluorophore, DCFH, which becomes trapped in the cytosol. The presence of 
endogenously generated ROS and reactive nitrogen species (RNS) trigger the 
formation of the fluorescent probe, 2′,7′-dichlorofluorescin (DFC). Results are 
shown as increases in cellular ROS levels after S1 exposure and are expressed in 
comparison to the ROS level of the unexposed control (Ctrl). A positive control 
of 0.5 µM H2O2 was utilised as it is considered a potent ROS generator. 
Fluorescence measurements were recorded at intervals between 15 and 300 min 
(Fig. II.4 B) with results showing a concentration-dependent propensity by S1 to 
generate intracellular ROS within this cancer cell line.  
 
Electrochemical measurements (Section II.5.5 †) were employed to elucidate the 
redox properties of S1 in aqueous solution (DMF, 10%), and typical 
voltammograms are presented in Fig. II.6 S1 exhibits good stability with well-
defined redox waves, centred about -0.062 and +0.097 V, describing the one-
electron quasi-reversible (ΔEP = 0.159 V) reduction (peak C1) and oxidation 
(peak A1) processes of S1, respectively. Addition of 2 mM ascorbate promotes 
more facile oxidation of S1, and complex reversibility is enhanced (ΔEP = 0.041 
V, 3-electron overall). These data indicate that one Cu2+ centre is reduced by 
ascorbate, the remaining Cu2+ is reduced electrochemically (1e-) and both are re-
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oxidised to Cu2+ (2 x 1e-). Comparison in pure DMF reveals added reductant has 
a marked enhancement on S1 reversibility and activity but has little effect on S2. 
The phthalate-bridge may confer structural stability on S1 resulting in redox 
potentials which are accessible within biological systems.14 
 
	  
Figure II.23	   Typical cyclic voltammograms describing the redox behaviour of 1 mM S1 in the 
absence (black trace) and presence (red trace) of 2 mM ascorbate, in 0.1 M KCl aqueous solution. 
Experimental details in section 2.5.5.† 
 
II.4 Conclusion 
In conclusion, we have demonstrated that [Cu2(µ-terph)(1,10-phen)4](terph) is a 
potent oxidizer of duplex DNA which operates independently of exogenous 
reagents and with enhanced activity in their presence. To our knowledge, this is 
the first “self-active” oxidative copper(II)-bis-1,10-phen system to be reported. 
We have shown, using innovative experimental design, that this di-copper(II) 
reagent cleaves DNA in a non-sequence-specific fashion, potentially at the 
minor-groove. The agent displays excellent in vitro chemotherapeutic activity 
toward cisplatin-resistant ovarian cancer and there is evidence of intracellular 
ROS production, at nano-molar exposure levels, within human-derived lung 
cancer cells. A major focus within our laboratory is to now develop probes 
suitable of inducing specific DNA cleavage, with high efficiency, at a 
predetermined locus. The innovative work by Barton et al. on the conjugation of 
sequence-specific proteins to DNA-targeting metal complexes may inform this 
effort.7b, 7d While other Cu2+ “self-active” oxidative DNA cleavers known,7f, 15 
none of these agents can be considered structurally similar to S1. Furthermore, it 
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is our belief that the development of cleaving agents from readily available 
commercial ligands (1,10-phen and terephthalic acid in this case) is of broad 
chemical interest.  
 
II.5 Materials and methods 
Materials: Chemicals and reagents of analytical grade were purchased from 
Sigma-Aldrich Ireland and used without further purification. 
 
II.5.1 Preparation of the Complexes. 
II.5.1.1 Synthesis of [Cu2(µ-terphthalate)(1,10-phen)4](µ-terphthalate) (S1): 
The complex was prepared and characterized according to the method reported 
by Kellett et al.9 Prior to biological analysis the complex was finely ground and 
suspended in DMF with the resultant suspension being heated on a water bath at 
70 oC for 2 hours. The suspension was then vortexed prior to buffer dilution.   
 
II.5.1.2 Synthesis of Cu(phen)2Cl2.3.5H2O (S2): An ethanolic solution of 
copper(II) chloride dihydrate (0.50 g, 2.9 mmol) was treated with 1,10-
phenanthroline monohydrate (1.2 g, 6.0 mmol) and refluxed under constant 
stirring at 90 oC for 2 hours. The green suspension was cooled on ice then 
filtrated with the resulting green powder being washed with a minimum amount 
of cold ethanol before being air-dried. Yield: 1.09 g (68.5 %), Elemental 
analysis: T%: C, 51.67; H, 4.16; N, 10.04, F%: C, 51.59; H, 4.56; N, 10.01, IR 
(KBr): 3392, 1624, 1517, 1427, 851, 722 cm-1. Solubility: methanol, ethanol. 
 
II.5.2 DNA cleavage experiments.  
II.5.2.1 General procedure: Reactions were carried out according to the 
literature procedure reported by Melvin et al.16 with slight modifications; in a 
total volume of 20 µL using 80 mM HEPES buffer (Fisher) at pH = 7.2 with 25 
mM NaCl, an aliquot of the stock complex (S1 initially prepared in DMF and S2 
and CuCl2.2H2O in MeOH) was mixed with 400 ng of pBR322 (Roche). Samples 
were incubated at 37 oC before being quenched with 6x loading dye (Fermentas), 
containing 10 mM Tris-HCl (pH 7.6), 0.03% bromophenol blue, 0.03% xylene 
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cyanol, 60% glycerol and 60 mM EDTA, then loaded onto agarose gel (1%) 
containing 2.0 µL of GelRedTM (10,000X). Electrophoresis was completed at 80 
V for 1.5 h using a wide mini-sub cell (BioRad) in 1XTAE buffer (Millipore). 
Experiments with exogenous reagents were conducted using 1 µL of 20 mM Na-
L-ascorbate and/or 1 µL of 20 mM H2O2. 
 
II.5.2.2 Experiments with restriction enzymes. General procedure: In a total 
volume of 20 µL using 2 µL of 100 mM HEPES buffer (pH = 7.2), 2 µL of 10x 
NEBuffer 3 (New England BioLabs), 0.2 µL 100x BSA (New England BioLabs), 
2 µL 10x NEBuffer EcoRI (New England BioLabs) [used where appropriate], 1 
µL of 20,000 U/mL EcoRV or 20,000 U/mL EcoRI (New England BioLabs) and  
30 µM of the complex (from stock DMF) were mixed with 400 ng of pBR322 
(Roche), and deionized H2O. Samples containing the complex were incubated at 
50 oC for 5 h then ice cooled prior to the restriction enzyme (EcoRI or EcoRV) 
being added. This mixture was further incubated at 37 oC for 1.5 h. 6x loading 
dye (Fermentas) was then added and samples were loaded onto agarose gel (1%) 
containing 2.0 µL of GelRedTM (10,000X). Electrophoresis was completed at 70 
V for 2.0 h using a wide mini-sub cell (BioRad) in 1XTAE buffer (Millipore). 
 
II.5.2.3 Religation experiments. In a total volume of 36 µL containing 30 µL of 
purified DNA (Qiagen QIAquick gel extraction kit as per manual protocol), 5 µL 
of 10x T4 ligation buffer (New England BioLabs) and 1 µL of T4 ligase 
(400,000 U/mL) (New England BioLabs) were incubated in a slush ice bath 
which was slowly allowed to reach room temperature overnight. 6x loading dye 
(Fermentas) was added and samples were loaded onto agarose gel (1%) 
containing 2.0 µL of GelRedTM (10,000X). Electrophoresis was completed at 70 
V for 2.0 h using a wide mini-sub cell (BioRad) in 1XTAE buffer (Millipore). 
 
II.5.3 Cytotoxicity experiments.  
II.5.3.1 Human Ovarian non-malignant cell line, HS-832 (passage 4 and 5, 
ATCC, USA), was grown in Dulbecco’s modified eagle’s medium 
supplemented with 2 mM L-glutamine and 10% fetal bovine serum (FBS) 
containing penicillin-streptomycin (100 U/mL and 100 µg/mL) at 37 ºC in a 
humidified atmosphere with 5% CO2.  
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II.5.3.2 Human Ovarian Cancer cell line,  SK-OV-3 (passage 51 to 64, 
ATCC, USA),   was grown in McCoys’s 5a Medium supplemented with 2 mM 
L-glutamine and 10% fetal bovine serum (FBS) containing penicillin-
streptomycin (100 U/mL and 100 µg/mL) at 37 ºC in a humidified atmosphere 
with 5% CO2. Compounds were tested by the MTT assay following 24 h 
exposure of cells to S1 and mitoxantrone (both prepared in DMSO).  Each 
value represents the mean IC50 of three independent experiments +/- STD 
error. 
 
II.5.3.3 MTT Assay. This method is based on the reduction of the tetrazolium 
salt, methylthiazolyldiphenyl-tetrazolium bromide (MTT), into a crystalline blue 
formazan product by the cellular oxidoreductases of viable cells.17 The resultant 
formazan crystal formation is proportional to the number of viable cells. Cells 
were seeded at 4x 105 cells/mL in 96-well plates and incubated at 37 ºC in 5% 
CO2 for 24 hours.  Cells were treated with a four log range of concentration of 
the test compounds in triplicate from 0.1 to 500 µM or with a solvent control 
(0.5% DMSO) in complete medium. Following 24 h incubation, cells were 
incubated with 20 µL of MTT (5 mg/mL) in 0.1 M PBS, pH 7.4 at 37 ºC in a 
humid atmosphere with 5% CO2 for 4 h. Media was then gently aspirated from 
test cultures and 100 µL of dimethyl sulphoxide (DMSO) was added to all wells. 
The plates were then shaken for 2 min and the absorbance was read at 550 nm in 
a Varioscan plate reader. The IC50 was defined as the concentration of test 
compound required to reduce the absorbance of the MTT-formazan crystals by 
50%, indicating 50% cell deactivation. 
 
II.5.3.4 Cellular reactive oxygen species (ROS) experiments. 
Intracellular oxidative stress. 
Intracellular oxidative stress was quantified using 2′,7′-Dichlorofluorescin 
diacetate (DCFH-DA).18 Briefly, healthy confluent A549 cells were harvested 
and seeded (1000 cells/well) into black bottomed 96 well plates (Nunc, 
Denmark) and allowed to attach for a period of 24 h prior to exposure. For ROS 
quantification, three independent experiments were performed. In each 
independent experiment, eight replicate wells were used for control, eight 
replicate wells were employed for the positive control and eight replicate wells 
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were used for each test compound per micro-plate. A working stock of 20 µM 
DCFH-DA in PBS was prepared and all test compounds, unexposed controls and 
positive controls were prepared and exposed to the cells in this working stock. 
The first control consisted of the working stock solely, namely a 20 µM DCFH-
DA solution in PBS, the positive control consisted of a 0.5 µM hydrogen 
peroxide (H2O2) prepared in the 20 µM DCFH-DA/PBS working stock solution 
and finally a concentration range (2000 – 2.0 nM) of the tested complex (S1) 
were prepared in the working stock of 20 µM DCFH-DA/PBS solution. After the 
initial 24 h attachment period, the media was removed, the cells were 
subsequently washed with 100 µL of PBS and treated with 100 µL of the control, 
positive control and the test compounds and then incubated. The rate of 
intracellular oxidative stress was then monitored by the emission at 529 nm (after 
504 nm excitation) of the DCFH-DA dye at time intervals of 15 to 300 minutes 
(the exposure plates were re-incubated for the remaining time after each 
measurement had been recorded). Fluorescence measurements were conducted 
using a microplate reader (TECAN GENios,Grödig,Austria).  
 
II.5.5 Electrochemical experiments 
II.5.5.1 Experimental Set-up: A glassy carbon working electrode (3 mm diam.) 
and a platinum counter electrode were used to determine electrochemical 
parameters on a Solartron potentiostat, model 1875. Compounds were analysed 
in 1 mM concentrations and (in a 1:2 ratio with added ascorbate) at a scan rate of 
100 mV s-1. Aqueous solutions were made up by dissolving S1 in 1 ml DMF and 
9 ml of H2O added. Aqueous (DMF, 10%) experiments were performed in 0.1 M 
KCl using saturated calomel reference electrode (SCE). Voltammetry was 
performed in DMF with 0.1 M tetrabutylammonium hexafluorophosphate 
(TBA+PF6-). Prior to electrochemical measurements all solutions were purged 
with N2 for 15 minutes. Experiments performed in DMF required the use of a 
Ag+/Ag non-aqueous reference electrode [E1/2 = 0.078V vs Fe(Cp)+/Fe(Cp)] and 
potentials were corrected and are presented here versus SCE.19 Electrodes were 
polished using 0.05 micron aluminium oxide paste on microcloth (both Buehler) 
and sonicated for ten minutes in ethanol 
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II.5.5.2 Electrochemical behaviour of S1 in aqueous solution (DMF, 10%) in 
the absence and presence of ascorbate. 
	  
	  
Figure II.24	   Enlargement of Figure 6 from manuscript; Typical cyclic voltammograms detailing 
the electrochemical behaviour of S1 in the absence (black trace) and presence (red trace) of 2 
mM ascorbate in 0.1 M KCl aqueous solution.  The A1/C1 peaks describe the coupled 1-electron 
Cu2+/Cu+ redox behaviour of S1 in the absence of ascorbate. On addition of reductant the peak C1 
describes two 1-electron processes. Peak A2 is the 2-electron, 2-proton oxidation of L-ascorbate. 
Glassy Carbon working electrode, platinum counter electrode, SCE reference electrode, and scan 
rate 100 mV s-1. The diminished solubility of S1, in aqueous solution, results in lower peak 
current values when compared to the S1 current values returned in pure DMF (II.5.5.5). 
 
II.5.5.3 Electrochemical stability of S1 with potential cycling in aqueous 
solution 
	  
Figure II.25	   Typical cyclic voltammograms detailing the stability of 1 mM S1, with potential 
cycling, in a 0.1 M KCl aqueous solution. Little activity is lost after 30 potential cycles. Glassy 
Carbon working electrode, platinum counter electrode, SCE reference electrode, and scan rate 
100 mV s-1. 
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II.5.5.4 Redox profile of [Cu(phen)2]2+ in DMF in the absence and presence 
of ascorbate 
	  
Figure II.26	   Typical cyclic voltammograms detailing the redox behaviour of 1 mM 
[Cu(phen)2]2+ (S2) in the absence (black trace) and presence (red trace) of 2 mM ascorbate in 0.1 
M TBAPF6/DMF. The peaks correspond to the following processes; A1/C1 - Cu2+/Cu+ couple, A2 
- ascorbate oxidation, A3/C3 - uncomplexed Cu2+/Cu+. Glassy Carbon working electrode, 
platinum counter electrode, Ag+/Ag non-aqueous reference electrode, and scan rate of 100 mV s-
1.  
II.5.5.5 Redox profile of S1 in DMF in the absence and presence of ascorbate 
	  
Figure II.27	   Typical cyclic voltammograms detailing the redox behaviour of 1 mM S1 in the 
absence (black trace) and presence (red trace) of 2 mM ascorbate, in 0.1 M TBAPF6/DMF. Peak 
A2 describes the irreversible oxidation of unreacted ascorbate. Glassy Carbon working electrode, 
platinum counter electrode, Ag+/Ag non-aqueous reference electrode, and scan rate of 100 mV s-
1. Note: No electrochemical redox activity is observed for uncomplexed Cu2+/Cu+, as is evident 
with the Cu2+/Cu+ couple in [Cu(phen)2]2+ (S2). 
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Tables II.1 (a) and (b) summarise the electrochemical parameters and all 
potentials are quoted versus SCE.19: 
 
Table II.1	  (a): Summary of the parameters calculated for S1 in the absence and presence of 2 
mM ascorbate in aqueous solution. In this table voltage values (V) are quoted versus the SCE 
calomel electrode.19 
	  
	  
EP	  (V)	   ΔEP	  (V)	   EP-­‐EP/2	  (V)	   n*	   α	  value	  
Reduction,	  C1	   -­‐0.062	   -­‐	   0.066	   1	   0.71	  
Oxidation,	  A1	   0.097	   0.159	   0.138	   1	   0.66	  
With	  2	  mM	  AA,	  C1	   -­‐0.072	   -­‐	   0.052	   1	   -­‐	  
With	  2	  mM	  AA,	  A1	   -­‐0.031	   0.041	   0.029	   2	   -­‐	  
          Summary of the calculated parameters for the redox behaviour of S1 in aqueous solution.  
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Table II.2 (b): Comparison of the redox behaviour of S1 and S2 in DMF 
S1	  (DMF)	   EP	  (V)	   ΔEP	  (V)	   EP-­‐EP/2	  
(V)	  
	  	  	  	  n*	   	  	  α*	   k0†(x	  10-­‐3)	  cm	  s-­‐1	  
Redn,	  C1	   -­‐0.196	   -­‐	   0.132	   1	   0.38	   -­‐	  
Oxidn,	  A1	   -­‐0.007	   0.189	   0.133	   1	   0.65	   1.6	  
With	  2	  mM	  
AA,	  C1	  
-­‐0.008	   -­‐	   0.062	   2	   0.33	   -­‐	   	  
With	  2	  mM	  
AA,	  A1	  
+0.071	   0.079	   0.074	   2	   0.68	   16.9	  
 
S2	  (DMF)	   EP	  (V)	   ΔEP	  (V)	   EP-­‐EP/2	  (V)	   n*	   α*	   k0†(x	  10-­‐3)	  cm	  s-­‐1	  
Redn,	  C1	   -­‐0.171	   -­‐	   0.092	   1	   0.51	   -­‐	  
Oxidn,	  A1	   -­‐0.076	   0.095	   0.071	   1	   0.32	   8.6	  
With	  2	  mM	  AA,	  
C1	  
-­‐0.105	   -­‐	   0.114	   1	   0.41	   -­‐	  
With	  2	  mM	  AA,	  
A1	  
+0.012	   0.117	   0.084	   1	   0.44	   10.3	  
Summary of the calculated parameters for the redox behaviour, at ν = 100 mV s-1, of S1 and 
[Cu(phen)2]2+      (S2), in the absence and presence of 2 mM ascorbate. In the absence of ascorbate 
S1 exhibits a 1-electron redox process. Addition of ascorbate promotes reversibility in S1, 
allowing the 2-electron reduction and oxidation of both Cu centres.  Experiments performed in 
0.1 M TBAPF6 in DMF and potentials corrected to the SCE reference electrode.19 
 
† Standard heterogeneous rate constant values, (k0), were estimated from the 
magnitude of peak separation, ΔEP, according to Nicholson.20  
Ψ =
𝑘𝑘�
𝜋𝜋𝜋𝜋 𝑛𝑛𝑛𝑛𝑛𝑛𝑅𝑅𝑅𝑅
� � 
The dimensionless kinetic parameter, Ψ, is obtained using ΔEP according to 
Nicholson;6 EP is the peak potential in (V), D is the diffusion coefficient of the 
compound (cm2 s-1), ν is the scan rate (V s-1), R is the gas constant = 8.314 J mol-
1 K-1, T is temperature = 295 K, n is the number of electrons involved in the 
process, and F is the Faraday constant = 96,485 C mol-1. Assumptions 1) 
Diffusion coefficient taken as 10-5 cm2 s-1 and 2) DO/DR = 1.  
* To determine the electrochemical parameters (n and α) summarised in Table 
II.1 (a), (b), the following equations can be used:21 
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For an reversible redox process 
𝐸𝐸� − 𝐸𝐸� � =
2.2	  𝑅𝑅𝑅𝑅
𝑛𝑛𝑛𝑛  
 
2) For an irreversible reduction process 
𝐸𝐸� − 𝐸𝐸� � =
1.857	  𝑅𝑅𝑅𝑅
α𝑛𝑛𝑛𝑛  
and  
3) For an irreversible oxidation process. 
𝐸𝐸� − 𝐸𝐸� � =
1.857	  𝑅𝑅𝑅𝑅
1 − 	  α 𝑛𝑛𝑛𝑛 
EP is the peak potential in volts, EP/2 is the potential at IP/2, R is the gas constant, 
8.314 J mol-1 K-1, T is temperature = 295 K, n is the number of electrons 
involved in the process, F is the Faraday constant = 96,485 C mol-1, and α is the 
transfer coefficient.  
For an irreversible process we expect to observe peak potential a shift of ca. 
1.15RT/(1-α)nF over a 10 fold increase in scan rate - this is the case here; EP, A1 = 
-0.098 V at 10 mV s-1, and E P, A1 = -0.007 V at 100 mV s-1.Theoretical shift = 
0.086 V, Experimental shift = 0.0 
	  68	  
References 
(a.) M. A. McMahon, M. Rahdar and M. Porteus, Nat. Methods, 2012, 9, 27-
31; (b.) J. A. Cowan, Curr. Opin. Chem. Bio., 2001, 5, 634-642. 
 (a.) M. Komiyama, Y. Aiba, Y. Yamamoto and J. Sumaoka, Nat. Protoc., 
2008, 3, 655-662; (b.) Y. Aiba, J. Sumaoka and M. Komiyama, Chem. Soc. 
Rev., 2011, 40, 5657-5668. 
(a.) J. San Filippo, P. Sung and H. Klein, Annu. Rev. Biochem., 2008, 77, 229-
257; (b.) D. J. Segal, Nat. Methods, 2011, 8, 53-55. 
 (a.) M. Pitie and G. Pratviel, Chem Rev, 2010, 110, 1018-1059; (b.) Q. 
Jiang, N. Xiao, P. Shi, Y. Zhu and Z. Guo, Coord. Chem. Rev., 2007, 251, 
1951-1972. 
F. Mancin, P. Scrimin, P. Tecilla and U. Tonellato, Chem. Comm., 2005, 
2540-2548. 
(a.) D. S. Sigman, D. R. Graham, V. D'Aurora and A. M. Stern, J. Biol. 
Chem., 1979, 254, 12269-12272; (b.) D. S. Sigman, Biochem., 1990, 29, 
9097-9105. 
(a.) B. C. Chu and L. E. Orgel, Proc. Natl. Acad. Sci. U.S.A, 1985, 82, 963-
967; (b.) K. D. Copeland, A. M. Lueras, E. D. Stemp and J. K. Barton, 
Biochem., 2002, 41, 12785-12797; (c.) J. C. Francois, T. Saison-Behmoaras, 
C. Barbier, M. Chassignol, N. T. Thuong and C. Helene, Proc. Natl. Acad. 
Sci. U.S.A, 1989, 86, 9702-9706; (d.) M. P. Fitzsimons and J. K. Barton, J. 
Am. Chem. Soc., 1997, 119, 3379-3380; (e.) B. C. Bales, T. Kodama, Y. N. 
Weledji, M. Pitie, B. Meunier and M. M. Greenberg, Nucl. Acids Res., 2005, 
33, 5371-5379; (f.) M. S. Melvin, J. T. Tomlinson, G. R. Saluta, G. L. 
Kucera, N. Lindquist and R. A. Manderville, J. Am. Chem. Soc., 2000, 122, 
6333-6334. 
J. Stubbe, J. W. Kozarich, W. Wu and D. E. Vanderwall, Acc. Chem. Res., 
1996, 29, 322-330. 
A. Kellett, M. O'Connor, M. McCann, M. McNamara, P. Lynch, G. Rosair, V. 
McKee, B. Creaven, M. Walsh, S. McClean, A. Foltyn, D. O'Shea, O. Howe 
and M. Devereux, Dalton Trans., 2011, 40, 1024-1027. 
	  69	  
 A. Kellett, M. O’Connor, M. McCann, O. Howe, A. Casey, P. McCarron, K.  
Kavanagh, M. McNamara, S. Kennedy, D. D. May, P. S. Skell, D. O’Shea 
and M. Devereux, Med. Chem. Comm., 2011, 2, 569-676. 
 C. A. Frederick, J. Grable, M. Melia, C. Samudzi, L. Jen-Jacobson, B. C. 
Wang, P. Greene, H. W. Boyer and J. M. Rosenberg, Nat., 1984, 309, 327-
331. 
 N. C. Horton, C. Otey, S. Lusetti, M. D. Sam, J. Kohn, A. M. Martin, V.  
Ananthnarayan and J. J. Perona, Biochem., 2002, 41, 10754-10763. 
 B. Halliwell and M. Whiteman, Br. J. Pharmacol., 2004, 142, 231-255. 
 O. Iranzo, Bioorg. Chem., 2011, 39, 73-87. 
 (a.) S. Borah, M. S. Melvin, N. Lindquist and R. A. Manderville, J. Am. 
Chem. Soc., 1998, 120, 4557-4562; (b.) P. U. Maheswari, S. Roy, H. den 
Dulk, S. Barends, G. van Wezel, B. Kozlevcar, P. Gamez and J. Reedijk, J. 
Am. Chem. Soc., 2006, 128, 710-711; (c.) P. U. Maheswari, M. v. d. Ster, S. 
Smulders, S. Barends, G. P. v. Wezel, C. Massera, S. Roy, H. d. Dulk, P. 
Gamez and J. Reedijk, Inorg. Chem., 2008, 47, 3719-3727. 
M. S. Melvin, J. T. Tomlinson, G. R. Saluta, G. L. Kucera, N. Lindquist and 
R. A. Manderville, J. Am. Chem. Soc. 2000, 122, 6333-6334 
T. Mosmann, J. Immunol. Meth., 1983; 65, 55–63 
B. Halliwell and M. Whiteman, Br. J. Pharmacol., 2004, 142, 231-255 
V. V. Pavlishchuk, A. W. Addison, Inorg. Chim. Acta, 2000, 298, 97-102. 
R. S. Nicholson, Anal. Chem, 1965, 37, 1351-1355. 
A. J. Bard, L. R. Faulkner, “Electrochemical Methods: Fundamentals and 
Applications”, 2nd Edition, Wiley, New York, 2001, p. 236. 
 
 
 
 
 
 
 
 
 
 
	  70	  
 
Chapter III  
A New Phenanthroline-Oxazine Ligand: 
Synthesis, Coordination Chemistry and 
Atypical DNA Binding Interaction 
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III.1. Abstract	  	  
	  
1,10-Phenanthroline-5,6-dione and L-tyrosine methyl ester react to form 
phenanthroline-oxazine (PDT) and from which [Cu(PDT)2](ClO4)2 and 
[Ag(PDT)2]ClO4·2MeOH are obtained. Binding to calf-thymus DNA by Ag(I) and 
Cu(II) PDT complexes exceed bis-1,10-phenanthroline analogues and the minor 
groove binding drugs, pentamidine and netropsin. Furthermore, unlike the artificial 
metallonuclease, [Cu(phen)2]2+, the [Cu(PDT)2]2+ complex does not cleave DNA in 
the presence of added reductant indicating unique interaction with DNA.  
III.2. Introduction 
1,10-Phenanthroline (phen), its organic derivatives and the plethora of metal 
complexes containing these N,N'-chelating heterocycles, find use as optical 
devices,1,2 catalysts3 and as integral components of supramolecular structures.4 In 
addition, these compounds have found application in the biological field as 
antimicrobial and anticancer agents,5 DNA intercalators,6 and as nucleoside 
constituents for incorporation into the DNA backbone.7 
 
The quest to make new and tailored phenanthrolines is ongoing, and methods 
include synthesising the bases from elementary building blocks1,8 and extending 
existing, functionalised phenanthrolines.1 In the latter context, the quinone, 1,10-
phenanthroline-5,6-dione (phendio), has been used as the starting material for 
grafting appendages onto the phenanthroline framework, via simple Schiff base 
condensation reactions with primary amines.7,9-14 All of these diimines were 
produced by the straightforward Schiff base condensation reaction of phendio 
with the appropriate diamine. However, not all reactions of phendio with primary 
amines have resulted in the expected Schiff base product. For example, 
combining phendio with urea15 and N,N'-bis(2-aminophenyl)ethylenediamine16 
unexpectedly produced a glycoluril and a gem-cis-bis(aminal), respectively. 
Generally, phendio and its Ag(I) and Cu(II) complexes are considerably more 
biologically active than phen and its corresponding metal complexes.5a,5b With 
this in mind, we sought to improve biological activity, selectivity and 
compatibility by attempting to prepare a double Schiff base, phen-type ligand by 
reacting phendio with two equivalents of (S)-methyl 2-amino-3-(4-
	  72	  
hydroxyphenyl)propanoate (L-tyrosine methyl ester). Herein, we report the 
synthesis of an unusual and unexpected phen derivative, the preparation of its 
Ag(I) and Cu(II) complexes, and also the DNA binding  and cleavage properties 
of the three new compounds. Phendio was initially treated with L-tyrosine 
methyl ester (1:2 mol ratio) in anticipation of forming a double Schiff base 
condensation product (Scheme III.1). Unexpectedly, this combination produced 
1,10-phenanthroline-5,6-diol and a relatively low yield of the new orange-yellow 
tetracyclic oxazine, PDT. The structure of PDT·MeOH (Figs. III.1A and B) 
showed that chirality within the compound is retained, with C13 being the 
stereogeniccentre (originally it was C20). The molecule crystallises in the 
centrosymmetric space group, P2(1)/c, and so is a racemic mixture. Interestingly, 
the phenol ring is almost orthogonal to the oxazine ring (bond angle 89.12(2)°) 
forming a ‘chair’ profile. The pdtme molecules are linked into zig-zag chains via 
hydrogen bonding through the methanol solvate; the phenol group makes a H-
bond to the oxygen of the methanol (2.6288(18)Å), and the methanol OH makes 
an unsymmetric, bifurcated H-bond to the phenanthroline nitrogen atoms of a 
second molecule (3.028(2) and 2.907(2)Å to N1 and N2, respectively, under 
symmetry operation -x+2,y-1/2,-z+3/2).	   
 
        
 
Scheme III.1 Proposed reaction mechanism of phendio with L-tyrosine methyl ester leading to 
the formation of PDT.  
 
What is the mechanism of the cyclization reaction that leads to the formation of 
the oxazine ring in pdtme? In their paper on the oxidation of α-amino acids by 
quinones, Lourak and co-workers17 obtained cyclic derivatives containing 
oxazine rings. These researchers proposed a mechanism for their reaction in 
which a second quinine molecule acted as a dehydrogenating agent to give the 
cyclic product. In the present work, the isolation of 1,10-phenanthroline-5,6-diol 
as a by-product of the reaction suggested that reduction of some phendio was 
occurring as part of the reaction mechanism. It is thought that the first step of the 
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mechanism is the formation of a Schiff base (molecule A in Scheme III.1). A 
plausible, concerted mechanism for formation of the oxazine ring is offered in 
Scheme 1 and involves the participation of a second phendio molecule as a 
dehydrogenating agent. Due to steric restraints, resulting from both A and 
phendio, this reaction is expected to be slow, which indeed is what was observed. 
 
Interestingly, in the preparation of the phendio-amino acid ternary complexes, 
[Cu(phendio)(L-Phe)(H2O)]ClO4·H2O and [Ni(phendio)(Gly)(H2O)]ClO4·H2O 
(L-PheH = L-phenylalanine,GlyH = glycine), no interaction between the phendio 
carbonyl functions and the amine group of the amino acid was reported.18 
Reaction of PDT with AgClO4 in a ca. 2:1 molar ratio gave the green solid, 
[Ag(PDT)2]ClO4·2MeOH (AgPDT), in good yield. The complex cation, 
[Ag(PDT)2]+, is thought to be essentially isostructural with the cation in the 
structurally characterised complex, [Ag(phendio)2]ClO4,19 where the metal has 
approximately tetrahedral geometry. In comparison to the 1H NMR spectrum of 
metal-free PDT, the spectrum of AgPDT showed shifts in the signals associated 
with the phen part of the pdtme molecule rather than the ester part of the 
molecule, indicating that the Ag+ ion is chelated by the two nitrogen atoms. In a 
similar reaction using Cu(ClO4)2·6H2O, the green solid, [Cu(PDT)2](ClO4)2 
(CuPDT), was obtained in moderate yield. Again, it is believed that 
[Cu(PDT)2]2+ is structurally similar to the known tetrahedral cation in 
[Cu(phen)2](ClO4)2 (CuPhen).20 
 
A.
	  
B.	  
	  
Figure III.28	   A. Space-fill view of pdtme in PDT·MeOH (MeOH shown in stick view), B. A 
view of PDT·MeOH with atoms depicted with displacement ellipsoids at their 50% probability 
level.  
 
In an effort to establish how the metal-free PDT ligand and its Cu(II) and Ag(I) 
complexes interact with DNA four distinct assays were conducted. To establish 
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an apparent DNA binding constant (Kapp) a sample of high-purity calf thymus 
(CT) DNA is firstly treated with an excess of EtBr and then this highly 
fluorescent, Et+-saturated DNA sample is exposed to a range of concentrations of 
the competitor test compound. A reduction in fluorescence indicates ejection of 
the bound Et+ from the DNA backbone and replacement by the test species. 
Samples are compared based on their Kapp values, which are calculated from the 
concentration of sample required to accomplish a 50% reduction of the initial 
fluorescence (Fig. III.2A, Table III.1A). Metal-free PDT, phen and the simple 
metal salts all showed considerably less DNA binding affinities than AgPDT and 
CuPDT, which have almost identical Kapp values (ca. 7.60 x 106). The Ag(I) and 
Cu(II) PDT complexes also showed a higher binding capacity than the known 
groove-binding drugs, pentamidine and netropsin (Kapp 1.09 x 106 and 4.77 x 106, 
respectively). The binding of metal-free PDT to DNA is significantly stronger 
than that of metal-free phen, suggesting that the additional functionalities on the 
backbone provide secondary binding interactions with the nucleic acid. The 
contribution of these extra interactions is also apparent when the binding 
constants of PDT and phen metal complexes are compared (Kapp for AgPDT is 
ca. 3 times larger than that for [Ag(phen)2]ClO4 (AgPhen), and CuPDT is ca. 11 
times greater than for CuPhen). Competitive displacement of DNA-bound 
Hoechst 33258 (minor groove binder) and ethidium cations (Et+, intercalator) 
was assessed using fluorescence quenching, which utilises an unsaturated dye-
DNA combination in which a limited number of binding spaces on the DNA 
polymer are occupied at any one time by the interacting dye, which strongly 
fluoresces once bound with a relatively high number of unoccupied sites 
remaining for test compound interaction. The introduction of a new compound to 
the DNA may then displace Hoechst or Et+ either directly or indirectly (i.e. 
through a conformational change which results in dye ejection) and can give 
valuable information regarding a binding interaction mode, 21 although, caution 
must be exercised here considering the binding constant and binding 
stoichiometry of ethidium bromide and Hoechst to CT-DNA. The minor groove 
binders, pentamidine and netropsin, displayed high quenching affinity (Q) for 
Hoechst 33258 bound DNA and were, as expected, an order of magnitude less 
effective in their quenching of ethidium (Table III.1B). Both AgPhen and 
CuPhen displayed higher Q values toward Et+ than compared with Hoechst. 
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Interestingly, both AgPDT and CuPDT displayed higher Q values, along with 
different profiles,† and were almost identical in their ejection of bound Hoechst 
and Et+. From these quenching data it is evident that the PDT complexes have 
significantly higher binding affinities (Kapp) and an alternate binding mode 
compared with their bis-phen analogues.	  	  	  
	  
A
	  
B.	  
	  
	  
	  
	  
Figure III.29 A. Competitive ethidium bromide displacement for netropsin, pentamidine, metal 
salts, free ligands and complexes with CT-DNA, and B. DNA cleavage reactions with 400 ng of 
pBR322 plasmid DNA carried out for 30 min at 37ºC in 80 mM HEPES at pH 7.2 with 25 mM 
NaCl and 1 mM Na-L-ascorbate then analysed using agarose gel electrophoresis. Lane 1: DNA 
control; lane 2: [Cu(OAc)2]; lane 3: AgNO3; lane 4: PDT; lane 5: CuPhen; lane 6: AgPhen; lane 
7: CuPDT; lane 8: AgPDT 
 
Table III.1	  A. Apparent DNA binding constants (Kapp) of the test compounds, and B. 
Fluorescence quenching (Q) values obtained against Hoechst 33258 (groove binder) and 
ethidium bromide (intercalator).	  
	   A.	   B.	  
Compound	   C50*(µM)	   Kapp**	   Q†	  
Hoechst	  
33258(µM)	  
Q†	  
Ethidium	  
Bromide	  (µM)	  
pentamidine	   109.41	   1.09	  x	  106	   35.86	   >150	  
netropsin	   39.99	   4.77	  x	  106	   3.50	   35.98	  
AgPDT	   15.75	   7.60	  x	  106	   24.65	   18.18	  
CuPDT	   15.70	   7.62	  x	  106	   18.00	   18.59	  
AgPhen	   45.01	   2.65	  x	  106	   45.54	   27.90	  
CuPhen	   179.21	   6.67	  x	  105	   34.96	   20.38	  
1,10-­‐phen	   >300	   N/A	   -­‐	   -­‐	  
PDT	   247.21	   4.80	  x	  105	   -­‐	   -­‐	  
AgClO4	   >300	   N/A	   -­‐	   -­‐	  
[Cu(OAc)2]	   >300	   N/A	   -­‐	   -­‐	  
                   * C50 = concentration required to reduce fluorescence by 50%; 
                   **Kapp = Ke x 12.6/C50 where Ke = 9.5 x 106M(bp)-1; N/A = not available; 
                   † Q = reduction of 50% initial fluorescence from DNA-bound dye 
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A.	   B.	  
	  
	  
Figure III.30 A. Relative viscosity changes in salmon testes dsDNA  (1 mM in DNAp in 80 mM 
HEPES) upon exposure to EtBr, netropsin, CuPhen and CuPDT, and B. typical cyclic 
voltammograms describing the redox behaviour of 1 mM CuPhen (left) and CuPDT (right), at a 
scan rate of  100 mV s-1, in the absence (solid black trace) and presence (dashed black trace) of 2 
mM ascorbate.† 
 
To further explore the DNA binding properties of PDT, viscosity experiments 
were conducted using salmon testes dsDNA (1 mM in DNAp) (Fig. III.3A).† 
Intercalating agents (e.g. ethidium) are known to increase viscosity which 
results from a conformational change induced after accommodation between 
DNA bases, while surface binding species (e.g. netropsin) can typically have 
only a moderate or diminished effect on viscosity. This expected pattern 
emerged during our analysis of both these standard agents (Fig. III.3). It was 
also evident that CuPhen, containing the [Cu(phen)2]2+ cation, produced an 
intercalative profile while, significantly, CuPDT did not appear to intercalate 
DNA but had a profile similar to the surface binding drugs, netropsin and 
pentamide. Furthermore, the viscosity profile for CuPDT was distinctive 
from that of the partial intercalating mono-phen complex, [Cu(phen)]2+. 
Relaxation of supercoiled pBR322 (Form I) into open circular (Form II) and 
linear (Form III) conformations was used to quantify the relative DNA 
cleavage efficiency (nuclease activity) of the test complexes. DNA cleavage 
by [Cu(phen)2]2+ is known to be dependent on the presence of added oxidant 
and/or reductant, and in the case of the present compounds the assay was 
conducted in an aerobic environment (O2 oxidant) along with the addition of a 
1 mM solution of the reductant, sodium L-ascorbate. Samples (5 µM) were 
incubated for 30 min at 37 oC before being quenched and analysed using gel 
electrophoreses. The only complex found to be active (Fig. III.2B) was the 
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known chemical nuclease, [Cu(phen)2]2+.22 This dication renders almost 
complete degradation of Form I to linear Form III by interacting at the surface 
of the minor groove of DNA and in the presence of a reductant, which can 
gain access to the Cu(II) centre in the complex, DNA oxidation occurs 
predominantly in this region. It was somewhat surprising that CuPDT was 
almost inactive compared with [Cu(phen)2]2+. Furthermore, any role that the 
phenol moiety in PDT may play in scavenging free radicals to prevent DNA 
damage looks quite unlikely as CuPhen, incubated with up to 100 µM of 
phenol, produced only a marginal inhibition of pBR322 cleavage (Fig. III.6†) 
The redox behaviour of CuPhen and CuPDT was investigated, using cyclic 
voltammetry, to shed light on the observed differences in their efficacy as 
DNA nuclease agents (Fig. III.3B and Fig. III.7 – Fig. III.12).† The 
Cu(II)/Cu(I) redox couple was centred around -0.46 and -0.39 V for CuPhen 
and CuPDT, respectively. Addition of 2 mM ascorbate results in a significant 
anodic shift in the Cu(II)/Cu(I) redox couple of both complexes, indicative of 
a more facile electron transfer regime. The original Cu(II) reduction peak for 
CuPhen is observed at -0.47 V but, interestingly, is not evident at scan rates 
≤ 40 mV s-1, which suggests a transient species. While CuPhen tends toward 
reversibility in the presence of ascorbate (ΔEP = 65 mV), CuPDT remains 
quasi-reversible (ΔEP = 119 mV, Table III.2). Thus, the reversibility of the 
Cu2+/Cu+ couple may justify the greater DNA cleavage ability of CuPhen. 
III.3 Conclusion 
In conclusion, the new oxazine, PDT, can be made in moderate yield from 
phendio and L-tyrosine methyl ester, and this N,N'-chelating base readily 
coordinates to Cu(II) and Ag(I) centres forming the respective bis-chelates, 
[Cu(PDT)2](ClO4)2 and [Ag(PDT)2]ClO4·2MeOH. There is a clear enhancement 
in the DNA binding properties of the Ag(I) and Cu(II) bis-PDT complexes 
compared with their bis-phen analogues. The binding constants for the two PDT 
complexes, at neutral pH, surpass those of the known minor groove binding 
agents, pentamidine and netropsin, and it appears they coordinate in quite an 
alternative manner compared with their bis-phen analogues. Though 
[Cu(PDT)2](ClO4)2 and [Ag(PDT)2]ClO4·2MeOH bind strongly to DNA they do 
not degrade the polymer. This may be rationalised in terms of non-constructive 
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binding orientation, by the Cu2+ PDT complex, that does not promote facile 
cleavage with its quasi-reversible nature when compared with [Cu(phen)2]2+ upon 
the addition of reductant.	  	  
III.4 Material and Methods 
III.4.1 Materials: Chemicals and reagents of analytical grade were purchased 
from Sigma-Aldrich Ireland and used without further purification. 
III.4.2 Preparation of the complexes 
III.4.2.1 Preparation of methyl 2-(4-hydroxyphenyl)-4a,12b-dihydro-2H-
[1,4]oxazino[2,3-f][1,10]phenanththroline-3-carboxylate (PDT) 
1,10-Phenanthroline-5,6-dione (0.80 g, 3.81 mmol) was dissolved in dry, 
refluxing methanol (95 cm3) and L-tyrosine methyl ester (0.74 g, 3.81 mmol) 
was added. The resulting orange solution was refluxed for 20 h and some yellow 
1,10-phenanthroline-5,6-diol precipitated. The solid diol was filtered off, washed 
with MeOH and air dried. Yield: 0.17 g (21%). The original filtrate was then 
concentrated and allowed to stand. After 1 week, orange-yellow crystals of 
PDT·MeOH formed. A few of these crystals in the mother liquor were 
forwarded for X-ray crystallographic studies. The remaining crystals were 
filtered off, washed with cold methanol and then air-dried. Yield: 0.30 g (19%). 
Using a similar experimental procedure, but with a 2:1 L-tyrosine methyl 
ester:phendio reactant ratio, the pdtme yield decreased to 11%. The compound 
was soluble in hot DMSO and sparingly soluble in hot MeOH and EtOH. Mp: 
decomposed at >250 oC. Anal. Calc. for C23H19N3O5 (PDT·MeOH): C, 66.18; H, 
4.59; N, 10.07. Found: C, 66.43; H, 4.21; N, 9.80. 1H NMR (d6-DMSO): 3.90 (s, 
3H ?OMe), 6.58 (s, 1H), 6.67 (d, J = 8.7 Hz, 2H), 7.20 (d, J = 8.7 Hz, 2H), 
7.79(dd, J1 = 4.2 Hz, J2 = 8.1 Hz,1H), 7.84 (dd, J1 = 4.2 Hz, J2 = 8.1 Hz, 1H), 
8.59 (dd, J1 = 1.8 Hz, J2 = 8.4 Hz, 1H), 8.88 (dd, J1 = 1.8 Hz, J2 = 8.1 Hz, 1H), 
9.03 (dd, J1 = 1.8 Hz, J2 = 4.2 Hz, 1H), 9.12 (dd, J1 = 1.8 Hz, J2 = 4.5 Hz, 1H), 
9.71 (s, b, 1H) ppm. 13C NMR (d6-DMSO): 48.6, 52.9, 72.0, 115.8, 121.2, 121.7, 
123.7, 124.1, 124.8, 126.0, 128.9, 129.8, 130.9, 138.4, 142.2, 146.4, 148.6, 
149.7, 151.5, 158.7, 162.6 ppm. IR: 3426, 1742, 1712, 1608, 1587, 1515, 1504, 
1434, 1345, 1325, 1287, 1259, 1173, 1132, 1112, 1020, 973, 808,741, 679, 632 
cm-1. Mass spec: M+1 = 386.3, found m/z = 386.1.  
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III.4.2.2 Preparation of [Ag(PDT)2]ClO4·2MeOH (AgPDT) 
To a yellow suspension of PDT (0.12 g, 0.29 mmol) in refluxing dry methanol 
(36 cm3) was added, drop-wise, a solution of AgClO4 (0.03 g, 0.14 mmol) in dry 
methanol (1 cm3). The resulting green suspension was refluxed for 0.5 h and then 
stirred for 2 h at room temperature. The green solid was filtered off, washed with 
methanol and then air-dried. Yield: 0.116 g (79%). The complex was only 
soluble in hot DMSO. Anal. Calc. for C46H38ClN6O14Ag 
([Ag(PDT)2]ClO4·2MeOH): C, 53.12; H, 3.48; N, 8.08. Found: C, 52.85; H, 
3.43; N, 7.92. 1H NMR (d6-DMSO): 3.92 (s, 3H), 6.66 (d, J = 3.6 Hz, 2H), 6.70 
(s, 1H),7.24 (d, J = 8.7 Hz, 2H), 7.97(dd, J1 = 5.1 Hz, J2 = 8.7 Hz, 1H), 8.02 (t, J 
= 5.4 Hz, 1H), 8.79 (dd, J1 = 1.5 Hz, J2 = 8.4 Hz, 1H), 9.04(d, J = 1.8 Hz, 1H), 
9.06(s, 1H), 9.12(t, J = 3.0 Hz, 1H), 9.78 (s, 1H). IR: 3431, 1715, 1611, 1509, 
1436, 1347, 1260, 1098, 812, 735, 623 cm-1. Mass spec: [Ag(PDT)2]+: M = 
879.5, found m/z = 879.1.  
 
III.4.2.3 Preparation of [Cu(PDT)2](ClO4)2 (CuPDT) 
To a yellow suspension of PDT (0.10 g, 0.25 mmol) in dry, refluxing methanol 
(45 cm3) was added, drop-wise, a solution of Cu(ClO4)2·6H2O (0.04 g, 0.12 
mmol) in dry methanol (2 cm3). Gradually, a green solution formed and this was 
then refluxed for 2 h. The solution was then concentrated to ca.5 cm3 and the 
green product precipitated. The mixture was centrifuged for 10 min at 5000 rpm 
and the supernatant then carefully removed. The remaining green solid was 
washed with cold methanol and then air-dried. Yield: 0.04 g (32%). The complex 
was soluble in MeOH, EtOH and DMSO. Anal. Calc. for C44H30Cl2N6O16Cu 
([Cu(PDT)2](ClO4)2): C, 51.15; H, 2.93; N, 8.13. Found: C, 50.57, H, 3.12, N, 
8.78. IR: 3430, 1720, 1611, 1516, 1437, 1353, 1267, 1174, 1107, 814, 731, 624 
cm-1. Mass spec: [Cu(PDT)2]+: M = 833.5, found m/z = 833.1. µeff = 1.67 B.M.  
 
III.4.3 X-ray crystallography 
Data for PDT·MeOH were collected at 150K on a Bruker APEX II CCD 
diffractometer and the structure was solved by direct methods and refined by 
full-matrix least-squares on F2 using all the data.1 All non-hydrogen atoms were 
refined with anisotropic atomic displacement parameters and the hydrogen atoms 
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bonded to carbon were inserted at calculated positions using a riding model. The 
hydrogen atoms bonded to oxygen were located from difference maps and 
refined with a fixed isotropic thermal parameter. Data collection and refinement 
parameters are summarized in Appendix A.A.1. 
 
 
III.4.4 DNA binding experiments. 
 
III.4.4.1 Competitive ethidium displacement This protocol was designed as a 
high-throughput version of the previously reported method.2 A working solution 
of 20.0 µM UltraPure calf thymus DNA (CT-DNA, Invitrogen 15633-019, ε260 = 
12,824 M (bp)-1 cm-1) along with 25.2 µM ethidium bromide (EtBr) in HEPES 
buffer (80 mM, pH = 7.2) and NaCl (40 mM) was prepared. Stock solutions of 
metal complexes, metal salts, free ligands and groove binding drugs were 
prepared at ~4.0 mM in DMSO and diluted further with ultra-pure water. 50 µL 
of DNA-Et working solution were placed each well of a 96 well microplate with 
the exception of the blanks which contained 100 µL HEPES buffer. Serial 
aliquots of the tested compound were added to the working solutions and the 
volume was adjusted to 100 µL in each well such that the final concentration of 
CT-DNA and EtBr were 10.0 µM and 12.6 µM, respectively. The plate was 
allowed to incubate at room temperature for 1 h before being analysed using a 
Bio-Tek synergy HT multi-mode microplate reader withexcitation and emission 
wavelengths being set to 530 and 590 nm, respectively. Concentrations of the 
tested compounds were optimizedsuch that fluorescence was 30-40% of the 
initial control (i.e. 50 µL working solution + 50 µL HEPES buffer) at their 
highest reading. Each drug concentration was measured in triplicate, on at least 
two separate occasions, and the apparent binding constants were calculated using 
Kapp = Ke x 12.6/C50 where Ke = 9.5 x 106M(bp)-1. 
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Figure III.31	   Competitive ethidium bromide displacement for netropsin, pentamidine, metal 
salts, free ligands and complexes with CT-DNA. 
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III.4.4.2 DNA–ethidium fluorescence quenching This protocol was also 
designed as a high-throughput version of the previously reported method.2 A 
working solution of 50.0 µM UltraPure calf thymus DNA (CT-DNA, Invitrogen 
15633-019,ε260 = 12,824 M (bp)-1 cm-1) along with either 10.0 µM ethidium 
bromide (EtBr) or Hoechst 33258 (Sigma) in HEPES buffer (80 mM, pH = 7.2) 
and NaCl (40 mM) was prepared. Stock solutions of metal complexes, metal 
salts, free ligands and groove binding drugs were prepared at ~4.0 mM in DMSO 
and diluted further with ultra-pure water. 50 µL of DNA-Et or DNA-Hoechst 
working solution were placed each well of a 96 well microplate with the 
exception of the blanks which contained 100 µLHEPES buffer and 5 µM of 
either Hoechst or EtBr. Serial aliquots of the tested compound were added to the 
working solutions and the volume was adjusted to 100 µLin each well such that 
the final concentration of CT-DNA and EtBr/Hoechst were 25.0 µM and 5 µM, 
respectively. The plate was allowed to incubate at room temperature for 5 min 
before being analysed using a Bio-Tek synergy HT multi-mode microplate 
reader with excitation and emission wavelengths being set to 530 and 590 nm for 
Et detection or 360 nm and 460 nm for Hoechst 33258 detection. Concentrations 
of the tested compounds were optimized such that fluorescence was 30-40% of 
the initial control at their highest reading. Each drug concentration was measured 
in triplicate, on at least two separate occasions. From a plot of fluorescence 
versus added drug concentration, the Q value is given by the concentration 
required to effect 50% removal of the initial fluorescence of bound dye. 
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Figure III.32	   Fluorescence quenching (Q) of EtBr-DNA and Hoechst 33258-DNA as a function 
of added test compound. 
 
III.4.5 DNA cleavage experiments 
III.4.5.1 Nuclease activity Reactions were carried out according to the literature 
procedure.3 Briefly, in a total volume of 20 µL using 80 mM HEPES buffer 
(Fisher) at pH 7.2 with 25 mM NaCl, an aliquot of the stock complex (prepared 
in DMSO) was mixed with 400 ng of pBR322 (Roche) and 1 µL of 20 mM Na-
L-ascorbate. Samples were incubated at 37 oC before being quenched with 6x 
loading dye (Fermentas), containing 10 mMTris-HCl (pH 7.6), 0.03% 
bromophenol blue, 0.03% xylene cyanol, 60% glycerol and 60 mM EDTA, then 
loaded onto agarose gel (1%) containing 2.0 µL of GelRedTM (10,000X). 
Electrophoresis was completed at 80 V for 1.5 h using a wide mini-sub cell 
(BioRad) in 1XTAE buffer (Millipore).  
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III.4.5.2 Phenol inhibition studies In order to determine the effect of phenol on 
the cleavage properties of [Cu(phen)2]2+, 5 µM of Cu(phen)2(ClO4)2 (CuPhen) 
was incubated with 1 mM Na-L-Ascorbate in presence of 5 – 100 µM phenol 
(Fig. III.6) as follow: in a total volume of 20 µL using 80 mM HEPES buffer 
(Fisher) at pH 7.2 with 25 mM NaCl, an aliquot of the phenol (prepared in 80 
mM HEPES buffer) was mixed with 400 ng of pBR322, 5 µM of 
Cu(phen)2(ClO4)2 (prepared in DMSO) and 1 µL of 20 mM Na-L-ascorbate. 
Samples were incubated at 37 oC for 30 min before being quenched with 6x 
loading dye (Fermentas), containing 10 mMTris-HCl (pH 7.6), 0.03% 
bromophenol blue, 0.03% xylene cyanol, 60% glycerol and 60 mM EDTA, then 
loaded onto agarose gel (1%) containing 2.0 µL of GelRedTM (10,000X). 
Electrophoresis was completed at 80 V for 1.5 h using a wide mini-sub cell 
(BioRad) in 1XTAE buffer (Millipore).   
	  
Figure III.33	   Cleavage reactions using Cu(phen)2(ClO4)2 with 1 mM Na-L-ascrobate with 
phenol (5 – 100 µM) in the presence of 1 mM added reductant. Lane 1: pUC19 control; lane 2:  
CuPhen; lane 3: CuPhen + 5 µM phenol; lane 4: CuPhen + 10 µM phenol; lane 5: CuPhen+ 20 
µM phenol; lane 6: CuPhen + 40 µM phenol; lane 7: CuPhen + 100 µM phenol 
 
III.5.6 Viscosity experiments 
 
15 mL dsDNA (Deoxyribonucleic acid sodium salt from Salmon Testes, Sigma-
Aldrich, D1626-1G) solution was prepared at 1 x 10-3 M in 80 mM HEPES 
buffer for each working sample. Stock solutions prepared in DMSO were added 
according to the gradual increasing [drug]/[DNA] (r) ratios of 0.02, 0.04, 0.06, 
0.08, 0.10, 0.12, 0.14, 0.16, 0.18 and 0.2. Viscosity values, η, (unit: cP) were 
directly obtained by running 0# spindle in working samples at 60 rpm via DV-II-
Programmable Digital Viscometer equipped with Enhanced Brookfield UL 
Adapter at room temperature. Data were presented as η / ηo versus 
[compound]/[DNA] ratio, in which ηo and η refers to viscosity of each DNA 
working sample in the absence and presence of complex.4 
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III.4.7 Electrochemistry 
III.4.7.1 Experimental: 
Cyclic Voltammetry experiments were performed on a Solartron 1825 
potentiostat. 1mM concentrations of CuPhen and CuPDT were used in all 
experiments and the CV’s were scanned initially in the cathodic direction. The 
working electrode was Glassy Carbon (2mm diameter), the reference was a non-
aqueous Ag/Ag+ (E1/2 = 0.075 V versus Fc/Fc+), and the counter was platinum. 
0.1 M TBAPF6 in DMF was used as the supporting electrolyte. 
III.4.7.2 Results: 
 
	  
Figure III.34	   Typical cyclic voltammograms detailing the redox behaviour of 1 mM CuPhen in 
the presence of 2 mM ascorbate, over a range of scan rates, in 0.1 M TBAPF6/DMF. Glassy 
Carbon working electrode, platinum counter electrode, Ag+/Ag non-aqueous reference electrode. 
 
	  
Figure III.35	   Typical cyclic voltammograms detailing the redox behaviour of 1 mM CuPDT in 
the presence of 2 mM ascorbate, over a range of scan rates, in 0.1 M TBAPF6/DMF. Glassy 
Carbon working electrode, platinum counter electrode, Ag+/Ag non-aqueous reference electrode. 
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Table III.2	   Summary of electrochemical parameters for CuPhen and CuPDT in the absence and 
presence of ascorbate. The redox behaviour of CuPhen is near reversible in the presence of 
ascorbate, ΔEp = 0.065 V. CuPDT remains quasi-reversible in the presence of ascorbate, ΔEp = 
0.119 V. 
Cu	  (I)/(II)	  	  
redox	  couple	  
Ep,a	   Ep,c	   ΔEp	   2mM	  AA,	  
Ep,a	  
Ep,c1	   Ep,c2	   ΔEp	  
Cu(phen)2(ClO4)2	   -­‐‑0.406	   -­‐‑0.514	   0.108	   -­‐‑0.220	   -­‐‑0.285	   -­‐‑0.473	   0.065	  
Cu(PDT)2(ClO4)2	   -­‐‑0.329	   -­‐‑0.458	   0.128	   -­‐‑0.175	   -­‐‑0.294	   -­‐‑0.492	   0.119	  
	  
III.4.7.3 Randles-Sevcik Analysis 
III.4.7.3.1 Cu(phen)2(ClO4)2: 
	  
Figure III.36	   Typical cyclic voltammograms detailing the redox behaviour of 1 mM CuPhen 
over a range of scan rates, in 0.1 M TBAPF6/DMF. Glassy Carbon working electrode, platinum 
counter electrode, Ag+/Ag non-aqueous reference electrode.  
 
 
	  
Figure III.37	   Corresponding Randles-Sevcik Plot, 1 mM CuPhen, the peak currents exhibit a 
linear dependence with the square root of the scan rate. Thus the redox behaviour of CuPhen is 
under diffusion control. 
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III.4.7.3.2 CuPDT 
      	  
Figure III.38	   Typical cyclic voltammograms detailing the redox behaviour of 1 mM CuPDT 
over a range of scan rates, in 0.1 M TBAPF6/DMF. Glassy Carbon working electrode, platinum 
counter electrode, Ag+/Ag non-aqueous reference electrode.  
 
 
 
	  
Figure III.39	  Randles-Sevcik behaviour of CuPDT, indicating a diffusion controlled redox 
regime 
. 
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CHAPTER IV  
Regulating Bioactivity of 
Cu2+ Bis-1,10-Phenanthroline Artificial 
Metallonucleases with Sterically 
Functionalised Pendant Carboxylates 
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IV.1 Abstract 
The synthetic chemical nuclease, [Cu(1,10-phenanthroline)2]2+, has stimulated 
research within metallonuclease development and in the area of cytotoxic 
metallodrug design. Our analysis reveals, however, that this agent is 
“promiscuous” as it binds both dsDNA and protein biomolecules, without 
specificity, and induces general toxicity to a diversity of cell lineages. Here, we 
describe the synthesis and characterisation of small-molecule metallonucleases 
containing the redox-active cation; [Cu(RCOO)(1,10-phen)2]+, where 1,10-phen 
= 1,10-phenanthroline and R = -H, -CH3, -C2H5, -CH(CH3)2 and –C(CH3)3. The 
presence of coordinated carboxylate groups in the complex cation function to 
enhance dsDNA recognition, reduce serum albumin binding and offer control of 
toxicity toward human cancer cells, gram positive and negative bacteria and 
fungal pathogens. The induction of genomic dsDNA breaks (DSBs) were 
identified in ovarian adenocarcinoma cells using immunodetection of γ-H2AX. 
Formate, acetate and pivalate functionalised complexes induced DSBs in a 
higher percentage of cells compared with [Cu(1,10-phen)2]2+ which supports the 
importance of inner-sphere modification toward enhancing targeted biological 
application. 
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IV.2 Introduction  
Small copper-phenanthroline molecules with DNA and RNA recognition 
properties represent important chemotypes capable of abrogating nucleic acid 
sequences through metal-driven oxidative cleavage.1,2 The chemical nuclease, 
[Cu(1,10-phen)2]2+, is a well studied reagent which randomly cleaves nucleic 
acids in the presence of molecular oxygen (or hydrogen peroxide) upon reduction 
to Cu+.3-7 This agent oxidises duplex DNA (dsDNA) without specificity, 
predominately at the minor groove with C-H bonds at C1′, C4′, and C5′ being the 
main targets of abstraction.8 Arising from this application, the attachment, or 
tethering, of 1,10-phen to DNA targeting agents, proteins and single-stranded 
nucleic acid vectors have successfully delivered sequence-specific scission upon 
incubation with Cu2+ ions in a reducing chemical environment.9-14 Furthermore, 
this complex may also have application as a chemical protease with the oxidative 
degradation of peptide bonds having already been reported.15,16 While the 
intracellular metal-chelating ligand, 1,10-phen, is known to elicit excellent in 
vitro antifungal,17,18 antibacterial19 and anticancer activities20 alone, or as part of 
a metal complex,21-24 recent interest has focused on the modification of this 
ligand to afford phenazine-type structures of extended π-symmetry for use within 
metal DNA-binding probes,25,26 some with selective chemotherapeutic utility.27 
The therapeutic potential of Cu2+1,10-phenathroline-based complexes continues 
to be actively explored and the inclusion of inner-sphere, oxygen-donor ligands, 
has recently produced a series of complexes with significant biological 
potential.28-35 For example, the complex [Cu(glycinate)(4,7-dimethyl-1,10-
phenanthroline)(H2O)](NO3) (Cas II-gly, Scheme IV.1) from the “Casiopeina” 
series36 was found to have excellent in vivo cytotoxicity toward glioma C6 
implanted mice with the mechanism being attributed to induction of both 
caspase-dependent and -independent apoptosis.37 Cas II-gly also induced nuclear 
fragmentation through a process linked with the intracellular generation of 
reactive oxygen species (ROS). Another variant of the “Casiopeina” series, 
[Cu(acetylacetonato)(4,4ʹ′-dimethyl-2,2ʹ′-bipyridine](NO3) (Cas III-ia, Scheme 
IV.1), was also found to exert antineoplastic effects on glioma C6.38 In this 
particular study the authors showed that mitogen-activated protein kinase, JNK, 
initiated autophagic and apoptotic pathways through sustained ROS intracellular 
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generation by Cas III-ia. Yet further examples of N,Nʹ′-O,Oʹ′ chelated Cu2+ 
complexes of this therapeutic class include the two reagents, [Cu(o-
phthalate)(1,10-phen)].2(H2O)39 and [Cu(3-methoxysalicylate)(1,10-phen)]40 
(Scheme IV.1), which were developed recently by this group. The o-phthalate 
complex was found to generate high levels of intracellular ROS, bind dsDNA 
and induce genomic dsDNA breaks (DSBs) within ovarian cancer cells (SK-OV-
3) that were identified by γ-H2AX immunofluorescence. Furthermore, the 
methoxysalicylate complex was found to be a potent superoxide dismutase 
mimetic (SODm), but did not exhibit catalase nor COX-1 / COX-2 mimetic 
properties. The proposed net effect here is the generation of an intracellular 
microenvironment rich in hydrogen peroxide (H2O2) that is not further detoxified 
(to O2 or H2O). Contaminant ROS-mediated apoptosis was suspected to follow 
thereafter with the complex displaying promising potential toward a range of 
epithelial malignancies. The final example of the therapeutic potential of this 
class arises from the activity of the dinuclear cytotoxin, [Cu2(µ-
terephthalate)(1,10-phen)4]2+ (Scheme IV.1).41,42 This agent, again, is a potent 
ROS generator that displays in vitro cytotoxicity toward epithelial malignancies 
and also has the capacity to induce oxidative degradation on duplex DNA 
without exogenous reductant.  
 
	  
Scheme IV.1	   Molecular structures of cytotoxic Cu2+ complexes incorporating N,Nʹ′-O,Oʹ′ or 
N,Nʹ′-O,Nʹ′ʹ′ chelators. 
 
Given the recent focus on Cu2+ based cytotoxic agents,43,44 in particular those 
containing coordinated carboxylate or carbonyl ligands,28,29 the current work 
seeks to identify, from a structure-activity perspective, the role that coordinated 
carboxylates have on modulating the biological profile of [Cu(1,10-phen)2]n+ 
based complexes. Thus, in this study we have prepared the cationic series, 
[Cu(RCOO)(1,10-phen)2]+ (where R = -H, -CH3, -C2H5, -CH(CH3)2 and –
C(CH3)3), in order to identify the effect that primary, sterically functionalized, 
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carboxylates have on modulating; (i.) serum albumin binding, (ii.) dsDNA 
binding, (iii.) superhelical and linearised plasmid dsDNA damage and (iv.) broad 
spectrum cytotoxicity toward human cells and pathogenic bacteria and fungi. 
Furthermore, (v.) interactions with hydrogen peroxide by Fenton chemistry, 
which are believed to be fundamental to the induction of ROS-mediated DNA 
damage,45 along with (vi.) the detection of intracellular DSBs on genomic DNA 
within human ovarian cancer cells (SK-OV-3) were examined by γ-H2AX 
antibody immunofluorescence using both confocal microscopy and flow 
cytometry.  
 
IV.3 Results And Discussion 
IV.3.1 Synthesis and characterisation 
Complexes were prepared by firstly isolating the Cu2+ bis-1,10-phen complex, 
[Cu(1,10-phen)2].(NO3)2 (Cu-Phen) via the treatment of copper nitrate with two 
molar equivalents of 1,10-phen in aqueous-ethanol solvent. Treatment of Cu-
Phen with excess sodium salt of the carboxylic acid (RCOO–Na+, R = -H, -CH3, 
-C2H5, -CH(CH3)2 and –C(CH3)3) yielded deep blue methanolic solutions from 
which the agents crystallized upon slow evaporation (Fig. IV.1 and section 
IV.6.1). Each complex contains the molecular cation, [Cu(RCOO)(1,10-phen)2]+, 
where the coordination cation is charge balanced by an anionic nitrate (NO3–), 
with the exceptions of Cu-Pro-Phen where the counterion is carbonate 
(presumably obtained from atmospheric CO2 during crystallization), and Cu-Piv-
Phen, for which the charge is balanced by an uncoordinated pivalate anion. Both 
Cu-Pro-Phen and Cu-Piv-Phen crystallise with two independent cations in the 
asymmetric unit (Appendix A.B.2). Each complex crystallises with a number of 
water solvate molecules in the lattice and Cu-Piv-Phen also contains a molecule 
of pivalic acid. Each cation has irregular geometry, perhaps best described as 
approximately square pyramidal, with N3O basal plane, one of the 
phenanthroline nitrogen donors axial, and a weak interaction with the second 
carboxylate oxygen. Comparison of the coordination geometry (Appendix Table 
A.B.26) shows that in each cation there is one long Cu-N(phen) bond (range 2.17 
– 2.22 Å) and the remaining three are significantly shorter (1.98 – 2.08 Å). The 
angles between the planes of the two phenanthroline units ranges from 62.03(7)° 
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to 88.5(1)°. In each complex the cations are π-stacked into chains and there is an 
extensive hydrogen bonded network involving the anions, the solvate water 
molecules and, in most cases, the coordinated carboxylate. The exception is Cu-
Piv-Phen, in which the cation is not included in the hydrogen bonding. Further 
details on each structure are given in the supplementary data. High-resolution 
ESI mass spectra of all complexes (section 3.6.2. and Appendix A.B.3) revealed 
parent m/z peaks of the bis-phen cation, [Cu(RCOO)(1,10-phen)2]+ ([M]+), with 
the base peak in each spectra corresponding to the equivalent mono-phen, 
cationic species, [Cu(RCOO)(1,10-phen)]+. IR spectroscopy (Appendix A.B.1) 
also confirmed each compound to contain vibrational peaks characteristic of 
coordinated aromatic imines and carboxylate ligands.46  
 
The electronic spectra of the carboxylate complexes are characteristic of the 
Cu-Phen spectrum (Fig. IV.2), with the presence of coordinated carboxylate 
groups conferring modest additional absorption intensity (ε) to the λd-d band. 
Furthermore, the electronic spectra of the phenanthroline complexes are 
distinctive compared to the simple Cu2+ nitrate salt, Cu(NO3)2, and metal-free 
1,10-phen. The redox behavior of the complexes was investigated, using cyclic 
voltammetry, in the presence and absence of exogenous reductant (Na-L-
ascorbate) (Table IV.1). In the absence of reductant, none of the complexes 
display reversibility and the presence of coordinated carboxylates results in 
larger Cu2+/Cu+ redox couple separation (∆EP ≥ 113 mV) when compared with 
Cu-Phen (∆EP = 75 mV). Addition of 2 mM ascorbate results in a significant 
anodic shift in the Cu2+/Cu+ redox couple of all complexes, indicative of a more 
facile electron transfer regime. While Cu-Phen and Cu-Pro-Phen complexes 
tend toward reversibility in the presence of ascorbate (∆EP = 69 and 66 mV, 
respectively), the remaining carboxylate complexes remain quasi-reversible with 
∆EP values of ≥ 98 mV. Electrochemical and electronic absorption properties of 
all complexes were investigated over a prolonged periods of time in order to 
examine their solution stability (section IV.6.4. and IV.6.5.). Negligible changes 
in redox behaviour and absorption maxima and intensity were observed for all 
samples and there was no evidence that complex breakdown to [Cu(1,10-
phen)]2+ or [Cu(1,10-phen)2]2+ had occurred.   
 
	  96	  
     
     
     
Cu-For-Phen Cu-Ace-Phen Cu-Pro-Phen Cu-Iso-Phen Cu-Piv-Phen 
Figure IV.40	   Molecular structures of the [Cu(RCOO)(1,10-phen)2]+ cations (top), single X-ray 
crystal structures of the complexes (centre), and perspective space-filled views of the five cations 
(bottom). 
 
Table IV.1 Electrochemical parameters (V) for complexes in the absence and presence of added 
reductant (2 mM Na-L-ascorbate). Analysis conducted in 10% v/v DMF.	  
Complex	  	   EPa[a]	   EPc[a]	   ∆EP[a]	   EPa[b]	   EPc[b]	   ∆EP[b]	  
Cu-­‐Phen	   -­‐0.041	   -­‐0.116	   0.075	   -­‐0.019	   -­‐0.088	   0.069	  
Cu-­‐For-­‐Phen	   -­‐0.036	   -­‐0.149	   0.113	   0.290	   0.180	   0.110	  
Cu-­‐Ace-­‐Phen	   -­‐0.314	   -­‐0.121	   0.193	   0.275	   0.171	   0.104	  
Cu-­‐Pro-­‐Phen	   -­‐0.143	   -­‐0.328	   0.185	   0.244	   0.178	   0.066	  
Cu-­‐Iso-­‐Phen	   -­‐0.194	   -­‐0.359	   0.165	   0.278	   0.180	   0.098	  
Cu-­‐Piv-­‐Phen	   -­‐0.146	   -­‐0.411	   0.265	   0.303	   0.186	   0.117	  
                            [a] complex without exogenous agent (V) [b] complex with added Na-L-ascorbate (V) 
 
O
O
Cu
N
N
N
N
O
O
Cu
N
N
N
N
O
O
Cu
N
N
N
N
O
O
Cu
N
N
N
N
O
O
Cu
N
N
N
N
	  97	  
	  
Figure IV.41	   Electronic spectra of selected metal complexes recorded in 100% methanol at 5 
mM complex or metal salt concentrations with λd-d maxima indicted; Cu(NO3)2 (····), Cu-Phen 
(– –) and Cu-Piv-Phen (—). 
 
IV.3.2 Binding affinity toward bovine serum albumin and calf thymus DNA 
Tryptophan fluorescence quenching of bovine serum albumin (BSA, 0.015 mM) 
was examined at 37°C using a 295 nm excitation and 350 nm emission 
wavelength with measurements being recorded 5 min post exposure to the tested 
agent ([Q], 1 - 50 µM). Simple Cu2+ ions, from Cu(NO3)2, and the bis-phen 
complexes all display upward-curving, non-linear Stern-Volmer, fluorescence 
quenching (Fig. IV.3). Data could be suitably modeled using a quenching 
‘Sphere-of-Action’ plot (Fig. IV.3 and Table IV.2) that accounts for immediate 
quenching of the fluorophore by the presence of a quencher molecule within a 
sphere of volume (V).47 Cu2+ ions display the highest affinity for BSA with Ksv 
(Stern-Volmer quenching constant for the accessible fraction) and KA (binding 
constant) being 1.02 x 105 M-1 and 4.23 x 104 M-1, respectively. The KA values 
and r (radius of sphere) for the complexes decrease in accordance with steric 
bulk of the coordinated carboxylates with the Cu-Piv-Phen complex displaying 
the lowest affinity of all toward BSA and being nearly an order of magnitude 
lower than free Cu2+ ions. Metal-free 1,10-phen displays linear Stern-Volmer 
quenching (Fig. VI.3) with quenching coefficient of 2.01 x 104 M-1 along with 
KA of 2.54 x 104 M-1. Analysis also revealed the average number of occupied 
tryptophan sites (from a maximum of 2) within BSA by these compounds; Cu2+ 
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ions interact with 1.48 TRP residues with the carboxylate complexes occupying 
between 1.20 - 1.38 residues (n = 1.20 for Cu-Piv-Phen. 
   
   
  
 
Figure IV.42	   BSA tryptophan fluorescence quenching for Cu2+ ions, 1,10-phen along with the 
carboxylate complexes. Cu2+ complexes display non-linear quenching (solid circles) and are 
modeled using a quenching ‘Sphere-of-Action’ (open circles) with data points being displayed as 
an average of triplicate measurement. 
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Table IV.2	  BSA tryptophan fluorescence quenching by Cu2+ ions, 1,10-phen and complexes.	  
Compound	   KSV	  x	  104	  M-­‐1	   V	  x	  104	  M-­‐1	   r	  (Å)	   n	   KA	  x	  104	  M-­‐1	   R2	  
Cu2+	   10.22	   2.50	   206	   1.48	   4.23	   0.99	  
1,10-­‐Phen	   2.01	   -­‐	   -­‐	   0.79	   2.54	   0.99	  
CuPhen	   1.75	   2.20	   215	   1.15	  	   2.83	   0.97	  
Cu-­‐For-­‐Phen	   1.77	   1.10	   164	   1.26	   1.26	   0.99	  
Cu-­‐Ace-­‐Phen	   2.53	   1.10	   164	   1.31	   1.13	   0.98	  
Cu-­‐Pro-­‐Phen	   2.52	   1.00	   158	   1.26	   1.32	   0.99	  
Cu-­‐Iso-­‐Phen	   1.99	   1.00	   158	   1.28	   1.04	   0.99	  
Cu-­‐Piv-­‐Phen	   1.22	   0.90	   153	   1.20	   0.93	   0.98	  
        n = number of occupied binding sites; KA = binding constant; KSV = Stern-Volmer quenching of accessible fraction; 
          R2 = goodness of fit; V = sphere of action volume; r = radius of sphere (Å); Cu2+ = Cu(NO3)2; 
          CuPhen =  [Cu(1,10-phen)2](ClO4)2; 
Sphere-of-action: 
 
N´ = Avogadro’s number / 1000 
 
Sphere-of-action plot: 
 
Complex binding to dsDNA was studied using competitive ethidium bromide 
(Et+) fluorescence displacement on ctDNA (calf-thymus, ultra-high purity) with 
further quenching analysis of Hoechst 33258 (groove binder) and Et+ 
(intercalator) revealing binding mode data. For these assays high-throughput, 96-
well plate methods were conduced using assays we recently reported.48 The 
competition assay utilizes an optimized mixture of ctDNA (10 µM in DNAp) and 
EtBr (12.6 µM) which was incubated for 1 h with added quencher ([drug]) in a 
total volume of 100 µL (Fig. IV.4) while a mixture of ctDNA (25 µM in DNAp) 
and either Hoechst 33258 or EtBr (5 µM) was incubated with added drug in the 
quenching study (Fig. IV.5). Measurements were conducted using excitation and 
emission filters of 530 and 590 nm for Et+ and 360 and 460 nm for Hoechst. The 
quenching by Cu2+ ions and 1,10-phen did not reach 50% up to 300 µM and thus 
these agents had weak apparent DNA binding constants (Kapp, Table IV.3A). 
Coordination of Cu2+ to bis-1,10-phen in the Cu-Phen complex induces a 
marked enhancement in DNA binding (Kapp = 6.67 x 105)48 with the agent 
displacing bound ethidium to higher degree than Hoechst (Table IV.3B). The 
Kapp values for the carboxylate complexes are significantly enhanced, by at least 
10-fold, relative to Cu-Phen and increase with steric bulk of the ancillary ligand. 
Cu-Piv-Phen displays the highest DNA affinity (8.26 x 106), greater even than 
the established groove-binding agents netropsin and pentamidine under these 
conditions (pH = 7.2). Quenching analysis (Figure IV.5, Table IV.3B) reveals all 
complexes displace DNA-bound Et+ with higher specificity than Hoechst, 
V
N ' =
4
3πr
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however, Q values between Et+ and Hoechst are relatively small compared with 
netropsin and pentamidine that have high specify for the minor groove.49 Thus, 
while the presence of coordinated carboxylates function to significantly enhance 
quenching relative to Cu-Phen, it appears the binding region of these small 
molecules is unselective. Viscosity measurements, on salmon testes dsDNA (1 
mM in DNAp), were conducted under identical buffered conditions as the 
fluorescence quenching and displacement assays (Fig. IV.6 and Table IV.3C). 
Results for the minor groove binding agent, pentamidine, and intercalating agent, 
ethidium bromide, displayed expected behavior with a decrease and significant 
increase in viscosity being observed, respectively. Furthermore, the partial 
intercalating agent Cu2+ mono-1,10-phenanthroline, [Cu(1,10-phen)]2+, exhibited 
hydrodynamic behavior between these two standard regents. Cu-Phen, and all of 
the carboxylate complexes strongly exhibited intercalative profiles and there was 
a notable overlap between viscosity measurements and ethidium quenching 
(Table IV.4B and IV.3C) with complexes of enhanced viscosity displaying 
higher quenching of bound ethidium. Overall, the acetate, propanoate and 
pivalate complexes appear to deliver a greater degree of intercalative penetration 
compared with Cu-Phen.   
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Figure IV.43 Competitive fluorescence quenching of ethidium bromide (12.6 µM) bound to 
ctDNA (10 µM in DNAp) by DNA binding drugs, Cu2+ and metal complexes. Data points 
displayed as an average of triplicate measurement. 
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Figure IV.44	   Fluorescence quenching of bound intercalator (ethidium) or minor groove binder 
(Hoechst 33258) to ctDNA by minor groove binding drugs, pentamidine and netropsin along and 
metal complexes. Data points are displayed as an average of triplicate measurement. 
 
 
 
Figure IV.45	  Viscosity data from the complexes, standard DNA binding agents and the partial 
intercalator [Cu(1,10-phen)]2+.  
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Table IV.3	   A. Apparent ctDNA binding constants (Kapp) determined using competitive ethidium 
bromide competitive quenching, B. fluorescence quenching (Q) values obtained against ctDNA 
bound with Hoechst 33258 (groove binder) or ethidium bromide (intercalator), and C. relative 
viscosity at r = 0.20 using dsDNA from salmon testes.  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  A.	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  B.	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  C.	  
Compound	   	   C50*	  
(µM)	  
Kapp**	  (M-­‐1)	   Q***	  
Hoechst	  	  
33258	  (µM)	  
Q***	  
Ethidium	  	  
Bromide	  
(µM)	  
η/ηo†	  
Cu2+	   	   >300	   N/A	   -­‐	   -­‐	   -­‐	  
1,10-­‐Phen	   	   >300	   N/A	   -­‐	   -­‐	   -­‐	  
Cu-­‐Phen48	   	   179.21	   6.67	  x	  105	   34.96	   20.38	   1.174	  
Cu-­‐For-­‐Phen	   	   18.66	   6.41	  x	  106	   28.05	   19.10	   1.161	  
Cu-­‐Ace-­‐Phen	   	   16.49	   7.20	  x	  106	   25.2	   16.97	   1.205	  
Cu-­‐Pro-­‐Phen	   	   15.39	   7.77	  x	  106	   26.38	   16.97	   1.204	  
Cu-­‐Iso-­‐Phen	   	   15.70	   7.62	  x	  106	   25.57	   18.70	   1.136	  
Cu-­‐Piv-­‐Phen	   	   14.48	   8.26	  x	  106	   25.5	   17.33	   1.198	  
Netropsin48	   	   39.99	   4.77	  x	  106	   3.50	   35.98	   1.007	  
Pentamidine48	   	   109.41	   1.09	  x	  106	   35.86	   >150	   0.987	  
                  *C50 = concentration required to reduce fluorescence by 50%; Cu2+ = Cu(OAc)2;  
                   CuPhen =  [Cu(1,10-phen2)](ClO4)2; **Kapp = Ke x 12.6/C50  
                   where Ke = 9.5 x 106 M (bp)-1; N/A = not applicable;  
                   ***Q = displacement of 50% initial fluorescence from DNA-bound dye.  
                   † relative viscosity at r = 0.20. 
 
IV.3.3 In vitro cytotoxicity 
To examine the broad-spectrum chemotherapeutic properties within this class, a 
range of cytotoxicity experiments were conducted with human cancer cells of the 
prostate (PC3), ovaries (SK-OV-3) and non-cancerous prostate (immortalised 
PNT1A) (Fig. IV.7 and Table IV.4). A range of gram positive (SA, 
Staphylococcus aureus; MRSA; methicillin resistant Staphylococcus aureus; SE, 
Staphylococcus epidermidis; EF, Enterococcus sp.) and gram negative (EC, 
Escherichia coli; KP, Klebsiella pneumonia; KP-E, Klebsiella pneumonia; PA, 
Pseudomonas aeruginosa) bacteria were also examined (Fig. IV.8 and Table 
IV.5) along with an extensive range of pathogenic fungi (CA1, Candida albicans 
ATCC 44859; CA2, Candida albicans ATCC 90028; CA3, Candida parapsilosis 
ATCC 22019; CK1, Candida krusei ATCC 6258, and clinical yeast isolates 
CK2, Candida krusei E28; CT, Candida tropicalis 156; CG, Candida glabrata 
20/I; CL, Candida lusitaniae 2446/I; TA, Trichosporon asahii 1188, along with 
filamentous fungi AF, Aspergillus fumigatus 231; AC, Absidia corymbifera 272; 
TM, Trichophyton mentagrophytes 445) (Fig. IV.9 and Table IV.6).  
The chemotherapeutic drug cisplatin and 1,10-phen displayed no activity, up to 
200 µM, over 24 h when tested in human cell lines, however, both agents were 
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active over 96 h with IC50 values ranging 1.0 - 4.5 µM (cisplatin) and 2.4 – 4.7 
µM (1,10-phen). CuPhen displayed higher 24 h activity within PC3 than at 96 h 
(1.1 µM versus 15.2 µM) while its 96 h IC50 in PNT1A and SK-OV-3 were 1.8 
µM and 0.6 µM, respectively. The presence of carboxylate groups were found to 
significantly modulate the 24 h cytotoxicity within PC3 and PNT1A with bulkier 
ligands markedly enhancing the IC50 response across the series (Cu-Piv-Phen; 
PC3 = 3.2 µM, PNT1A = 14.5 µM). The Cu2+ complexes were unanimously 
more active, at both 24 and 96 h, within platinum-resistant ovarian cancer cells 
(SK-OV-3) when compared with PC3 and PNT1A cells.  
 
The antibacterial values (MIC95) of the compounds were examined at 24 and 48 
h and against a wide range of microbes. 1,10-phen displayed low or no activity 
among the gram positive and negative bacteria, with the exception of 
Enterococcus where an MIC95 of 62.5 µM was recorded. The most active species 
against all bacterial strains was Cu-Iso-Phen with MIC95 values ranging 15.60 – 
31.25 µM (except on P. aeruginosa). Remarkably, the least active agent was the 
next complex in the series, Cu-Piv-Phen, which was significantly less cytotoxic 
than all other complexes with MIC95 ranging between 62.5 – 1000 µM.  
 
In contrast to its antibacterial properties, the antifungal activity of metal-free 
1,10-phenathroline surpassed all of the tested metal complexes and ranged 
consistently between 7.81 – 15.61 µM across both filamentous and non-
filamentous lineages. This result is in broad agreement with previous findings of 
this group and others.18 Indeed, the activity of this chelator is attributed to the 
sequestering of essential intracellular trace metals (e.g. Zn2+), which seriously 
impedes the survival of fungal pathogens. Cu-Phen was also found to be 
consistently cytotoxic across this complete fungal panel (MIC80 range: 7.81 – 
31.25 µM) while Cu-Pro-Phen was remarkably less toxic to all isolates (MIC80 = 
250 µM). The overall trend of the antifungal activities appears to be somewhat 
Gaussian in shape; activity decreases going from 1,10-phen to Cu-Pro-Phen 
before an increase in the antimycotic effects of the bulkier carboxylate 
complexes, Cu-Iso-Phen and Cu-Piv-Phen, becomes evident.    
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Figure IV.46 IC50 data (at the 95% confidence interval) of metal complexes, 1,10-phen and 
cisplatin toward human cancer cells of the prostate (PC3), ovaries (SK-OV-3), non-cancerous 
prostate (PNT1A) post 24 h and 96 h exposure.       
 
 
 
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
0
10
20
30
100
150
200
IC
50
 [µ
M
]
PC3
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
0
10
20
30
100
150
200
IC
50
 [µ
M
]
PNT1A
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
24
 h
96
 h
0
10
20
30
100
150
200
IC
50
 [µ
M
]
SK-OV-3
1,10-PhenCisplatin Cu-For-Phen
Cu-Ace-Phen Cu-Pro-Phen Cu-Iso-Phen Cu-Piv-Phen
CuPhen
	  106	  
 
 
	  
Figure IV.47	   MIC95 data of metal complexes and 1,10-phen toward a range of gram positive and 
negative bacteria post 24 h or 48 h exposure (note: both 24 h and 48 h activities were identical). 
SA, Staphylococcus aureus; MRSA, methicillin resistant Staphylococcus aureus; SE, 
Staphylococcus epidermidis; EF, Enterococcus sp.; EC, Escherichia coli; KP, Klebsiella 
pneumonia; KP-E, Klebsiella pneumonia; PA, Pseudomonas aeruginosa.    
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Figure IV.48	   MIC data of metal complexes and 1,10-phen toward a range of pathogenic fungi 
post 24 h or 48 h exposure to non-filamentous fungi and post 72 h or 120 h exposure to 
filamentous fungi  (note: both 24 h / 48 h and 72 h / 120 h activities were identical). CA1, 
Candida albicans ATCC 44859; CA2, Candida albicans ATCC 90028; CA3, Candida 
parapsilosis ATCC 22019; CK1, Candida krusei ATCC 6258, clinical yeast isolates CK2, 
Candida krusei E28; CT, Candida tropicalis 156; CG, Candida glabrata 20/I; CL, Candida 
lusitaniae 2446/I; TA, Trichosporon asahii 1188, and filamentous fungi AF, Aspergillus 
fumigatus 231; AC, Absidia corymbifera 272; TM, Trichophyton mentagrophytes 445.  
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Table IV.4 In vitro cytotoxicity data for complexes, Cu2+ ions, 1,10-phen and cisplatin toward 
human derived cancer and non-cancers cells. 
Compound	   IC50	  (µM)	  
	   PC3	   PNT1A	   SKOV3	  
	   24	  h	   96	  h	   24	  h	   96	  h	   24	  h	   96	  h	  
Cu2+	   >200	   >200	   >200	   >200	   >200	   >200	  
Cisplatin	   >200	   1.30±0.23	   >200	   1.07±0.37	   121.00±0.37	  	   4.53±0.43	  
1,10-­‐Phen	   >200	   4.52±0.32	   >200	   2.67±0.23	   >200	   2.79±0.37	  
CuPhen	   1.10±2.68	   15.20±6.74	   51.14±14.13	   1.82±0.86	   2.91±0.33	   0.61±0.00	  
Cu-­‐For-­‐Phen	   >200	   4.32±1.14	   52.01±7.02	   1.98±0.23	   2.88±0.14	   1.41±0.07	  
Cu-­‐Ace-­‐Phen	   >200	   5.41±3.01	   75.02±30.29	   1.51±0.18	   3.04±0.19	   2.05±0.14	  
Cu-­‐Pro-­‐Phen	   26.09±1.56	   2.25±0.22	   27.60±11.37	   2.62±0.66	   3.02±0.10	   2.07±0.19	  
Cu-­‐Iso-­‐Phen	   52.00±12.70	   2.31±0.08	   23.89±3.74	   2.05±0.07	   2.86±1.36	   1.91±0.09	  
Cu-­‐Piv-­‐Phen	   3.26±4.34	   3.96±1.45	   14.56±2.44	   1.90±0.21	   3.59±0.10	   1.78±0.05	  
                                                          Cu2+ = CuCl2; CuPhen = [Cu(1,10-phen)2](NO3)2 
 
Table IV.5 In vitro cytotoxicity data for complexes, Cu2+ ions and 1,10-phen toward gram 
positive and negative bacteria.  
 
Cu2+ = CuCl2; CuPhen = [Cu(1,10-phen)2](NO3)2; *24 h and 48 h MIC95 activities were identical in each test; MIC95 values 
for all complexes against PA were 2000  
 
Compound	   MIC95	  (µM)	   	  
	   Gram	  positive	   Gram	  negative	  
	   SA	   MRSA	   SE	   EF	   EC	   KP	   KPE	   PA	  
	   *24	  h	  /	  48	  h	  
Cu2+	   2000	   2000	   2000	   2000	   2000	   2000	   2000	   >2000	  
1,10-­‐Phen	   125	   500	   1000	   62.5	   2000	   1000	   1000	   2000	  
CuPhen	   31.25	  	   15.62	   62.5	   15.62	   62.5	   62.5	   62.5	   >1000	  
Cu-­‐For-­‐Phen	   31.25	   31.25	   62.5	   31.25	   62.5	   62.5	   62.5	   >1000	  
Cu-­‐Ace-­‐Phen	   31.25	   31.25	   31.25	   15.62	   125	   62.5	   62.5	   >1000	  
Cu-­‐Pro-­‐Phen	   31.25	   15.62	   125	   15.62	   125	   125	   125	   >1000	  
Cu-­‐Iso-­‐Phen	   15.62	   15.62	   31.25	   15.62	   31.25	   31.25	   31.25	   1000	  
Cu-­‐Piv-­‐Phen	   62.5	   62.5	   250	   250	   125	   500	   1000	   >1000	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Table IV.6 In vitro cytotoxicity data for complexes, Cu2+ ions and1,10-phen toward filamentous and non-filamentous pathogenic fungi.    	  
	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  MIC80	  (µM)	   MIC50	  (µM)	  
	   Non-­‐filamentous*	   	   Filamentous**	  
Compound	   	   CA1	   CA2	   CA3	   CK1	   CK2	   CT	   CG	   CL	   TA	   AF	   AC	   TM	  
	   	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  24	  h	  /	  48	  h	  
Cu2+	   	   2000	   2000	   2000	   2000	   2000	   2000	   2000	   2000	   2000	   2000	   	  	  	  	  	  2000	   2000	  
1,10-­‐Phen	   	   7.81	   7.81	   15.62	   7.81	   7.81	   31.25	   7.81	   15.62	   7.81	   15.62	   15.62	   7.81	  
CuPhen	   	   15.62	   15.62	   15.62	   7.81	   15.62	   31.25	   15.62	   7.81	   15.62	   31.25	   31.25	   15.62	  
Cu-­‐For-­‐Phen	   	   15.62	   31.25	   62.50	   15.62	   15.62	   62.50	   62.50	   15.62	   31.25	   62.50	   62.50	   31.25	  
Cu-­‐Ace-­‐Phen	   	   15.62	   15.62	   15.62	   15.62	   15.62	   62.50	   31.25	   7.81	   15.62	   31.25	   31.25	   62.50	  
Cu-­‐Pro-­‐Phen	   	   250	   250	   250	   250	   250	   250	   250	   250	   250	   250	   250	   250	  
Cu-­‐Iso-­‐Phen	   	   15.62	   31.25	   31.25	   15.62	   15.62	   31.25	   31.25	   15.62	   15.62	   31.25	   31.25	   31.25	  
Cu-­‐Piv-­‐Phen	   	   15.62	   31.25	   31.25	   15.62	   15.62	   62.50	   31.25	   7.81	   31.25	   62.50	   15.62	   31.25	  
                                       Cu2+ = CuCl2; CuPhen = [Cu(1,10-phen)2](NO3)2; *24 h and 48 h MIC80 values were identical in each test; **72 h and 120 h MIC50 values were identical in each test
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IV.3.4 Artificial metallonuclease activity    
The artificial metallonuclease activity of the complexes was studied using both 
supercoiled (SC) and linearized dsDNA. None of the complexes cleaved 
superhelical plasmid DNA (pBR322; Roche (Cat. 10481238001) or NEB (Cat. 
N3033L)) when incubated for up to 10 hours. SC pBR322 was degraded, 
however, in the presence of exogenous reductant (Na-L-ascorbate) or oxidant 
(H2O2) (Fig. IV.10 A and B). In these experiments 400 ng of SC DNA was 
incubated with 2.5 – 20.0 µM of tested complex, along with 1 mM of exogenous 
substance, for 30 min before being quenched and examined using agarose gel 
electrophoresis. Simple Cu2+ ions had no effect on the plasmid under these 
conditions (data not shown). With added reductant, Cu-Phen was the most 
efficient cleavage agent; almost complete conversion from SC (Form I) to nicked 
(Form II, open circular, OC) form at 5 µM was observed with linear 
conformation (Form III) being generated at 10 and 20 µM. Furthermore, the 
presence of 20 µM of Cu-Phen was found to completely depredate DNA as 
evidenced by laddering of the FIII band. The carboxylate complexes also induce 
significant degradation of SC DNA with added reducant at 10 and 20 µM with 
nuclease activity at lower concentrations not being evident. Propinoate, 
isobutyrate and pivalate complexes can be described as the more active within 
the functionalised series owning to the amount of Form I DNA remaining after 
10 µM of exposure in addition to the relative amount of Form III at 20 µM (Fig. 
IV.10 A). Cu-Phen was again the most active species in the presence of 
exogenous oxidant (Fig. IV.10 B) although it was obvious that reductant is more 
influential, overall, in the cleavage reactions. The propinoate, isobutyrate and 
pivalate complexes were again the most active carboxylate-containing nucleases 
with exogenous H2O2 as evidenced by the amount of Form I remaining at the 
highest exposure level (20 µM). Linearized pBR322, generated using the 
endonuclease EcoRI then purified using anion exchange column chromatography 
(Qiagen, section IV.6.3 for protocol), was subsequently examined as a substrate 
for artificial metallonuclease activity. Interestingly, it was found that this 
conformation of DNA was more susceptible to degradation by Cu2+ bis-phen 
complexes (5 µM) (Fig. IV.10 C). In order to study the mechanism of DNA 
degradation on linearised DNA a series of trapping species were added to the 
reactions (Fig. IV.10 D – G). The trapping of hydrogen peroxide generated by 
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the addition of 1000 units of catalase enzyme (Fig IV.10 D) and the cuprous 
(Cu+) species through the introduction of 100 µM of neocuproine (Fig IV.10 G) 
were found to almost completely inhibit the cleavage of linearised dsDNA. 
Furthermore, it appears the cleavage mechanism is also dependent, somewhat, on 
the production of superoxide (O2−) and the hydroxyl radical (OH) as the addition 
of bovine superoxide dismutase (1000 units) and the hydroxyl radical scavenger, 
DMSO (10% v/v) were found to hinder the cleavage reactions somewhat (Fig 
IV.10 E and F).    
   
	  
Figure IV.49	   Degradation of superhelical pBR322 with Cu2+ complexes, using 2.5, 5.0, 10.0 and 
20.0 µM of tested agent (from left to right), in the presence of A. 1 mM Na-L-ascorbate and B. 1 
mM H2O2. Reactions were carried out using 400 ng of pBR322 plasmid DNA for 30 min at 37 ºC 
in 80 mM HEPES at pH 7.2 with 25 mM NaCl before being quenched and analysed using 
agarose gel electrophoresis. Degradation of linearized pBR322 (by EcoRI) in C. with 5 µM of 1. 
CuPhen, 2. Cu-For-Phen, 3. Cu-Ace-Phen, 4. Cu-Pro-Phen, 5. Cu-Iso-Phen and 6. Cu-Piv-
Phen; D. + 1000 Units of Catalase; E. + 1000 Units of SOD; F. + 10% v/v DMSO, and; G. + 100 
µM neocuproine.   
 
IV.3.5 Interactions with H2O2 
The importance of hydrogen peroxide in the cleavage mechanism of dsDNA 
(Fig. IV.8D) is believed to arise from superoxide dismutase mimetic (SODm) 
activity (eq. 1 and 2) which is followed thereafter by the Fenton reaction (eq. 3). 
Thus, H2O2 is both generated and transformed to the hydroxyl radical (OH), 
which is capable of C−H deoxyribose bond activation, by Cu+/Cu2+ catalysis at 
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the DNA interface.1 Furthermore, this group and others have published on the 
excellent SOD mimetic properties of Cu2+ bis-phenanthroline complexes. 40,50 
 
SOD: 
Cu2+  +  O2−  →  Cu+  +  O2  (eq. 1) 
Cu+  +  O2− +  2H+ →  Cu2+  +  H2O2 (eq. 2) 
Fenton: 
Cu+  +  H2O2  →  Cu2+  + OH  +  OH− (eq. 3) 
 
The interactions of all complexes with 5 µM of hydrogen peroxide (H2O2) was 
followed using the Amplex Red assay (Invitrogen). In this assay the 
concentration of peroxide was detected fluorometrically, in the presence of 
horseradish peroxidase, using 530 nm excitation and 590 nm emission (Fig. 
IV.11 A). All complexes had no effect on H2O2 in the absence of exogenous 
reductant (Na-L-ascorbate) (data not shown). However, in the presence of 100 
µM of Na-L-ascorbate, peroxide degradation was identified kinetically over a 2 h 
window (Fig. IV.11 B). The most active complex, CuPhen, reduced the H2O2 
concentration by almost 50% at ~19 min while the bulkier carboxylate 
derivatives (Cu-Pro-Phen, Cu-Iso-Phen and Cu-Piv-Phen) induced 50% 
degradation between 40 – 45 min with the remaining two reagents, Cu-For-
Phen and Cu-Ace-Phen, ablating 50% of H2O2 fluorescence at ~53 and ~63 min 
respectively. It is significant to note the strong correlation between the artificial 
metallonuclease activity (Fig. IV.11 A and B) and Fenton-type breakdown of 
H2O2 in this overall series. 
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Figure IV.50	   A. Standard fluorescence response curve from H2O2 detected using the Amplex 
Red assay (Invitrogen) using 530 nm excitation and 590 nm emission; B. Fenton breakdown of 
H2O2 (5 µM) over a period of 120 min in the presence of Cu2+ complexes (5 µM in EtOH) and 
100 µM of Na-L-ascorbate.  	  
	  
IV.3.6 Induction of dsDNA breaks in SK-OV-3 cells 
Double strand DNA breaks (DSBs) were identified using immunodetection of γ-
H2AX foci in SK-OV-3 cells exposed for 24 h to an IC25 dose of cisplatin and 
the carboxylate-derivatised complexes and were compared to a non-drug treated 
control. It should be noted that while the IC25 for the Cu2+ complexes against SK-
OV-3 are all quite similar (0.78 – 1.78 µM), a much higher concentration of 
cisplatin (25.65 µM) was required to induce the IC25 response in this cell line. 
After double-strand break induction, formation of γ-H2AX foci due to 
phosphorylation at Ser-139 of histone H2AX represents an early event of DNA 
damage response to DSBs.51 These foci represent DSBs in a 1:1 manner and thus 
can be used as an excellent biomarker for the repair process to DNA damage.52 
The detection and visualization of γ-H2AX by flow cytometry allow the 
assessment of DNA damage, related DNA damage proteins and DNA repair. γ-
H2AX therefore has application in detecting genomic damage caused by 
cytotoxic chemical agents, especially in the context of cancer treatment and 
therapy.53 γ-H2AX foci were visualised by confocal microscopy (Fig. IV.12) 
with nuclei being shown in red (propidium iodide (PI) staining, 543 nm 
excitation) and DSBs being shown in green (primary antibody, anti-phospho-
histone H2A.X, 488 nm excitation). Foci could clearly be visualised in the cells 
treated with cisplatin and the complexes when compared to the untreated control. 
Interstrand crosslinking (ICL) agents, such as cisplatin, are known to stimulate 
the DNA repair pathway that initiates dual incisions on either side of one arm of 
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the crosslink, releasing the covalent linkage between the two DNA strands.54 
ROS active metallo-drugs with DNA binding properties have also been 
purported to inducing DSBs due to free radical DNA oxidation.39 All Cu2+ 
complexes examined in this series displayed foci due to DSBs that could be 
visualised by confocal microscopy (Fig. IV.12). In order to quantify DSBs 
through γ-H2AX fluorescence, flow cytometry analysis was employed (Fig. 
IV.13). Mean intensity fluorescence (MIF) analysis of γ-H2AX positive nuclei 
showed CuPhen as producing the highest intensity foci, however, these foci 
were present only within a relatively low proportion of cells (~11%). Of the 
carboxylate complexes examined, the formate, acetate and pivalate complexes 
(Cu-For-Phen, Cu-Ace-Phen and Cu-Piv-Phen), displayed both high MIF 
values and were present in a significant proportion of cells (46%, 24% and 17% 
respectively). The least active agent, overall, was Cu-Pro-Phen while cisplatin 
displayed both high MIF and percentage positive γ-H2AX cells. It is highly 
significant, however, that the Cu2+ 1,10-phen complexes were examined at a far 
lower, >25 times lower in some instances, than this clinical therapeutic. 
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Negative  Control  
  
Cisplatin  (25.65  µM)    
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Cu-­Piv-­Phen  (1.71  µM)  
  
  
  
Figure IV.51	   Confocal microscopy images of γ-H2AX foci (green) within propidium iodide 
stained SK-OV-3 nuclei (red) after 24 h of drug treatment at the IC25 level (indicated in µM). 
 
 
  
Figure IV.52	   Mean intensity fluorescence ± SD, in arbitrary units, of γ-H2AX fluorescence in 
SK-OV-3 cells (left) and percentage of overall γ-H2AX positive SK-OV-3 cells (± SD) (right).   
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IV.4 Conclusion  
The coordination of sterically functionalised carboxylate groups to the cation, 
[Cu(1,10-phenanthroline)2]2+, enhances dsDNA binding by at least 10-fold, and 
the activity increases with steric bulk of the ancillary ligand with the pivalate 
complex, Cu-Piv-Phen, displaying the highest binding constant (Kapp = 8.26 x 
106 M-1 (bp)). Conversely, the bovine serum albumin (BSA) binding constant 
decreases with steric bulk and thus, Cu-Piv-Phen displayed the lowest affinity 
(KA = 0.94 x 104 M-1) to this protein.  
 
The presence of carboxylate groups were found to enhance cytotoxicity within 
human prostate cancer cells (PC3) and immortalised, non-cancerous prostate 
epithelial cells (PNT1A) over 24 hours, with the bulkier ligands markedly 
enhancing the IC50 response (e.g. Cu-Piv-Phen, PC3, IC50 = 3.26 µM). All 
carboxylate complexes, however, were equal in their efficacy (IC50 0.61 – 3.59 
µM) over both 24 and 96 h periods against human ovarian cancer cells (SK-OV-
3). The antibacterial and antifungal properties of the complexes were examined 
against a wide range of pathogenic microbes and Cu-Iso-Phen was found to be 
highly active against both gram positive and negative strains (MIC95 15.62 – 
31.25 µM), while Cu-Iso-Phen was also active against both filamentous and 
non-filamentous fungi (MIC80, filamentous, 15.62 – 31.25 µM; MIC50, non-
filamentous = 31.25 µM). Significantly, cytoselectivity was identified in this 
series with Cu-Piv-Phen being remarkably less cytotoxic than all others toward 
both gram positive and negative bacteria (MIC95 62.5 – 1000 µM) while Cu-
Pro-Phen had significantly lower selectivity against all fungal strains (MIC80/50 
= 250 µM).  The addition of carboxylate groups to the Cu-Phen reagent did not 
enhance DNA cleavage activity, with Cu-Phen being the most active of all 
complexes tested in the presence exogenous reductant and oxidant. However, 
Cu-Prop-Phen, Cu-Iso-Phen and Cu-Piv-Phen can be described as the most 
active within the functionalised series. This trend was also seen in their Fenton-
type interaction with hydrogen peroxide using the Amplex Red assay, with Cu-
Phen being the most active, followed thereafter by Cu-Pro-Phen, Cu-Iso-Phen 
and Cu-Piv-Phen. Detection of double-strand breaks (DSBs) on genomic DNA 
within ovarian cancer cells (SK-OV-3), identified using immunodetection of γ-
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H2AX foci, revealed that the simple formate and acetate complexes, Cu-For-
Phen and Cu-Ace-Phen, along with Cu-Piv-Phen, could induce high intensity 
foci and were, unlike Cu-Phen, present in a significant proportion of cells, 
∼46%, ∼24% and ∼17% respectively.  
Our analysis on [Cu(1,10-phen)2]2+ (Cu-Phen) reveals this complex as having 
both moderate protein (bovine serum albumin, BSA) binding and DNA 
intercalating (calf thymus dsDNA) properties. Cu-Phen can also be classified as 
a non-selective cytotoxin of human cancer cells, gram positive and negative 
bacteria and pathogenic fungi. Furthermore, while this species is an excellent in 
vitro artificial metallonuclease, its induction of double strand DNA breaks 
(DSBs) in SK-OV-3 cells occur in a relatively low proportion of cells (∼11%) 
only. Thus, Cu-Phen can be considered a “promiscuous” agent and most likely 
targets multiple cellular processes, via free-radical oxidative stress. The 
coordination of sterically functionalised carboxylates to this cation, however, 
results in series of compounds with enhanced DNA recognition, reduced albumin 
binding with improved cytoselectivity between human cancer cells, bacterial and 
fungal cells. Overall, the importance of inner-sphere modification by carboxylate 
ligands to the targeted biological application (genomic DNA damage) in this 
class of compound is evident as formate, acetate and pivalate complexes induce 
DSBs in a higher percentage of SK-OV-3 cells compared to the parent Cu-Phen 
complex. With this in mind, we are exploiting the possibility of generating 
engineered metallonucleases via functional modification to the organic group of 
the carboxylate anion. The synthetic methodology we have reported here could 
be a very effective approach and, in principle, would involve two synthetic steps. 
Firstly, a sequence-targeting protein or nucleic acid (T) is selected and attached 
via the organic group of the carboxylate ligand, T-RCOOH. Secondly, the 
sodium salt of this funcationalised carboxylate, T-RCOO−Na+, is bound to the 
[Cu(1,10-phen)2]2+ cation to form the engineered artificial metallonuclease, [T-
RCOO-Cu(1,10-phen)2]+. 
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IV.5 Experimental  
Chemicals and deoxyribonucleic acid sodium salt from salmon testes were 
purchased from Sigma Aldrich (Ireland) and used without further purification. 
Ultra Pure ctDNA was supplied from Invitrogen (Cat.15633-019), supercoiled 
plasmid DNA (pBR322) was supplied by Roche Diagnostics Ltd. (UK) (Cat. 
10481238001) or NEB (Cat. N3033L). Solid-state IR were recorded on a KBr 
matrix using a Nicolet FT-IR 5DXB FT-IR. Elemental analytical data for all 
complexes were recorded by the Microanalytical Laboratory, University College 
Dublin, Ireland and correspond to >95% purity. Electronic spectra were recorded 
at 25 oC in HPLC grade methanol using an Agilent Cary 100 spectrophotometer. 
Electrospray ionisation mass spectra were recorded on a Thermo Fisher Exactive 
Orbitrap mass spectrometer coupled to an Advion TriVersa Nanomate injection 
system. Note: although Cu-Pro-Phen and Cu-Piv-Phen crystallise with two 
independent cations in the asymmetric unit, both complexes were examined as 
monomeric cations in all biological tests conducted. 
 
IV.5.1 Synthesis 
[Cu(1,10-Phen)2](NO3)2 (Cu-Phen) was obtained as a green solid by refluxing 
copper(II) nitrate hemi(pentahidrate) (0.51 g, 2.1 mmol) and 1,10 phenanthroline 
monohydrate (0.85 g, 4.2 mmol) in ethanol for 2 hours at 90 oC. On cooling to 
room temperature the product was filtrated, washed with a minimum amount of 
cold ethanol and then air-dried. Yield: 0.90 g (77 %). Anal. Calc. for 
C24H16CuN6O6:  Percent calcd. C, 52.60; H, 2.92; N, 15.34, Percent found: C, 
54.58; H, 2.98; N, 15.83 IR (KBr): 3415, 1513, 1386, 1363, 1297, 1034, 845, 
718 cm-1, UV-vis (methanol): λd-d = 709 nm, εmax = 65.86 mol-1 dm3 cm-1. 
 
[Cu(R-COO)(1,10-Phen)2]+ general procedure: samples were obtained as blue 
crystals upon treating an aqueous solution of the sodium carboxylate salt with a 
methanolic solution of Cu-Phen (0.51g, 0.93 mmol) (1:1) in an 
methanol/aqueous (2:1 v/v) solution under stirring at room temperature for 15 
min. The resulting clear, dark blue solutions were allowed to stand at room 
temperature and after slow evaporation blue prismatic crystals formed within 10 
days. Cu-For-Phen, [Cu(For)(1,10-Phen)2](NO3)⋅6H2O, empirical formula: 
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C25H29CuN5O11, 0.48 g (81 %); IR(KBr): 3436, 1611, 1584, 1514, 1424, 1383, 
1348, 851, 723 cm-1,  UV-vis (methanol): λd-d = 693 nm, εmax = 70.75 mol-1 dm3 
cm-1,  solubility: MeOH, DMF, DMSO, H2O (partially), ESI–MS: 468.06 m/z = 
[M]+, 287.99 m/z = [M - 1,10-phenanthroline]+. Cu-Ace-Phen, [Cu(Ace)(1,10-
Phen)2](NO3)⋅2H2O, empirical formula: C26H23CuN5O7, Yield: 0.49 g (91 %); 
IR(KBr): 3346, 1576, 1570, 1514, 1427, 1364, 846, 722, 675 cm-1, UV-vis 
(methanol): λd-d = 691 nm, εmax = 84.29 mol-1 dm3 cm-1, solubility: MeOH, EtOH, 
DMF, DMSO (partially), ESI–MS: 482.08 m/z = [M]+, 302.01 m/z = [M - 1,10-
phenanthroline]+. Cu-Pro-Phen, [Cu(Pro)(1,10-Phen)]·½(CO3)·4½H2O, 
empirical formula: C27.50H30CuN4O8 Yield: 0.41 g (72 %); IR(KBr): 3362, 1576, 
1559, 1516, 1395, 1382, 849, 729 cm-1, UV-vis (methanol): λd-d = 696 nm, εmax = 
79.40 mol-1 dm3 cm-1, solubility: MeOH, EtOH, DMSO, DMF and CHCl3 
(partially), ESI–MS: 496.09 m/z = [M]+, 316.03 m/z = [M - 1,10-
phenanthroline]+. Cu-Iso-Phen, [Cu(Iso)(1,10-Phen)2]2·2(NO3)·4H2O, 
empirical formula: C28H27CuN5O7 Yield: 0.37 g (65 %); IR(KBr): 3366, 1568, 
1552, 1512, 1401, 1376, 1367, 851, 723 cm-1, UV-vis (methanol): λd-d = 698 nm, 
εmax = 79.65 mol-1 dm3 cm-1, solubility: MeOH, DMF, CHCl3, DMSO, ESI–MS: 
510.11 m/z = [M]+, 330.04 m/z = [M - 1,10-phenanthroline]+. Cu-Piv-Phen, 
[Cu(Piv)(1,10-Phen)2]2(piv)2·(Hpiv)·9H2O, empirical formula: 
C36.50H48CuN4O9.50 Yield: 0.56 g (79 %); IR(KBr): 1545, 1516, 1478, 1369, 
1363, 1229, 1103, 850, 721cm-1, UV-vis (methanol): λd-d = 701 nm, εmax = 93.67 
mol-1 dm3 cm-1, solubility: MeOH, DMSO, ESI–MS: 522.23 m/z = [M – 2H]+, 
344.06 m/z = [M - 1,10-phenanthroline]+. 
 
IV.5.2 Electrochemistry 
Cyclic Voltammetry experiments were performed on a Solartron 1825 
potentiostat and data analysed using CorrView software. The concentrations of 
[Cu(RCOO)(1,10-phenanthroline)2]+ complexes and Na-L-ascorbate were 1 mM 
and 2 mM (1:2 ratio), respectively, in all experiments and the CVs were scanned 
initially in the cathodic direction. The working electrode was Glassy Carbon (2 
mm diameter), the reference electrode was a non-aqueous Ag+/Ag (E1/2 = 0.075 
V versus Fc/Fc+), and the counter electrode was platinum. The supporting 
electrolyte was 0.1 M TBAPF6 in 10% v/v DMF. Electrodes were polished using 
0.05 micron aluminium oxide paste on microcloth (both Buehler) and sonicated 
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for ten minutes in ethanol prior to analysis. All quoted potentials were obtained 
at a scan rate of 100 mV s-1. 
 
IV.5.3 X-Ray Crystallography 
Data were collected at 150(2)K on a Bruker Apex II CCD diffractometer using 
MoK  radiation (  = 0.71073Å) (Table IV.7 and Appendix A.B.2). The 
structures were solved by direct methods and refined on F2 using all the 
reflections  with SHELXL  or SHELXL2012.55 Unless otherwise stated, all the 
non-hydrogen atoms were refined using anisotropic atomic displacement 
parameters and hydrogen atoms were inserted at calculated positions using a 
riding model. In Cu-Ace-Phen  the coordinated nitrate anion is disordered over 
two positions and was refined with 85:15 occupancy of the sites. In Cu-Pro-
Phen one of the phen groups is disordered and was modelled with 50:50 
occupancy over two sites and the asymmetric unit contains two full-occupancy 
water molecules and four refined as 50% occupancy. The hydrogen atoms of the 
water molecules were not located and have not been included in the refinement. 
Cu-Piv-Phen was refined as a 2-component merohedral twin (twin matrix -1 0 0 
0 1 0 0 1 -1 and BASF 0.21. 
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Table IV.7 Crystrallographic data for the five carboxylate complexes generated 
Identification	  code	   Cu-­‐For-­‐Phen	   	   Cu-­‐Ace-­‐Phen	   	   Cu-­‐Pro-­‐Phen	   Cu-­‐Iso-­‐Phen	   Cu-­‐Piv-­‐Phen	  
Formula	   [Cu(phen)2(HCOO)]	  
(NO3)⋅6H2O	  
	  
	  
[Cu(phen)2(OAc)]	  
(NO3)⋅2H2O	  
	  
	  
[Cu(phen)2(pro)]·∙	  
½(CO3)·∙4½H2O	  
[Cu(phen)2(isobut)]2·∙	  
2(NO3)·∙4H2O	  
[Cu(phen)2(piv)]2(piv)2·∙	  
(Hpiv)·∙9H2O	  
Empirical	  formula	   C25H29CuN5O11	   	   C26H23Cu	  N5O7	   	   C27.50H30CuN4O8	   C28H27CuN5O7	   C36.50H48CuN4O9.50	  
Formula	  weight	   639.07	   	   581.03	   	   608.09	   609.09	   758.33	  
Crystal	  system	   Monoclinic	   	   Triclinic	   	   Monoclinic	   Orthorhombic	   Triclinic	  
Space	  group	   P21/n	   	   P1	   	   C	  2/c	   P212121	   P1	  
Unit	  cell	  	  a	  (Å)	   14.8372(12)	   	   8.5126(4)	   	   31.873(5)	   14.9422(10)	   16.091(2)	  
b	  (Å)	   12.4670(10)	   	   10.3864(5)	   	   12.4716(19)	   17.0635(12)	   17.367(2)	  
	   c	  (Å)	   15.5706(12)	   	   14.6033(6)	   	   14.264(2)	   21.2699(14)	   17.454(2)	  
 	  (º)	   90	   	   83.2710(10)	   	   90	   90	   60.321(2)	  
 	  (º)	   109.0920(10)	   	   82.9980(10)	   	   93.879(2)	   90	   66.311(2)	  
 	  (º)	   90	   	   76.2690(10)	   	   90	   90	   89.747(2)	  
Volume	  (Å3)	   2721.8(4)	   	   1239.68(10)	   	   5656.9(15)	   5423.1(6)	   3762.8(9)	  
Z	   4	   	   2	   	   8	   8	   4	  
Density	  calc.	  	  (Mg/m3)	   1.560	   	   1.557	   	   1.428	   1.492	   1.339	  
Absorption	  coeff	  	  (mm-­‐1)	   0.873	   	   0.939	   	   0.828	   0.862	   0.640	  
F(000)	   1324	   	   598	   	   2528	   2520	   1600	  
Crystal	  description	   blue	  plate	   	   blue	  block	   	   blue	  block	   blue	  lath	   blue	  plate	  
Reflections	  collected	   22925	   	   17094	   	   23362	   55103	   29693	  
Independent	  refl	  [Rint]	   5353	  [0.0463]	   	   6174	  [0.0260]	   	   5815	  [0.0593]	   13446	  [0.0708]	   13193	  [0.0560]	  
Data	  /	  restraints	  /	  param	   5353	  /	  18	  /	  415	   	   6174	  /	  12	  /	  381	   	   5815	  /	  984	  /	  527	   13446	  /	  12	  /	  763	   13193	  /	  27	  /	  974	  
Goodness-­‐of-­‐fit	  on	  F2	   1.068	   	   1.054	   	   1.050	   1.004	   1.046	  
R	  indices	  R1,	  wR2	  [I>2s(I)]	   0.0463,	  	  0.1232	   	   0.0309,	  	  0.0779	   	   0.0943,	  	  0.2839	   0.0422,	  	  0.0847	   0.0643,	  	  	  0.1663	  
R	  indices	  R1,	  wR2	  (all	  data)	   0.0659,	  	  	  0.1361	   	   0.0380,	  	  	  0.0812	   	   0.1419,	  	  	  0.3299	   0.0771,	  	  	  0.0973	   0.0960,	  	  	  0.1891	  
Absolute	  structure	  param	   n/a	   	   n/a	   	   n/a	   -­‐0.022(9)	   n/a	  
Diff.	  peak	  and	  hole	  (e.Å-­‐3)	   1.310	  and	  -­‐0.872	   	   0.398	  and	  -­‐0.321	   	   1.873	  and	  -­‐0.885	   0.383	  and	  -­‐0.580	   0.564	  and	  -­‐0.680	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IV.5.4 Bovine Serum Albumin Binding 
To a quartz cuvette containing 15 µM of Bovine Serum Albumin (A7030, 
Sigma) in HEPES buffer (10 mM, pH = 7.2) and NaCl (25 mM), an aliquot of 
complex, ligand or metal salt was added and the resulting solution was incubated 
at 37oC for 5 min. Triplicate experiments were conducted, across a drug 
concentration range of 1–50 µM, on an LS55 PerkinElmer Fluorescence 
Spectrometer using an excitation wavelength of 295 nm using a slit width of 7 
nm. An emission wavelength of 350 nm was used for the quenching analysis of 
BSA.   
 
IV.5.5 DNA Binding48 
IV.5.5.1 Competitive ethidium displacement. See section III.4.4.1 
IV.5.5.2 DNA–ethidium fluorescence quenching. See section III.4.4.2 
IV.5.5.2 Viscosity. See section III.5.6 
IV.5.6 In Vitro Cytotoxicity with Human-Derived Cancer Cell Lines 
The human ovarian cancer cell line SK-OV-3 (ATCC® HTB-77™), the human 
prostate  cancer cell line PC-3 (ATCC® CRL-1435™)(ATCC, Manassas, VA, 
USA), the  and the normal prostate epithelial cell PNT1A immortalised with 
SV40 (Sigma-Aldrich)  were all grown in RPMI1640 (Sigma) supplemented with 
2 mM L-glutamine and 10% fetal bovine serum (FBS) in T75 flasks (Nunc) in a 
37 oC in a humidified atmosphere with 5% CO2. Cells were maintained by 
splitting 70-80% confluent cultures with 0.25% trypsin/EDTA solution and 
seeding at high densities (2-4 x 10,000cells/cm2). All drugs were tested on all 
cell lines using the 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay.  The cells were trypsinised as described previously to 
obtain a cell suspension of each of the adherent cell lines. The cells were then 
counted on a coulter counter (Beckman Coulter) so that appropriate cell numbers 
could be plated in 96-well plates (Nunc) for the required timepoints of 24 h 
(2,500 cells) or 96 h (1,250 cells) exposures of cells to each compound. Each 
IC50 value represents the mean of three independent experiments (± standard 
error).  
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IV.5.6.1 MTT assay This method is based on the reduction of the tetrazolium 
salt MTT into a crystalline blue formazan product by the cellular oxidoreductases 
of viable cells.57 The resultant formazan crystal formation is proportional to the 
number of viable cells. Cells were seeded in 96-well plates and incubated at 37 
oC in 5% CO2 for 24 h to ensure attachment and growth of all cells. Cells were 
treated with a 4-log range of concentration of the test compounds, in triplicate, 
from 0.1 to 500 mM or with a solvent control (0.5% DMSO) in complete 
medium for 24 or 96 hr exposure times by incubation. The cells were then 
incubated with 20 µl of MTT (5 mg/ml) in 0.1 M phosphate-buffered saline 
(PBS), pH = 7.4, at 37 oC in a humid atmosphere with 5% CO2 for 4 h. The 
medium was then gently aspirated from test cultures and 100 µl of DMSO was 
added to each well. The plates were then shaken for 2 min and the absorbance 
was read at 550 nm in a Varioscan plate reader. The IC50 value was defined as 
the concentration of test compound required to reduce the absorbance of the 
MTT–formazan crystals by 50%, indicating 50% cell deactivation. 
 
IV.5.7 Antibacterial Activity58 
In vitro antibacterial activities of the compounds were evaluated on a panel of 
three ATCC strains (Staphylococcus aureus ATCC 6538, Escherichia coli ATCC 
8739, Pseudomonas aeruginosa ATCC 9027) and five clinical isolates 
(Staphylococcus aureus MRSA HK5996/08, Staphylococcus epidermidis 
HK6966/08, Enterococcus sp. HK14365/08, Klebsiella pneumoniae 
HK11750/08, Klebsiella pneumoniae ESBL HK14368/08) from the collection of 
fungal strains deposited at the Department of Biological and Medical Sciences, 
Faculty of Pharmacy, Charles University, Hradec Králové, Czech Republic. The 
above-mentioned ATCC strains also served as the quality control strains. All the 
isolates were maintained on Mueller-Hinton agar prior to being tested. Dimethyl 
sulfoxide (100%) served as a diluent for all compounds; the final concentration 
did not exceed 2%. Mueller-Hinton agar (MH, HiMedia, Čadersky-Envitek, 
Czech Republic) buffered to pH 7.4 (±0.2) was used as the test medium. The 
wells of the microdilution tray contained 200 µL of the Mueller-Hinton medium 
with 2-fold serial dilutions of the compounds (1000 to 0.244 µmol/L) and 10 µL 
of inoculum suspension. Inoculum in MH medium was prepared to give a final 
concentration of 0.5 McFarland scale (1.5 × 108 cfu.mL-1). The trays were 
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incubated at 37 °C and MICs were read visually after 24 h and 48 h. The MICs 
were defined as 95% inhibition of the control growth. MICs were determined 
twice and in duplicate. The deviations from the usually obtained values were no 
higher than the nearest concentration value up and down the dilution scale. 
 
IV.5.8. Antifungal Activity59,60  
In vitro antifungal activities of the compounds were evaluated on a panel of four 
ATCC strains (Candida albicans ATCC 44859, Candida albicans ATCC 90028, 
Candida parapsilosis ATCC 22019, Candida krusei ATCC 6258) and eight 
clinical yeast isolates (Candida krusei E28, Candida tropicalis 156, Candida 
glabrata 20/I, Candida lusitaniae 2446/I, Trichosporon asahii 1188) and 
filamentous fungi (Aspergillus fumigatus 231, Absidia corymbifera 272, 
Trichophyton mentagrophytes 445) from the collection of fungal strains 
deposited at the Department of Biological and Medical Sciences, Faculty of 
Pharmacy, Charles University, Hradec Králové, Czech Republic. Three ATCC 
strains were used as the quality control strains. All of the isolates were 
maintained on Sabouraud dextrose agar prior to being tested. Minimum 
inhibitory concentrations (MICs) were determined by modified CLSI standard of 
microdilution format of the M27-A3 and M38-A2 documents.59,60 Dimethyl 
sulfoxide (100 %) served as a diluent for all compounds; the final concentration 
did not exceed 2%. RPMI 1640 (Sevapharma, Prague) medium supplemented 
with L-glutamine and buffered with 0.165 M morpholinepropanesulfonic acid 
(Serva) to pH 7.0 by 10 M NaOH was used as the test medium. The wells of the 
microdilution tray contained 200 µL of the RPMI 1640 medium with 2- fold 
serial dilutions of the compounds (1000 to 0.244 µmol/L for the new 
compounds) and 10 µL of inoculum suspension. Fungal inoculum in RPMI 1640 
was prepared to give a final concentration of 5 × 103 ± 0.2 cfu.mL-1. The trays 
were incubated at 35 °C and MICs were read visually after 24 h and 48 h. The 
MIC values for the dermatophytic strain (T. mentagrophytes) were determined 
after 72 h and 120 h. The MICs were defined as 80% inhibition (IC80) of the 
control growth for yeasts and as 50% inhibition (IC50) of the control growth for 
filamentous fungi. MICs were determined twice and in duplicate. The deviations 
from the usually obtained values were no higher than the nearest concentration 
value up and down the dilution scale. 
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IV.5.9 DNA Cleavage Studies 
IV.5.9.1 Nuclease activity using plasmid pBR322 Reactions were carried out 
according to the literature procedure.3 Briefly, in a total volume of 20 µL using 
80 mM HEPES buffer (Fisher) at pH 7.2 with 25 mM NaCl, an aliquot of the 
stock complex (prepared in DMF) was mixed with 400 ng of supercoiled 
pBR322 (Roche) and/or 400 ng of linearised pBR322 (see ESI for procedure) 
and 1 µL of 20 mM Na-L-ascorbate and/or H2O2 where appropriate. Samples 
were incubated at 37 oC before being quenched with 6x loading dye (Fermentas), 
containing 10 mM Tris-HCl (pH 7.6), 0.03% bromophenol blue, 0.03% xylene 
cyanol, 60% glycerol and 60 mM EDTA, then loaded onto agarose gel (1%) 
containing 2.0 µL of GelRedTM (10,000X). Electrophoresis was completed at 80 
V for 1.5 h using a wide mini-sub cell (BioRad) in 1xTAE buffer (Millipore).  
 
IV.5.10 Quantitation of Hydrogen Peroxide with Amplex Red 
A 5 mL stock solution of 100 uM Amplex Red containing 10 mM Amplex Red 
reagent and 10 U/ml horseradish Peroxidase (HRP) was prepared in 1x buffer as 
per Amplex Red hydrogen peroxide/peroxidase assay kit (Invitrogen, A22188). 
A standard fluorescence response curve from H2O2 was obtained by adding a 
series of aliquots (0.5 – 5 µM) H2O2 to 50 uL Amplex Red stock solution and the 
volume was adjusted to 100 µL with 1x buffer in each well. An aliquot 
containing 5 µM of tested compounds, 5 µM H2O2 and 100 µM Na-L-Ascorbate  
(where appropriate) previously incubated for 30-120 min were added to 50 µL 
Amplex Red solution and the volume was adjusted to 100 µL using 1x buffer. 
The fluorescence intensity of the reaction mixture was measured with a Bio-Tek 
synergy HT multi-mode microplate reader equipped with filter set for excitation 
and emission at 530 nm and 590 nm.61  	  
IV.5.11 Detection of double-strand DNA breaks (DSBs) within SK-OV-3 
Cancer cells 
The ability of the complexes, metal-free 1,10-phenanthroline and cisplatin to 
induce DSBs within SK-OV-3 cells was determined using immunodetection of 
γH2AX foci. DSBs were visualized via confocal microscopy using an LSM 510 
META laser scanning microscope equipped with an argon laser (488 nm) and 
HeNe laser (543 nm) and quantified via flow cytometry using a CyFlow Space 
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Flow cytometer equipped with a blue diode pumped solid-state laser (488 nm). 
SK-OV-3 cells were exposed to an IC25 dose of tested compound over 24 h and 
were then were incubated for 2 h with the primary antibody (anti-phosphohistone 
H2A.X (Ser139), clone JBW301, mouse; Millipore) and thereafter with the 
fluorescein isothiocyanate (FITC)-labeled secondary antibody (Alexa Fluor 488 
goat anti-mouse immunoglobulin G; Invitrogen) for 1 h in darkness. For 
visualization of the nucleus, cells were stained with the fluorescent DNA 
intercalator propidium iodide (PI). After exposure, the drug-treated and control 
cells were divided equally, with 50% being used for confocal analysis and 50% 
for flow cytometry. Flow analysis was conducted in triplicate for three 
independent experiments. Full experimental details are similar to those recently 
reported by Schmitz and colleagues.62	  
IV.6 Methods 
IV.6.1 Crystallography 
IV.6.1.1 Computing details Data collection: Bruker APEX2, for cell refinement: 
Bruker SAINT; data reduction: Bruker SAINT; program(s) used to solve structure: 
SHELXS97 (Sheldrick, 2008). Program(s) used to refine structure: SHELXL97 
(Sheldrick, 2008) for Cu-for-phen, Cu-ace-phen, Cu-iso-phen;SHELXL2012 
(Sheldrick, 2012) for Cu-pro-phen, Cu-piv-phen. For all compounds, molecular 
graphics: Bruker SHELXTL; software used to prepare material for publication: 
Bruker SHELXTL. 
IV.6.1.2 Solution and Refinement Data were collected at 150(2)K on a Bruker 
Apex II CCD diffractometer using MoK  radiation (  = 0.71073Å). The 
structures were solved by direct methods and refined on F2 using all the 
reflections.63 The weighted R-factor wR and goodness of fit S are based on F2, 
conventional R-factors R are based on F, with F set to zero for negative F2. The 
threshold expression of F2> 2sigma(F2) is used only for calculating R-factors(gt) 
etc. and is not relevant to the choice of reflections for refinement. R-factors 
based on F2 are statistically about twice as large as those based on F, and R- 
factors based on ALL data will be even larger. Unless otherwise stated, all the 
non-hydrogen atoms were refined using anisotropic atomic displacement 
parameters and hydrogen atoms were inserted at calculated positions using a 
riding model.  
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IV.6.1.3 Geometry All esds (except the esd in the dihedral angle between two 
l.s. planes) are estimated using the full covariance matrix.  The cell esds are 
taken into account individually in the estimation of esds in distances, angles  and 
torsion angles; correlations between esds in cell parameters are only used when 
they are defined by crystal symmetry. An approximate (isotropic) treatment of 
cell esds is used for estimating esds involving l.s. planes. 
IV.6.2 Electrospray ionisation mass spectra (ESI-MS) 
Samples were prepared in 100% methanol prior to electrospray ionisation mass 
spectra analysis recorded on a Thermo Fisher ExactiveOrbitrap mass 
spectrometer coupled to an AdvionTriVersaNanomate injection system. 
 
IV.6.3 Linearisation of pBR322 
In a total volume of 20 µL using 5 µL of 1 µg/µLsuperoiled pBR322 (NEB), 5 µL 
of 10 x HEPES, 2.5 µL of 20,000 U/mL EcoRV (NEB) or 2.5 µLof  20,000 
U/mL HindIII (NEB), 5 µL of NeBuffer 3 or 5 µL of NeBuffer 2 (NEB), 1 µL 
BSA (NEB) (where appropriate) and nuclease free H2O were added to bring up 
volume to 20 µL. This mixture was allowed to incubate at 37 oC for 2.5 h. 1 µL 
of the mixture was loaded onto agarose gel and run at 70 V for 30 min to confirm 
linearization. Linear DNA from the mixture was then cleaned up from the 
enzymatic reactions, using QIAquick Purification Protocol (QIAGEN) as per 
manual instructions. The linear DNA obtained was quantified using the 
NanoDrop, ND-1000 Spectrophotometer.	  
IV.6.4 Electrochemical Stability of Complexes 
The electrochemical stability of the Cu complexes was investigated over a period 
of 13 hours. Voltammograms were performed on 1 mM solutions of Cu complex 
every 4 hours to monitor any changes in redox behaviour. Deviation from the 
complex redox profiles, performed in freshly prepared samples, would indicate 
complex instability. Negligible changes in the solution phase electrochemistry 
was observed for all complexes - the electrochemical stability of Cu-For-Phen 
over the 13 hour time period is displayed in Fig. IV.14(a) to illustrate this point. 
Further evidence that the complexes remain structurally intact is shown in Fig. 
IV.14(b), where the redox profile of [Cu(1,10phenanthroline)]2+(NO3-)2 is 
compared to that of [Cu(bis-1,10 phenanthroline)]2+(NO3-)2. The Cu mono-phen 
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complex exhibits poor reversibility, with ill-defined redox peaks and 
corresponding low currents. In addition, on continuous potential cycling of a GC 
electrode in the Cu mono-phen solution, some copper deposition onto the GC 
surface is observed. In contrast, the electrochemical activity of the Cu bis-phen 
complex is very well defined and exhibits near reversible (ΔEP = 69 mV) redox 
behaviour at this scan rate. 
 
 
	  
Figure IV.53	   Typical cyclic voltammogram traces, recorded at a scan rate of 100 mV s-1, for (a) 
1 mM solution of Cu-For-Phen, after 1 hour (solid black trace), 4 hours (solid blue trace), and 13 
hours (dashed trace); (b) 1 mM solutions of Cu(bis-phen), (solid trace), and Cu(mono-phen), 
(dashed trace). Experimental conditions; glassy carbon working electrode, platinum counter 
electrode, non-aqueous Ag /Ag+ reference electrode, 0.1M TBAPF6 in 10% v/v DMF.	  
	  
IV.6.5 UV-vis stability studies 
 
The UV-vis spectrophotometric stability of all Cu2+ complexes were investigated 
over a period of 10 days and were compared with [Cu(1,10-phen)]2+ and 
[Cu(1,10-phen)2]2+ complexes. Scans were performed, at 5 mM in 80 mM 
HEPES with 3.5 % v/v methanol, every 24 h between 400 and 900 nm. 
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Negligible changes to the absorption maxima and intensity were observed for all 
complexes and are presented in Fig. IV.15i. Further evidence that the complexes 
remain structurally intact, is illustrated in Fig. IV.15ii., where the absorption 
spectra of [Cu(1,10-phen)]2+ (mono-phen) is shown along with [Cu(1,10-
phen)2]2+ (bis-phen). The absorption maximum (λd-d) of the mono-phen complex 
was found to be 644 nm, whereas the absorption maximum of bis-phen was 697 
nm.  
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Figure IV.54	  Absorption spectra of i. 5 mM [Cu(1,10-phen)(R-COO)]2+ in 80 mM HEPES with 3.5% v/v methanol between 0- 168 h, recorded every 24 h, ii. 
Absorption spectra of 5 mM Cu-bis-phen (a.) and Cu-mono-phen (b.) in 80 mM HEPES.	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 Chapter V  
Copper Phenanthrene Oxidative Chemical 
Nucleases 
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V.1. Abstract 
Here we report the synthesis and isolation of a series of bis-chelate Cu2+ 
phenanthroline–phenazine cationic complexes of [Cu(DPQ)(Phen)]2+, 
[Cu(DPPZ)(Phen)]2+ and [Cu(DPPN)(Phen)]2+ (where DPQ = 
dipyridoquinoxaline, DPPZ = dipyridophenazine and DPPN = 
benzo[i]dipyridophenazine). These compounds have enhanced DNA recognition 
relative to the well studied chemical nuclease, [Cu(Phen)2]2+ (bis-Phen), with calf 
thymus DNA binding constants of DPQ and DPPZ agents (~107 M(bp)-1) being 
the highest currently known for Cu2+ phenanthrene compounds. Complex DNA 
binding follows DPQ ≈ DPPZ > DPPN > bis-Phen with fluorescence quenching 
and thermal melting experiments on poly[d(A-T)2] and poly[d(G-C)2] supporting 
intercalation at both the minor and major groove. Phenazine complexes, 
however, show enhanced targeting and oxidative cleavage on CpG rich DNA, 
and have comparable in vitro cytotoxicity toward the cisplatin resistant ovarian 
cancer line SKOV3, as the clinical oxidative DNA damaging drug, doxorubicin 
(adriamycin). In this study we also describe how a novel “on chip” method 
devised for the Bioanalyser 2100 was employed to quantify dsDNA damage, 
with high precision, by the complex series on pUC19 DNA (49% A-T, 51% G-
C). Both DPQ and bis-Phen complexes are highly efficient oxidizers of pUC19, 
with DPQ being the most active of the overall series. It is apparent therefore, that 
oxidative chemical nuclease activity on homogenous canonical DNA is not 
entirely dependent on dynamic nucleotide binding affinity or intercalation and 
this observation is corroborated through catalytic interactions with the 
superoxide anion radical and Fenton breakdown of hydrogen peroxide.  
V.2. Introduction 
The advent of coordinating phenanthrene-based intercalators to transition metal 
cations has unveiled a new frontier for DNA-targeted metallodrug development.1 
While the application of cis-diamminedichloroplatinum(II) (cisplatin) continues 
to be a cornerstone of modern cancer chemotherapy,2 the functionalisation of this 
agent with intercalating ligands3 and the construction of non-platinum metallo-
intercalators with bis- and tris-phenanthrene chelated symmetry,4 has revealed 
unique but structurally interrelated chemotypes of promising biological utility. 
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Significant examples of these cationic agents (see Scheme V.1) include; cis-
[Pt(NH3)2(phenanthridine)Cl]+ (phenanthriplatin)5 which exhibits a unique 
spectrum of activity within the National Cancer Institute 60-cell tumoral panel 
and enhanced cellular uptake relative to cisplatin; Δ-[Ru(DPPZ)(Phen)2]2+ which 
has excellent DNA recognition properties and is widely known as a ‘light switch’ 
complex due to photoluminescence nucleotide binding enhancement,6 and; 
[Cu(Phen)2]2+ which is an effective chemical nuclease that induces DNA 
degradation through free radical oxidation of deoxyribose.7-9 Thus, by varying 
both the metal centre and coordinated phenanthrene base, unique interactions on 
DNA and within human-derived cancer cells can be achieved. 
	  
Scheme V.1	   Molecular structures of cytotoxic platinum(II) complexes cisplatin and 
phenanthriplatin, the ruthenium(II) DNA light switch complex, Δ-[Ru(DPPZ)(Phen)2]2+, and the 
copper(II) chemical nuclease, [Cu(Phen)2]2+. 
 
The chemical nuclease [Cu(Phen)2]2+ is capable of abstracting hydrogen (PH) 
from the pentose ring of DNA in the presence of both exogenous reductant (Cu2+ 
→ Cu+) and oxidant (O2 or H2O2), under a quasi-reversible electrochemical 
process,7,8 and has served as an important template for cytotoxic metallodrug 
design.10 The mechanism of abstraction is sequential and is dependent on both 
Cu+ and hydrogen peroxide (H2O2).11 Furthermore, the production of H2O2 in the 
reaction is believed to result from superoxide dismutase (SOD) mimetic 
activity,12 post electron-transfer from Cu+ to O2. [Cu(Phen)2]2+ oxidises DNA 
without specificity, predominately at the minor groove and in an effort to 
improve this lack of specificity, chimeric [Cu(Phen)2]2+molecules have been 
generated using target-specific, DNA-recognition vectors of single-stranded 
DNA13,14 and also with the adenine-thymine (A-T) specific minor groove binder, 
distamycin.15,16  
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In this study we report the synthesis and isolation of a series of bis-chelate Cu2+ 
phenanthroline–phenazine cationic complexes of [Cu(DPQ)(Phen)]2+, 
[Cu(DPPZ)(Phen)]2+ and [Cu(DPPN)(Phen)]2+ (where DPQ = dipyrido[3,2-
f:2′,3′-h]quinoxaline, DPPZ = dipyrido[3,2-a:2',3'-c]phenazine and DPPN = 
benzo[i]dipyrido[3,2-a:2',3'-c]phenazine). Since designer metal-chelating 
phenazine ligands have shown outstanding potential within Ru2+ DNA-selective 
binding probes,17-20 a question remains unanswered regarding their biological 
activity within Cu2+ complexes towards, (i.) nucleotide equilibrium binding 
affinity, base-specific targeting and intercalation, (ii.) oxidative chemical 
nuclease activity, (iii.) redox behaviour including interactions with superoxide 
and hydrogen peroxide, and (iv.) cytotoxicity toward platinum resistant human-
derived cancer cells. Our aim here was to investigate how systematic extension 
of the ligated phenazine ligand influences DNA recognition and oxidative 
degradation, and how this study can ultimately supply basic information toward 
the design of enhanced artificial chemical nucleases of biological utility. In order 
to identify and compare the DNA degradation profiles in this family of 
structurally related compounds, we proposed the development of a capillary 
electrophoresis, microfluidic chip, assay for the Bioanalyzer 2100 (Agilent 
Technologies) which is capable of high resolution sizing and quantitation of 
dsDNA fragments based on normalisation to internal markers and a standard 
DNA ladder.21-23  
 
V.3. Results 
V.3.1 Preparation of the complexes The quinoxaline and phenazine ligands 
(DPQ, DPPZ and DPPN), were generated through Schiff-base condensation 
reactions of 1,10-phenanthroline-5,6-dione with either ethylenediamine, o-
phenylenediamine or 2,3-diaminonaphthalene, with some modification to 
previously reported methods.24-26 The bis-phenanthroline complex, 
[Cu(Phen)2](NO3)2 (Cu-Phen, 1), was prepared by aqueous-ethanol reflux of 
1,10-phenathroline with copper(II) nitrate (2:1).27 The complexes, 
[Cu(DPQ)(Phen)](NO3)2 (Cu-DPQ-Phen, 2), [Cu(DPPZ)(Phen)](NO3)2 (Cu-
DPPZ-Phen, 3) and [Cu(DPPN)(Phen)](NO3)2 (Cu-DPPN-Phen, 4) (Scheme 
V.2) were generated by firstly isolating the mono-phenanthroline complex, 
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[Cu(Phen)](NO3)2, and subsequently treating this with one equivalent of the 
corresponding phenazine ligand.  
 
	  
Scheme V.2	  Molecular structures of the Cu2+ coordination complexes 1-4. 
 
 
V.3.2 Binding affinity to calf thymus and salmon testes DNA The DNA 
binding affinity of the complex series was determined using calf-thymus DNA 
(ctDNA, Ultra-Pure, Invitrogen) and salmon testes double stranded DNA 
(Sigma) by ethidium bromide and Hoechst 33258 fluorescence quenching and 
competition studies28 and also through viscosity analysis (Figure V.1 and Table 
V.1). The presence of phenazine ligands in the complex cation function to 
significantly enhance ctDNA binding affinity with Kapp (apparent DNA binding 
constant) values for Cu-DPQ-Phen and Cu-DPPZ-Phen reagents being at the 
order of ~3 x 107 M(bp)-1 and of similar magnitude as the intercalating 
polypeptide antibiotic, actinomycin D. The DPPN-containing complex, although 
binding by an order of magnitude over Cu-Phen, was the lowest ctDNA binding 
phenazine complex at ~6 x 106 M(bp)-1. Fluorescence quenching (Q) of limited 
bound Hoechst 33258 (minor groove binder) and ethidium bromide (intercalator) 
bound ctDNA were examined to identify potential binding specificity. Unlike the 
classical intercalator, actinomycin D, and minor groove binding agent, netropsin, 
the complex series did not display a large degree of discrimination for the 
quenching either of the selected fluorophores. The quenching effects of the DPQ 
and DPPZ complexes are stronger, overall, than Cu-Phen, however, this trend is 
reversed as the phenazine agents displace bound Hoechst with slightly more 
efficiency than ethidium bromide compared with Cu-Phen. Viscosity analysis on 
salmon testes dsDNA fibres revealed Cu-DPQ-Phen as having a significant 
intercalating (hydrodynamic) binding effect, followed thereafter by Cu-DPPZ-
Phen, Cu-Phen and finally Cu-DPPN-Phen. In nearly all experiments 
conducted, the Cu2+ complexes exhibited distinctive behaviour compared to the 
simple [Co(NH3)6]3+ complex which is known only to have electrostatic binding 
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affinity to the surface of DNA. Indeed this effect was confirmed by our analysis 
of its inability to displace intercalated ethidium, enhanced ability to displace 
minor groove, surface bound, Hoechst 33258, and an overall decrease in relative 
viscosity.  
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Table V.2	   Fluorescence quenching (Q) of limited ethidium bromide (5 µM) bound poly[d(G-C)2] 
and poly[d(A-T)2]  (25 µM) by standard agents netropsin, actinomycin D and Cu2+ complexes.	  
Compound	  	   Q	  (µM)	  
poly[d(A-­‐T)2]	  	  	  
Q	  (µM)	  
poly[d(G-­‐C)2]	  
Netropsin	   4.08	   >>200	  
Actinomycin	  D	   >>200	   5.47	  
Cu-­‐Phen	   13.34	   7.96	  
Cu-­‐DPQ-­‐Phen	   8.34	   3.97	  
Cu-­‐DPPZ-­‐Phen	   11.60	   10.12	  
Cu-­‐DPPN-­‐Phen	   96.56	   44.18	  
  
Table V.3   Influence of standard agents (netropsin, actinomycin D) and copper phenazine 
complexes on the thermal denaturation of poly[d(G-C)2] and poly[d(A-T)2] alternating co-
polymers.  
Compound	  	   ΔTM	  (°C)	  poly[d(A-­‐T)2]	   ΔTM	  (°C)	  poly[d(G-­‐C)2]	  
Netropsin	   12.32	  ±	  0.79	   2.83	  ±	  0.38	  
Actinomycin	  D	   -­‐0.32	  ±	  0.29	   12.10	  ±	  0.95	  
Cu-­‐Phen	   -­‐0.02	  ±	  0.29	   6.64	  ±	  1.58	  
Cu-­‐DPQ-­‐Phen	   0.60	  ±	  0.18	   11.39	  ±	  1.10	  
Cu-­‐DPPZ-­‐Phen	   0.50	  ±	  0.10	   10.44	  ±	  1.10	  
Cu-­‐DPPN-­‐Phen	   -­‐0.39	  ±	  0.21	   2.10	  ±	  1.03	  
ΔTM = difference in thermal melting (TM) of drug treated nucleotide at r = 0.1 compared with drug untreated nucleotide 
 
V.3.5 Chemical nuclease activity. The oxidative chemical nuclease activity of 
the complex series was identified using a novel ‘on chip’ method devised for the 
Agilent 2100 Bioanalyzer which is outlined in Figure V.3. The DNA 7500 
microfluidic chip was employed as it can detect and quantify linear dsDNA 
fragments sized between 100–7500 bp by capillary electrophoresis. Superhelical 
plasmid DNA (pUC19, 2686 bp) was generated by E. coli and subsequently 
linearised by the type II endonuclease, HindIII, which has one recognition 
sequence on this vector. Linear pUC19 (400 ng) was then purified on an anion 
exchange column (Qiagen) and incubated with 500 nM of complex, under 
standard atmospheric conditions, in the presence of 1 mM reductant (sodium-L-
ascorbate). At successive time periods, between 1-30 min, aliquots were removed 
from each reaction and quenched with 100 µM of both neocuproine (2,9-
dimethyl-1,10-phenanthroline) and EDTA (ethylenediamine-tetraacetic acid). 
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Complex-treated and untreated linear DNA samples (1 µL) were then loaded 
onto the Agilent DNA 7500 microfluidic chip. Further, sample wells were also 
loaded with standard DNA markers sized at 50 and 10380 bp which are evident 
in each electrogram. Untreated pUC19 produced a single, high-resolution, peak 
located at ~2870 bp (Figure V.4 [A], time = 0) which was within the 
experimental error margin for nucleotide sizing accuracy (± 10% CV). 
Degradation of pUC19 by each complex was followed by a reduction in peak 
area and peak height intensity and was accompanied by asymmetric tailing; 
indicative of smaller fragments being sheared off through chemical nuclease 
activity. Typical electrograms generated are shown in Figure V.4 [A] which 
details the untreated control DNA (time = 0) and each copper complex 
kinetically exposed to pUC19 at specific time points indicated. Further, typical 
electropherograms generated by each complex are shown in Figure V.4 [D] 
which detail the standard DNA ladder (L), untreated control pUC19 (lane 1) and 
complex treated DNA between either 1-15 min (for Cu-Phen and Cu-DPQ-
Phen complexes) or 1-30 min (for Cu-DPPZ-Phen and Cu-DPPN-Phen 
complexes) (lanes 2-12). In our preliminary experiments we discovered that bis-
phen and DPQ complexes were much more efficient in degrading pUC19, hence, 
our analysis on the Bioanalyzer was conducted on a shorter timeframe for both 
these agents. Quantification of pUC19 damage was achieved (Figure V.4, centre) 
using peak height reduction and peak area reduction analysis from triplicate 
electrograms and comparisons of cleavage efficiency were made based on the 
time taken to degrade 50% (D50) of pUC19 with 100% being taken as the 
normalised intensity of triplicate untreated pUC19 DNA. Both Cu-Phen and Cu-
DPQ-Phen are remarkably efficient in degrading dsDNA and are similar, in 
terms of both their D50 values and overall profile. Analysis by pUC19 peak 
height reduction shows that both agents similarly reduce intensity, by 50%, after 
~2 min, however, Cu-Phen has a marked enhancement over DPQ-Phen between 
4.0-7.5 min on comparison of peak area degradation. Nonetheless, the DPQ 
agent totally degrades the plasmid by 7.5 min under both analyses whereas it is 
~10 min before this is achieved by Cu-Phen. The DPPZ and DPPN reagents are 
less efficient in their chemical nuclease activity with Cu-DPPZ-Phen displaying 
rapid degradation between 5 and 12.5 min (D50 ~7.5 min by peak height) while 
Cu-DPPN-Phen delivers a somewhat linear profile over the complete timeframe 
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(D50 ~12.5 min by peak height). Further evidence the DPPZ agent is a more 
efficient chemical nuclease compared with Cu-DPPN-Phen can be gleaned from 
peak area analysis. DPPZ completely digests the plasmid by ~20 min while at the 
end of our analysis (30 min) a small concentration of nucleotide remained within 
the DPPN treated sample.  
V.3.6 Interactions with superhelical pUC19. The interaction of purified 
superhelical pUC19 (generated using E. coli as described above) with the 
complex series was studied under similar conditions (500 nM [complex] with 1 
mM reductant) (Figure V.5) using standard agarose gel electrophoresis. All 
complexes induced complete degradation of the superhelix with the exception of 
Cu-DPPN-Phen, where evidence of nicked (Form I) and linear (Form II) tertiary 
conformations remained after 30 min. The importance of Cu+ and hydrogen 
peroxide in the cleavage mechanism were demonstrated by the complete 
inhibition of nuclease activity upon addition of 1000 U of bovine liver catalase 
(Figure V.5b) and 100 µM of neocuproine (Figure V.5c). Further trapping 
studies revealed that bovine superoxide dismutase (1000 U, Figure V.5d) could 
strongly inhibit Cu-DPPN-Phen from plasmid digestion and this complex, along 
with Cu-DPPZ-Phen, were also impeded by the hydroxyl radical scavenger, 
DMSO (10 % v/v, Figure V.5e).  
 
	  
Figure V.57	  ‘On-Chip’ protocol for examining artificial metallonuclease activity using the 
Bioanalyzer 2100. 
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Cu-­‐‑Phen	   Cu-­‐‑DPQ-­‐‑Phen	   Cu-­‐‑DPPZ-­‐‑Phen	   Cu-­‐‑DPPN-­‐‑Phen	  
	   	   	   	  
	   	   	   	  
	   	   	   	  
	   	  
	   	  
Figure V.58 [A] Electrograms of linearized pUC19 (400 ng) exposed to metal complex (500 nM) 
between 0 – 12.5 min on the Bioanalyzer 2100 with DNA 7500 microfluidic chips, [B] %DNA 
degradation (from peak height analysis of triplicate experiments, error bars ± S.D.) of pUC19 
exposed to Cu2+ complexes between 0-30 min, [C] %DNA degradation (from peak area analysis 
of triplicate experiments, error bars ± S.D.) of pUC19 exposed to Cu2+ complexes between 0-30 
min, and, [D] typical electropherograms generated by the Bioanalyzer 2100, L = ladder, lane 1 = 
pUC19 control, lanes 2-12 = pUC19 + complex exposed between 1-15 min for bis-phen (i.) and 
DPQ (ii.) samples and between 1-30 min for DPPZ (iii.) and DPPN (iv.) samples.	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Figure V.59	   Agarose gel electrophoresis of purified (EDTA free) supercoiled pUC19 (400 ng) 
with 1 mM Na-L-ascorbate incubated for 30 min with 500 nM of metal complexes (A), and in the 
presence of 1000 units of bovine liver catalase (B), 100 µM neocuproine (C), 1000 units of 
bovine SOD (D) and 10% v/v DMSO (E). Ctrl = pUC19 complex untreated control, Lanes 1-4 = 
500 nM Cu-Phen, Cu-DPQ-Phen, Cu-DPPZ-Phen and Cu-DPPN-Phen, respectively.  
 
V.3.7 Comparison study of pUC19 and pBC4 cleavage efficacy In order to 
determine the chemical nuclease on DNA of different guanine-cytosine (G-C) 
composition, commercially available pUC19 (2686 bp, 51% G-C, NEB, 
N3033L), and pBC4 (10673 bp, 59% G-C, donated by NEB) were analysed 
using gel electrophoresis in the presence of 1 mM of added reductant (Na-L-
acrobrate). It should be noted that both plasmids are supplied in EDTA buffered 
solution and so chemical nuclease activity was examined at higher complex 
concentration. Further, the pBC4 plasmid is recA+ and so does not have dimer 
deficiency usually associated with commercially available strains used for 
plasmid production. As a consequence, pBC4 migrates as two bands: the plasmid 
monomer followed by the dimer, and so this plasmid is not suitable to identify 
conversion between superhelical (Form I) to nicked (Form II) or linear (Form III) 
conformations due to the overlapping nature of the dimer and FII or FIII bands. 
This plasmid, however, can be exploited for artificial metallonuclease activity in 
its linearised form and we employed the type II endonuclease, AgeI, to generate 
FIII of the plasmid. For comparison purposes, pUC19 was also required in a 
linearised form and this was completed using the type II endonuclease, ScaI. 
Both pBC4 and pUC19 (400 ng) were then exposed, over 30 min, to between 2.5 
– 10.0 µM of the complex series, in the presence of 1 mM exogenous ascorbate, 
with each reaction containing the same amount of EDTA (40.0 µM) (Figure 
V.6). The chemical nuclease activity of Cu-DPQ-Phen and Cu-DPPZ-Phen 
were found to be independent of %G-C content with the DPQ complex being the 
most effective cleaving agent, overall, inducing complete digestion of both 
pUC19 and pBC4 upon 5 µM exposure. Cu-DPPN-Phen was found to have a 
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remarkably low effect on pUC19 oxidation but was more reactive toward pBC4. 
In contrast to the observed activities of the phenazine reagents, Cu-Phen was 
selectively reactive toward the plasmid of lower %G-C content, and this was 
evidenced through complete disappearance of pUC19 at a 5 µM, while the 
majority of pBC4 remained unaffected under identical conditions.  
The final aspect of this study involved the characterisation of nuclease activity on 
commercial (EDTA buffered) supercoiled pUC19 plasmid. In this experiment a 
fixed concentration of metal complex (10 µM) was exposed to 400 ng of 
superhelical DNA over 30 min in the presence of 1 mM added reductant (Figure 
V.7) and reactions all contained a final concentration of EDTA of 56 µM. 
Surprisingly, Cu-Phen was found to only partially nick (FI → FII) pUC19 while 
Cu-DPPN-Phen had little or no oxidative affect. Cu-DPQ-Phen and Cu-DPPZ-
Phen, however, facilitated complete conversion to the nicked form (FII) of 
pUC19 and this observation supports the enhanced stability of these chemical 
nucleases within a competing, EDTA chelated, environment.  
 
	   	  
Figure V.60	   Degradation of 400 ng of linearised plasmid pBC4 (A.) and pUC19 (B.) DNA with 
2.5, 5.0, and 10.0 µM of tested metal complex in the presence of 1 mM of added reductant for 30 
min at 37 oC; A. pBC4 (59% G-C); B. pUC19 (51% G-C).	  
	  
Figure V.61	   DNA cleavage reactions with 10 µM of Cu-Phen, Cu-DPQ-Phen, Cu-DPPZ-
Phen, and Cu-DPPN-Phen (lanes 1 – 4, respectively) with 400 ng of commercial (EDTA 
buffered) superhelical pUC19. Reactions were carried out with 1 mM of added Na-L-ascorbate 
over 30 min at 37 oC. 
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V.3.8 In vitro cytotoxicity toward SKOV3 cancer cells. 
Flow cytometric analysis using Guava ViaCount reagent was used to examine 
the cytotoxic properties of the complex series and the clinical antitumor agent, 
doxorubicin, on human SKOV3 ovarian cancer cells. This cell line was selected 
as it possesses both a mutant p53 gene and is intrinsically resistant to 
cisplatin.29,30 The ViaCount reagent determines viability of a cell population 
based upon differential membrane permeability of two fluorescent DNA 
intercalators which classify live and dead cell ratios. SKOV3 cells were 
incubated with drug concentrations ranging 100 – 0.10 µM over 24 h (Figure 
V.8). Cytotoxicity data used to calculate the IC50 values (at the 95% confidence 
interval) were derived from sigmoidal, non-linear regression curves (Fig. V.11). 
The IC50 complex trend follows Cu-DPPZ-Phen > Cu-DPQ-Phen > Cu-Phen > 
Cu-DPPN-Phen, with all compounds exhibiting significant 24 h in vitro 
cytotoxicity values of 0.59, 1.34, 1.40 and 3.55 µM, respectively. The most 
active complex, Cu-DPPZ-Phen, is comparable to that of the clinically used 
chemotherapeutic drug doxorubicin, with both agents exhibiting potent inhibitory 
values in the nano-molar region. Indeed, doxorubicin (adriamycin) was 
specifically selected for this study due to its clinical DNA damaging properties 
related to intercalation and topoisomerase II inhibition.31-33  
 
	  
Compound	   	   IC50	  (µM)	  
Cu-­‐Phen	   	   1.40	  
Cu-­‐DPQ-­‐Phen	   	   1.34	  
Cu-­‐DPPZ-­‐Phen	   	   0.59	  
Cu-­‐DPPN-­‐Phen	   	   3.55	  
Doxorubicin	   	   0.52	  
	  
Figure V.62	   Dose response inhibition and IC50 values (at the 95% confidence interval) of Cu2+ 
complexes and the clinical agent, doxorubicin, within SKOV3 human cancer cells over 24 h of 
drug exposure.	  
 
V.3.9 Electrochemistry and redox interactions with the superoxide radical 
anion and hydrogen peroxide The electrochemical behaviour of each complex 
was investigated in the absence and presence of an excess of Na-L-ascorbate and 
hydrogen peroxide (Figure V.9). All complexes exhibit well-defined, quasi-
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reversible redox profiles, with added oxidant or reductant having little effect on 
the reversibility of electron transfer reactions for each complex. Added reductant 
does shift the redox potentials anodically, while added oxidant shifts the complex 
redox potentials to more cathodic values. It is interesting to note that added 
reductant does increase the concentration of Cu(I) species in solution; this is 
reflected in the observed enhancement of complex oxidation peak currents. 
Conversely, on addition of peroxide, the expected increase in reduction peak 
currents for each complex, corresponding to a solution phase increase in Cu(II) 
species, is not observed. Thus, a kinetic constraint exists in the electrochemical 
regeneration of Cu(I) in the presence of oxidant, and may be indicative of the 
presence of copper-hydroperoxo species being generated in solution. The 
superoxide dismutase mimetic (SODm) properties of the group were investigated 
using the NBT (nitro-blue-tetrazolium) assay where a xanthine / xanthine oxidase 
system served as the source of superoxide radical anion (O2K−).34 All complexes 
displayed similar, concentration-dependent, SODm activity (Figure V.10b) and 
have notable catalytic rates with Kcat values ranging between 9.80 x 106 M-1 s-1 
(Cu-DPPZ-Phen) and 7.64 x 106 M-1 s-1 (Cu-DPPN-Phen). Complexes were 
then examined for their Fenton-like activity using the Amplex Red hydrogen 
peroxide assay (Invitrogen). None of the compounds were found to degrade H2O2 
(5 µM) in the absence of reductant (results not shown), however, in the presence 
of Na-L-ascorbate (100 µM) all four chemical nucleases displayed one-phase 
exponential decay of peroxide (Figure V.10a and Table V.4). The rate of 
degradation, overall, is kinetically sluggish with the rate constants for Cu-Phen 
and Cu-DPQ-Phen being 3.22 and 3.54 s-1, respectively, and being over two 
times that of Cu-DPPZ-Phen (1.56 s-1) and Cu-DPPN-Phen (1.26 s-1) 
complexes. It is significant to note the overlap between Fenton behaviour and 
chemical nuclease activity with the most efficient reagents, [Cu(DPQ)(Phen)]2+ 
and [Cu(Phen)2]2+, ablating H2O2 fluorescence at twice the rate of the DPPZ and 
DPPN complexes. Furthermore, given the series significant SODm activity and 
redox electrochemical profiles, it seems the rate-limiting factor in the chemical 
nuclease activity is, predominately, due to the subsequent metallo-hydroperoxo 
reaction.  
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   [i]	   	   [ii]	   	   	   [iii]	   	  
Entry	   Complex	   EPa	   EPc	   ∆EP	   EPa	   EPc	   EPa	   EPa	   EPc	   ∆EP	  
[a]	   1	   -­‐0.096	   -­‐0.171	   0.075	   	  0.074	   -­‐0.137	   0.069	   -­‐0.104	   	  0.190	   0.086	  
[b]	   2	   -­‐0.081	   -­‐0.175	   0.094	   -­‐0.	  51	   -­‐0	  129	   0.	  78	   -­‐0.124	   -­‐0.211	   0.087	  
[c]	   3	   	  0.082	   -­‐0.162	   0.080	   -­‐0.057	   -­‐0.131	   0.074	   -­‐0.105	   -­‐0.211	   0.	  06	  
[d]	   4	   -­‐0.100	   -­‐0.181	   0.081	   -­‐0.060	   -­‐0.144	   0	  084	   -­‐0.100	   -­‐0.190	   0.	  90	  
Figure V.63	   Cyclic voltammograms describing the redox behavior of 1 mM of complex, at a 
scan rate of 100 mV s-1, (solid black trace), and in the presence of 2 mM Na-L-ascorbate (dashed 
black trace), and 2 mM H2O2 (solid blue trace), [a] Cu-Phen, [b] Cu-DPQ-Phen, [c] Cu-DPPZ-
Phen and, [d] Cu-DPPN-Phen, and, electrochemical parameters (V) for complexes, and in the 
presence of added Na-L-ascorbate, and H2O2 (bottom). Analysis conducted in 10% v/v DMF; [i] 
complex without exogenous treatment (V) [ii] complex with added Na-L-ascorbate (V) [iii] 
complex with added H2O2 (V). 
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Figure V.64 [A] Fenton-like degradation of hydrogen peroxide (5 µM) in the presence of 5 µM of metal complex and 100 µM Na-L-ascorbate determined 
using the Amplex Red hydrogen peroxide assay kit (Invitrogen) (replicate experiments conducted on four separate occasions), a calibration curve is also shown 
which details the linear (r2 >0.99) fluorescent response achieved from hydrogen peroxide detection in the assay, [B] superoxide dismutase mimetic (SODm) 
activity determined by the xanthine/xanthine-oxidase system, metal complexes were examined between 0.98 – 0.33 µM at 25 °C under constant enzymatic 
production of superoxide (~1 µM / min) using the detector molecule, nitrobluetetrazolium chloride and this data was plotted as a function of V0/Vc (catalytic 
rate in the absence / presence of catalyst) as a function of [complex] to yield the catalytic rate Kcat in units, M-1 s-1.     
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Table V.4	  Kinetic properties of the complex series under Fenton-like and SODm conditions and 
catalytic cycle of Cu+/Cu2+ ions with molecular oxygen, superoxide and hydrogen peroxide.	  
Compound	   H2O2	  
(Fenton)	  
SODm	  
	   K	  (s-­‐1)	  [a]	   Kcat	  (M-­‐1	  s-­‐1)	  [b]	  
Cu-­‐Phen	   3.22	   8.97	  x	  106	  
Cu-­‐DPQ-­‐Phen	   3.54	   7.82	  x	  106	  
Cu-­‐DPPZ-­‐Phen	   1.56	   9.80	  x	  106	  
Cu-­‐DPPN-­‐Phen	   1.26	   7.64	  x	  106	  
  
 
[a] Fenton degradation of 5 µM hydrogen peroxide in the 
presence of 5 µM complex and 100 µM Na-L-ascorbate. [b] 
Superoxide dismutase mimetic (SODm) activity determined 
by the xanthine/xanthine-oxidase system. 
 
V.4 Discussion 
The incorporation of designer phenazine ligands in the “bis-phen”, 
[Cu(Phen)2]2+, chemical nuclease model pronounces DNA recognition and 
intercalation with significant enhancement to the dynamic binding constant for 
dipyrido[3,2-f:2′,3′-h]quinoxaline (DPQ) and dipyrido[3,2-a:2',3'-c]phenazine 
(DPPZ) containing complexes; [Cu(DPQ)(Phen)]2+ and [Cu(DPPZ)(Phen)]2+. To 
our knowledge these binding constants (Kapp ~3 x 107 M(bp)-1) are the highest 
reported to date for any existing copper(II) phenanthrene complex and surpass 
the [Cu(Phen)2]2+ cation by ~60 fold. Additionally, these values compare 
favourably with the binding constants of actinomycin D, identified in this study 
as 2.92 x 107 M(bp)-1, and rhodium(III) complexes rac-[Rh(phi)(phen)2]3+ and 
rac-[Rh(phi)2(bipy)]3+ (Kb ≈ 106 – 107 M-1)35 (where phi  = 9,10-phenanthrene-
quinone-diimine and bpy = 2,2′-bipyridine) but do not match the ctDNA binding 
affinity of ruthenium(II) DPPZ complexes, Δ-[Ru(DPPZ)(Phen)2]2+ or Λ-
[Ru(DPPZ)(Phen)2]2+ (Keff ≈ 108 M-1).6 Indeed, the lowest binding constant 
among the three phenazine complexes generated (Kapp ~6 x 106 M(bp)-1), 
observed for the [Cu(DPPN)(Phen)]2+ complex, is on par with many high affinity 
copper(II) binding constants in the literature.36 Interestingly, copper(II) DPQ and 
DPPZ compounds have shown only mediocre DNA binding constants (Kb = 104 – 
103 M-1) when complexed with amino acid chelators L-leucine, L-tryptophan and 
+
e-
Cu+
O2
O2
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L-tyrosine which, surprising, have far lower binding constants than the amino 
acid complex [Cu(glycine)(DPPZ)]+ (Kb ~106 M-1) along with [Cu(L-
arginine)(DPQ)]+ and [Cu(L-arginine)(DPPZ)] (Kb ~105 M-1 and Kapp ~106 M-
1).37-41 Enhanced binding constants (Kapp ≈ 5 × 106 M−1) were observed, however, 
for binuclear complexes, [{Cu(DPQ)(DMF)}2(µ-OH)2]2+ and 
[{Cu(DPPZ)(DMF)}2(µ-OH)2]2+, which feature two phenazine ligands spanning 
opposite directions along the hydroxide bridged Cu-Cu axis.42 Thus, in addition 
to the influence of an extended phenazine π-framework, our results suggest a 
prominent role for the ancillary chelated phenanthroline in nucleotide binding 
affinity. These ligands are presumably involved in secondary interactions with 
DNA bases or at the surface of the minor groove and may function to optimise 
complex binding geometry.17,18,43 
 
The complex series have distinctive nucleotide binding specificity compared 
with netropsin and actinomycin D. Their ability to similarly quench Hoechst 
33258 and ethidium bromide bound ctDNA flurogenic dyes, along with their 
broadly analogous displacement of limited bound ethidium to poly[d(G-C)2] and 
poly[d(A-T)2], departs substantially from the observed binding specificity of 
these classical minor groove binding or intercalating agents. Thermal melting 
analysis, however, reveals that both DPQ and DPPZ complexes extensively 
stabilize poly[d(G-C)2] denaturation, comparable to actinomycin D, and that the 
overall complex series have a large degree of similarity with this intercalator 
given their negligible stabilization on poly[d(A-T)2]. Taken together, it appears 
likely that the complexes intercalate DNA at both the minor and major groove, 
and this interaction is appreciably enhanced by the presence of coordinated 
phenazine ligands, in particular DPQ and DPPZ.  
 
We have reported a novel “on chip” microfluidic method for the Agilent 
Bioanalyzer 2100 for examining, with high precision, chemical nuclease activity. 
In our view, this technique offers advantages over existing methodologies (e.g. 
band densitometry) in the quantitation of dsDNA damage and undoubtedly has 
application in quantifying the activity of cytotoxic DNA damaging drugs, in 
particular those from families of structurally related agents. Further, this 
technique is suited for detecting sequence-specific metallodrug DNA interactions 
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as in our laboratory we have observed the effects of introducing a second 
endonuclease (SalI) with single site-recognition specificity on this sequence. The 
analysis methods we have employed on the Bioanalyzer 2100 to detect DNA 
degradation involve both peak height and peak area intensity reduction. Our 
motivation for applying both techniques stems from the observation that the Cu2+ 
complexes induced random damage, and thus asymmetric peak tailing on the 
pUC19 fragments (due to shearing chemical nuclease effects) were evident in 
each electrogram. This factor had an influence on peak area intensity and so we 
found that peak height analysis was suitable to employ as a tandem method to 
enhance the overall accuracy of the technique. Our work revealed the 
[Cu(DPQ)(Phen)]2+ complex as the most active chemical nuclease within this 
series, however, the degradation kinetics of this reagent are closely followed by 
[Cu(Phen)2]2+. The interaction of the phenazine complexes with pBC4 (59% G-
C) and pUC19 (51% G-C) plasmid DNA, however, reveal significant differences 
compared with the [Cu(Phen)2]2+ cation in terms of chemical nuclease efficacy. 
[Cu(Phen)2]2+ had enhanced activity toward the lower G-C containing plasmid 
(pUC19) while each of the phenazine complexes maintained, or enhanced, their 
activity toward the higher G-C content plasmid (pBC4). This data suggests Cu2+ 
phenazine compounds may have targeting properties toward CpG (cytosine-
phosphate-guanine) islands which are found in the promoter regions of many 
mammalian genes.44,45 Thus, it is of significant future importance to examine the 
DNA targeting properties of these phenazine complexes within cisplatin resistant 
cancer cell models such as SKOV3. While these complexes, in particular Cu-
DPPZ-Phen, display interesting in vitro chemotherapeutic potential compared 
with doxorubicin on SKOV3, their targeted DNA damaging effects have yet to 
be identified. Indeed, we have recently reported that although Cu-Phen has 
significant cytotoxic properties toward SKOV3, this agent non-selectively 
induces DNA damage and can be classified as a “promiscuous” cytotoxin.27 
All complexes in this study have excellent superoxide dismutase mimetic 
activities (Kcat 7.6 – 9.8 x 106 M-1 s-1) but are slow, kinetically, within the Fenton 
reaction (Cu+ + H2O2 → Cu2+ + ZOH + OH-). Significantly, however, Fenton 
breakdown follows linearized pUC19 chemical nuclease efficiency in the overall 
series (Cu-DPQ-Phen > Cu-Phen >> Cu-DPPZ-Phen > Cu-DPPN-Phen) with 
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DPQ and the bis-phen complex consuming peroxide at twice the rate constant of 
DPPZ and DPPN reagents.  
 
In summary, we have shown that phenazine functionalized Cu2+ phenanthroline 
complexes offer a clear enhancement toward DNA binding affinity relative to the 
well studied [Cu(Phen)2]2+ cation and possess the highest ctDNA binding 
affinities currently known for Cu2+ phenanthrene complexes. We have reported 
new on-chip methodology for determining dsDNA degradation and it is our 
opinion that both this technique and these Cu2+ phenazine reagents will have an 
important future role to play in the development of site-directed, gene-silencing, 
artificial metallonucleases for use as targeted chemotherapeutics for human 
disease. 
V.5 Materials And Methods  
V.5.1 Preparation of ligands and metal complexes. Chemicals and reagents of 
analytical grade for the preparation of organic ligands and metal complexes were 
purchased from Sigma-Aldrich (Ireland) and used without further purification.  
 
V.5.1.1 Preparation of 1,10-phenanthroline-5, 6-dione (phendio). Phendio 
was prepared according to the literature method reported by Dickeson and 
Summers with slight modification.24 1,10-phenanthroline (4.00 g, 22.19 mmol) 
and potassium bromide (4.00 g, 33.6 mmol) were thoroughly mixed and slowly 
added to an ice-cold mixture of H2SO4 (40 mL) and HNO3 (20 mL). The solution 
was refluxed for 3 hours at 100 °C, then cooled to room temperature, poured onto 
crushed ice (~400 mL) and neutralised with an aqueous NaOH solution (80.0 g 
per 400 mL) to a pH between 4-5, yielding a yellow solution. The solution was 
extracted by CHCl3 (in 8 × 100 mL portions). The organic phase was combined 
and dried with anhydrous magnesium sulphate then filtered before being 
evaporated to dryness, whereupon a bright yellow solid (4.03 g) was obtained. 
The product could be further purified by recrystallisation from HPLC grade 
methanol but was sufficiently pure to use in subsequent reactions. Yield: 4.03 g 
(86 %). 1H NMR (400 MHz, CDCl3): 9.05 (dd, J = 4.6, 1.8 Hz, 2H), 8.44 (dd, J = 
7.9, 1.8 Hz, 2H), 7.52 (dd, J = 7.9, 4.6 Hz, 2H). IR (ATR, cm-1): 3348, 3061, 
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1678, 1559, 1458, 1412, 1290, 1204, 1114, 1009, 924, 806, 734. Solubility: 
DMF, EtOH, DMSO (partially), Mp: 258-260 °C.  
V.5.1.2 Preparation of dipyrido[3,2-f:2′,3′-h]quinoxaline (DPQ). DPQ was 
prepared according to the literature method reported by Hambley et al. with 
some modification.26 To a solution of phendio (0.510 g, 2.44 mmol) in water (35 
mL) was added ethylenediamine (0.70 mL, 7.50 mmol) and the resultant 
suspension was refluxed for 12 hours at 60 °C. The resulting product was washed 
with water (10 mL) and minimum volume of diethyl ether. Yield: 0.372 g (66 
%). 1H NMR (400 MHz, CDCl3): 9.47 (dd, J = 8.2, 1.8 Hz, 2H), 9.24 (dd, J = 
4.3, 1.8 Hz, 2H), 9.19 (s, 2H), 7.96 (dd, J = 8.2, 4.3 Hz, 2H). IR (ATR, cm-1): 
2990, 1570, 1472, 1466, 1206, 1073, 1077, 825, 803, 739. Solubility: DMF, 
EtOH, DMSO (partially). Mp: 330-335 °C. 
 
V.5.1.3 Preparation of dipyrido[3,2-a:2′,3′-c]phenazine (DPPZ). DPPZ was 
prepared according to literature with slight changes made to the method.24 A 
methanolic solution (20 mL) of 1,2-phenylenediamine dihydrochloride (0.640 g, 
3.53 mmol) was refluxed until it was dissolved. A warm ethanolic solution of 
phendio (0.500 g, 2.38 mmol) was prepared (20 mL), added over the methanolic 
solution and refluxed with constant stirring for 3 hours. The resulting solution 
was vacuum filtered and recrystallised from EtOH producing metallic-like 
orange filaments. Yield: 0.521 g (78 %). 1H NMR (400 MHz, CDCl3): 9.58 (dd, J 
= 8.1, 1.7 Hz, 2H), 9.20 (dd, J = 4.5, 1.7 Hz, 2H), 8.29 (dd, J = 6.5, 3.4 Hz, 2H), 
7.86 (dd, J = 6.5, 3.4 Hz, 2H), 7.73 (dd, J = 8.1, 4.5 Hz, 2H). IR (ATR, cm-1): 
3040, 1615, 1570, 1486, 1412, 1336, 1077, 1072, 808, 739. Solubility: DMF, 
EtOH, DMSO (partially). Mp: 248-253 °C.   
 
V.5.1.4 Preparation of benzo[i]dipyrido[3,2-a:2′,3′-c]phenazine (DPPN). 
DPPN was prepared according to literature with slight changes made to the 
method.25 To a solution of phendio (0.300 g, 1.422 mmol), in EtOH (45 mL) was 
added 2,3-diaminonaphthalene (0.339 g, 2.136 mmol) and the resulting 
suspension was refluxed for 3 hours, during which time an orange precipitate 
formed. The precipitate was vacuum filtered, washed with cold ethanol and 
allowed to dry. Yield: 0.443 g (93 %). 1H NMR (400 MHz, CDCl3): 9.49 (dd, J = 
8.1, 1.8 Hz, 2H), 9.16 (dd, J = 4.4, 1.8 Hz, 2H), 8.80 (s, 2H), 8.09 (dd, J = 6.5, 
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3.1 Hz, 2H), 7.68 (dd, J = 8.1, 4.4 Hz, 2H), 7.53 (dd, J = 6.5, 3.1 Hz, 2H). IR 
(ATR, cm-1): 3362, 1628, 1583, 1565, 1409, 1360, 1274, 1128, 1070, 1033, 892, 
871, 850, 817. Solubility: DMF (partially). Mp: 283-285 °C.  
  
V.5.1.5 Preparation of [Cu(Phen)](NO3)2. To a solution of copper(II) nitrate 
hemipentahydrate (1 g, 4.3 mmol), in EtOH (75 ml) was added Phen (0.78 g, 4.3 
mmol) and the resulting suspension was refluxed for 2 hours. The solution was 
left to stand for 12 hours, then vacuum filtered and washed with a minimum 
volume of cold EtOH.  Yield: 1.43 g (90 %). Anal. Calc. for C12H8CuN4O6: C, 
39.19; H, 2.19; N, 15.23. %Found: C, 39.65; H, 2.06; N, 14.92. IR (ATR, cm-1): 
3068, 1583, 1451, 1426, 1270, 1151, 1110, 1011, 972, 847, 807, 739, 719. 
Solubility: DMF, EtOH.  
 
V.5.1.6 Preparation of [Cu(Phen)2](NO3)2 (Cu-Phen). This complex was 
prepared according to the method reported by Prisecaru et al.27  
V.5.1.7 General procedure for preparing [Cu(N,N´)(phen)](NO3)2 complexes 
(where N,N´ = DPPZ, DPPN and DPQ). To a solution of [Cu(phen)(NO3)2] 
(0.1 g, 0.27 mmol) in EtOH (30 mL) was added 0.27 mmol of either DPQ (0.063 
g), DPPZ (0.076 g) or DPPN (0.090 g) and the resulting suspension was stirred 
for 12 hours at 50 °C. The solution was vacuum filtered and washed with a 
minimum volume of cold EtOH. [Cu(DPQ)(phen)](NO3)2·0.5H2O (Cu-DPQ-
Phen). Yield: 0.1207 g (73 %). Anal. Calc. for C26H17CuN8O6.5: C, 51.28; H, 
2.81; N, 18.40. %Found: C, 51.15; H, 2.29; N, 18.68. IR (ATR, cm-1): 3034, 
1581, 1472, 1360, 1288, 1210, 1081, 818, 718. Solubility: DMF, DMSO 
(partially). [Cu(DPPZ)(phen)](NO3)2 (Cu-DPPZ-Phen). Yield: 0.0709 g (41 
%). Anal. Calc. for C30H18CuN8O6: C, 55.43; H, 2.79; N, 17.24. %Found: C, 
56.38; H, 2.88; N, 17.83. IR (ATR, cm-1): 3023, 1578, 1451, 1376, 1292, 1076, 
819, 718, 729. Solubility: DMF, DMSO (partially). 
[Cu(DPPN)(phen)](NO3)2·2H2O (Cu-DPPN-Phen). Yield: 0.1341 g (67 %). 
Anal. Calc. for C34H24CuN8O8: C, 55.47; H, 3.29; N, 15.22. %Found: C, 55.42; 
H, 2.76; N, 15.38. IR (ATR, cm-1): 3020, 1578, 1518, 1375, 1358, 1290, 1046, 
868, 719. Solubility: DMF, DMSO (partially).  
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V.5.2 DNA binding studies. 
The fluorescence quenching assay, the competitive ethidium bromide 
displacement assay and viscosity measurements we all conducted according to 
the method reported by Kellett et al.28 (see section III.4.4) 
 
V.5.2.1 Fluorescence quenching for poly[d(A-T)2] and poly[d(G-C)2]. 
Solutions of double stranded alternating co-polymers, poly[d(A-.Z:-T)] 
(Sigma PO883, ε260 = 13,100 M (bp)-1 cm-1) and poly[d(G-Z:!-C)] (Sigma 
P9389, ε260 = 16,800 M(bp)-1 cm-1) were prepared in nuclease free water and 
quantified on a Cary 100 UV-vis spectrophotometer. A working solution of 50 
µM poly[d(A-T)2] (or poly[d(G-C)2]) along with 10 µM ethidium bromide (EtBr) 
in HEPES buffer (80 mM, pH = 7.2) and NaCl (40 mM) was prepared. Stock 
solutions of metal complexes, metal salts and groove binding drugs were 
prepared a ~4 mM in DMF and further diluted with 80 mM in HEPES buffer. 50 
µL of the poly[d(A-T)2] (or (poly[d(G-C)2]) EtBr working solution were placed 
in each well of a 96 well microplate with the exception of the blanks which 
contained 95 µL of 80 mM HEPES and 5 µM of EtBr. Serial aliquots of the 
tested compound were added to the working solutions and the volume adjusted to 
100 µL in each well such that the final concentration of nucleotide and EtBr were 
25 µM and 5 µM respectively. The plate was then allowed to incubate at room 
temperature for 5 min before being analysed using a Bio-Tek synergy HT multi-
mode microplate reader with excitation and emission wavelengths being set to 
530 and 590 nm for EtBr detection. Concentrations of the tested compounds 
were optimized such that fluorescence was 30-40% of the initial control at their 
highest reading. Each drug concentration was measured in duplicate. From a plot 
of fluorescence versus added drug concentration, the Q value is given by the 
concentration required to effect 50% removal of the initial fluorescence of the 
bound dye. 
 
V.5.3 Thermal melting experiments. Analysis was carried out on an Agilent 
Cary 100 dual beam spectrophotometer equipped with a 6x6 Peltier multicell 
system with temperature controller. For poly[d(G-C)2]; In a final volume of 1 mL 
using Starna black-walled quartz cuvettes with tight-fitting seals, 2 mM of 
NaOAc buffer (pH = 5.0), 1 mM NaCl and poly[d(G-C)2] (Sigma, P9389) were 
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added to give a final absorbance of between 0.18 – 0.20 absorbance units at 260 
nm (εmax = 8,400 M
-1 cm-1). For poly[d(A-T)2]; in a final volume of 1 mL using 
Starna black-walled quartz cuvettes with tight-fitting seals, 50 mM NaOAc 
buffer (pH = 5.0), 250 mM NaCl and poly[d(A-T)2] (Sigma, PO883) were added 
to give a final absorbance of between 0.18 – 0.20 absorbance units at 260 nm 
(εmax = 6,600 M
-1 cm-1). Stock solutions of metal complexes, netropsin and 
actinomycin D, prepared beforehand in DMF, were dissolved in 80 mM HEPES 
(pH 7.2). An aliquot of test reagent was then added to each cuvette such that an r 
value of 0.1 was achieved (r = [compound]/[nucleotide]). The test reagent and 
respective alternating co-polymer were then incubated for 10 minutes at 20 °C 
prior to commencing the temperature ramp. Thermal melting measurements were 
recorded at 260 nm at 0.25 s intervals. Temperature was ramped at 3 °C / min 
over then range 20.0 – 97.0 °C. The spectral bandwidth (SBW) was set to 1. 
Temperature was calibrated, for each measurement, using a temperature probe 
placed in an identical black-walled cuvette containing equivalent buffer and 
NaCl. Samples were run in triplicate and the melting temperature, TM (°C), was 
calculated using the built-in derivative method on the instrument. 
V.5.4 Artificial metallonuclease activity 
	  
V.5.4.1 Generation of pUC19 DNA. The vector pUC19 was generated 
following the transformation of E. coli using an LB ampicillin resistant media 
protocol and extracted using a maxi-prep kit protocol (NucleoBond Xtra Midi 
Plus, EF-Macherey-Nagel) and then quantified using the NanoDrop (ND-1000 
Spectrophotometer). 
 
V.5.4.2 Gel electrophoresis experiments on pUC19 DNA. Reactions were 
carried out according to the literature procedure by Kellett et al.46 (see section 
III.4.5.1) Trapping experiments with 100 µM neocuprione (Sigma, N1501), 10% 
v/v of DMSO, and 1000 units of bovine SOD enzyme (Sigma, S7571) and 1000 
units of catalase enzyme from bovine liver (Sigma, C1345) were also examined 
using this procedure. 
 
V.5.4.3 Linearization of supercoiled pUC19. In a total volume of 20 µL using 5 
µg of supercoiled pUC19, 5 µL of 10x HEPES buffer, 2.5 µL of 20,000 U/mL 
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HindIII (NEB), 5 µL of NeBuffer 2 (NEB), 1 µL BSA (NEB) and nuclease free 
water were added. This mixture was allowed to incubate at 37 oC for 2.5 h after 
which 1 µL of this mixture was loaded onto an agarose gel to confirm 
linearization. Linear DNA from the mixture was then purified from the 
enzymatic reaction, using a QIAquick Purification column (QIAGEN. Linearised 
DNA was quantified using the NanoDrop (ND-1000 Spectrophotometer).  
 
V.5.4.4 Microfluidic chip analysis of DNA degradation on the Agilent 
Bioanalyzer 2100. In a total volume of 20 µL using 80 mM HEPES buffer 
(Fisher) at pH 7.2 with 25 mM NaCl, 500 nM of the complex was mixed with 
400 ng of linear pUC19 and 1 mM Na-L Ascorbate. Samples were incubated at 
37 oC for between 1-30 min and quenched with both neocuproine (100 µM) and 
EDTA (100 µM) before being loaded onto a DNA 7500 microfluidic chip as per 
the manufacturers protocol.23 Data was then collected using Agilent 2100 
Bioanalyzer. Electrograms generated by the Bioanalyzer 2100 for all complexes 
are available in the supporting material. 
 
V.5.4.5 Chemical nuclease of linearized pUC19. In a total volume of 20 µL 
using 400 ng of supercoiled pUC19 (2686 bp), 1 µL SalI (20,000 U/mL, NEB, 
cleaving the plasmid at one site located at 429 bp), 2 µL 10x HEPES buffer, 2 µL 
NEBufer 3.1, and nuclease free water were added. The reaction mixture was 
allowed to incubate at 37 °C for 1.5 h, after which the endonuclease was heat 
inactivated at 65 oC for 20 min. After cooling, an aliquot of the stock complex 
and 1 mM Na-L ascorbate were added to the reaction mixture and the final 
concentration of EDTA was adjusted (where appropriate) to ensure a final 
concentration 56.0 µM before incubation at 37 oC for 30 min was completed. The 
reaction was then quenched with 6x loading dye (Fermentas) and DNA 
fragments were subjected to gel electrophoresis (prepared and stained as 
previously described).  
 
V.5.4.6 Chemical nuclease of linearized pBC4. In a total volume of 20 µL 
using 400 ng of supercoiled pBC4 (10,673 bp), 1 µL AgeI (20,000 U/mL, NEB, 
cleaving the plasmid at one site located at 5037 bp), 2 µL 10x HEPES buffer, 2 
µL NEBufer 1, 0.2 µL BSA and nuclease free water were added.  Reaction 
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mixture was allowed to incubate at 37 oC for 1.5 h, after which the endonuclease 
was heat inactivated at 65 oC for 20 min. After cooling, an aliquot of the stock 
complex and 1 mM Na-L ascorbate were added to the reaction mixture and the 
final concentration of EDTA was adjusted (where appropriate) to ensure a final 
concentration 40.0 µM before incubation at 37 oC for 30 min was completed. The 
reaction was then quenched with 6x loading dye (Fermentas) and DNA 
fragments were subjected to gel electrophoresis (prepared and stained as 
previously described).  
 
V.5.5 Cell culture experiments SKOV-3 cells were grown in RPMI 1640 
supplemented with 10% fetal calf serum (FCS) at 37 oC in a humidified 
atmosphere with 5% CO2. Compound viability was tested using Guava Viacount 
reagent following 24 h exposure. Positive control, doxorubicin, was purchased 
from Sigma Aldrich as a European Pharmacopoeia reference standard. DMSO 
stocks for the complexes Cu-Phen, Cu-DPQ-Phen, Cu-DPPZ-Phen, Cu-
DPPN-Phen and doxorubicin were prepared in 1 mL ranging from 11-34 mM. 
 
V.5.5.1 ViaCount Assay SKOV3 cells were seeded at an initial density of 4 x 
104 cell/mL in 96-well plates and incubated overnight prior to drug addition. 
DMSO stocks of the complexes and controls diluted in RPMI 1640 containing 
10% FCS, to give following final concentrations in 200 µL wells: 5.0, 2.5, 1.0, 
0.5 and 0.25 µM. A DMSO control of the highest incubation concentration was 
also included. Cells were incubated for 24 h at 37oC in a humidified atmosphere 
with 5% CO2. After 24 h exposure, spent media was removed and cells were 
washed once with 200 µL PBS and detached using 50 µL 1X trypsin subsequent 
addition of 50 µL media. Cells were transferred to 96-well round bottom plates 
with 100 µL Millipore’s ViaCount reagent incubated at room temperature in the 
dark for 10 min. Viability data was collected on Guava EasyCyte HT flow 
cytometer using Guava Viacount software. 
V.5.6 Electrochemistry Electrochemical measurements were performed on a 
Solartron 1825 potentiostat and data were analysed using CorrView software. 
Electrochemistry was performed in 1 mM solutions of each complex, made up in 
0.1 M TBAPF6 in 10% v/v DMF, as the supporting electrolyte. Concentrations of 
added reductant and oxidant were 2 mM to ensure an excess was present in 
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solution (ratio 1:2, complex:reductant/oxidant). Electrochemical cell set-up: 
Glassy Carbon working electrode (2 mm diameter), platinum wire counter 
electrode, non-aqueous Ag/Ag+ reference electrode (E1/2 = 0.075 V versus 
Fc/Fc+). Glassy carbon electrodes were polished using alumina oxide powder 
(0.05 micron) on a microcloth (Buehler). Cyclic voltammetric data presented 
were obtained after steady-state was attained, at a scan rate of 100 mV s-1, with 
scans initiating in the cathodic direction.  
 
V.5.7 Superoxide dismutase mimetic activity. The SOD mimetic activities of 
the complexes were determined using a nitroblue tetrazolium (NBT) assay,34 in 
which the xanthine/xanthine oxidase system serves as the source of superoxide 
radicals. The quantitative reduction of NBT to blue formazan by O2Z− was 
followed spectrophotometrically using a thermostatically controlled Agilent Cary 
100 dual-beam spectrophotometer at 550 nm at 25 °C. Reagents were obtained 
from Sigma–Aldrich and the assays were run in a total volume of 3 mL. 
Tabulated results were derived from linear regression analyses and are reported 
as Vo / Vc (rate in the absence of catalyst / rate in the presence) versus catalyst 
concentration which yielded the catalytic rate (Kcat M-1 s-1). 
 
V.5.8 H2O2 breakdown assay. A 5 mL stock solution of 100 µM Amplex Red 
containing 10 mM Amplex Red reagent and 10 U/ml horseradish Peroxidase 
(HRP) was prepared in 1x buffer as per Amplex Red hydrogen 
Peroxide/Peroxidase assay kit instruction (Invitrogen – Cat. A22188). A standard 
fluorescence response curve from H2O2 was obtained by adding a series of 
aliquots (0.5 – 5 µM) H2O2 the Amplex Red stock solution and the volume was 
adjusted to 100 µL with 1x buffer in each sample well. An aliquot containing 5 
µM of tested compounds, 5 µM H2O2 and 100 µM Na-L-Ascorbate that were 
previously incubated between 0 – 120 min were added to 50 µL Amplex Red 
solution and again the volume was adjusted to 100 µL using 1x buffer. The 
fluorescence intensity of the reaction mixture was measured with a Bio-Tek 
synergy HT multi-mode microplate reader equipped with excitation and emission 
filters at 530 nm and 590 nm.47  
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V.5.9 Optimization of thermal melting on poly[d(A-T)2] and poly[d(G-C)2] 
 
V.5.9.1 Overview. In order to examine the stabilization effects on poly[d(G-C)2] 
and poly[d(A-T)2], a series of optimisation experiments were conducted to 
identify the most suitable pH and ionic buffer strength required (ESI). Previous 
reports on drug binding effects to G-C polynucleotides, where strands are bound 
through three hydrogen bonds at each base pair, could not be identified owing to 
polymer stabilization beyond the limit of detection (>110 °C). In our 
experiments, suitable conditions for the melting of poly[d(G-C)2] (TM = 80.74 
°C) were found at pH 5.0 in 2.0 mM sodium acetate buffer containing 1.0 mM 
NaCl. In order to maintain similar experimental conditions for the thermal 
melting on poly[d(A-T)2], where strands are bound through two hydrogen bonds 
between each base pair only, pH 5.0 sodium acetate buffered (50 mM) solutions 
containing 250 mM of NaCl were employed for the thermal melting of this 
polynucleotide (TM = 69.32 °C). 
 
V.5.9.2 Poly[d(G-C)2]. It was necessary to carry out experimental optimisation 
before commencing thermal melting analysis as it was noted in literature 
previously published, the TM for poly(dG-dC)poly(dC-dG) could not be 
determined as it was beyond the level of detection, in some cases >110 °C.48.49 
Thermal melting analysis was initially investigated in potassium phosphate 
buffer at pH 7.2 with varying NaCl concentrations of 0.1 mM, 1 mM and 2 mM 
generating TM values of 90.60 °C, 89.57 °C and 91.52 °C for the untreated 
polymer, respectively. It was therefore necessary to identify conditions where the 
TM of poly[d(G-C)2] would be lower prior to the addition of any stabilizing test 
compound. Varying concentrations (2.0 – 5.0 mM) of sodium acetate buffer 
(NaOAc) at pH 5.0 were then investigated in the presence and absence of added 
NaCl (Table 5). 2.0 mM NaOAc buffer with 1.0 mM of added NaCl gave a 
favourable TM value of 80.74 °C which was used in all thermal denaturation 
studies. 
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Table V.5	   Thermal melting analysis of poly[d(G-C)2] under alternating buffer, pH and ionic 
strength.	  
Buffer	  	   Buffer	  (mM)	   Added	  NaCl	  (mM)	   TM	  (°C)	  	  
Phosphate	  (pH	  7)	   50	   0.1	   90.60	  
50	   1.0	   89.57	  
50	   2.0	   91.52	  
NaOAc	  (pH	  5)	   2.0	   0.0	   73.02	  
2.0	   1.0	   80.74	  
2.5	   0.0	   89.02	  
5.0	   0.0	   86.02	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Chapter VI 
	  
The phosphate clamp: sequence selective 
nucleic acid binding profiles and 
conformational induction of endonuclease 
inhibition by cationic Triplatin complexes 
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VI. 1 Abstract  
The substitution-inert polynuclear platinum(II) complex (PPC) series, [{trans-
Pt(NH3)2(NH2(CH2)nNH3)}2-µ-(trans-Pt(NH3)2(NH2(CH2)nNH2)2}](NO3)8, 
where n = 5 (AH78P), 6 (AH78 TriplatinNC) and 7 (AH78H),  are potent non-
covalent DNA binding agents where nucleic acid recognition is achieved through 
use of the “phosphate” clamp where the square-planar tetra-am(m)ine Pt(II) 
coordination units all form bidentate N-O-N complexes through hydrogen 
bonding with phosphate oxygens. The modular nature of PPC-DNA interactions 
results in high affinity for calf thymus DNA (Kapp ~5x107 M-1). The phosphate 
clamp-DNA interactions result in condensation of superhelical and B-DNA, 
displacement of intercalated ethidium bromide, and facilitate cooperative binding 
of Hoechst 33258 at the minor groove. The effect of linker chain length on DNA 
conformational changes was examined and the pentane-bridged complex, 
AH78P, was optimal for condensing DNA with results in the nanomolar region. 
Analysis of binding affinity and conformational changes for sequence-specific 
oligonucleotides by ITC, dialysis, ICP-MS, CD and 2D-1H NMR experiments 
indicate that two limiting modes of phosphate clamp binding can be 
distinguished through their conformational changes and strongly suggest that 
DNA condensation is driven by minor-groove spanning. Triplatin-DNA binding 
prevents endonuclease activity by type II restriction enzymes BamHI, EcoRI and 
SalI and inhibition was confirmed through the development of an on-chip 
microfluidic protocol.        
  
VI.2 Introduction 
The X-ray crystal structure of the Dickerson-Drew Dodecamer, (DDD, 
[d(CGCGAATTCGCG)]2) with the non-covalently binding trinuclear platinum 
compound TriplatinNC (AH78), Scheme VI.1,  described a new mode of ligand-
DNA recognition distinct from the conventional modes of intercalation and 
groove binding (NDB entry 2DYW) (1). Hydrogen bonding with phosphate 
oxygens results in either backbone tracking or groove spanning through 
formation of “phosphate clamps” where the square-planar tetra-am(m)ine Pt(II) 
coordination units all form bidentate N-O-N complexes with phosphate oxygen 
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OP atoms, Figure VI.1. The generality of the motif has been confirmed by a 
second crystal and molecular structure with TriplatinNC-A (AH44) – that is with 
L = NH3 (6+) instead of –NH2(CH2)6NH3+ (8+), See Scheme VI.1 (2). In both 
cases, the conformation in the DDD-Phosphate Clamp complexes differs 
significantly from that of the native structure (NDB entry BDL084). The 
structural distortions caused are principally axial bending and axial path length 
shortening ratio, which are significantly greater than those of the control DDD. 
Helical parameters are perturbed and the minor groove width profile is modestly 
impacted. The axial bending is similar to that induced by the cisplatin intrastrand 
1,2-GG adduct, (3), but achieved solely through H-bonding and electrostatic 
interactions. The phosphate clamp is analogous to that of the guanidino group of 
arginine which shows an analogous, but attenuated clamping ability in which two 
OP atoms form a clamp-like structure, the Arginine Fork (4, 5). The discovery of 
new molecular mechanisms by which small molecules modify DNA structure, 
reactivity and biological repair contributes significantly to potential drug 
development as DNA is a clinically important target (6, 7). The broad class of 
polynuclear platinum complexes (PPCs) may now be divided into those 
complexes capable of Pt-DNA covalent bond formation such as BBR3464, the 
only “non-classical” platinum drug to enter human clinical trials, and those “non-
covalently binding” compounds depicted in Scheme VI.1 with inherently 
substitutionally-inert PtN4 coordination spheres (8).  Specifically, TriplatinNC 
has demonstrated interesting biological activity in its own right. The complex is 
cytotoxic at micromolar concentrations, similar to cisplatin, in a range of human 
tumor cell lines but is unaffected by serum degradation (9). The induction of 
apoptosis in tumor cells suggests that covalent Pt-DNA bond formation is not a 
prerequisite for antitumor activity for compounds with high DNA affinity, a 
further shift in the structure-activity paradigm of platinum antitumor agents.  
Simultaneous multi-element imaging using NanoSIMS (nano-scale secondary 
ion mass spectrometry), exploiting the novel combination of 195Pt and 15N in 
platinum-am(m)ine antitumor drugs, confirmed localization of TriplatinNC in the 
nucleolus of MCF7 cells (10), with implications for interaction with ribosomal 
DNA and/or RNA within the nucleolus. 
 
	  177	  
The nature of the PPC chemotype means it is a discrete and modular DNA 
binding device with high potential as a drug-design scaffold. Within the non-
covalently binding motif, possible systematic changes include dinuclear 
complexes such as [{Pt(NH3)3}2-µ-spermidine]5+ and [{Pt(NH3)3}2-µ-spermine]6+ 
connected via polyamine central linkers rather than the {Pt(tetraamine)} 
trinuclear unit, and the use of the 'dangling' amine versus NH3 as ligand to add 
further overall charge diversity (8). Binding studies of AH44 to DNA polymers 
of varying base composition—or topology—revealed high affinity and limited 
discrimination in terms of binding constant and mode (11,12). Both TriplatinNC 
and AH44 are significantly more effective nucleic acid condensing agents 
compared to spermine (11,12). A further modification to affect DNA binding 
interactions is variation of alkanediamine chain length in the trinuclear structures 
of Scheme VI.1. In principle, modifying distances between phosphate clamp 
coordination units (12.46 Å from NDB entry 2DYW) could be used to maximize 
overlap with phosphate-phosphate distances of RNA and differing DNA 
conformations. In this contribution we describe the effects of TriplatinNC 
congeners, Scheme VI.1, on DNA binding affinity and inhibition of 
endonuclease enzyme recognition by various biophysical and molecular 
biological methods. Preliminary comparisons with tRNA affinity are made and in 
all cases the minor groove binding agents, netropsin and pentamidine, along with 
the cationic cobalt(III) complex, [Co(NH3)6]3+, were examined to delineate new 
properties within this class of drug molecule. A general question in all of this 
work is: how do the solution binding properties reflect the crystallographically 
determined modes of groove spanning and backbone tracking as shown in Figure 
VI.1. This contribution demonstrates that the two distinctive limiting interaction 
modes may be distinguished by their formational dependence on tertiary DNA 
helical topology and G⋅C content and suggests that DNA condensation is driven 
by minor-groove recognition. 
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Scheme VI.1	  Molecular structures of [{Pt(NH3)3}2-µ-{trans-Pt(NH3)2(NH2(CH2)6NH2)2}]6+  
(AH44, TriplatinNC-A) and [{trans-Pt(NH3)2(NH2(CH2)nNH3)}2-µ-(trans 
Pt(NH3)2(NH2(CH2)nNH2)2}]8+ cations where n = 5 (AH78P), 6 (AH78H, TriplatinNC) and 7 
(AH78H).  
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Figure VI.65	   Perspective views of the double-stranded B-DNA Dickerson-Drew dodecamer 
bound to TriplatinNC via backbone tracking (A) and groove-spanning (B) modes (1, NDB entry 
2DYW). DNA backbone (connecting P positions), orange; carbon, grey80; oxygen, red; nitrogen, 
slate (all in cartoon mode). Triplatin complex (space-filling mode) atoms coloured as DNA; 
platinum, grey30. Platinum(II) amine nitrogen atoms, and selected phosphate coordinated oxygen 
atoms, engaged in phosphate clamping shown with dotted surface. Figures generated by PyMOL 
Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC. 
	  
VI. 3 Materials and Methods 
Chemicals and deoxyribonucleic acid sodium salt from salmon testes were 
purchased from Sigma Aldrich (Ireland) and used without further purification. 
Ultra Pure calf-thymus DNA (CT-DNA, Cat.15633-019) and transfer RNA 
(tRNA, AM7119) was supplied from Invitrogen, supercoiled plasmid DNA 
(pUC19, Cat. N3033L) and restriction endonucleases AatII (R0117 S; 20,000 
U/ml), BamHI (R0136 S; 20,000 U/ml), EcoRI (R0101 S; 20,000 U/ml) and SalI 
(R 0138 S; 20,000 U/ml) were supplied by NEB. Fluorescence measurements 
A.	  
B.	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were conducted using a Bio-Tek Synergy HT multi-mode microplate reader; 
viscosity was measured with DV-II Programmable Digital Viscometer equipped 
with Enhanced Brookfield UL Adapter; thermal melting analysis was carried out 
on an Agilent Cary 100 dual beam spectrophotometer equipped with a 6x6 
Peltier system and microfluidic chip experiments were conducted on the 
Bioanalyzer 2100 platform using DNA 7500 chips supplied by Agilent 
Technologies Ireland. 
 
VI.3.1. Preparation of Triplatin complexes [{trans-
Pt(NH3)2(NH2(CH2)nNH3)}2-µ-trans-Pt(NH3)2(NH2(CH2)nNH2)2] (NO3)8  
The “non-covalent’ compounds with varying chain lengths (n = 5,6,7) were 
synthesized by adapting published procedures (8,13). The complexes AH78P, 
AH78 (TriplatinNC) and AH78H were characterized by C,H,N, elemental 
analysis and 1H and 195Pt NMR Spectroscopy. Purity was confirmed by HPLC. 
For n = 5, 1H NMR (δ(1H), D2O, ppm):  2.99 (t, 4H); 2.66 (t,12H); 1.66 (m, 
16H); 1.38 (m,8H).  δ (195Pt NMR, D2O, ppm): -2675. HPLC Purity 99.8%. For n 
= 6, 1H NMR (δ(1H), D2O, ppm):  2.95 (t, 4H); 2.62 (t,12H); 1.60 (m, 16H); 1.38 
(m,16H).  δ (195Pt NMR, D2O, ppm): -2680. HPLC Purity 99.0%. For n = 7, 1H 
NMR (δ(1H), D2O, ppm):  2.98 (t, 4H); 2.62 (t,12H); 1.62 (m, 16H); 1.32 
(m,24H).  δ (195Pt NMR, D2O, ppm): -2680. HPLC Purity 99.0% 
 
VI.3.2. DNA binding experiments  
VI.3.2.1. Competitive ethidium bromide displacement Experiments were 
conducted in a similar manner to the high-throughput method reported by Kellett 
et al. (14). Each drug concentration was measured in triplicate, on at least two 
separate occasions, and the apparent binding constants were calculated using Kapp 
= Kb x 12.6/C50 where Kb = 8.80 x 106 M(bp)-1 (Kapp = apparent binding 
constant). (see section III.4.4.1) 
 
VI.3.2.2. DNA binding kinetic studies A working solution of 20.0 µM of 
ctDNA along with 25.2 µM of EtBr in HEPES buffer (80 mM, pH = 7.2) and 
NaCl (40 mM) was prepared. 50 µL of DNA-EtBr working solution were placed 
in each well of a 96 well microplate with the exception of the controls, which 
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contained 100 µL of buffer. A 1.0 µM aliquot of test complex was then added to 
each well plate such that an r value of 0.1 was achieved (r = [complex] / 
[ctDNA], εmax = 12824 M(bp)-1 cm-1 for ctDNA) and the volume was adjusted to 
100 µL such that the final concentration of CT-DNA and EtBr were 10.0 µM and 
12.6 µM, respectively. Fluorescence measurements were recorded using a Bio-
Tek synergy HT multi-mode microplate reader with excitation and emission 
wavelengths being set to 530 and 590 nm. Kinetic studies were analysed over 1 h 
period at room temperature with measurements taken at 68-second intervals.  
 
VI.3.2.3. DNA fluorescence quenching Experiments were conducted in a 
similar manner to the high-throughput method reported previously (14). (see 
section III.4.4.2) 
 
VI.3.2.4. Viscosity studies (15). See section III.5.6 for experimental 
 
 
 
Figure VI.66   A. Competitive fluorescence binding of TriplatinNC (AH78), pentamidine, and 
netropsin to ethidium bromide (12.6 µM) saturated solutions of calf thymus DNA (10 µM) (data 
points generated from triplicate measurement, error bars ± S.D.). B. Relative viscosity changes in 
salmon testes dsDNA (1 mM) upon treatment with tested agents. C. Kinetic competitive 
fluorescence binding of ethidium bromide (12.6 µM) bound calf thymus DNA(ctDNA) (10.0 
µM) upon titration of Triplatin complex at r = 0.10 (data points generated from triplicate 
measurement, error bars ± S.D., note that AH78 and AH78H produced identical, overlapping, 
quenching profiles). 
	  
VI.3.2.5 Viscosity analysis on sheared stDNA 
A concentrated solution of dsDNA (deoxyribonucleic acid sodium salt from 
salmon testes fibres (stDNA), Sigma-Aldrich, D1626) was prepared by 
dissolving the fibres in 80 mM HEPES buffer. The solution was initially 
vortexed for ∼20 min until all visible DNA fibres had dissolved and then, in 
order to shear the DNA, the solution passed rapidly through an 18-gauge needle 
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15 times before being sonicated for 90 min. A 15 mL stDNA solution was then 
prepared at 1 x 10-3 M in 80 mM HEPES buffer with viscosity being recorded as 
previously described.   
	  
Figure VI.67	  .Relative viscosity changes in salmon testes dsDNA (1 mM) upon treatment with 
AH78P using both sheared and non-sheared stDNA. 
 
 
VI.3.2.6 ctDNA thermal melting analysis (16). In a final volume of 1 mL using 
black-walled quartz cuvettes (Starna) with tight-fitting seals, 50 mM potassium 
phosphate buffer (pH = 7.8), 2.0 mM NaCl and CT-DNA were added to give a 
final absorbance of 0.5 absorbance units at 260 nm. Stock solutions of platinum 
complexes were prepared in nuclease-free H2O, minor-groove binders (netropsin 
and pentamidine), the cobalt(III) complex, [Co(NH3)6](NO3)3, and the 
intercalator EtBr, were prepared in 80 mM HEPES. A 3.75 µM aliquot of test 
reagent was then added to each cuvette such that an r value of 0.05 was achieved 
(r = [compound] / [ctDNA], εmax = 6,600). Thermal melting measurements were 
recorded at 260 nm at 0.5 s intervals over a temperature range of 20 – 97 °C. 
Temperature was calibrated for each measurement using a temperature probe 
placed in an identical black-walled cuvette containing 50 mM of phosphate 
buffer. The temperature was ramped at 3.5 °C / min with data being collected 
every 0.5 °C. The spectral bandwidth (SBW) was set to 1. Replicate samples 
were run in triplicate and the melting temperature, TM (°C), was calculated using 
the built-in derivative method on the instrument.  
 
VI.3.2.7 Thermal melting analysis on modified DNA The concentrations of 
nucleic acids (expressed as nucleotides) were determined spectrophotometrically 
using the extinction coefficients ε260 = 6000 M-1 cm-1 for calf thymus DNA, ε260 
= 6225 M-1 cm-1 for Clostridium perfringens (Type XII, Sigma) (17), ε262 = 6650 
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M-1cm-1 for poly[d(A-T)2] (16) and ε260 = 6000 M-1cm-1 for poly(dA)-poly(dT) 
(18). The 100 µM polynucleotide DNA samples were incubated with 
TriplatinNC at a ratio r = 0.05 (r being the ratio of drug per nucleotide) in 10 
mM NaClO4 at 37 °C for 1 h. All samples were degassed prior to measurement. 
The absorbance at 260 nm was recorded while the temperature was increased 
from 20 to 95 °C at a rate of 0.5 °C/min.  
VI.3.2.8 DNA association assay 100 µM CT-DNA, poly(dA-dT)2 or poly(dG-
dC)2 were incubated with 5 µM TriplatinNC (r = 0.05) at 37°C protected from 
light for 1 h in 10 mM phosphate buffer and 50 mM NaCl at pH 7.4. 
Subsequently the samples were divided into two equal parts. One mixture was 
used as control and the other one was dialyzed against the same buffer for 24 h. 
The buffer solution was exchanged every 8 h. The modified DNA was digested 
with 500 µL HNO3 concentrated and 500 µL water at 95 °C for 3 h. 1000 µL of 
water was added and the platinum content was determined by ICP-MS. The 
experiment was conducted thrice and the determined platinum concentrations 
were averaged. 
 
VI.3.2.9 Comparative binding of mithramycin towards poly(dG-dC)2 in the 
presence and absence of TriplatinNC Samples were prepared in buffer 
solutions containing 10 mM PO43-, 50 mM NaCl and 10 mM MgCl2 (pH 7.4). 
The concentrations of mithramycin A (ε400 = 10000 M-1 cm-1) and poly(dG-dC)2 
(ε254 = 8400 M-1 cm-1) were determined spectrophotometrically. Poly(dG-dC)2 
was incubated with TriplatinNC at a ratio of 0.05 drug/nucleotide at 37°C for 1 h. 
Varying amounts of mithramycin A were added in the r range of 0.0 – 0.25 to 
modified and untreated DNA. The samples were kept for 24h at 37 °C in the 
dark. The final concentration of poly(dG-dC)2 in the samples was 100 µM. 
Fluorescence spectra were recorded with a Cary Eclipse spectrofluorometer. To 
avoid photodegradation the fluorescence excitation wavelength was set to 470 
nm. The absorbance of the samples at this wavelength was less than 0.05 with the 
inner filter effect therefore being neglected. Spectra were recorded in the range 
of 525 to 625 nm. 
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VI.3.2.10 Circular dichroism experiments The polynucleotides poly(dG-dC)2 
and poly(dA-dT)2 were incubated with TriplatinNC at 37°C in the dark for 1h at 
variable r values (r = [initial number of molecules of platinum complex in 
solution] / [number of bases of DNA in solution]). CD spectra were recorded at 
room temperature using a Jasco J600 Spectropolarimeter and a 10 mm sub-micro 
cuvette. The buffer background was subtracted from the obtained spectra. 
Concentration of DNA was 50 µM bases in a phosphate buffer (10 mM 
phosphate, 50 mM NaCl, pH 7.0). 
  
VI.3.2.11 ITC of polynuclear DNA titrated with TriplatinNC   The 
polynucleotides poly(dG-dC)2, poly[d(A-T)2] and poly(dA)-poly(dT) as well as 
the TriplatinNC solutions each were prepared in 10 mM PO43- and 50 mM NaCl 
buffer solution with pH 7.0. All samples were degassed immediately before use. 
The drug solution (250 µM) was titrated into the DNA mixture (300 µM) by 
making 25 injections of 11 µL each every 300 sec at a stirring rate of 310 rpm at 
20 °C. The actual heats of binding were obtained after subtracting the heats of 
dilution for the injections of TriplatinNC into buffer. Origin 7.0 software was 
used to fit the corrected data and determine the thermodynamic parameters. The 
heat of the first injection was not included in the fitting process. Each experiment 
was performed in duplicate. 
VI.3.2. NMR Analysis of TriplatinNC Modified DNA Oligomers  
VI.3.2.1. NMR Spectroscopy The NMR spectra were recorded on a Bruker 
AVANCE III 600 MHz spectrometer (1H, 600.1 MHz) fitted with a pulsed field 
gradient module and 5mm inverse quadruple resonance (QXI) probe.  The 1H 
NMR chemical shifts are internally referenced to TSP. The two-dimensional 
[1H,1H] COSY and NOESY spectra were acquired with water suppression using 
the excitation sculpting, TOCSY spectra were recorded with the watergate 3-9-
19 pulse sequence.   
G-­C-­duplex  
5ʹ′—A1—  A2  —  C3  —G4—  C5  —  G6  —  C7—  G8—  C9  —  G10—A11—A12—3ʹ′    
3ʹ′—T24—T23—G22—C21—G20—C19—G18—C17—G16—C15—T14—T13—5ʹ′  
A-­T-­duplex  
5ʹ′—C1—  G2  —  T3  —  T4—  T5  —  T6  —  T7—  T8  —  T9  —  T10—C11—G12—3ʹ′    
3ʹ′—G24—C23—A22—A21—A20—A19—A18—A17—A16—A15—G14—C13—5ʹ′  
Figure VI.4	   Sequences of double-stranded dodecamers examined for interactions with 
TriplatinNC by 2D NMR Spectroscopy 
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VI.3.2.2. NMR experimental and results All samples were prepared in 99.99% 
D2O or 8% D2O / 92% H2O with 10 mM PO43-, 300 mM NaCl and adjusted to 
pD 6 or pH 6 with DNO3/NaOD or HNO3/NaOH. All two-dimensional [1H,1H] 
NMR experiments were obtained with 1 mM oligomer and 1 mM oligomer with 
1 mM TriplatinNC. The assignments of the resonances for the oligomers and in 
the presence of TriplatinNC were conducted in the standard manner as described 
in previous reports (19,20). 
VI.3.3. Endonuclease enzyme inhibition  
VI.3.3.1. Linearization of pUC19 Supercoiled plasmid pUC19 (2686 bp) was 
linearised by the AatI endonuclease according to the standard methods. Linear 
DNA was then purified from the enzymatic reaction using QIAquick PCR 
purification (QIAGEN) and quantified using the NanoDrop (ND-1000) 
spectrophotometer.  
 
VI.3.3.2. Inhibition study In a typical binding experiment, 400 ng of linear 
pUC19 was mixed with a series of aliquots of platinum complexes prepared in 
nuclease-free H2O (Ambion, AM9932) and the reaction mixture was incubated at 
37 °C for 24 h. Subsequent digestions experiments were performed by incubating 
the drug treated and untreated primary digest of pUC19 with BamHI, EcoRI or 
SaII endonucleases. This reaction was carried out by adding 1 µL of restriction 
enzyme (20,000 U/mL), and 2.5 µL NEBuffer 3.1 (NEB) and/or 2.5 µL EcoRI 
buffer (where applicable) to the digestion reaction which was allowed to incubate 
at 37 °C for 2.5 h. Reactions were then subjected to electrophoresis (in 1.0% 
agarose, stained as previously described). Reactions of BamHI and SalI were 
then examined using the DNA 7500 microfluidic chip prepared as per the 
manufacturers protocol with data being collected on the Agilent Bioanalyzer 
2100 platform  
{http://www.genomics.agilent.com/en/Bioanalyzer-TapeStation-/?pgid=AG-PG-
1}. 
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Figure VI.5   Experimental protocol designed for the Bioanalyzer 2100 to identify site-specific 
endonuclease inhibition by Triplatin complexes with EcoRI, BamHI and SalI. 
 
VI.3.4. tRNA binding  
VI.3.4.1 tRNA–ethidium fluorescence quenching A working solution of 160.0 
µM transfer RNA (tRNA, Invitrogen AM7119, ε260 = 9250 M-1 cm-1 expressed as 
molarity of the phosphate group for tRNA (22) along with 25.2 µM EtBr in 
HEPES buffer (80 mM, pH = 7.2) and NaCl (40 mM) was prepared. Stock 
solutions of metal complexes and metal salt were prepared in nuclease-free H2O 
(Ambion, AM9932). 50 µL of the tRNA-EtBr working solution were placed in 
each well of a 96 well microplate with the exception of the blanks, which 
contained 100 µL of buffer. Serial aliquots of the tested compound were added to 
the working solutions and the volume was adjusted to 100 µL in each well such 
that the final concentration of tRNA and EtBr were 80.0 µM and 12.6 µM, 
respectively. The plate was allowed to incubate at room temperature for 1 h 
before analysis using a Bio-Tek synergy HT multi-mode microplate reader with 
excitation and emission wavelengths being set to 530 and 590 nm, respectively. 
Each drug concentration was measured in triplicate, and the apparent binding 
constants were calculated using Kapp = Kb x 12.6/C50 where Kb = 6.78 x 104 
M(bp)-1 (Kapp = apparent binding constant). 
 
VI.3.4.2 tRNA thermal melting analysis In a final volume of 1 mL using Starna 
black-walled quartz cuvettes with tight-fitting seals, 50 mM potassium phosphate 
buffer (pH = 7.8), 1 M NaCl and tRNA were added to give a final absorbance of 
∼1.1 absorbance units at 260 nm. Stock solutions of metal complexes were 
prepared in nuclease-free H2O. An aliquot of test reagent was then added to each 
5' 3'G A C G T C
3' 5'C T G C A G
AatII
5' 3'G A A T T C
3' 5'C T T A A G
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SalI
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cuvette such that an r value of 0.1 was achieved (r = [compound]/[tRNA], εmax = 
9250 M-1cm-1 expressed as molarity of phosphate group for tRNA). Thermal 
melting measurements were recorded at 260 nm at 0.5 s intervals over a 
temperature range of 20-90 °C. Temperature was calibrated for each 
measurement using a temperature probe placed in an identical black-walled 
cuvette containing 50 mM of phosphate buffer and 1M NaCl. The temperature 
was ramped at 4 °C / min with data being collected every 0.5 °C. The spectral 
bandwidth (SBW) was set to 1. Replicate samples were run in triplicate and the 
overall melting temperature, TM (°C), was calculated using the built-in derivative 
method on an Agilent Cary 100 dual beam spectrophotometer equipped with a 6 
x 6 multicell system. 
 
VI.4. Results And Discussion  
VI.4.1. Binding to calf thymus and salmon testes DNA 
To identify DNA binding properties of this series, calf thymus DNA (ctDNA) 
and salmon testes DNA (stDNA) were examined through a variety of biophysical 
methods including ethidium bromide (EtBr) fluorescent competition studies, 
fluorescence quenching of limited bound EtBr (23) and Hoechst dye 33258 (24), 
thermal melting and viscosity analysis. In all tests conducted, the minor groove 
binding agents, netropsin and pentamidine, along with the cationic cobalt(III) 
complex, [Co(NH3)6]3+, were examined as reference agents against which new 
properties of these phosphate clamping platinum(II) complexes could be 
identified.  
 
Thermal melting on ctDNA (Table VI.1 and appendix A.C.2) revealed netropsin 
extensively stabilised the thermal denaturation (ΔTM = +7.47 ± 0.50) (25) while 
pentamidine and [Co(NH3)6]3+ yielded either no, or negligible, effects under our 
tested conditions. Triplatin complexes all stabilised ctDNA melting temperature 
to a similar degree as netropsin (e.g. ΔTM = +8.20 ± 0.26 for AH78) and by 
analogy it is likely that this effect arises through the groove spanning-interaction 
where platinum(II) phosphate clamps form on opposing sides of the minor 
groove rather than backbone tracking along one single strand (1, 2). Indeed, the 
minor groove, which is A⋅T rich, is the first tract to melt within B-DNA (16) and 
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thus groove-spanning Triplatin interactions at A⋅T sequences are likely to confer 
thermal stabilisation on the nucleotide polymer. 
 
Competitive fluorescence binding to EtBr-saturated ctDNA solutions were 
performed in triplicate using a high-throughput binding method (14) and results 
are shown in Figure VI.2A and Table VI.1. The intrinsic binding constant (Kb) of 
EtBr, was identified as 8.8 x 106 M(bp)-1 through direct spectrophotometry 
(appendix A.C.6) and the apparent DNA binding constants (Kapp) for the tested 
compounds were calculated based on the Kb of EtBr and concentration required 
to displace 50 % of this bound fluorophore. The Kapp values for netropsin and 
pentamidine were identified as 2.55 x 106 and 8.77 x 105 M(bp)-1, respectively, 
while the cobalt(III) complex and metal free diamine ligand, 1,6-hexanediamine, 
were unable to displace 50% of bound intercalator up to 300 µM. Triplatin 
complexes were highly efficient at displacing bound EtBr with all three having 
almost identical binding constants of ~5 x 107 M(bp)-1.  In order to identify their 
relative binding kinetics to DNA, each complex was examined under constant 
fluorescence measurement at 10% drug load (r = [complex] / [DNA] = 0.10), in 
the presence of saturated EtBr bound ctDNA (Figure VI.2C). Hexane- and 
heptanediamine-bridged complexes (AH78 and AH78H) were 50 % bound by 
~34 min while for the pentanediamine complex a considerably faster interaction 
was evident at ~4.5 min.  
 
In order to characterise condensation of DNA, viscosity experiments were 
conducted using stDNA fibres exposed to the Triplatin series at drug:DNA ratios 
(r) between 0.01 to 0.20 (Figure VI.2B and Table VI.1). As expected, EtBr 
exhibited classical intercalative binding with concentration-dependent relative 
viscosity enhancement (26) while the groove-binding agent, netropsin, had 
negligible influence only. The cobalt(III) cation, [Co(NH3)6]3+, condensed DNA,  
in broad agreement with previous work by Kankia et al. (27). Triplatin 
complexes compact and precipitate DNA and this effect is pronounced with 
distinctive η/ηo values for all three complexes. Indeed, viscosity by Triplatin 
molecules decreases in linear fashion with the overall trend almost dwarfing the 
relative viscosity changes of the standard tested agents. To mitigate the effects of 
long range coiling, which can significantly impact viscosity (28), high molecular 
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weight stDNA fibres were vigorously sheared (see section VI.3.2.5)(29) before 
being examined under identical conditions describe above. Long range coiling 
effects of non-sheared stDNA can be discounted as Triplatin had greater 
condensation effects on sheared stDNA (Figure VI.3). We postulate that shorter 
DNA fragments aggregate more efficiently due to enhanced intramolecular 
phosphate clamping interactions driven by greater accessibility to smaller 
nucleotide fragments.      
 
   
   
Figure VI.6	   Normalised fluorescence quenching of limited ethidium bromide or Hoechst 33258 
(5 µM) bound dsDNA (ctDNA) (25 µM) upon titration of minor groove binding agents, netropsin 
and pentamidine, [Co(NH3)6]Cl3 and the TriplatinNC (data points presented as an average of 
triplicate measurement, error bars ± S.D.). 
	  
Binding mode interactions were determined using fluorescence quenching of 
limited bound EtBr and Hoechst 33258 to ctDNA (Figure VI.15). The minor 
groove binding agents, netropsin and pentamidine, and the cationic cobalt(III) 
complex – which has surface binding properties on nucleic acids (30) – displaced 
the minor groove fluorogen Hoechst 33258 with greater specificity than 
intercalated EtBr. In contrast to these standards, the Triplatin series exhibited 
unique profiles. Firstly, the Triplatin series efficiently ablated EtBr fluorescence 
with quenching values (Q) of the order of ~5 µM. Secondly, the complexes 
induce cooperative binding of Hoechst 33258 at the minor groove as evident 
through fluorescence enhancement by approximately 25% within each assay. The 
cooperative binding of Hoechst 33258 can be understood from the minor groove 
width opening caused by the phosphate clamps as structurally characterised in 
the Dickerson Drew Dodecamer (1,2,31). This interaction may conceivably 
facilitate selective binding by A⋅T targeting molecules such as Hoechst dye. The 
quenching of EtBr fluorescence, in contrast, may be connected to a 
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conformational change, or condensation effect, on the tertiary structure of DNA 
that disfavours intercalative penetration. 
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Table VI.1	  DNA binding properties of test compounds.	  
Compound	  	   C50	  (µM)[a]	   Kapp	  (M-­‐1)[b]	   	   Q	  Hoechst[c]	   Q	  Ethidium[c]	   η	  /	  ηo[d]	   ΔTM	  (oC)[e]	  
Netropsin	   44.26	   2.50	  x	  106	   	   03.31	   22.55	   1.007	   +7.47	  ±	  0.50	  
Pentamidine	   126.38	   8.77	  x	  105	   	   58.45	   N/A	   0.987	   +0.03	  ±	  0.02	  
[Co(NH3)6]Cl3	   >300	   N/A	   	   23.18	   273.62	   0.828	   +0.08	  ±	  1.12	  
AH78	   1.96	   5.65	  x	  107	   	   N/A	   4.88	   0.385	   +6.98	  ±	  0.02	  
AH78H	   1.97	   5.62	  x	  107	   	   N/A	   5.42	   0.381	   +8.20	  ±	  0.26	  
AH78P	   2.14	   5.18	  x	  107	   	   N/A	   5.07	   0.443	   +6.74	  ±	  0.64	  
[a] C50 = concentration required to reduce fluorescence by 50% during competitive ethidium bromide displacement assay on ctDNA [b] Kapp = Kb x 12.6/C50 where Kb = 8.8 x 106 M(bp)-1 [c] quenching 
of 50% initial fluorescence (µM) from limited DNA-bound dye [d] relative viscosity at r = 0.20 [e] ΔTM = difference in thermal melting (Tm) (oC) of drug treated CT-DNA at r = 0.05 compared with 
drug untreated CT-DNA. 
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VI.4.2 Base-specific nucleic acid interactions 
The “classical” minor groove binders such as netropsin and Hoechst 32258 by 
definition show distinct binding preferences for A-T tracts.  In the case of the 
platinum compounds studied here it is of fundamental interest to examine how 
the two canonical modes of binding elucidated by crystallography are reflected in 
base-specific interactions. The presence of specific A-T interactions for non-
covalent polynuclear platinum complexes is indicated by protection of the minor 
groove toward alkylation and is also confirmed (specifically for AH44) through 
2D NMR experiments on the self-complementary duplex d(GGTAATTACC)2, 
which is a ‘high-affinity’ sequence for minor groove binders such as Hoechst 
33258 and used extensively for solution and solid-state studies of ‘classical’ 
minor groove binders (19). Base-specific interactions were studied using 
predominantly TriplatinNC (AH78) given the similarities in behaviour on 
random-sequence DNA observed above. There is a clear correlation between A⋅T 
content and the stabilising effect of TriplatinNC (Figure VI.7). The difference in 
melting temperature increases with the amount of A⋅T base pairs from ΔTM = 
+7.0 °C for ctDNA to +22.6 °C for Clostridium perfringens DNA (73% A⋅T), 
and then finally to > +28 °C for pure A⋅T polynucleotides. To our knowledge 
such a high increase in melting temperature is unprecedented for a non-covalent 
DNA-binding small molecule at such low concentration (r = 0.05). It is 
noteworthy that the ΔTM of TriplatinNC-modified homopolymeric and 
alternating copolymeric sequences are almost identical showing that stabilisation 
arises from the discrete binding of TriplatinNC, and is not influenced by the 
initial melting temperature of the untreated polynucleotide. The associated 
binding strength of TriplatinNC to three sets of polymers - poly[d(G-C)2],  
poly[d(A-T)2] and poly(dA)-poly(dT) - were then identified through ICP-MS and 
revealed that platinum content is reduced by approximately 50 % after dialysis 
on all DNA types but there is no apparent selectivity with base composition 
(Figure VI.7). 
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   AT	  Content	  (%)	   ΔTm	  (oC)	  
	  CP-­‐DNA	   73	   22.6	  
poly(dA)-­‐poly(dT)	   100	   28.1	  
Poly[d(A-­‐T)2]	   100	   28.5	  
	   	   	  
 
Figure VI.7	   Thermal melting temperatures (at r = 0.05) of TriplatinNC on modified DNA (CP-
DNA = clostridium perfringens DNA) (left) and platinum concentration (in ppb) determined 
using ICP-MS on various DNA types (100 µM) upon treatment with TriplatinNC (5 µM) (right).  
 
VI.4.3 Fluorescence Inhibition Assay A selection of double stranded DNA 
polymers of varying G⋅C content—poly[d(G⋅C)2] (100%), Micrococcus 
lysodeikticus DNA (ML-DNA; 72%), ctDNA (42%), and poly[d(A⋅T)2] (0%)—
were next examined under saturated EtBr competitive binding conditions (Figure 
VI.8 and Table VI.2) to characterise potential base-specific binding constants.  
The classical agents netropsin and actinomycin D exhibited predictable 
behaviour with the minor groove binder favouring A⋅T rich polymers while, 
conversely, the intercalator preferred G⋅C.   Affinity values for netropsin and all 
trinuclear platinum compounds for the G-C and ML DNAs were similar to those 
found for ctDNA, See Tables VI.1 and Table VI.2. Unexpectedly, detectable 
binding constants (up to 500 µM exposure) were not obtained for poly[d(A⋅T)2] 
for TriplatinNC. The congeners were then examined and a detectable binding 
constant was observed only for AH78P (Kapp = 9 x 105 M(bp)-1). This finding is 
in contrast to complex AH44 (Scheme VI.1) that displays some slight preference 
for A-T sequences when compared to nucleic acids of varying base composition 
(12). This evidence suggests that the DNA binding constants for the TriplatinNC 
class are dependent, and highly conserved, on polymers containing G⋅C content. 
But given the evidence of strong ΔTm, questions now arise regarding the binding 
mode of this class toward conformationally distinct regions on DNA. Are there 
limited but high-affinity binding sites on A-T rich tracts, and are the distinctive 
binding modes—groove spanning and backbone tracking—linked to base-
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specificity or tertiary helical topology, and if so, which of these modes are the 
drivers behind binding affinity and condensation? To probe these significant 
issues, further experiments on selected A⋅T and G⋅C polymers and 
oligonucleotides using circular dichroism, isothermal titration calorimetry, and 
2D-NMR Spectroscopy were undertaken.        
Table VI.2 Apparent DNA binding constants (Kapp) of test compounds to dsDNA of varying A⋅T 
content. 
	  
Kapp	  M(bp)-­‐1	  
	  
poly[d(A⋅T)2]	   ctDNA	   ML-­‐DNA	   poly[d(G⋅C)2]	  
	   	  (100%	  AT)	   	  (58%	  AT)	   	  (28%	  AT)	   	  	  	  	  	  (0%	  AT)	  
Actinomycin	  D	   N/A	   2.92	  x	  107	   3.03	  x	  107	   5.25	  x	  107	  
Netropsin	   5.75	  x	  107	   2.50	  x	  106	   N/A	   N/A	  
AH78	   N/A	   5.65	  x	  107	   2.78	  x	  107	   3.18	  x	  107	  
AH78H	   N/A	   5.62	  x	  107	   1.44	  x	  107	   1.95	  x	  107	  
AH78P	   9.03	  x	  105	   5.18	  x	  107	   1.36	  x	  107	   3.58	  x	  107	  
 
   
Figure VI.8	   Competitive fluorescence binding of netropsin, actinomycin D, and TriplatinNC to 
ethidium bromide (12.6 µM) saturated solutions of calf thymus DNA, Micrococcus lysodeikticus 
DNA (ML-DNA), poly[d(A-T)2], and poly[d(G-C)2] polynucleotides (10 µM). 
 
VI.4.4 Conformational Changes The changes in ellipticity of poly[d(A⋅T)2] and 
poly[d(G⋅C)2] with varying amounts of TriplatinNC are shown in Figures VI.9. 
The platinum compound significantly alters the secondary structure of poly[d(A-
T)2] with ellipticity of the band at 263.5 nm gradually diminishing upon complex 
treatment resulting in positive to negative shifts up to a drug loading ratio of 5% 
(r = 0.05). Furthermore, the appearance of a positive band around 290 nm at 
higher molar ratios – a wavelength where DNA normally does not absorb – 
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indicates the formation of ψ-DNA. On the other hand, almost no change in the 
secondary structure of the poly[d(G⋅C)2] polymer is induced upon TriplatinNC 
binding. The only significant alteration in the spectrum occurs at high drug 
loading when DNA condensation leads to ψ-DNA arrangement and subsequently 
precipitation takes place. Negligible changes in the secondary structure of 
poly[d(G⋅C)2] upon TriplatinNC binding were corroborated through competitive 
fluorescence binding analysis of mithramycin A; one of the few small molecules 
that binds to the minor groove of G-C rich sequences (32,33). Binding of 
mithramycin A is not affected by the presence of TriplatinNC as fluorescence 
intensities of the DNA-bound antibiotic increase in a linear fashion to exactly the 
same extent for the TriplatinNC modified poly[d(G⋅C)2], as for the untreated 
polynucleotide (Figure VI.9C).  Control experiments confirmed that TriplatinNC 
did not interfere with the intrinsic fluorescence of mithramycin A itself (results 
not shown). This result confirms that TriplatinNC does not span the minor 
groove of poly[d(G⋅C)2] and therefore does not prevent the interaction of other 
molecules within this region of DNA. Taken together these results suggest that, 
although the association strength of TriplatinNC to A⋅T and G⋅C polynucleotides 
are indistinguishable, backbone tracking is the predominant binding mode for the 
G-C duplex. Minor groove spanning interactions by the trinuclear platinum 
complexes, however, are characteristic of polynucleotides with A⋅T content. For 
example, cooperative enhancement of the minor groove binding fluorophore 
Hoechst 33258 occurs for both ctDNA and, to a larger extent, poly[d(A⋅T)2] 
(Figure VI.9D). Isothermal titration calorimetry (ITC) analysis lends further 
support toward the concept of selective groove spanning of A⋅T, rather than G⋅C, 
polynucleotides (Appendix A.C.4). Not only do the shapes of the isotherms differ 
appreciably but also the generated reaction heat is about 10 times lower for the 
G⋅C polynucleotide (Table VI.3). While a high signal-to-noise ratio of the 
poly[d(G⋅C)2] isotherm made mathematical analysis unreasonable, analysis was 
possible for both poly[d(A⋅T)2] and poly(dA)-poly(dT) isotherms (34,35). The 
curves of both A⋅T polynucleotides are very similar and show three reaction 
stages for binding, condensation and precipitation. Excluding the integrated heats 
of precipitation, isotherms were then fitted using a two-stage binding site model 
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that revealed a highly exothermic condensation phase for both A⋅T 
polynucleotides (36). 
 
  
  
Figure VI.9 Changes in helical ellipticity of key absorbance bands upon treatment of poly[d(A-
T)2] (A) and poly[d(G-C)2] (B) with TriplatinNC (AH78), the comparative binding of 
mithramycin A (MTR) to poly[d(G-C)2] in the presence and absence of TriplatinNC (C), and 
quenching of limited bound Hoechst (5 µM) or ethidium bromide (5 µM) to ctDNA and 
poly[d(A-T)2] (25 µM) polynucleotides (D). 
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Table VI.3 Best fit parameters for the titration of poly[d(A-T)2] and poly(dA)-poly(dT) with 
TriplatinNC 
	   N	   K	  x	  107	   ΔH	   ΔS	   ΔG	  
	   	   [M-­‐1]	   [cal/mol]	   [cal/mol*K]	   [kcal/mol]	  
Parameters	  for	  first	  binding	  step	  
CT-­‐DNA	   0.062	  ±0.003	   22.7	  ±8.0	   3438	  ±32	   49.8	  ±0.8	   -­‐11.2	  ±0.02	  
Poly[d(A-­‐T)2]	   0.041	  ±0.003	   42.9	  ±13.3	   7880	  ±335	   66.3	  ±1.7	   -­‐11.5	  ±0.20	  
poly(dA)-­‐poly(dT)	   0.026	  ±0.002	   125.5	  ±63.5	   9709	  ±30	   74.5	  ±1.3	   -­‐12.1	  ±0.30	  
Parameters	  for	  second	  binding	  step	  
CT-­‐DNA	   0.070	  ±0.001	   0.483	  ±0.151	   402	  ±128	   31.8	  ±0.5	   -­‐8.9	  ±0.2	  
Poly[d(A-­‐T)2]	   0.050	  ±0.002	   0.85	  ±0.33	   -­‐7101	  ±232	   7.3	  ±0.1	   -­‐9.2	  ±0.2	  
poly(dA)-­‐poly(dT)	   0.039	  ±0.003	   1.65	  ±1.01	   -­‐3107	  ±74	   22.0	  ±1.2	   -­‐9.5	  ±0.4	  
 
 
VI.4.5 2D NMR Spectroscopy Finally, 2D NMR spectroscopy was used to 
examine the binding modes using both an A-T rich and a G-C rich duplex, 
section VI.3.2 and appendix A.C.5. 
 
VI.4.6 TriplatinNC modified A-T-Duplex The changes in the proton 
resonances for the A-T-rich dodecamer (Figure VI.4) in the presence of 
TriplatinNC confirm that for both strands mainly the thymines and adenosines 
are affected by platinum drug binding, appendix A.C.5. A preference of binding 
towards one strand over the other is not observed. The changes in chemical shifts 
for T-NH and T-CH3 result from structural changes of the dodecamer upon 
binding of TriplatinNC. In NOESY analysis there are many NOE contacts 
between the TriplatinNC and the non-exchangeable protons of the 
oligonucleotide.  NOE cross peaks are observed with all A-H2 protons as 
connections seem to be stronger for  TpNC-L2/L5 than L3/L4, suggesting that 
TriplatinNC spans/binds in minor groove, and there are strong connectivities 
with A-H1' and T-H1', and somewhat weaker contacts with C-H1' (Figure 
VI.10).  Cross-peaks with H2'/H2" can not be conclusively identified due to 
overlapping peaks but strong NOE contacts with H3'/H4' and H5’/H5’’ protons 
are present. These latter sugar connectivities in the proximity of the backbone 
phosphates point toward backbone binding.  No cross-peaks with A-NH2 or C-
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NH2 or T-CH3 are visible indicating that major groove binding can be ruled out. 
Contacts to the imino protons of the nucleobases are also not detected. For the 
platinum compound, participation of the L1 protons is inconclusive since many 
H2" protons have a similar chemical shift. Connectivities for NH3/NH2 groups of 
TriplatinNC with the oligomer are not observed. It is noteworthy that the NOE 
contacts between A-H2 protons and H2'/H2" seem to be stronger in the presence 
of TriplatinNC. This could reflect the narrowing of the minor groove as a 
consequence of the binding of the platinum drug. In summary the results strongly 
suggest that TriplatinNC spans the minor groove. 
 
 
Figure VI.10 Summary of NOE contacts between TriplatinNC and the self-complementary A-T 
rich duplex. 
 
VI.4.7 Consequences for the TriplatinNC modified GC-duplex In contrast to 
the AT-duplex the changes in the GC-rich dodecamer upon binding of 
TriplatinNC are considerably smaller, with changes mainly occurring for the H1’ 
chemical shifts,. These shift variations arise most probably from induced 
structural changes since the spectra showed only few contacts in the minor 
groove.  Weak cross-peaks are observed between TpNC-L3/L4 and G-H8 and C-
H6 as well as G-H1’ and C-H1'. The cross-peaks with H2’/H2” sugar protons 
seem to be more pronounced but the strongest connectivities are observed in the 
H3’/H4’/H5’/H5’’ region. The fact that no connections with G-NH2 or C-NH2 
are detected implies that binding via major or minor groove spanning can be 
excluded. Connectivities between NH2R/NH3 protons of the platinum drug with 
the dodecamer can not be detected. Overall these results suggest that TriplatinNC 
binds predominantly in a backbone tracking manner towards GC-rich DNA. 
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In summary, elucidation of solution binding by TriplatinNC and congeners to 
DNA clearly display two modes consistent with backbone tracking and groove-
spanning interactions. What is clear from these experiments, and is of particular 
significance toward our understanding of novel “non-covalent” platinum nucleic 
acid interactions, is that each mode is dependent on base specificity or local 
helical topological parameters. We suggest that backbone tracking is the 
predominant binding mode of TriplatinNC type complexes in duplexes 
containing G-C nucleobases. Conversely, groove-spanning interactions are 
localised to the minor groove and are specifically dependent of A-T content. 
Furthermore, the groove-spanning motif has far greater impact on tertiary nucleic 
acid structure and is the main driver of DNA condensation and cooperative 
interactions at the minor groove.    
 
VI.4.8 Binding to yeast tRNA 
To characterize Triplatin interactions with ribonucleic acid, and thus potentially 
differentiate binding activity with DNA, yeast transfer RNA (tRNA) was 
examined through fluorescence quenching experiments and thermal melting 
analysis. We initially characterised the intrinsic binding constant (Kb) of 
ethidium bromide to tRNA using direct spectrophotometry at 260 nm as 6.78 x 
104 M-1 (Appendix A.C.6) which is in good agreement with Sakai et al. (37). A 
fixed concentration of EtBr (12.6 µM) was then titrated against increasing 
concentrations of tRNA in order to identify the fluorescence saturation binding 
point (80.0 µM). Further, we then defined the apparent binding constant of tested 
samples to tRNA (Kapp) within this method as; Kapp = Kb x 12.6/C50, where Kb is 
the intrinsic binding constant of EtBr to tRNA and C50 is the concentration (in 
µM) of tested agent required to displace 50% of the bound intercalated 
fluorophore (38, 39). Quenching experiments were then examined with Triplatin 
complexes and [Co(NH3)6]Cl3 titrated against EtBr-saturated tRNA solutions 
(Figure VI.11). Somewhat unexpectedly, only the pentanediamine Triplatin 
complex (AH78P) displaced 50% of bound EtBr and we estimate the binding 
constant of this agent to the fluorescent EtBr binding region of tRNA as 4.80 x 
103 M(bp)-1, an order of magnitude below the [Co(NH3)6]Cl3 complex (7.95 x 104 
M(bp)-1). Indeed, electrostatic binding by [Co(NH3)6]3+ to RNA has previously 
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been identified on ribozyme (P4-P5-P6 portion) tandem G-U base pairs in the 
major groove (40). Thermal denaturation was then identified (Figure VI.11B and 
Figure VI.11C) with AH78P once again being the only platinum(II) complex to 
appreciably stabilise tRNA. Overall, the ability of Triplatin complexes to 
displace fluorogenically bound EtBr and stabilise thermal denaturation of tRNA 
appears favoured by shorter linker chain length molecules. It is possible, 
however, that Triplatin molecules may bind tRNA at non-fluorescent EtBr 
binding sites (41) that have negligible influence on thermal denaturation. Atomic 
Force Microscopy experiments on tRNA adducted by AH78 do indeed show 
condensation of the ribonucleotide but the results are not inconsistent if there is a 
subset of Triplatin binding sites different to those of EtBr (12).    
 
      
 
Compound	  	   C50	  (µM)	  [a]	   Kapp	  (M-­‐‑1)[b]	   ΔTm	  (oC)[c]	  
EtBr	   -­‐‑	   -­‐‑	   +2.14	  ±	  0.31	  
[Co(NH3)6]Cl3	   10.74	   7.95	  x	  104	   +1.10	  ±	  0.10	  
AH78	   >300	   	   +0.20	  ±	  0.56	  
AH78H	   >300	   	   +0.13	  ±	  0.63	  
AH78P	   177.61	   4.80	  x	  103	   +1.39	  ±	  0.60	  
 
 [a] C50 = concentration required to reduce fluorescence by 50% during competitive EtBr displacement assay [b] Kapp = Kb 
x 12.6/C50 where Kb = 6.78 x 104 M(bp)-1 [c] ΔTM = differential thermal melting (Tm) (oC) of drug treated tRNA at r = 0.10 
compared with drug untreated tRNA.   
Figure VI.11 A. Competitive fluorescence binding of platinum complexes (AH78, AH78P and 
AH78H) and the cobalt(III) complex, [Co(NH3)6]Cl3, to EtBr (12.6 µM) saturated solutions of 
transfer RNA (tRNA) (80 µM) (data points presented as an average of triplicate measurement, 
error bars ± S.D.). B. Normalised thermal melting profiles of untreated tRNA (~130 µM in 
tRNAp) along with AH78P and [Co(NH3)6]3+ treated (13 µM) tRNA examined in 50 mM 
potassium phosphate buffer with 1 M NaCl. C. tRNA binding properties of test compounds. 
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VI.4.9 Interactions with superhelical pUC19 and endonuclease inhibition  
It is axiomatic that strong ligand binding to nucleic acids will interfere with 
protein recognition and processing. The effects of complex interactions on 
superhelical pUC19 plasmid DNA (pDNA) migration and subsequently sequence 
recognition by type II restriction endonucleases were examined. Agarose gel 
electrophoresis of superhelical pUC19 showed that the pentanediamine complex, 
AH78P, begins to inhibit plasmid migration at 0.50 µM with complete 
condensation occurring thereafter, Figure VI.12A. Higher concentrations of the 
longer hexanediamine AH78 and heptanediamine AH78H were required to 
initiate condensation (3.0 µM) while the metal-free ligand yielded no effect. The 
behaviour by all Triplatin compounds here is entirely different to classical cis-
platinum(II) and trinuclear BBR3464 type complexes. These agents covalently 
platinate superhelical pDNA and engage in concentration-dependent unwinding 
of the Form I superhelix (42,43,44).   
To identify if Triplatin-bound DNA can prevent sequence recognition by type II 
restriction endonucleases, pUC19 was then linearised by the restriction enzyme 
AatII and subjected to a second endonuclease treatment of either BamHI, EcoRI 
or SalI, each of which also have one recognition sequence on pUC19 (Figure 
VI.12). The results of these control experiments are shown in Figure VI.12B 
where the linearised band of pUC19 at 2,686 bp disappears and two smaller 
fragments emerge between 2,188–2,221 bp and 465–498 bp corresponding to 
site-selective excision. With Triplatin experiments, complexes were pre-
incubated for 24 h at 37 °C with linearised pUC19 at the range 1.0 – 10.0 µM for 
AH78 and AH78H, and between 0.25 – 1.00 µM for AH78P before the 
introduction of BamHI, EcoRI or SalI, (Figure VI.12 C–E). Triplatin complexes 
inhibit endonuclease excision in a concentration-dependent manner as 
characterised by the disappearance of pUC19 fragments at higher complex 
exposure. Inhibition is comparable between the hexanediamine and 
heptanediamine- bridged AH78 and AH78H, respectively, where concentrations 
of 2.5 µM initiate condensation with bands becoming fainter and then 
disappearing >5 µM. The pentanediamine-linked AH78P displays a similar 
concentration-dependent inhibitory trend with the exception that lower 
concentrations (0.50 µM) are required to inhibition excision, before complete 
condensation occurs thereafter (0.75 – 1.00 µM). It is notable that Triplatin 
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complexes do not preferentially inhibit cutting by any of these three site-specific 
endonucleases. Instead, the inhibitory properties are congruent, depending only 
on complex concentration and the linker chain length (AH78P >> AH78 ≈ 
AH78H). 
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Figure VI.12   A. Influence of Triplatin complexes and the metal-free ligand on superhelical pUC19 (400 ng) migration examined under agarose gel 
electrophoresis. B. AatII linearized pUC19 (CTRL) after exposure to type II endonucleases. C. – E. Cleavage experiments on linearised pUC19, pre-incubated 
for 24 h with either; AH78 (1.0 – 10 µM), AH78P (0.25 – 1.0 µM) or AH78H (1.0 – 10 µM) by type II endonucleases BamHI, EcoRI and SalI. 
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VI.4.10  On-chip identification of endonuclease inhibition  
Although the condensation effects of DNA by Triplatin complexes have clearly 
been demonstrated through changes in viscosity and gel electrophoresis in this 
study and also through atomic force microscopy (AFM) analysis in recent work 
(11,12), a question remains regarding the exact nature of endonuclease inhibition 
by the Triplatin series – condensation effects rendering both bands undetectable 
by gel electrophoresis should be distinguished from endonuclease inhibition 
through ligand (Triplatin)-DNA binding.  In order to provide answers to this 
question, an on-chip DNA microfluidic method was devised using the 
Bioanalyzer 2100 platform (Agilent Technologies) and is shown in Figure VI.5. 
The Bioanalyzer 2100 was selected due to its ability for high-resolution sizing 
and quantitation of dsDNA fragments through capillary electrophoresis (45,46) 
{http://www.agilent.com}. We employed DNA 7500 microfluidic chips, 
designed to identify dsDNA fragments sized between 100–7500 bp, for the 
detection of endonuclease excision on linearised pU19 (2,686 bp). Superhelical 
pUC19, initially linearised by the restriction enzyme AatII and purified using 
anion exchange chromatography, was then exposed to two restriction 
endonucleases, BamHI and SaII, in a similar manner as described above. 
Electrograms from the microfluidic chip analysis of untreated and enzyme-
treated pUC19 are shown in Figure VI.13A and Appendix A.C.1 In each 
electrogram, internal standard upper and lower DNA markers sized at 50 and 
10380 bp are evident. Linear pUC19 produced a single high-resolution peak 
located at ~2870 bp which was clearly within the experimental error margin for 
nucleotide sizing accuracy (± 10% CV). Treatment by BamHI or SalI resulted in 
the disappearance of this band and the emergence of two smaller sequences 
located at ~500 bp, and ~2200 bp which correspond to the expected site-selective 
enzymatic restriction activity. Triplatin complexes were then incubated for 24 h 
with linearised pUC19 (400 ng) prior to the exposure to BamHI or SalI. Tests 
were conducted in a similar manner to the electrophoresis experiments described 
above with AH78 and AH78H complexes being examined across a higher range 
than AH78P (Figure VI.15B–E). Concentration dependent endonuclease 
inhibition was identified in each set of experiments conducted. Taking complex 
AH78 with BamHI treatment as an example (Figure VI.13B): at lower complex 
concentrations of 1.0 and 2.5 µM the restriction enzyme efficiently cuts pUC19 
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into two smaller fragments and the results here are almost identical to the control 
experiment in Figure VI.13A. At higher concentrations however, the native 
pUC19 band at ~2,870 bp begins to appear and this band intensifies at the 
maximum exposure level (10 µM) as the BamHI excision fragments at ~490 and 
~2200 bp diminish. Thus, in the presence of Triplatin complex, the pUC19 vector 
is protected from site-selective endonuclease excision. The trend observed in 
Figure VI.12C–E is largely present in these experiments, however, 10 µM of 
AH78H was unable to completely protect pUC19 from endonuclease excision by 
SalI (Figure VI.12D). On comparison with the agarose gel of this same 
experiment (Figure VI.12E), no bands are evident for pUC19 or the excision 
fragments. This indicates that complex AH78H has condensed both the native, or 
protected, plasmid along with the excised fragments. Another significant 
observation is the ability of AH78P to block endonuclease activity at nano-molar 
concentration levels (<1.0 µM) as evident in Figure VI.12C. The pentanediamine 
bridged triplatinum(II) complex, therefore, has excellent selectivity for 
condensation and endonuclease inhibition on this dsDNA particular sequence 
(51% GC and 49% AT content).   
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Figure VI.13	   A. Electrograms generated using the Bioanalyzer 2100 of AatII linearised pUC19 
plasmid DNA with treatment by endonucleases BamHI and SalI. Electrograms of linearised 
pUC19 pre-incubated for 24 h with either AH78, AH78P or AH78H, followed by exposure over 
2.5 h to the type II restriction endonuclease BamHI (B and C) or SalI (D). 
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VI.5 Conclusions  
The results here demonstrate the unique nucleic acid binding properties of 8+ 
charged “non-covalent” PtN4 type complexes binding through the phosphate 
clamp motif previously characterised by ‘backbone tracking’ and ‘groove 
spanning’ (1, 2).  The overall features from this and complementary studies, 
(11,12), confirm that the crystallographically observed structures exist in solution 
and are relevant in explaining the biological activity of this series. The phosphate 
clamp, through its groove spanning, has apparent similarities to classical minor 
groove binders (e.g. netropsin) – indicated by quenching of intercalated ethidium 
bromide and stabilisation of nucleic acid thermal denaturation, protection of the 
minor groove toward alkylation, (19), and the presence of many A-T minor 
groove contacts observed through 2D NMR experiments on self-complementary 
A-T rich duplexes (Figure VI.10 and Ref. 19). However, the phosphate clamp is 
distinguished by higher apparent binding constants to ctDNA and highly efficient 
condensation effects on both DNA and tRNA (11,12). The structural 
modifications of the phosphate clamp result in cooperative enhancement of 
minor groove binders such as netropsin and Hoechst 32258. The base-specific 
studies allow differentiation between the dynamic effects of backbone tracking 
and groove spanning - backbone tracking is the predominant binding mode of 
TriplatinNC type complexes in duplexes containing G-C nucleobases while, 
conversely, groove-spanning interactions are localised to the minor groove and 
are specifically dependent of A-T content. The latter has far greater impact on 
tertiary nucleic acid structure and the minor-groove residency of the platinum 
complex is the main driver of DNA condensation and cooperative interactions at 
the minor groove. The combined results further identify the phosphate clamp as a 
distinct mode of DNA binding, discrete from the canonical intercalator and 
minor groove binders. The modular nature of the polynuclear chemotype allows 
for systematic modification of the chemotype. Apparent binding constants on 
ctDNA are identical among the series (Kapp ~5 x107 M-1) and are similar to 
recently reported non-terminally functionalised di- and tri-platinum(II): AH44 
(Scheme VI.1), [{Pt(NH3)3}2-µ-spermidine]5+ and [{Pt(NH3)3}2-µ-spermine]6+ 
(Kapp ~3 x107 M-1). However, more subtle effects may be identified and in this 
study the slightly shorter pentanediamine-linked compound shows a number of 
effects (rapid interaction in competitive fluorescence experiments, EtBr 
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displacement from tRNA, more efficient inhibition of pUC19 plasmid migration) 
suggesting the nucleic acid “fit” may be modulated by the choice of diamine 
linker in this complex class. The combined effects of high binding constants and 
condensation effects of Triplatin complexes, has significant consequences for 
inhibition of protein-DNA interactions. Type II restriction endonuclease 
inhibition on pUC19 was witnessed at G-G, G-A and G-T excision regions of 
BamHI, EcoRI, and SalI enzymes in the presence of Triplatin-bound DNA. 
These results were visualised using agarose gel electrophoresis and then 
confirmed through the development of an on-chip microfluidic protocol for the 
Bioanalyzer 2100. There is again, a distinct dependency on linker chain length 
with the pentanediamine complex inhibiting, or protecting, linearised pUC19 
from digestion at the nanomolar exposure level while a ten-fold concentration 
increase (≥5.0 µM) by hexane- and heptane-bridged Triplatin cations were 
required to block restriction activity. In summary, the studies clearly display two 
modes of DNA binding consistent with backbone tracking and groove-spanning 
interactions where each mode is dependent on base specificity or local helical 
topological parameters.  
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Appendix A   
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A.A.1 X-ray crystallography of methyl 2-(4-hydroxyphenyl)-4a,12b-dihydro-
2H-[1,4]oxazino[2,3-f][1,10]phenanththroline-3-carboxylate (PDT) 
Table A.A.1 Crystal data and structure refinement for PDT·MeOH. 
Empirical formula  C23 H19 N3 O5 
Formula weight  417.41 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/c 
Unit cell dimensions a = 10.2862(8) Å  = 90°. 
 b = 20.0798(16) Å  = 
90.1550(10)°. 
 c = 9.6427(8) Å   = 90°. 
Volume 1991.6(3) Å3 
Z 4 
Density (calculated) 1.392 Mg/m3 
Absorption coefficient 0.100 mm-1 
F(000) 872 
Crystal size 0.43 x 0.35 x 0.14 mm3 
Crystal description colourless block 
Theta range for data collection 1.98 to 28.33°. 
Index ranges -13<=h<=13, -26<=k<=26, -12<=l<=12 
Reflections collected 20407 
Independent reflections 4961 [R(int) = 0.0268] 
Completeness to theta = 26.00° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9861 and 0.9583 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4961 / 0 / 287 
Goodness-of-fit on F2 1.049 
Final R indices [I>2sigma(I)] R1 = 0.0410, wR2 = 0.1061 
R indices (all data) R1 = 0.0551, wR2 = 0.1150 
Largest diff. peak and hole 0.290 and -0.237 e.Å-3 
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Table A.A.2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 
103).  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
______________________________________________________________________________
__ 
 x y z U(eq) 
______________________________________________________________________________
__ 
N(1) 7704(1) 3902(1) 10605(1) 32(1) 
C(1) 8269(2) 4394(1) 9916(2) 36(1) 
C(2) 9234(1) 4295(1) 8917(2) 32(1) 
C(3) 9624(1) 3657(1) 8615(1) 26(1) 
C(4) 9038(1) 3120(1) 9313(1) 23(1) 
C(5) 9356(1) 2437(1) 9018(1) 22(1) 
C(6) 8724(1) 1936(1) 9696(1) 23(1) 
C(7) 7742(1) 2066(1) 10709(1) 24(1) 
C(8) 7079(1) 1553(1) 11410(1) 29(1) 
C(9) 6168(1) 1718(1) 12380(2) 36(1) 
C(10) 5924(1) 2391(1) 12629(2) 37(1) 
N(2) 6513(1) 2890(1) 11985(1) 32(1) 
C(11) 7423(1) 2732(1) 11026(1) 25(1) 
C(12) 8079(1) 3272(1) 10306(1) 24(1) 
O(1) 8939(1) 1284(1) 9406(1) 27(1) 
C(13) 10171(1) 1124(1) 8747(1) 24(1) 
C(14) 11208(1) 962(1) 9798(1) 23(1) 
C(15) 11547(1) 306(1) 10081(1) 27(1) 
C(16) 12460(1) 150(1) 11089(2) 30(1) 
C(17) 13079(1) 659(1) 11819(1) 28(1) 
O(2) 13972(1) 544(1) 12825(1) 38(1) 
C(18) 12775(1) 1319(1) 11510(1) 28(1) 
C(19) 11847(1) 1466(1) 10523(1) 26(1) 
C(20) 10598(1) 1688(1) 7821(1) 24(1) 
C(21) 11529(1) 1477(1) 6712(1) 27(1) 
O(3) 11614(1) 907(1) 6344(1) 42(1) 
O(4) 12246(1) 1975(1) 6229(1) 37(1) 
C(22) 13159(2) 1789(1) 5151(2) 49(1) 
N(3) 10260(1) 2299(1) 7958(1) 23(1) 
O(31) 14632(1) -721(1) 12893(1) 41(1) 
C(32) 15288(2) -950(1) 11693(2) 54(1) 
Table A.A.3. Bond lengths [Å] and angles [°]. 
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_____________________________________________________ 
N(1)-C(1)  1.3262(18) 
N(1)-C(12)  1.3539(16) 
C(1)-C(2)  1.399(2) 
C(2)-C(3)  1.3730(18) 
C(3)-C(4)  1.4072(17) 
C(4)-C(12)  1.4096(17) 
C(4)-C(5)  1.4405(17) 
C(5)-C(6)  1.3647(17) 
C(5)-N(3)  1.4101(16) 
C(6)-O(1)  1.3580(15) 
C(6)-C(7)  1.4318(18) 
C(7)-C(8)  1.4087(17) 
C(7)-C(11)  1.4098(18) 
C(8)-C(9)  1.367(2) 
C(9)-C(10)  1.395(2) 
C(10)-N(2)  1.3254(18) 
N(2)-C(11)  1.3556(17) 
C(11)-C(12)  1.4542(18) 
O(1)-C(13)  1.4552(15) 
C(13)-C(14)  1.5053(18) 
C(13)-C(20)  1.5089(17) 
C(14)-C(15)  1.3893(17) 
C(14)-C(19)  1.3945(17) 
C(15)-C(16)  1.3856(19) 
C(16)-C(17)  1.3942(19) 
C(17)-O(2)  1.3534(16) 
C(17)-C(18)  1.3933(18) 
C(18)-C(19)  1.3778(19) 
C(20)-N(3)  1.2817(16) 
C(20)-C(21)  1.4989(18) 
C(21)-O(3)  1.2006(16) 
C(21)-O(4)  1.3284(16) 
O(4)-C(22)  1.4509(17) 
O(31)-C(32)  1.418(2)
C(1)-N(1)-C(12) 117.63(12) 
N(1)-C(1)-C(2) 123.52(12) 
C(3)-C(2)-C(1) 119.10(12) 
C(2)-C(3)-C(4) 119.14(12) 
C(3)-C(4)-C(12) 117.49(11) 
C(3)-C(4)-C(5) 122.52(11) 
C(12)-C(4)-C(5) 119.96(11) 
C(6)-C(5)-N(3) 121.25(11) 
C(6)-C(5)-C(4) 119.89(11) 
N(3)-C(5)-C(4) 118.72(10) 
O(1)-C(6)-C(5) 122.26(11) 
O(1)-C(6)-C(7) 115.60(11) 
C(5)-C(6)-C(7) 122.06(11) 
C(8)-C(7)-C(11) 118.42(12) 
C(8)-C(7)-C(6) 122.50(12) 
C(11)-C(7)-C(6) 119.08(11) 
C(9)-C(8)-C(7) 119.00(13) 
C(8)-C(9)-C(10) 118.43(13) 
N(2)-C(10)-C(9) 124.68(13) 
C(10)-N(2)-C(11) 117.34(12) 
N(2)-C(11)-C(7) 122.12(12) 
N(2)-C(11)-C(12) 118.25(12) 
C(7)-C(11)-C(12) 119.64(11) 
N(1)-C(12)-C(4) 123.11(12) 
N(1)-C(12)-C(11) 117.49(11) 
C(4)-C(12)-C(11) 119.37(11) 
C(6)-O(1)-C(13) 116.42(9) 
O(1)-C(13)-C(14) 111.69(10) 
O(1)-C(13)-C(20) 110.37(10) 
C(14)-C(13)-C(20) 110.76(10) 
C(15)-C(14)-C(19) 118.19(12) 
C(15)-C(14)-C(13) 120.97(11) 
C(19)-C(14)-C(13) 120.84(11) 
C(16)-C(15)-C(14) 121.39(12) 
C(15)-C(16)-C(17) 119.79(12) 
O(2)-C(17)-C(18) 117.90(12) 
O(2)-C(17)-C(16) 122.97(12) 
C(18)-C(17)-C(16) 119.12(12) 
C(19)-C(18)-C(17) 120.46(12) 
C(18)-C(19)-C(14) 120.99(12) 
	  A-­‐‑5	  
N(3)-C(20)-C(21) 121.25(11) 
N(3)-C(20)-C(13) 125.31(11) 
C(21)-C(20)-C(13) 113.39(10) 
O(3)-C(21)-O(4) 124.95(13) 
O(3)-C(21)-C(20) 121.84(12) 
O(4)-C(21)-C(20) 113.19(11) 
C(21)-O(4)-C(22) 114.72(12) 
C(20)-N(3)-C(5) 116.22(11) 
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Table A.A.4   Anisotropic displacement parameters (Å2x 103).  The anisotropic 
displacement factor exponent takes the form: -2 2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
N(1) 36(1)  25(1) 36(1)  -1(1) 8(1)  5(1) 
C(1) 45(1)  20(1) 43(1)  -2(1) 8(1)  4(1) 
C(2) 38(1)  21(1) 37(1)  3(1) 6(1)  -2(1) 
C(3) 29(1)  22(1) 29(1)  2(1) 4(1)  0(1) 
C(4) 23(1)  21(1) 24(1)  0(1) -1(1)  0(1) 
C(5) 22(1)  20(1) 23(1)  1(1) 1(1)  0(1) 
C(6) 23(1)  19(1) 28(1)  1(1) -2(1)  -1(1) 
C(7) 21(1)  26(1) 26(1)  3(1) -2(1)  -2(1) 
C(8) 25(1)  30(1) 34(1)  6(1) -2(1)  -5(1) 
C(9) 26(1)  42(1) 38(1)  11(1) 3(1)  -8(1) 
C(10) 27(1)  46(1) 38(1)  4(1) 10(1)  -2(1) 
N(2) 27(1)  37(1) 33(1)  1(1) 7(1)  0(1) 
C(11) 21(1)  29(1) 25(1)  2(1) 0(1)  1(1) 
C(12) 25(1)  23(1) 26(1)  0(1) 1(1)  2(1) 
O(1) 26(1)  18(1) 38(1)  1(1) 3(1)  -2(1) 
C(13) 28(1)  17(1) 28(1)  -1(1) 3(1)  0(1) 
C(14) 25(1)  19(1) 25(1)  1(1) 4(1)  -1(1) 
C(15) 27(1)  18(1) 37(1)  0(1) -1(1)  -3(1) 
C(16) 29(1)  19(1) 42(1)  5(1) -2(1)  -2(1) 
C(17) 26(1)  28(1) 30(1)  5(1) 1(1)  -2(1) 
O(2) 39(1)  32(1) 43(1)  7(1) -13(1)  -3(1) 
C(18) 32(1)  23(1) 29(1)  -3(1) 0(1)  -5(1) 
C(19) 32(1)  18(1) 27(1)  0(1) 4(1)  -1(1) 
C(20) 27(1)  21(1) 23(1)  0(1) -1(1)  0(1) 
C(21) 33(1)  24(1) 25(1)  1(1) 0(1)  5(1) 
O(3) 55(1)  27(1) 44(1)  -11(1) 12(1)  2(1) 
O(4) 47(1)  26(1) 39(1)  4(1) 20(1)  6(1) 
C(22) 57(1)  49(1) 43(1)  5(1) 28(1)  13(1) 
N(3) 26(1)  21(1) 24(1)  1(1) 1(1)  1(1) 
O(31) 33(1)  37(1) 51(1)  16(1) 8(1)  -2(1) 
C(32) 43(1)  64(1) 56(1)  9(1) 9(1)  2(1) 
______________________________________________________________________________
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Table A.A.5 Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103). 
______________________________________________________________________________
__ 
 x y  z  U(eq) 
______________________________________________________________________________
__ 
 
H(1) 8005 4837 10110 43 
H(2) 9615 4664 8454 39 
H(3) 10281 3579 7943 32 
H(8) 7262 1100 11211 35 
H(9) 5712 1383 12874 43 
H(10) 5290 2500 13307 44 
H(13) 10035 721 8153 29 
H(15) 11146 -44 9572 33 
H(16) 12663 -302 11283 36 
H(18) 13209 1670 11982 33 
H(19) 11640 1918 10333 31 
H(22A) 13648 2183 4856 74 
H(22B) 12682 1605 4357 74 
H(22C) 13762 1453 5512 74 
H(32A) 15877 -602 11359 82 
H(32B) 14651 -1056 10968 82 
H(32C) 15789 -1350 11922 82 
H(2O) 14135(16) 87(9) 12894(17) 40 
H(31) 14065(18) -1005(9) 13122(18) 40 
______________________________________________________________________________
__
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Table A.A.6 Hydrogen bonds [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 O(2)-H(2O)...O(31) 0.935(18) 1.700(18) 2.6295(15) 171.8(16) 
 O(31)-H(31)...N(1)#1 0.846(18) 2.205(18) 2.9090(16) 140.7(15) 
 O(31)-H(31)...N(2)#1 0.846(18) 2.299(18) 3.0297(17) 144.8(15) 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  #1 -x+2,y-1/2,-z+5/2      
Least-squares planes (x,y,z in crystal coordinates) and deviations from them 
 (* indicates atom used to define plane) 
 
7.2066 (0.0018) x + 0.5999 (0.0046) y + 6.8562 (0.0017) z = 13.0561 (0.0018)  
 
 *    0.0008 (0.0011)  N1 
 *   -0.0350 (0.0013)  C1 
 *   -0.0301 (0.0013)  C2 
 *    0.0055 (0.0012)  C3 
 *    0.0300 (0.0011)  C4 
 *    0.0153 (0.0010)  C5 
 *   -0.0053 (0.0010)  C6 
*   -0.0107 (0.0011)  C7 
*   -0.0389 (0.0012)  C8 
 *   -0.0199 (0.0012)  C9 
 *    0.0148 (0.0012)  C10 
 *    0.0281 (0.0011)  N2 
 *    0.0169 (0.0012)  C11 
 *    0.0283 (0.0012)  C12 
 3.1659 (0.0022)  C1_$2 
      3.2947 (0.0015)  C3_$2 
      3.2947 (0.0015)  C3_$2 
3.3836 (0.0014)  C4_$2 
      3.4510 (0.0013)  C5_$2 
      3.2608 (0.0016)  N1_$2 
      3.4094 (0.0014)  N2_$2 
      3.4904 (0.0015)  C6_$2 
      3.4694 (0.0016)  C7_$2 
      3.3638 (0.0015)  C12_$2 
 
Rms deviation of fitted atoms =   0.0231 
eqiv $2 x, 0.5-y, 0.5+z 
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Fig. A.A.1 A view of PDT·MeOH showing the orthogonal nature of the phenol ring with respect 
to the oxazine ring and also the hydrogen bonding involving the phenol OH and methanol OH. 
 
 
Fig. A.A.2 A view of PDT·MeOH showing that hydrogen bonding occurs only between the same 
layers of molecules. 
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Appendix B   
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A.B.1 Infrared spectroscopy of [Cu(R-COO)(1,10-Phen)2]+  
 
  
  
Figure A.B.1 IR spectra of [Cu(1,10-Phen)2](NO3)2, (Cu-Phen) 
  
  
  
Figure A.B.2 IR spectra of [Cu(For)(1,10-Phen)2](NO3)⋅6H2O, (Cu-For-Phen)  
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Figure A.B.3 IR spectra of [Cu(Ace)(1,10-Phen)2](NO3)⋅2H2O, (Cu-Ace-Phen)  
  
  
Figure A.B.4 IR spectra of [Cu(Pro)(1,10-Phen)]·½(CO3)·4½H2O, (Cu-Pro-Phen)  
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Figure A.B.5 IR spectra of [Cu(Iso)(1,10-Phen)2]2·2(NO3)·4H2O, (Cu-Iso-Phen) 
  
  
  
  
Figure A.B.6 IR spectra of [Cu(Piv)(1,10-Phen)2]2(piv)2·(Hpiv)·9H2O, (Cu-Piv-Phen)  
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A.B.2 Crystallography 
A.B.2.1 [Cu(For)(1,10-Phen)2](NO3)⋅6H2O, (Cu-For-Phen) 
 
 
                                       Figure A.B.7 Crystal structure of Cu-For-Phen 
  
  
  
                     Figure A.B.9 π−π stacking linking the cations into zig-zag chains. 
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Figure A.B.10 The chains are linked by H-bonding involving the nitrate anions and water 
molecules. 
 
Table A.B.1 Crystal data of Cu-For-Phen 
C25H29CuN5O11 F(000) = 1324 
Mr = 639.07 Dx = 1.560 Mg m-3 
Monoclinic, P21/n Mo Kα radiation, λ = 0.71073 Å 
a = 14.8372 (12) Å Cell parameters from 4135 reflections 
b = 12.467 (1) Å θ = 2.3–25.0° 
c = 15.5706 (12) Å µ = 0.87 mm-1 
β = 109.092 (1)° T = 150 K 
V = 2721.8 (4)  Å3 Plate, blue 
Z = 4 0.49 × 0.30 × 0.05 mm 
 
Table A.B.2 Data collection of Cu-For-Phen 
Bruker APEX-II CCD  
diffractometer 
5353 independent reflections 
Radiation source: fine-focus sealed tube 3939 reflections with I> 2σ(I) 
graphite Rint = 0.046 
φ and ω scans θmax = 26.0°, θmin = 1.7° 
Absorption correction: multi-scan  
SADABS v2008/1, Sheldrick, G.M., (2008) 
h = -18→18 
Tmin = 0.674, Tmax = 0.958 k = -15→15 
22925 measured reflections l = -19→19 
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Table A.B.3 Refinement data of Cu-For-Phen 
Refinement on F2 Primary atom site location: structure-invariant 
direct methods 
Least-squares matrix: full Secondary atom site location: difference Fourier 
map 
R[F2> 2σ(F2)] = 0.046 Hydrogen site location: inferred from 
neighbouring sites 
wR(F2) = 0.136 H atoms treated by a mixture of independent 
and constrained refinement 
S = 1.07 w = 1/[σ2(Fo2) + (0.0678P)2 + 2.7897P]   
where P = (Fo2 + 2Fc2)/3 
5353 reflections (Δ/σ)max = 0.001 
415 parameters Δ〉max = 1.31 e Å-3 
18 restraints Δ〉min = -0.87 e Å-3 
 
Table A.B.4 Geometric parameters (Å, º) of Cu-For-Phen 
Cu1—N2 1.982 (3) N3—C13 1.329 (4) 
Cu1—N3 1.988 (3) N3—C24 1.365 (4) 
Cu1—O31 2.027 (2) C13—C14 1.404 (5) 
Cu1—N1 2.057 (3) C14—C15 1.367 (5) 
Cu1—N4 2.181 (3) C15—C16 1.407 (5) 
N1—C1 1.330 (4) C16—C24 1.397 (4) 
N1—C12 1.357 (4) C16—C17 1.438 (5) 
C1—C2 1.400 (5) C17—C18 1.336 (5) 
C2—C3 1.367 (5) C18—C19 1.439 (5) 
C3—C4 1.408 (5) C19—C20 1.405 (5) 
C4—C12 1.406 (4) C19—C23 1.411 (4) 
C4—C5 1.437 (5) C20—C21 1.371 (5) 
C5—C6 1.349 (5) C21—C22 1.399 (5) 
C6—C7 1.428 (5) C22—N4 1.324 (4) 
C7—C11 1.406 (4) N4—C23 1.360 (4) 
C7—C8 1.407 (5) C23—C24 1.437 (4) 
C8—C9 1.369 (5) O31—C31 1.268 (4) 
C9—C10 1.397 (5) O32—C31 1.234 (4) 
C10—N2 1.331 (4) N11—O12 1.166 (5) 
N2—C11 1.361 (4) N11—O13 1.190 (4) 
C11—C12 1.424 (4) N11—O11 1.257 (4) 
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N2—Cu1—N3 176.80 (10) N1—C12—C11 117.0 (3) 
N2—Cu1—O31 91.58 (10) C4—C12—C11 119.3 (3) 
N3—Cu1—O31 89.71 (10) C13—N3—C24 118.7 (3) 
N2—Cu1—N1 81.78 (10) C13—N3—Cu1 125.7 (2) 
N3—Cu1—N1 98.73 (10) C24—N3—Cu1 115.0 (2) 
O31—Cu1—N1 146.33 (9) N3—C13—C14 122.0 (3) 
N2—Cu1—N4 96.51 (10) C15—C14—C13 119.6 (3) 
N3—Cu1—N4 80.46 (10) C14—C15—C16 119.4 (3) 
O31—Cu1—N4 95.07 (9) C24—C16—C15 117.8 (3) 
N1—Cu1—N4 118.41 (10) C24—C16—C17 118.9 (3) 
C1—N1—C12 117.9 (3) C15—C16—C17 123.3 (3) 
C1—N1—Cu1 131.0 (2) C18—C17—C16 121.4 (3) 
C12—N1—Cu1 111.04 (19) C17—C18—C19 121.3 (3) 
N1—C1—C2 122.3 (3) C20—C19—C23 116.7 (3) 
C3—C2—C1 119.9 (3) C20—C19—C18 124.4 (3) 
C2—C3—C4 119.6 (3) C23—C19—C18 118.9 (3) 
C12—C4—C3 116.6 (3) C21—C20—C19 120.2 (3) 
C12—C4—C5 118.7 (3) C20—C21—C22 119.0 (3) 
C3—C4—C5 124.6 (3) N4—C22—C21 123.0 (3) 
C6—C5—C4 121.3 (3) C22—N4—C23 118.3 (3) 
C5—C6—C7 121.4 (3) C22—N4—Cu1 132.3 (2) 
C11—C7—C8 117.2 (3) C23—N4—Cu1 108.70 (19) 
C11—C7—C6 118.1 (3) N4—C23—C19 123.0 (3) 
C8—C7—C6 124.7 (3) N4—C23—C24 117.7 (3) 
C9—C8—C7 119.7 (3) C19—C23—C24 119.3 (3) 
C8—C9—C10 119.7 (3) N3—C24—C16 122.4 (3) 
N2—C10—C9 122.0 (3) N3—C24—C23 117.3 (3) 
C10—N2—C11 118.8 (3) C16—C24—C23 120.3 (3) 
C10—N2—Cu1 127.4 (2) C31—O31—Cu1 106.6 (2) 
C11—N2—Cu1 113.8 (2) O32—C31—O31 125.4 (3) 
N2—C11—C7 122.5 (3) O12—N11—O13 115.4 (5) 
N2—C11—C12 116.3 (3) O12—N11—O11 117.9 (4) 
C7—C11—C12 121.1 (3) O13—N11—O11 126.6 (4) 
N1—C12—C4 123.7 (3)   
 
 
 
 
 
	  B-­‐‑9	  
Table A.B.5 Hydrogen-bond geometry (Å, º) of Cu-For-Phen 
D—H···A D—H H···A D···A D—H···A 
O1W—H1WA···O3Wi 0.85 (2) 2.03 (2) 2.870 (4) 167 (4) 
O1W—H1WB···O11 0.84 (2) 2.01 (2) 2.846 (4) 170 (5) 
O2W—H2WB···O11 0.84 (2) 1.97 (2) 2.798 (4) 171 (4) 
O2W—H2WA···O6Wii 0.82 (2) 1.94 (2) 2.752 (4) 172 (4) 
O3W—H3WA···O2Wiii 0.82 (2) 1.99 (2) 2.782 (4) 162 (5) 
O3W—H3WB···O13 0.81 (2) 2.67 (3) 3.260 (7) 132 (4) 
O4W—H4WB···O5Wiv 0.80 (2) 2.04 (2) 2.837 (4) 170 (5) 
O4W—H4WA···O1Wiv 0.80 (2) 2.05 (3) 2.804 (4) 157 (5) 
O5W—H5WA···O4W 0.79 (2) 2.00 (2) 2.781 (4) 169 (5) 
O5W—H5WB···O32 0.81 (2) 1.98 (2) 2.777 (4) 168 (5) 
O6W—H6WB···O4Wv 0.82 (2) 1.96 (2) 2.765 (4) 168 (6) 
O6W—H6WA···O13 0.81 (2) 2.02 (2) 2.830 (6) 172 (5) 
Symmetry codes:  (i) -x-1/2, y-1/2, -z+3/2; (ii) -x, -y+1, -z+2; (iii) -x-1/2, y+1/2, -
z+3/2; (iv) -x-1, -y+1, -z+1; (v) x+1/2, -y+3/2, z+1/2. 
 
A.B.2.2 [Cu(Ace)(1,10-Phen)2](NO3)⋅2H2O, (Cu-Ace-Phen) 
	  
  
                                     Figure A.B.11 Crystal structure of Cu-Ace-Phen 
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Figure A.B.12 The coordinated nitrate anion is disordered over two positions and was refined 
with 85:15 occupancy of the sites. 
 
 
Figure A.B.13 The cations are linked into zig-zag chains by π−π stacking 
 
 
Figure A.B.14 The chains are linked by H-bonding involving the nitrate anions and water 
molecules. 
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Table A.B.6 Crystal data of Cu-Ace-Phen 
C26H23CuN5O7 Z = 2 
Mr = 581.03 F(000) = 598 
Triclinic, P¯1 Dx = 1.557 Mg m-3 
a = 8.5126 (4) Å Mo Kα radiation, λ = 0.71073 Å 
b = 10.3864 (5) Å Cell parameters from 6002 reflections 
c = 14.6033 (6) Å θ = 2.4–28.2° 
α = 83.271 (1)° µ = 0.94 mm-1 
β = 82.998 (1)° T = 150 K 
γ = 76.269 (1)° Block, blue 
V = 1239.68 (10)  Å3 0.47 × 0.24 × 0.08 mm 
 
Table A.B.7 Data collection of Cu-Ace-Phen 
Bruker APEX-II CCD  
diffractometer 
6174 independent reflections 
Radiation source: fine-focus sealed tube 5328 reflections with I> 2σ(I) 
graphite Rint = 0.026 
φ and ω scans θmax = 28.3°, θmin = 2.0° 
Absorption correction: multi-scan  
SADABS v2008/1, Sheldrick, G.M., (2008) 
h = -11→11 
Tmin = 0.667, Tmax = 0.929 k = -13→13 
17094 measured reflections l = -19→19 
 
Table A.B.8 Refinement of Cu-Ace-Phen 
Refinement on F2 Primary atom site location: structure-invariant 
direct methods 
Least-squares matrix: full Secondary atom site location: difference Fourier 
map 
R[F2> 2σ(F2)] = 0.031 Hydrogen site location: inferred from 
neighbouring sites 
wR(F2) = 0.081 H atoms treated by a mixture of independent 
and constrained refinement 
S = 1.05 w = 1/[σ2(Fo2) + (0.0368P)2 + 0.5118P]   
where P = (Fo2 + 2Fc2)/3 
6174 reflections (Δ/σ)max< 0.001 
381 parameters Δ〉max = 0.40 e Å-3 
12 restraints Δ〉min = -0.32 e Å-3 
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Table A.B.9 Geometric parameters (Å, º) of Cu-Ace-Phen 
Cu1—N1 1.9981 (14) N3—C24 1.356 (2) 
Cu1—O21 2.0076 (17) C13—C14 1.400 (3) 
Cu1—N4 2.0156 (14) C14—C15 1.367 (3) 
Cu1—O22' 2.019 (9) C15—C16 1.407 (3) 
Cu1—N2 2.0559 (14) C16—C24 1.410 (2) 
Cu1—N3 2.1815 (14) C16—C17 1.438 (3) 
Cu1—O22 2.589 (2) C17—C18 1.354 (3) 
Cu1—O21' 2.599 (10) C18—C19 1.436 (3) 
N1—C1 1.330 (2) C19—C23 1.403 (2) 
N1—C12 1.358 (2) C19—C20 1.410 (3) 
C1—C2 1.397 (3) C20—C21 1.366 (3) 
C2—C3 1.368 (3) C21—C22 1.401 (2) 
C3—C4 1.408 (3) C22—N4 1.328 (2) 
C4—C12 1.404 (2) N4—C23 1.365 (2) 
C4—C5 1.434 (3) C23—C24 1.439 (2) 
C5—C6 1.352 (3) O21—C25 1.279 (5) 
C6—C7 1.435 (3) O22—C25 1.242 (6) 
C7—C11 1.398 (2) C25—C26 1.505 (4) 
C7—C8 1.412 (3) O21'—C25' 1.25 (2) 
C8—C9 1.365 (3) O22'—C25' 1.273 (18) 
C9—C10 1.400 (3) C25'—C26' 1.515 (16) 
C10—N2 1.326 (2) N31—O32 1.229 (2) 
N2—C11 1.362 (2) N31—O31 1.239 (2) 
C11—C12 1.431 (2) N31—O33 1.243 (2) 
N3—C13 1.324 (2)   
    
N1—Cu1—O21 91.81 (6) C11—N2—Cu1 111.44 (11) 
N1—Cu1—N4 174.22 (6) N2—C11—C7 123.42 (15) 
O21—Cu1—N4 93.20 (6) N2—C11—C12 116.58 (14) 
N1—Cu1—O22' 92.2 (3) C7—C11—C12 119.99 (15) 
O21—Cu1—O22' 52.8 (3) N1—C12—C4 122.92 (15) 
N4—Cu1—O22' 93.1 (3) N1—C12—C11 116.84 (14) 
N1—Cu1—N2 81.76 (6) C4—C12—C11 120.22 (15) 
O21—Cu1—N2 156.96 (6) C13—N3—C24 118.31 (15) 
N4—Cu1—N2 94.68 (5) C13—N3—Cu1 131.59 (12) 
O22'—Cu1—N2 105.1 (3) C24—N3—Cu1 110.09 (11) 
N1—Cu1—N3 96.66 (5) N3—C13—C14 122.66 (17) 
O21—Cu1—N3 98.06 (6) C15—C14—C13 119.53 (18) 
N4—Cu1—N3 79.79 (5) C14—C15—C16 119.52 (17) 
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O22'—Cu1—N3 149.8 (3) C15—C16—C24 117.07 (16) 
N2—Cu1—N3 104.63 (5) C15—C16—C17 123.71 (17) 
N1—Cu1—O22 94.57 (5) C24—C16—C17 119.22 (17) 
O21—Cu1—O22 55.67 (5) C18—C17—C16 120.65 (17) 
N4—Cu1—O22 90.63 (5) C17—C18—C19 121.54 (17) 
O22'—Cu1—O22 3.7 (3) C23—C19—C20 117.30 (16) 
N2—Cu1—O22 102.59 (5) C23—C19—C18 118.92 (17) 
N3—Cu1—O22 151.75 (5) C20—C19—C18 123.78 (16) 
N1—Cu1—O21' 94.7 (2) C21—C20—C19 119.70 (16) 
O21—Cu1—O21' 4.1 (2) C20—C21—C22 119.55 (17) 
N4—Cu1—O21' 90.2 (2) N4—C22—C21 122.25 (17) 
O22'—Cu1—O21' 55.7 (3) C22—N4—C23 118.73 (15) 
N2—Cu1—O21' 160.5 (2) C22—N4—Cu1 126.16 (12) 
N3—Cu1—O21' 94.8 (2) C23—N4—Cu1 115.11 (11) 
O22—Cu1—O21' 58.4 (2) N4—C23—C19 122.47 (16) 
C1—N1—C12 118.25 (15) N4—C23—C24 117.57 (14) 
C1—N1—Cu1 128.40 (12) C19—C23—C24 119.97 (15) 
C12—N1—Cu1 113.36 (11) N3—C24—C16 122.90 (16) 
N1—C1—C2 122.57 (17) N3—C24—C23 117.39 (15) 
C3—C2—C1 119.51 (17) C16—C24—C23 119.68 (15) 
C2—C3—C4 119.53 (16) C25—O21—Cu1 103.9 (2) 
C12—C4—C3 117.20 (16) C25—O22—Cu1 77.9 (2) 
C12—C4—C5 118.54 (16) O22—C25—O21 122.1 (3) 
C3—C4—C5 124.25 (16) O22—C25—C26 121.0 (4) 
C6—C5—C4 121.25 (17) O21—C25—C26 116.8 (4) 
C5—C6—C7 121.11 (17) C25'—O21'—Cu1 77.0 (10) 
C11—C7—C8 116.98 (16) C25'—O22'—Cu1 103.0 (10) 
C11—C7—C6 118.89 (16) O21'—C25'—O22' 123.3 (16) 
C8—C7—C6 124.11 (16) O21'—C25'—C26' 119.2 (16) 
C9—C8—C7 119.38 (16) O22'—C25'—C26' 117.5 (17) 
C8—C9—C10 119.77 (17) O32—N31—O31 119.77 (17) 
N2—C10—C9 122.53 (17) O32—N31—O33 119.98 (18) 
C10—N2—C11 117.91 (15) O31—N31—O33 120.23 (17) 
C10—N2—Cu1 130.65 (12)   
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Table A.B.10 Hydrogen-bond geometry (Å, º) of Cu-Ace-Phen 
D—H···A D—H H···A D···A D—H···A 
O1W—H1WA···O22 0.84 (2) 1.87 (2) 2.704 (2) 170 (3) 
O1W—H1WB···O2W 0.83 (2) 1.91 (2) 2.732 (2) 176 (3) 
O2W—H2WA···O33 0.81 (2) 2.05 (2) 2.853 (2) 169 (3) 
O2W—H2WB···O1Wi 0.78 (2) 1.99 (2) 2.748 (3) 164 (3) 
Symmetry code:  (i) -x+1, -y, -z. 
 
A.B.2.3 [Cu(Pro)(1,10-Phen)]·½(CO3)·4½H2O, (Cu-Pro-Phen) 
 
 
Figure A.B.15 Crystal structure of Cu-Pro-Phen  
 
 
Figure A.B.16  One of the 1,10-phen groups is disordered and was modeled with 50:50 
occupancy over two sites.  
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Figure A.B.17 The cations are  -stacked into chains and the chains are linked by H-bonding, 
which includes the counter ion. H-bond network resulting is also disordered; a reasonable set of 
interactions is shown in the final H-bond table (Table A.B.15). 
 
Table A.B.11 Crystal data of Cu-Pro-Phen 
C27.50H30CuN4O8 F(000) = 2528 
Mr = 608.09 Dx = 1.428 Mg m-3 
Monoclinic, C2/c Mo Kα radiation, λ = 0.71073 Å 
a = 31.873 (5) Å Cell parameters from 5053 reflections 
b = 12.4716 (19) Å θ = 2.2–25.0° 
c = 14.264 (2) Å µ = 0.83 mm-1 
β = 93.879 (2)° T = 150 K 
V = 5656.9 (15)  Å3 Block, blue 
Z = 8 0.40 × 0.26 × 0.26 mm 
 
Table A.B.12 Data collection of Cu-Pro-Phen 
Bruker APEX 2 CCD  
diffractometer 
3442 reflections with I> 2σ(I) 
ω rotation with narrow frames scans Rint = 0.059 
Absorption correction: multi-scan  
SADABS v2009/1, Sheldrick, G.M., (2009) 
θmax = 26.4°, θmin = 1.8° 
Tmin = 0.522, Tmax = 0.745 h = -39→39 
23362 measured reflections k = -15→15 
5815 independent reflections l = -17→17 
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Table A.B.13 Refinement of Cu-Pro-Phen 
Refinement on F2 984 restraints 
Least-squares matrix: full Hydrogen site location: inferred from 
neighbouring sites 
R[F2> 2σ(F2)] = 0.094 H-atom parameters constrained 
wR(F2) = 0.330 w = 1/[σ2(Fo2) + (0.1958P)2 + 25.9775P]     
where P = (Fo2 + 2Fc2)/3 
S = 1.05 (Δ/σ)max = 0.006 
5815 reflections Δ〉max = 1.87 e Å-3 
527 parameters Δ〉min = -0.88 e Å-3 
 
Table A.B.14 Geometric parameters (Å, º) of Cu-Pro-Phen 
Cu1—O32 1.955 (8) C21—C22 1.400 (15) 
Cu1—N2 1.998 (5) C22—N4 1.325 (13) 
Cu1—N3' 2.008 (13) N4—C23 1.344 (13) 
Cu1—N3 2.035 (14) C23—C24 1.442 (13) 
Cu1—N4' 2.087 (13) N3'—C13' 1.304 (13) 
Cu1—N1 2.093 (6) N3'—C24' 1.355 (13) 
Cu1—N4 2.171 (14) C13'—C14' 1.377 (13) 
Cu1—C31 2.513 (9) C14'—C15' 1.363 (15) 
N1—C1 1.319 (8) C15'—C16' 1.406 (15) 
N1—C12 1.362 (7) C16'—C24' 1.390 (12) 
C1—C2 1.378 (10) C16'—C17' 1.429 (15) 
C2—C3 1.362 (10) C17'—C18' 1.334 (16) 
C3—C4 1.417 (10) C18'—C19' 1.436 (14) 
C4—C12 1.391 (9) C19'—C20' 1.392 (15) 
C4—C5 1.423 (10) C19'—C23' 1.407 (12) 
C5—C6 1.338 (10) C20'—C21' 1.345 (15) 
C6—C7 1.440 (9) C21'—C22' 1.401 (14) 
C7—C8 1.391 (9) C22'—N4' 1.314 (13) 
C7—C11 1.402 (8) N4'—C23' 1.339 (12) 
C8—C9 1.373 (10) C23'—C24' 1.442 (13) 
C9—C10 1.391 (9) O31—C31 1.189 (11) 
C10—N2 1.333 (8) O32—C31 1.235 (9) 
N2—C11 1.342 (8) C31—C32 1.587 (13) 
C11—C12 1.433 (8) C32—C33 1.486 (11) 
N3—C13 1.313 (13) C40—O43i 0.87 (2) 
N3—C24 1.362 (13) C40—O41 1.206 (15) 
C13—C14 1.384 (14) C40—O43 1.207 (14) 
C14—C15 1.359 (16) C40—O42 1.216 (16) 
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C15—C16 1.411 (15) C40—C40i 1.57 (3) 
C16—C24 1.395 (13) C40—O42i 1.879 (19) 
C16—C17 1.429 (15) O42—O43i 0.711 (16) 
C17—C18 1.332 (17) O42—C40i 1.879 (19) 
C18—C19 1.438 (16) O43—O42i 0.711 (16) 
C19—C20 1.389 (15) O43—C40i 0.87 (2) 
C19—C23 1.407 (12) O43—O43i 1.39 (3) 
C20—C21 1.353 (16)   
    
O32—Cu1—N2 93.5 (3) C22—N4—C23 117.7 (12) 
O32—Cu1—N3' 86.3 (4) C22—N4—Cu1 131.5 (10) 
N2—Cu1—N3' 173.4 (4) C23—N4—Cu1 110.6 (8) 
O32—Cu1—N3 95.2 (4) N4—C23—C19 122.8 (12) 
N2—Cu1—N3 170.9 (4) N4—C23—C24 117.8 (10) 
O32—Cu1—N4' 105.8 (10) C19—C23—C24 119.4 (11) 
N2—Cu1—N4' 92.0 (4) N3—C24—C16 123.1 (11) 
N3'—Cu1—N4' 81.7 (5) N3—C24—C23 116.5 (10) 
O32—Cu1—N1 148.2 (3) C16—C24—C23 120.2 (10) 
N2—Cu1—N1 81.4 (2) C13'—N3'—C24' 119.4 (12) 
N3'—Cu1—N1 102.3 (4) C13'—N3'—Cu1 127.4 (10) 
N3—Cu1—N1 89.7 (4) C24'—N3'—Cu1 113.1 (8) 
N4'—Cu1—N1 105.7 (10) N3'—C13'—C14' 122.4 (12) 
O32—Cu1—N4 107.0 (10) C15'—C14'—C13' 119.5 (12) 
N2—Cu1—N4 101.1 (4) C14'—C15'—C16' 119.5 (10) 
N3—Cu1—N4 79.0 (5) C24'—C16'—C15' 117.0 (10) 
N1—Cu1—N4 104.7 (10) C24'—C16'—C17' 118.8 (12) 
O32—Cu1—C31 28.8 (3) C15'—C16'—C17' 124.3 (11) 
N2—Cu1—C31 92.3 (2) C18'—C17'—C16' 121.2 (12) 
N3'—Cu1—C31 90.7 (4) C17'—C18'—C19' 121.4 (12) 
N3—Cu1—C31 93.9 (4) C20'—C19'—C23' 116.0 (11) 
N4'—Cu1—C31 134.5 (10) C20'—C19'—C18' 124.5 (11) 
N1—Cu1—C31 119.7 (3) C23'—C19'—C18' 119.5 (11) 
N4—Cu1—C31 135.1 (10) C21'—C20'—C19' 120.5 (12) 
C1—N1—C12 118.4 (6) C20'—C21'—C22' 119.1 (12) 
C1—N1—Cu1 131.3 (5) N4'—C22'—C21' 122.6 (12) 
C12—N1—Cu1 110.4 (4) C22'—N4'—C23' 117.8 (11) 
N1—C1—C2 122.3 (7) C22'—N4'—Cu1 131.7 (10) 
C3—C2—C1 120.5 (7) C23'—N4'—Cu1 110.5 (8) 
C2—C3—C4 118.8 (7) N4'—C23'—C19' 123.7 (11) 
C12—C4—C3 116.9 (6) N4'—C23'—C24' 118.0 (10) 
C12—C4—C5 118.7 (6) C19'—C23'—C24' 117.9 (10) 
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C3—C4—C5 124.4 (7) N3'—C24'—C16' 122.1 (11) 
C6—C5—C4 121.9 (7) N3'—C24'—C23' 116.7 (10) 
C5—C6—C7 121.0 (6) C16'—C24'—C23' 121.2 (11) 
C8—C7—C11 117.8 (6) C31—O32—Cu1 101.6 (8) 
C8—C7—C6 123.9 (6) O31—C31—O32 122.9 (10) 
C11—C7—C6 118.3 (6) O31—C31—C32 119.8 (7) 
C9—C8—C7 119.4 (6) O32—C31—C32 117.2 (10) 
C8—C9—C10 119.3 (7) O31—C31—Cu1 73.4 (6) 
N2—C10—C9 122.1 (7) O32—C31—Cu1 49.6 (5) 
C10—N2—C11 118.8 (5) C32—C31—Cu1 166.7 (6) 
C10—N2—Cu1 127.3 (5) C33—C32—C31 110.9 (7) 
C11—N2—Cu1 113.9 (4) O43i—C40—O41 152 (2) 
N2—C11—C7 122.5 (6) O43i—C40—O43 82 (2) 
N2—C11—C12 117.6 (5) O41—C40—O43 124.5 (16) 
C7—C11—C12 119.9 (6) O43i—C40—O42 35.1 (14) 
N1—C12—C4 123.0 (6) O41—C40—O42 120.5 (14) 
N1—C12—C11 116.8 (6) O43—C40—O42 114.9 (16) 
C4—C12—C11 120.2 (6) O43i—C40—C40i 49.6 (16) 
C13—N3—C24 117.2 (12) O41—C40—C40i 154.7 (15) 
C13—N3—Cu1 127.4 (10) O43—C40—C40i 33.1 (9) 
C24—N3—Cu1 114.9 (9) O42—C40—C40i 83.7 (13) 
N3—C13—C14 124.4 (13) O43i—C40—O42i 88 (2) 
C15—C14—C13 118.5 (13) O41—C40—O42i 119.7 (13) 
C14—C15—C16 120.0 (12) O43—C40—O42i 8.8 (14) 
C24—C16—C15 116.7 (11) O42—C40—O42i 118.5 (13) 
C24—C16—C17 118.4 (12) C40i—C40—O42i 40.0 (8) 
C15—C16—C17 124.8 (12) O43i—O42—C40 44 (2) 
C18—C17—C16 122.0 (13) O43i—O42—C40i 15 (2) 
C17—C18—C19 121.2 (13) C40—O42—C40i 56.2 (12) 
C20—C19—C23 117.1 (12) O42i—O43—C40i 100 (3) 
C20—C19—C18 124.4 (12) O42i—O43—C40 156 (4) 
C23—C19—C18 118.6 (12) C40i—O43—C40 97 (2) 
C21—C20—C19 120.7 (12) O42i—O43—O43i 152 (3) 
C20—C21—C22 118.1 (13) C40i—O43—O43i 59.4 (15) 
N4—C22—C21 123.4 (14) C40—O43—O43i 38.2 (12) 
Symmetry code:  (i) -x+1, y, -z+1/2. 
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Table A.B.15 Hydrogen-bond geometry (Å, º) of Cu-Pro-Phen 
D—H···A  D···A 
O1W···O2Wi  2.74(1) 
O1W···O6W  2.59(2) 
O1W···O41  2.98(2) 
O2W···O31  2.64(1) 
O2W···O4Wii  2.80(2) 
O3W···O32  2.77(1) 
O3W···O5W  2.35(3) 
O4W···O5W  2.90(2) 
O6W···O1Wiii  2.79(1) 
O6W···O43iv  2.78(2) 
Symmetry codes:  (i) x,2-y,1/2+z;(ii) 1/2-x,1/2+y,1/2-z;  
(iii)1-x,2-y,1-z;(iv) 1-x,y,1/2-z 
  
A.B.2.4 [Cu(Iso)(1,10-Phen)2]2·2(NO3)·4H2O, (Cu-Iso-Phen) 
 
 
Figure A.B.18 Cu-Iso-Phen crystallises in the chiral space group P212121 with two independent 
cations in the asymmetric unit. The carboxylate bonding is notably asymmetric. 
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Figure A.B.19  The cations are π-­stacked into zig-zag chains running parallel to the a axis. 
  
 
Figure A.B.20 The chains are linked together via H-bonding involving the water molecules and 
the nitrate anions. 
 
Table A.B.16 Crystal data of Cu-Iso-Phen 
C28H27CuN5O7 Dx = 1.492 Mg m-3 
Mr = 609.09 Mo Kα radiation, λ = 0.71073 Å 
Orthorhombic, P212121 Cell parameters from 7191 reflections 
a = 14.9422 (10) Å θ = 2.4–23.6° 
b = 17.0635 (12) Å µ = 0.86 mm-1 
c = 21.2699 (14) Å T = 150 K 
V = 5423.1 (6)  Å3 Lath, blue 
Z = 8 0.51 × 0.19 × 0.06 mm 
F(000) = 2520  
 
Table A.B.17 Data collection of Cu-Iso-Phen 
Bruker APEX 2 CCD  
diffractometer 
13446 independent reflections 
Radiation source: fine-focus sealed tube 9498 reflections with I> 2σ(I) 
graphite Rint = 0.071 
ω rotation with narrow frames scans θmax = 28.3°, θmin = 1.8° 
Absorption correction: multi-scan  
SADABS v2008/1, Sheldrick, G.M., (2008) 
h = -19→19 
Tmin = 0.668, Tmax = 0.950 k = -22→22 
55103 measured reflections l = -27→28 
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Table A.B.18 Refinement data of Cu-Iso-Phen 
Refinement on F2 Secondary atom site location: difference Fourier 
map 
Least-squares matrix: full Hydrogen site location: inferred from 
neighbouring sites 
R[F2> 2σ(F2)] = 0.042 H atoms treated by a mixture of independent 
and constrained refinement 
wR(F2) = 0.097 w = 1/[σ2(Fo2) + (0.0406P)2]   
where P = (Fo2 + 2Fc2)/3 
S = 1.00 (Δ/σ)max = 0.001 
13446 reflections Δ〉max = 0.38 e Å-3 
763 parameters Δ〉min = -0.58 e Å-3 
12 restraints Absolute structure:  Flack H D (1983), 
ActaCryst. A39, 876-881 
Primary atom site location: structure-invariant 
direct methods 
Flack parameter: -0.022 (9) 
 
Table A.B.19 Geometric parameters (Å, º) of Cu-Iso-Phen 
Cu1—O21 1.960 (2) Cu2—N6 2.083 (2) 
Cu1—N4 2.004 (3) Cu2—N8 2.182 (3) 
Cu1—N1 2.008 (3) Cu2—O52 2.725 (2) 
Cu1—N3 2.062 (3) N5—C31 1.341 (4) 
Cu1—N2 2.203 (3) N5—C42 1.362 (4) 
Cu1—O22 2.751 (2) C31—C32 1.394 (5) 
N1—C1 1.335 (4) C32—C33 1.372 (5) 
N1—C12 1.364 (4) C33—C34 1.411 (5) 
C1—C2 1.399 (5) C34—C42 1.400 (4) 
C2—C3 1.368 (5) C34—C35 1.425 (4) 
C3—C4 1.398 (5) C35—C36 1.347 (5) 
C4—C12 1.423 (5) C36—C37 1.431 (5) 
C4—C5 1.437 (5) C37—C41 1.405 (4) 
C5—C6 1.333 (5) C37—C38 1.409 (5) 
C6—C7 1.433 (5) C38—C39 1.364 (5) 
C7—C8 1.390 (5) C39—C40 1.403 (4) 
C7—C11 1.404 (5) C40—N6 1.324 (4) 
C8—C9 1.368 (5) N6—C41 1.367 (4) 
C9—C10 1.389 (5) C41—C42 1.433 (4) 
C10—N2 1.330 (4) N7—C43 1.329 (4) 
N2—C11 1.361 (4) N7—C54 1.361 (4) 
C11—C12 1.433 (5) C43—C44 1.399 (4) 
N3—C13 1.334 (4) C44—C45 1.366 (5) 
N3—C24 1.362 (4) C45—C46 1.407 (5) 
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C13—C14 1.395 (4) C46—C54 1.401 (4) 
C14—C15 1.357 (5) C46—C47 1.435 (5) 
C15—C16 1.415 (5) C47—C48 1.346 (5) 
C16—C24 1.399 (4) C48—C49 1.438 (5) 
C16—C17 1.437 (5) C49—C50 1.401 (5) 
C17—C18 1.361 (5) C49—C53 1.403 (4) 
C18—C19 1.429 (5) C50—C51 1.364 (5) 
C19—C23 1.403 (4) C51—C52 1.396 (5) 
C19—C20 1.413 (5) C52—N8 1.329 (4) 
C20—C21 1.356 (5) C53—N8 1.363 (4) 
C21—C22 1.398 (5) C53—C54 1.435 (4) 
C22—N4 1.322 (4) O51—C55 1.277 (4) 
N4—C23 1.356 (4) O52—C55 1.247 (4) 
C23—C24 1.434 (4) C55—C56 1.524 (4) 
O21—C25 1.288 (4) C56—C58 1.515 (5) 
O22—C25 1.237 (4) C56—C57 1.522 (5) 
C25—C26 1.508 (4) N61—O61 1.240 (4) 
C26—C28 1.525 (5) N61—O63 1.240 (4) 
C26—C27 1.538 (5) N61—O62 1.249 (4) 
Cu2—O51 1.978 (2) N71—O73 1.247 (4) 
Cu2—N5 1.985 (3) N71—O71 1.249 (4) 
Cu2—N7 1.997 (3) N71—O72 1.259 (4) 
    
O21—Cu1—N4 92.41 (10) O51—Cu2—N6 146.72 (9) 
O21—Cu1—N1 92.67 (10) N5—Cu2—N6 81.38 (10) 
N4—Cu1—N1 174.03 (11) N7—Cu2—N6 95.14 (10) 
O21—Cu1—N3 152.68 (9) O51—Cu2—N8 120.79 (9) 
N4—Cu1—N3 81.56 (10) N5—Cu2—N8 93.38 (10) 
N1—Cu1—N3 95.30 (10) N7—Cu2—N8 79.85 (11) 
O21—Cu1—N2 115.14 (9) N6—Cu2—N8 92.39 (9) 
N4—Cu1—N2 95.84 (11) O51—Cu2—O52 53.47 (8) 
N1—Cu1—N2 79.15 (11) N5—Cu2—O52 93.31 (9) 
N3—Cu1—N2 92.04 (9) N7—Cu2—O52 93.78 (9) 
O21—Cu1—O22 53.05 (8) N6—Cu2—O52 93.86 (8) 
N4—Cu1—O22 92.54 (9) N8—Cu2—O52 171.45 (8) 
N1—Cu1—O22 93.02 (10) C31—N5—C42 117.6 (3) 
N3—Cu1—O22 100.38 (8) C31—N5—Cu2 128.0 (2) 
N2—Cu1—O22 165.93 (8) C42—N5—Cu2 114.0 (2) 
C1—N1—C12 118.4 (3) N5—C31—C32 122.7 (3) 
C1—N1—Cu1 125.8 (2) C33—C32—C31 119.4 (3) 
C12—N1—Cu1 115.9 (2) C32—C33—C34 119.9 (3) 
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N1—C1—C2 122.1 (4) C42—C34—C33 116.7 (3) 
C3—C2—C1 120.3 (4) C42—C34—C35 118.8 (3) 
C2—C3—C4 119.4 (3) C33—C34—C35 124.4 (3) 
C3—C4—C12 117.5 (3) C36—C35—C34 121.4 (3) 
C3—C4—C5 124.5 (3) C35—C36—C37 121.5 (3) 
C12—C4—C5 118.0 (4) C41—C37—C38 117.1 (3) 
C6—C5—C4 121.5 (4) C41—C37—C36 118.1 (3) 
C5—C6—C7 122.2 (4) C38—C37—C36 124.7 (3) 
C8—C7—C11 117.4 (3) C39—C38—C37 119.3 (3) 
C8—C7—C6 124.4 (4) C38—C39—C40 120.1 (3) 
C11—C7—C6 118.2 (4) N6—C40—C39 122.4 (3) 
C9—C8—C7 119.8 (3) C40—N6—C41 118.0 (3) 
C8—C9—C10 119.5 (4) C40—N6—Cu2 131.2 (2) 
N2—C10—C9 122.8 (3) C41—N6—Cu2 110.8 (2) 
C10—N2—C11 117.8 (3) N6—C41—C37 123.1 (3) 
C10—N2—Cu1 132.0 (2) N6—C41—C42 116.5 (3) 
C11—N2—Cu1 110.0 (2) C37—C41—C42 120.3 (3) 
N2—C11—C7 122.8 (3) N5—C42—C34 123.7 (3) 
N2—C11—C12 116.9 (3) N5—C42—C41 116.5 (3) 
C7—C11—C12 120.3 (3) C34—C42—C41 119.7 (3) 
N1—C12—C4 122.3 (3) C43—N7—C54 118.6 (3) 
N1—C12—C11 117.9 (3) C43—N7—Cu2 125.9 (2) 
C4—C12—C11 119.8 (3) C54—N7—Cu2 115.5 (2) 
C13—N3—C24 117.7 (3) N7—C43—C44 122.1 (3) 
C13—N3—Cu1 130.9 (2) C45—C44—C43 119.9 (3) 
C24—N3—Cu1 111.4 (2) C44—C45—C46 119.1 (3) 
N3—C13—C14 122.2 (3) C54—C46—C45 117.8 (3) 
C15—C14—C13 120.5 (3) C54—C46—C47 118.9 (3) 
C14—C15—C16 119.2 (3) C45—C46—C47 123.3 (3) 
C24—C16—C15 116.9 (3) C48—C47—C46 120.9 (3) 
C24—C16—C17 119.4 (3) C47—C48—C49 121.9 (3) 
C15—C16—C17 123.7 (3) C50—C49—C53 117.4 (3) 
C18—C17—C16 120.2 (3) C50—C49—C48 124.5 (3) 
C17—C18—C19 121.5 (3) C53—C49—C48 118.1 (3) 
C23—C19—C20 116.9 (3) C51—C50—C49 119.8 (3) 
C23—C19—C18 119.0 (3) C50—C51—C52 119.3 (3) 
C20—C19—C18 124.0 (3) N8—C52—C51 122.9 (3) 
C21—C20—C19 119.3 (3) N8—C53—C49 122.7 (3) 
C20—C21—C22 119.9 (3) N8—C53—C54 117.0 (3) 
N4—C22—C21 122.4 (3) C49—C53—C54 120.3 (3) 
C22—N4—C23 118.3 (3) N7—C54—C46 122.4 (3) 
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C22—N4—Cu1 128.7 (2) N7—C54—C53 117.7 (3) 
C23—N4—Cu1 113.1 (2) C46—C54—C53 119.9 (3) 
N4—C23—C19 123.0 (3) C52—N8—C53 117.9 (3) 
N4—C23—C24 117.1 (3) C52—N8—Cu2 132.1 (2) 
C19—C23—C24 119.8 (3) C53—N8—Cu2 109.7 (2) 
N3—C24—C16 123.6 (3) C55—O51—Cu2 108.8 (2) 
N3—C24—C23 116.3 (3) C55—O52—Cu2 74.58 (18) 
C16—C24—C23 120.0 (3) O52—C55—O51 123.0 (3) 
C25—O21—Cu1 109.78 (19) O52—C55—C56 119.9 (3) 
C25—O22—Cu1 73.91 (18) O51—C55—C56 117.0 (3) 
O22—C25—O21 123.0 (3) C58—C56—C57 111.4 (3) 
O22—C25—C26 121.5 (3) C58—C56—C55 113.1 (3) 
O21—C25—C26 115.4 (3) C57—C56—C55 108.7 (3) 
C25—C26—C28 112.1 (3) O61—N61—O63 120.3 (3) 
C25—C26—C27 108.2 (3) O61—N61—O62 119.9 (3) 
C28—C26—C27 110.9 (3) O63—N61—O62 119.7 (3) 
O51—Cu2—N5 93.22 (10) O73—N71—O71 120.0 (3) 
O51—Cu2—N7 93.41 (10) O73—N71—O72 120.6 (3) 
N5—Cu2—N7 172.30 (11) O71—N71—O72 119.3 (3) 
 
Table A.B.20 Hydrogen-bond geometry (Å, º) of Cu-Iso-Phen 
D—H···A D—H H···A D···A D—H···A 
O1W—H1WA···O22 0.84 (2) 2.01 (2) 2.808 (4) 160 (4) 
O1W—H1WB···O61 0.84 (2) 2.06 (2) 2.889 (4) 170 (5) 
O2W—H2WA···O52 0.85 (2) 1.94 (2) 2.786 (3) 171 (4) 
O2W—H2WB···O72 0.84 (2) 2.05 (2) 2.872 (4) 166 (4) 
O3W—H3WA···O2W 0.84 (2) 2.01 (2) 2.856 (5) 179 (6) 
O3W—H3WB···O63 0.83 (2) 2.10 (3) 2.889 (4) 158 (6) 
O4W—H4WA···O1W 0.83 (2) 2.03 (2) 2.847 (5) 174 (6) 
O4W—H4WB···O73i 0.82 (2) 2.16 (2) 2.972 (4) 169 (6) 
Symmetry code:  (i) x, y-1, z. 
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A.B.2.5 [Cu(Piv)(1,10-Phen)2]2(piv)2·(Hpiv)·9H2O, (Cu-Piv-Phen) 
	  
  
Figure A.B.21 The structure of Cu-Piv-Phen was refined as a 2-component merohedral twin 
(twin matrix -1 0 0 0 1 0 0 1 -1 and BASF 0.21).  
 
 
Figure A.B.22   The asymmetric unit contains two independent [Cu(phen)2(piv)]+ cations, two 
pivalate anions and one pivalic acid molecule as well as nine solvate water molecules. The acidic 
proton of the pivalic acid molecule was located from a difference map. 
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Figure A.B.23   The cations form two independent chains by π−π stacking, while the anions, 
pivalic acid and water molecules are linked by a H-bonding network. 
 
Table A.B.21Crystal data of Cu-Piv-Phen 
C36.50H48CuN4O9.50 Z = 4 
Mr = 758.33 F(000) = 1600 
Triclinic, P¯1 Dx = 1.339 Mg m-3 
a = 16.091 (2) Å Mo Kα radiation, λ = 0.71073 Å 
b = 17.367 (2) Å Cell parameters from 4276 reflections 
c = 17.454 (2) Å θ = 2.4–21.4° 
α = 60.321 (2)° µ = 0.64 mm-1 
β = 66.311 (2)° T = 150 K 
γ = 89.747 (2)° Plate, blue 
V = 3762.8 (9)  Å3 0.28 × 0.22 × 0.09 mm 
 
Table A.B.22 Data collection of Cu-Piv-Phen 
Bruker APEX 2 CCD  
diffractometer 
9396 reflections with I> 2σ(I) 
Radiation source: fine-focus sealed tube Rint = 0.056 
ω rotation with narrow frames scans θmax = 25.0°, θmin = 1.5° 
Absorption correction: multi-scan  
SADABS v2009/1, Sheldrick, G.M., (2009) 
h = -19→19 
Tmin = 0.607, Tmax = 0.745 k = -20→20 
29693 measured reflections l = -20→20 
13193 independent reflections  
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Table A.B.23 Refinement data of Cu-Piv-Phen 
Refinement on F2 27 restraints 
Least-squares matrix: full Hydrogen site location: mixed 
R[F2> 2σ(F2)] = 0.064 H atoms treated by a mixture of independent 
and constrained refinement 
wR(F2) = 0.189 w = 1/[σ2(Fo2) + (0.1075P)2 + 0.1184P]     
where P = (Fo2 + 2Fc2)/3 
S = 1.05 (Δ/σ)max = 0.001 
13193 reflections Δ〉max = 0.56 e Å-3 
974 parameters Δ〉min = -0.68 e Å-3 
 
 
Table A.B.24 Geometric parameters (Å, º) of Cu-Piv-Phen 
Cu1—N1 1.993 (5) C33—C34 1.410 (9) 
Cu1—N4 1.995 (5) C34—C42 1.392 (8) 
Cu1—O1 1.999 (4) C34—C35 1.420 (8) 
Cu1—N2 2.068 (5) C35—C36 1.331 (10) 
Cu1—N3 2.217 (5) C36—C37 1.422 (9) 
N1—C1 1.319 (8) C37—C38 1.411 (9) 
N1—C12 1.362 (7) C37—C41 1.413 (8) 
C1—C2 1.404 (9) C38—C39 1.368 (9) 
C2—C3 1.357 (10) C39—C40 1.402 (9) 
C3—C4 1.398 (9) C40—N6 1.330 (7) 
C4—C12 1.400 (8) N6—C41 1.354 (7) 
C4—C5 1.433 (9) C41—C42 1.433 (8) 
C5—C6 1.340 (10) C43—N7 1.321 (7) 
C6—C7 1.441 (9) C43—C44 1.400 (8) 
C7—C11 1.401 (8) N7—C54 1.360 (7) 
C7—C8 1.411 (9) C44—C45 1.366 (9) 
C8—C9 1.350 (10) C45—C46 1.422 (9) 
C9—C10 1.412 (9) C46—C54 1.396 (8) 
C10—N2 1.327 (8) C46—C47 1.425 (9) 
N2—C11 1.348 (7) C47—C48 1.344 (10) 
C11—C12 1.435 (8) C48—C49 1.434 (9) 
N3—C13 1.347 (8) C49—C53 1.414 (8) 
N3—C24 1.348 (7) C49—C50 1.415 (9) 
C13—C14 1.399 (9) C50—C51 1.373 (9) 
C14—C15 1.367 (9) C51—C52 1.392 (8) 
C15—C16 1.399 (9) C52—N8 1.316 (7) 
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C16—C24 1.413 (8) N8—C53 1.355 (7) 
C16—C17 1.419 (8) C53—C54 1.443 (8) 
C17—C18 1.364 (9) O3—C55 1.273 (7) 
C18—C19 1.417 (8) O4—C55 1.227 (7) 
C19—C20 1.399 (8) C55—C56 1.520 (8) 
C19—C23 1.413 (8) C56—C57 1.492 (10) 
C20—C21 1.359 (8) C56—C59 1.527 (9) 
C21—C22 1.386 (8) C56—C58 1.562 (10) 
C22—N4 1.342 (8) O61—C61 1.200 (8) 
N4—C23 1.350 (7) O62—C61 1.296 (8) 
C23—C24 1.429 (8) C61—C62 1.520 (10) 
O1—C25 1.278 (7) C62—C64 1.503 (11) 
O2—C25 1.234 (7) C62—C63 1.522 (11) 
C25—C26 1.516 (8) C62—C65 1.566 (10) 
C26—C29 1.516 (10) O71—C71 1.226 (8) 
C26—C27 1.529 (9) O72—C71 1.266 (8) 
C26—C28 1.542 (9) C71—C72 1.550 (9) 
Cu2—N5 1.994 (5) C72—C75 1.493 (10) 
Cu2—N8 2.000 (5) C72—C74 1.512 (9) 
Cu2—O3 2.025 (5) C72—C73 1.550 (10) 
Cu2—N6 2.085 (5) O81—C81 1.224 (8) 
Cu2—N7 2.216 (5) O82—C81 1.232 (8) 
N5—C31 1.309 (7) C81—C82 1.552 (9) 
N5—C42 1.372 (7) C82—C85 1.514 (9) 
C31—C32 1.410 (8) C82—C84 1.518 (9) 
C32—C33 1.364 (9) C82—C83 1.550 (9) 
    
N1—Cu1—N4 174.27 (19) C33—C32—C31 119.1 (6) 
N1—Cu1—O1 92.10 (18) C32—C33—C34 120.2 (6) 
N4—Cu1—O1 93.57 (18) C42—C34—C33 116.3 (5) 
N1—Cu1—N2 81.53 (19) C42—C34—C35 118.8 (6) 
N4—Cu1—N2 93.75 (19) C33—C34—C35 124.8 (6) 
O1—Cu1—N2 152.75 (18) C36—C35—C34 121.5 (6) 
N1—Cu1—N3 99.04 (19) C35—C36—C37 121.9 (6) 
N4—Cu1—N3 78.76 (18) C38—C37—C41 116.7 (6) 
O1—Cu1—N3 104.28 (16) C38—C37—C36 125.1 (6) 
N2—Cu1—N3 102.88 (18) C41—C37—C36 118.3 (6) 
C1—N1—C12 117.6 (5) C39—C38—C37 119.5 (6) 
C1—N1—Cu1 128.4 (4) C38—C39—C40 119.7 (6) 
C12—N1—Cu1 114.0 (4) N6—C40—C39 122.7 (6) 
N1—C1—C2 122.9 (6) C40—N6—C41 117.8 (5) 
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C3—C2—C1 119.4 (6) C40—N6—Cu2 130.8 (4) 
C2—C3—C4 119.5 (6) C41—N6—Cu2 111.3 (4) 
C3—C4—C12 117.5 (6) N6—C41—C37 123.6 (5) 
C3—C4—C5 124.9 (6) N6—C41—C42 117.0 (5) 
C12—C4—C5 117.7 (6) C37—C41—C42 119.3 (5) 
C6—C5—C4 122.5 (6) N5—C42—C34 123.6 (5) 
C5—C6—C7 120.2 (6) N5—C42—C41 116.2 (5) 
C11—C7—C8 116.6 (6) C34—C42—C41 120.2 (5) 
C11—C7—C6 119.6 (6) N7—C43—C44 122.2 (6) 
C8—C7—C6 123.8 (6) C43—N7—C54 118.5 (5) 
C9—C8—C7 119.6 (6) C43—N7—Cu2 132.0 (4) 
C8—C9—C10 120.3 (6) C54—N7—Cu2 109.4 (3) 
N2—C10—C9 121.2 (6) C45—C44—C43 120.1 (6) 
C10—N2—C11 118.7 (5) C44—C45—C46 118.9 (6) 
C10—N2—Cu1 130.1 (4) C54—C46—C45 117.0 (6) 
C11—N2—Cu1 111.1 (4) C54—C46—C47 119.7 (6) 
N2—C11—C7 123.5 (5) C45—C46—C47 123.3 (6) 
N2—C11—C12 117.6 (5) C48—C47—C46 121.5 (6) 
C7—C11—C12 118.9 (5) C47—C48—C49 120.4 (6) 
N1—C12—C4 123.0 (5) C53—C49—C50 116.3 (6) 
N1—C12—C11 115.8 (5) C53—C49—C48 119.9 (6) 
C4—C12—C11 121.1 (5) C50—C49—C48 123.7 (6) 
C13—N3—C24 118.0 (5) C51—C50—C49 119.7 (6) 
C13—N3—Cu1 132.5 (4) C50—C51—C52 119.5 (6) 
C24—N3—Cu1 109.4 (4) N8—C52—C51 122.6 (6) 
N3—C13—C14 121.9 (6) C52—N8—C53 119.0 (5) 
C15—C14—C13 119.9 (6) C52—N8—Cu2 125.4 (4) 
C14—C15—C16 119.9 (6) C53—N8—Cu2 115.7 (4) 
C15—C16—C24 116.8 (6) N8—C53—C49 122.8 (5) 
C15—C16—C17 123.5 (6) N8—C53—C54 118.5 (5) 
C24—C16—C17 119.6 (5) C49—C53—C54 118.6 (5) 
C18—C17—C16 121.1 (6) N7—C54—C46 123.3 (5) 
C17—C18—C19 120.9 (6) N7—C54—C53 116.8 (5) 
C20—C19—C23 118.1 (5) C46—C54—C53 119.9 (5) 
C20—C19—C18 122.7 (6) C55—O3—Cu2 103.4 (4) 
C23—C19—C18 119.1 (6) O4—C55—O3 121.2 (6) 
C21—C20—C19 119.2 (5) O4—C55—C56 121.0 (6) 
C20—C21—C22 119.8 (6) O3—C55—C56 117.8 (6) 
N4—C22—C21 122.9 (6) C57—C56—C55 111.8 (6) 
C22—N4—C23 117.9 (5) C57—C56—C59 111.4 (6) 
C22—N4—Cu1 125.5 (4) C55—C56—C59 108.0 (5) 
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C23—N4—Cu1 116.6 (4) C57—C56—C58 110.3 (7) 
N4—C23—C19 122.1 (5) C55—C56—C58 109.4 (5) 
N4—C23—C24 117.6 (5) C59—C56—C58 105.7 (6) 
C19—C23—C24 120.2 (5) O61—C61—O62 123.7 (6) 
N3—C24—C16 123.5 (5) O61—C61—C62 124.0 (7) 
N3—C24—C23 117.5 (5) O62—C61—C62 112.2 (6) 
C16—C24—C23 118.9 (5) C64—C62—C61 109.8 (6) 
C25—O1—Cu1 103.8 (3) C64—C62—C63 111.3 (8) 
O2—C25—O1 122.1 (6) C61—C62—C63 110.4 (6) 
O2—C25—C26 120.4 (6) C64—C62—C65 108.8 (7) 
O1—C25—C26 117.5 (5) C61—C62—C65 107.4 (7) 
C29—C26—C25 110.2 (5) C63—C62—C65 109.0 (6) 
C29—C26—C27 110.0 (6) O71—C71—O72 122.6 (6) 
C25—C26—C27 107.0 (6) O71—C71—C72 119.6 (6) 
C29—C26—C28 109.4 (6) O72—C71—C72 117.8 (6) 
C25—C26—C28 111.1 (5) C75—C72—C74 112.3 (6) 
C27—C26—C28 109.2 (6) C75—C72—C73 109.7 (6) 
N5—Cu2—N8 174.88 (18) C74—C72—C73 106.3 (6) 
N5—Cu2—O3 92.17 (18) C75—C72—C71 108.5 (6) 
N8—Cu2—O3 92.93 (17) C74—C72—C71 110.6 (5) 
N5—Cu2—N6 81.13 (19) C73—C72—C71 109.3 (6) 
N8—Cu2—N6 94.08 (18) O81—C81—O82 122.3 (6) 
O3—Cu2—N6 162.73 (17) O81—C81—C82 117.0 (6) 
N5—Cu2—N7 99.54 (18) O82—C81—C82 120.6 (6) 
N8—Cu2—N7 79.61 (17) C85—C82—C84 109.8 (6) 
O3—Cu2—N7 94.91 (17) C85—C82—C83 110.2 (5) 
N6—Cu2—N7 101.87 (17) C84—C82—C83 109.5 (5) 
C31—N5—C42 118.2 (5) C85—C82—C81 107.2 (5) 
C31—N5—Cu2 127.8 (4) C84—C82—C81 109.7 (5) 
C42—N5—Cu2 114.0 (4) C83—C82—C81 110.6 (5) 
N5—C31—C32 122.6 (6)   
 
Table A.B.25 Hydrogen-bond geometry (Å, º) of Cu-Piv-Phen 
D—H···A D—H H···A D···A D—H···A 
O62—H62···O5W 0.84 1.73 2.553 (7) 164 
O1W—H1WA···O71i 0.84 (2) 1.94 (2) 2.773 (7) 176 (8) 
O1W—H1WB···O71 0.83 (2) 2.14 (3) 2.964 (7) 170 (7) 
O1W—H1WB···O72 0.83 (2) 2.61 (5) 3.268 (7) 137 (7) 
O2W—H2WB···O9W 0.82 (2) 2.04 (2) 2.862 (7) 173 (7) 
O2W—H2WA···O72i 0.84 (2) 2.13 (4) 2.927 (7) 158 (8) 
	  B-­‐‑31	  
O3W—H3WA···O81 0.85 (2) 2.40 (2) 3.238 (8) 174 (7) 
O3W—H3WA···O82 0.85 (2) 2.57 (7) 3.166 (9) 129 (7) 
O3W—H3WB···O81ii 0.84 (2) 2.34 (9) 2.767 (7) 112 (7) 
O4W—H4WA···O7W 0.85 (2) 2.27 (5) 2.920 (7) 134 (6) 
O4W—H4WB···O82 0.86 (2) 2.05 (4) 2.857 (7) 155 (7) 
O5W—H5WA···O82 0.82 (2) 1.95 (4) 2.682 (8) 149 (8) 
O5W—H5WB···O6W 0.82 (2) 2.14 (6) 2.775 (8) 134 (7) 
O6W—H6WA···O1W 0.85 (2) 1.86 (2) 2.708 (7) 176 (7) 
O6W—H6WB···O5W 0.85 (2) 2.42 (9) 2.775 (8) 106 (7) 
O7W—H7WA···O72 0.85 (2) 2.02 (3) 2.856 (8) 167 (9) 
O7W—H7WB···O81ii 0.84 (2) 1.95 (4) 2.742 (7) 157 (8) 
O8W—H8WA···O3Wii 0.83 (2) 2.21 (4) 3.015 (8) 163 (8) 
O8W—H8WB···O4W 0.85 (2) 1.99 (4) 2.809 (8) 161 (10) 
O9W—H9WA···O71 0.84 (2) 1.97 (3) 2.769 (6) 160 (7) 
O9W—H9WB···O6Wi 0.85 (2) 2.07 (4) 2.864 (7) 155 (8) 
Symmetry codes:  (i) -x+1, -y, -z+2; (ii) -x+2, -y, -z+2.
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Table A.B.26 Comparison Geometric Data  
Complex	   Angle	  between	  	  
N-­‐Cu-­‐N	  planes	  (°)	  
Short	  Cu-­‐O	  (Å)	   Long	  Cu-­‐O	  (Å)	   Long	  Cu-­‐N(Å)	   Shorter	  Cu-­‐N(Å)	  
Cu-­‐For-­‐Phen	  
[Cu(phen)2(HCOO)](NO3)⋅6H2O	  
62.03(7)	   2.027(2)	   2.731(2)	   2.181(3)	   1.982(3)	  
1.988(3)	  
2.057(3)	  
Cu-­‐Ace-­‐Phen	  
[Cu(phen)2(OAc)](NO3)⋅2H2O	  
75.62(4)	   2.008(2)*	  
2.019(9)*	  
2.589(2)*	  
2.599(10)*	  
2.1815(14)	   1.9981(14)	  
2.0156(14)	  
2.0559(14)	  
Cu-­‐Pro-­‐Phen	  
[Cu(phen)2(pro)]·∙½(CO3)·∙2H2O	  
75.0(9)*	  
74.5(9)*	  
1.955(8)	   2.513(9)	   2.171(14)*	   1.998(5)	  
2.035(14)*	  
2.093(6)	  
Cu-­‐Iso-­‐Phen	  
[Cu(phen)2(isobut)]2·∙2(NO3)·∙4H2O	  
88.5(1)	  
87.9(1)	  
1.960(2)	  
1.978(2)	  
2.751(2)	  
2.725(2)	  
2.203(3)	  
2.182(3)	  
2.004(3)	  	  1.985(3)	  
2.008(3)	  	  1.997(3)	  
2.0062(3)	  	  2.083(2)	  
Cu-­‐Piv-­‐Phen	  
[Cu(phen)2(piv)]2(piv)2·∙(Hpiv)·∙9H2O	  
77.4(2)	  
78.5(2)	  
1.999(4)	  
2.025(5)	  
2.576(5)	  
2.551(5)	  
2.217(5)	  
2.216(5)	  
1.993(5)	  	  1.994(5)	  
1.995(5)	  	  2.000(5)	  
2.068(5)	  	  2.085(5)	  
* Affected by disorder 
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A.B.3 Electrospray ionisation mass spectra (ESI-MS) 
 
 
Figure A.B.24 Mass spec. of Cu-For-Phen 
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Figure A.B.25 Mass spec. of Cu-Ace-Phen 
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Figure A.B.26 Mass spec. of Cu-Pro-Phen 
 
	  B-­‐‑36	  
	  
Figure A.B.27 Mass spec. of Cu-Iso-Phen 
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Figure A.B.28 Mass spec. of Cu-Piv-Phen 
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Appendix C   
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A.C.1 Electrogram data generated by the Bioanalyzer 2100 
	   	   	  
	  
Figure A.C.1 Control bioanalyzer electrograms of (a.) a standard DNA ladder, (b.) linearised 
pUC19 plasmid DNA, and linearised pUC19 after treatment with type II restriction 
endonucleases: (c.) BamHI and (d.) SalI. 
a.   b.   c.  
d.  
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Figure A.C.2 Bioanalyzer electrograms of linearised pUC19 pre-incubated for 24 h with AH78 
followed by exposure (4 h) to the type II restriction endonuclease BamHI or SalI. (a.) 1.0 µM 
AH78 + BamHI, (b.) 2.5 µM AH78 + BamHI, (c.) 5.0 µM AH78 + BamHI, (d.) 10.0 µM AH78 + 
BamHI, (e.) 1.0 µM AH78 + SalI, (f.) 2.5 µM AH78 + SalI, (g.) 5.0 µM AH78 + SalI, and (h.) 
10.0 µM AH78 + SalI. 
a.   b.   c.  
d.  
e.   f.   g.  
h.  
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Figure A.C.3 Bioanalyzer electrograms of linearised pUC19 pre-incubated for 24 h with AH78P 
followed by exposure (4 h) to the type II restriction endonuclease BamHI or SalI. (a.) 0.25 µM 
AH78 + BamHI, (b.) 0.50 µM AH78 + BamHI, (c.) 0.75 µM AH78 + BamHI, (d.) 1.00 µM 
AH78 + BamHI, (e.) 0.25 µM AH78 + SalI, (f.) 0.50 µM AH78 + SalI, (g.) 0.75 µM AH78 + SalI, 
and (h.) 1.00 µM AH78 + SalI. 
 
 
 
 
 
	  
a.   b.   c.  
d.  
e.   f.   g.  
h.  
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Figure A.C.4 Bioanalyzer electrograms of linearised pUC19 pre-incubated for 24 h with AH78H 
followed by exposure (4 h) to the type II restriction endonuclease BamHI or SalI. (a.) 1.0 µM 
AH78 + BamHI, (b.) 2.5 µM AH78 + BamHI, (c.) 5.0 µM AH78 + BamHI, (d.) 10.0 µM AH78 + 
BamHI, (e.) 1.0 µM AH78 + SalI, (f.) 2.5 µM AH78 + SalI, (g.) 5.0 µM AH78 + SalI, and (h.) 
10.0 µM AH78 + SalI. 
 
 
 
 
 
 
 
 
 
 
a.   b.   c.  
d.  
e.   f.   g.  
h.  
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A.C.2 ctDNA thermal melting analysis 
	  
   
   
Figure A.C.5 Typical thermal melting profiles of untreated CT-DNA (75 µM in DNAp) and drug 
treated (+3.75 µM of tested complex or organic drug) in 50 mM potassium phosphate buffer with 
2 mM NaCl, [Drug]/[DNA] drug loading was at r = 0.05. 
 
A.C.3 Circular dichroism experiments 
	  
Figure A.C.6	   CD spectra of poly(dA-dT)2 (left) and poly(dG-dC)2 (right) treated with various 
amounts of TpNC  
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A.C.4 ITC of polynuclear DNA titrated with TriplatinNC 
	  
Figure A.C.7	   Isotherms of the reaction of TriplatinNC poly(dA-dT)2 (A), poly(dA)-poly(dT) 
(B), and poly(dG-dC)2 (C); the top panels show the heat of each injection, bottom panels 
represent the integrated heat signals versus molar ratio. 
A.C.5 NMR Analysis of TriplatinNC Modified DNA Oligomers 
	  
	  
Figure A.C.8	  A: Change in chemical shifts for nucleotides of the T-rich strand (δ(oligomer+AH78) - 
δoligomer)  
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Figure A.C.8	  B: Change in chemical shifts for nucleotides of the A-rich strand (δ(oligomer+AH78) - 
δoligomer) 
	  
	  
Figure A.C.9	   The interaction of AT-rich dodecamer and TriplatinNC, NOE contacts of 
TriplatinNC (TpNC) with A-H2 ( green   ) and H1' ( blue   ) protons 
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Figure A.C.10	   Change in chemical shifts for GC-rich nucleotides (δ(oligomer+AH78) - 
δoligomer), Top: 1-12 strand 1 and Bottom: 13-24 strand 2.	  
  
	  
Figure A.C.11	   The interaction of GC-rich dodecamer and TriplatinNC, NOE contacts of H1’ of 
the GC with TriplatinNC-L2/L5 (purple ) and TriplatinNC-L3/L4 (blue  ) protons. 
 
A.C.6 Binding affinity of ethidium bromide to ctDNA and tRNA 
	  
Figure A.C.12	    Fraction of ethidium bromide (EtBr, 100 µM) bound to either tRNA or ctDNA 
determined by direct spectrophotometry at 480 nm (EtBr) and fitted with nonlinear regression 
using the Bard equation. Af0 = abs. of free EtBr, A = abs. of EtBr after each aliquot of titrated 
nucleotide, Ab0 = abs. of fully bound EtBr.	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   [1]	  
	  
	   [2]	  
	  
Table A.C.1	   Binding affinity of ethidium bromide (100 µM) to ctDNA (ε = 12,824) and tRNA (ε 
=  9,250) determined by direct spectrophotometry at 480 nm using the Bard equation [1] and [2]. 
	  
	  
Nucleotide	   Kb	  M(bp)-­‐1	   n	   r2	  
ctDNA	   8.80	  x	  106	   1.82	   >0.99	  
tRNA	   6.78	  x	  104	   1.35	   >0.99	  
Kb = intrinsic binding constant, n = number of binding sites, r2 = goodness of fit (Bard equation)  
 
A.C.8 tRNA thermal melting analysis 
   
   
Figure A.C.13   Typical thermal melting profiles of untreated tRNA (~130 µM in tRNAp) and 
drug treated (+13 µM of tested complex or organic drug) in 50 mM potassium phosphate buffer 
with 1 M NaCl; [Drug]/[DNA] drug loading was at r = 0.10. 
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Appendix D   
“Metal-Based Antimicrobial Protease 
Inhibitors” 
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A.D.1 Abstract 
 
Limitations associated with the production cost, metabolic instability, side-
effects, resistance and poor pharmacokinetics of organic protease inhibitors (PIs), 
which form an essential component of the front line HAART treatment for HIV, 
have fuelled efforts into finding novel, transition metal-based alternatives. Some 
of the attractive features of metal-based therapeutics include synthetic simplicity, 
solubility control, redox capability, expansion of coordination number and 
topography matching of the complex to the protein’s active site. Building 
asymmetry into the complex, which may offer better discrimination between host 
and rogue cell, can readily be achieved through coordination of chiral ligands to 
the metal centre. Although the scope of this review has been limited to metal-
based agents that have been reported to bind/inhibit HIV-1 and parasitic 
proteases, some desirables, such as high activity, low dosage, minimal toxicity, 
cross-inhibition, unique binding modes and selectivity, have already been 
delivered. The variability of the d-block metals, coupled with the availability of 
designer organic ligands, augers well for the future development of clinical 
metallo-drugs for deployment against protease-associated, fatal diseases. 
A.D.2 Introduction 
In this review we describe the current state-of-art in metallo-drug design for 
antimicrobial protease inhibition (PI). Rather than attempting an exhaustive list 
of protease-active metal-based agents, we discuss a selection of compounds 
active against the viral protease, HIV-1P, along with tropical parasitic proteases 
of malaria, trypanosomiasis and leishmaniasis. While attempts have been made 
to include every class of these biologically active compounds, it is possible that 
existing metallo-antimicrobial agents, with yet unidentified mechanism, target 
protease (PR) enzymes. Thus, our prerequisite for including each complex was 
that an inhibitory effect against either microbial or viral PR was registered. In 
many instances, an associated microbial inhibitory study accompanied PI, from 
which it was possible to elucidate structure-activity-relationships.  
The interaction of metallo-drugs with protein targets has recently gained 
significant traction in the literature.  In-depth reviews entitled “Targeting 
proteins with metal complexes”,[1] “Metal-based antitumour drugs in the post-
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genomic era: what comes next?”,[2] “Gold compounds as therapeutic agents for 
human diseases”[3] and “Metal compounds as enzyme inhibitors”[4] describe 
important protein molecular targets outside that of genomic DNA, which for 
decades captured almost total focus arising from the clinical advancement of 
Pt(II) chemotherapeutics. In this context, the development of metallo-drugs 
associated with abrogation of PR, is now of significant appeal in the treatment of 
infectious viral and parasitic human disease. Significantly, numerous 
shortcomings with efficacy, production cost, emerging resistance, poor 
pharmacokinetics and a limited number of viable lead compounds are now 
complicating many of the current treatment regimes used against HIV, malaria, 
trypanosomiasis and leishmaniasis. In each of these maladies, some of which are 
among the world's leading infectious killers and impose a devastating health 
burden throughout developing countries, PR is known to pay an integral role in 
the disease pathology.[5-7] For example, HIV-1 protease contains an aspartic-
active residue that is essential in the replication lifecycle of new, infectious viral 
particles[8]; Falcipain-2, a cysteine protease, plays a vital role in the malarial life 
cycle by degrading hemoglobin at the early trophozoite stage,[9] and; the 
cysteine protease, cruzain, is known to play a crucial biological role in cell 
remodeling during transformation of the insect epimastigote stage of 
Trypanosoma cruzi to the infectious metacyclic stage.[10] Additionally, 
Escherichia coli protease, FtsH, has interesting characteristics as it is the only 
membrane-bound ATP-dependent protease, and it is the only PR that is essential 
for E. coli cell growth and viability.[11] A review of serine, cysteine, aspartyl 
and metalloproteases mechanisms has recently been published by Fass and Bibi 
et al.[12] 
 The field of bioinorganic chemistry is actively being explored in order to 
discover therapeutically diverse, nonpeptidic, PIs.[13] Significantly, a variety of 
molecular symmetries can be produced and controlled through the use of selected 
metal ions which give rise to square-planar, tetrahedral and polyhedral structures. 
Additionally, coordinated ligands can be held in specific orientations to match 
the active binding site of the protease enzyme. Other properties of these 
compounds, such as ionic radius, redox potential, acidity and solubility, can be 
controlled through the use of selected metal ions and counterions, giving rise to 
potentially bioavailable, minimally toxic and site-specific PIs.     
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A.D.3 HIV-1 Protease Inhibitors 
 A.D.3.1 Introduction 
The human immunodeficiency virus (HIV) is a retrovirus belonging to the 
family, retroviridae. HIV is the precursor to the debilitating, progressive and 
eventually fatal disease, acquired immunodeficiency syndrome (AIDS).[8] HIV-
1 protease is an aspartic protease that is essential in the replication lifecycle of 
new, infectious viral particles. HIV-1 protease is a homodimer protein,[6] 
containing two identical subunits composed of 99 amino acids with the active 
site lying between these subunits and containing a highly conserved sequence 
(Asp25-Thr26-Gly27) (Figure A.D.1).[8, 14] These conserved triads contain the 
catalytically active aspartate residues,[8] responsible for peptide cleavage of 
polyproteins at specific sites, mediated by water molecules.[14] The aspartates 
are located in a hydrophobic pocket, enclosed by six amino acids; Pro-81, Val-82 
and Ile-84 at the base of the active site, with Ile-47, Gly-48 and Ile-54 located on 
two flexible molecular flaps that encase the polyprotein substrate when bound to 
the active site.[6] PR plays a crucial role in the viral replication cycle as it is 
essential for the processing of polyproteins previously transcribed from gag and 
pol genes of the viral genome.[15] The polyproteins are cleaved by protease to 
generate the mature proteins and enzymes[16] essential for the proteolytic 
maturation and generation of infectious viral particles. The inhibition or mutation 
of the protease active site can lead to the development of morphologically 
immature and non-infectious viral particles, which are incapable of infecting host 
immune cells.[8] Indeed, the absence of this functional protease (e.g. through 
mutation at Asp25) has previously been shown to produce immature and non-
infectious particles.[17, 18] Protease inhibitors can act as polyprotein mimics 
that are recognised and cleaved by the enzyme, rendering it inactive.[19]  
 
 
 
 
 
 
 
	  D-­‐‑5	  
 
a.	  
	  
b.	  
	  
c.	  
	  
Figure A.D.68	   Top-down views of HIV-1 protease, a. unbound (PDB 1HHP) and, b. bound to 
the organic antiviral agent saquinavir (PDB 1HXB). A rear view of saquinavir bound in the 
active site is show in c.  
 
Currently, there are ten organic-based, FDA approved protease inhibitors 
(PIs).[20] These compounds, which act via competitive enzyme inhibition 
(Figure VII.1 b and c), are employed in conjugation with nucleoside reverse 
transcriptase inhibitors (NRTIs) for the treatment of HIV. However, various 
limitations in their therapeutic application are known to exist owing to; multistep 
synthetic production costs, adverse side-effects, poor pharmacokinetics and 
emerging resistant strains of the HIV virus. [21] Organic PIs are also known to 
be metabolically unstable, have low oral bioavailability and have low tolerance 
levels when administered in conjugation with other pharmaceuticals.[22] 
Resistance due to amino acid substitution in the active site or distance sites[23] 
results in alterations in the active, site-specific structure changing both the 
number and nature of contact points between the inhibitor and the binding 
domain and thus perturbing the overall binding affinity of the inhibitor.[24-26]  
Metal-based therapeutics represent attractive PIs owing to their relative ease of 
synthesis, three-dimensional variability, charge and unique binding affinity 
compared to organic PIs. In this section, we discuss the development of 
metallacarborane, polyoxometalate, gold and copper compounds which have 
been designed to inhibit the HIV-1 protease enzyme. 
	  D-­‐‑6	  
A.D.3.2 Metallacarboranes 
Carboranes are a class of inorganic, polyhedral boron clusters that contain at 
least one carbon atom bound into an electron-delocalised cage skeleton.[27] 
Metallacarboranes contain carbon, boron, hydrogen along with metal atoms 
present in, or associated with, the cage framework (Figure A.D.2). Carboranes 
were initially used as high-boron content molecules for boron neutron capture 
therapy (BNCT) but have now expanded into areas of drug discovery and 
molecular imagining, such as radio-immunodetection and 
radioimmunotherapy.[28] These molecules have had a significant impact on 
environmental chemistry, organic synthesis, medicine and materials science.[27] 
Metallacarboranes have become a subject of growing interest due to properties 
such as the cage rigidity and its relative rotary motion, hydrophobicity and 
chemical and thermal stability.[29] The stability of these compounds originates 
from the delocalized bonding within their triangular boron facets over the 
complete cage structure, giving rise to three-dimensional aromaticity.[30] 
Metallacarboranes are known to vary in size from 4 to 14 vertices in a single 
polyhedral framework, the majority of which contain C2B3, C2B4 or C2B9 (Figure 
A.D.1 g. – j.) ligands capable of functioning as 6-electron donors to a metal 
centre.[29] Larger, multicage systems can be formed from the linkage or fusion 
of two or more of these subunits. The metal centre can be replaced by a wide 
number of transition metals, thus changing the total charge of the compound. The 
shape and charge of metallacarboranes, therefore, can be adapted to a specific 
biological function such as inhibition of the HIV-1 protease enzyme.  
 
 
 
 
	  D-­‐‑7	  
	  
Figure A.D.69	   Molecular structures of octahedral (a.), dodecahedral (b.) and icosahedral (c.) 
borane cages; ortho-, meta- and para-icosahedral carboranes are represented in structures d. to f. 
respectively; formation of nido-carboranes results through modification of o-, m- and p-cages in 
g. to i., respectively; metallacarboranes such as the commo-metallabisdicarbollide (j.) are 
generated from metal coordinated nido-clusters. ( = boron;  = carbon)     
 
In 2005, Cígler, Konvalinka et al. reported that a range of anionic, icosahedral 
metallacarboranes (commo-cobaltabisdicarbollide type) and substituted 
derivatives thereof, possessed potent inhibitory activity against HIV-1 protease 
(Table A.D.1, 1-6).[31] The agents exhibited impressive inhibitory constants 
with the most active agent (6) reporting a Ki (inhibition constant) value of 2.2 
nM and an EC50 of 0.25 µM. These agents showed no toxicity in tissue culture 
and were selective toward protease. The compounds showed only weak 
inhibition toward human cathepsin D and pepsin and no activity against trypsin, 
papain and amylase. In a subsequent study by the same group these agents were 
also shown to be specific, competitive inhibitors of drug-resistant HIV 
proteases.[32] These cobaltacarboranes demonstrated nanomolar Ki values 
toward the wild-type HIV-1 protease, and, although their activity was not as 
efficient as the clinical agents tested, they showed a low relative loss of activity 
against a range of mutated PRs, some of which had been amplified from HIV-1 
positive patients who were heavily pre-treated with various PIs. In this study a 
“vitality” model was introduced as a measure of the relative capability of a 
mutated enzyme to cleave its substrate in the presence of an inhibitor. 
Interestingly, specific mutations in the PR were found to dramatically increase 
(50- to 1000-fold) the vitality for saquinavir, indinavir and nelfinavir, while the 
metallacarboranes did not suffer the same fate. The crystal structure of the wild-
type enzyme in complex with cobalt bis(1,2-dicarbollide) (1) revealed a unique 
M
a. b. c.
d. e. f.
g.
h.
i.
j.
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binding mode of metallacarboranes in the HIV PR active site (Figure A.D.3).[31] 
The molecules bind asymmetrically into two hydrophobic pockets that are 
formed by the side chains of residues Pro81, Ile84 and Val82 residues and 
covered by the flap residues, Ile47, Gly48 and Ile54.  
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Table A.D.1 Structures and activities of metallacarborane HIV-1 protease inhibitors. ( = boron; 
 = carbon;  = cobalt)     
Entry	  
	  
Structure	   EC50	  (µM)	  
1	  
	  
6	  
	  
2	  
	  
20	  
	  
3	  
	  
6	  
	  
4	  
	  
13	  
	  
5	  
	  
3	  
	  
6	  
	  
0.25	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Figure A.D.70 HIV-1 protease ligated by two cobaltabis(1,2-dicarbollide) molecules (PDB 
1ZTZ). 
 
As a consequence of the enhanced activity exhibited by the dual cage compounds 
5 and 6, an expanded study of PR inhibition was undertaken using modified dual 
cage, metallacarbollide clusters linked with N-substituted dioxane groups.[30] 
Substituents were altered in the linker region, differing in functionality, bulkiness 
and charge, and their in vitro inhibitory effects were observed using HIV-1 PR 
(Table A.D.2). The dual cage cobalt bis(dicarbollide) compounds, 7 to 20, 
showed impressive IC50 values in the nanomolar range, while compound 20 had 
a significantly lower PI value of 8.5 µM. Interestingly, in this study, compounds 
17 and 18, which contain three borane cages, displayed the highest PI activity 
and although compound 19 had lower comparable inhibitory activity, its Ki 
constant was 20 times greater than the parent compound 7.  
The X-ray crystal structure of the dual cage compound 7 with the HIV-1 
PR enzyme revealed some differences in its binding mode when 
compared to the single cage cobaltabis(1,2-dicarbollide) molecule 
(1).[30] In both crystal structures, the cobalt bis(1,2-dicarbollide) cluster 
occupies a hydrophobic pocket whose base is formed by enzyme 
residues. However, whereas asymmetrical binding of the two individual 
bis(1,2-dicarbollide) clusters occurs for clusters 1 (Figure A.D.4, b.), the 
dual cage cluster compound 7 occupy their binding sites symmetrically 
(Figure A.D.4, a.). 
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a.	  
	  
b.	  
	  
Figure A.D.71	   Perspective views of a. the dual cage metallacarbollide compound 7, bound to 
HIV-1 PR (PDB 3I8W) and, b. two individual cobaltabis(1,2-dicarbollide) molecules from 
compound 1 bound to HIV-1 PR (PDB 1ZTZ). 
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 Table A.D.2	  Structures and activities of dual cage metallacarborane HIV-1 protease inhibitors.  
( = boron;  = carbon;  = cobalt)     
General	  formula:	  
	  
Substituent	  groups	   IC50	  (nM)	  
Entry	   R1	   	   R2	  
7	   H	   	   H	   140	  
8	   	   	   	   160	  
9	   	   	   H	   100	  
10	   	  
	   H	   140	  
11	   	  
	   H	   130	  
12	  
	  
	  
H	   190	  
13	   	  
	   H	   110	  
14	  
	  
	   H	   110	  
15	  
	  
	   H	   140	  
16	  
	  
	  
none	   70	  
17	  
	  
	  
H	   50	  
18	  
	  
	  
H	   58	  
19	  
	  
	  
H	   250	  
20	  
	  
8500	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A.D.3.3 Polyoxometalates  
Polyoxometalates (POMs) are early transition metal oxygen clusters, held 
together by metal-to-oxygen bonds.[33] POMs have been extensively studied 
due to their antibacterial, anticancer and antiviral activities,[33-35] along with 
electrocatalytic[36] and, more recently, nanotechnology applications.[37] The 
five types of d0 transition metal ions that form POMs are; VV, NbV, TaV, MoVI 
and WVI, with the last two forming the largest number of complexes.[38] The 
principle structural unit in POMs is composed of MO6 octahedra and they are 
further sub-categorised into isopoly- and heteropoly-compounds, the former 
containing only metal and oxygen atoms, with the latter having one or more 
heteroatoms at defined sites. Hetero-polyoxometalates can incorporate 
approximately 78% of the elements of the Periodic Table in their structural 
framework and with the heteroatom being either surface accessible or 
inaccessible.[39] POMs are arranged into families (Table A.D.3) based on their 
geometric structure, for example, Lindqvist (hexametalate), Keggin, Wells-
Dawson and Decatungstate, with further tri-vacant and double structural 
derivates being found within these classes.  POMs can be extensively 
synthetically-modified in composition, size, shape, charge density, redox activity 
and acidity.[21] The solubility of POMs can also be easily altered, rendering the 
compounds soluble in virtually all media via counterion choice. Another 
advantage of POMs is their inexpensive synthesis compared to multi-step 
organic peptide-mimics.[40] For these reasons, POMs are extensively studied as 
they represent ideal pharmacophores capable of high efficacy combined with low 
toxicity. POMs, which are often considered structurally analogous to the 
fullerenes,[41] represent lead compounds as HIV-1 inhibitors and have been 
shown to possess potent in vitro antiviral properties.   
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Table A.D.3 Selected polyoxometalate families, formulae and structures.    
Family	   Molecular	  Formula	  	   Structure	  
Lindqvist	   	   [W6O19]x-­‐	  
	  
Keggin	   	   [XW12O40]x-­‐	  
	  
Wells-­‐Dawson	   	   [X2W18O62]x-­‐	  
	  
Decatungstate	   	   [W10O32]4-­‐	  	  
	  
 
One of the most prominently studied POMs is the cryptate HPA-23, 
(NH4)17Na(NaSb9W21O86).[42] The agent dominated much of the early POM 
antiviral research[43-45] with spectroscopy studies revealing that, despite the 
anion’s high charge density, it was capable of crossing cell membranes and 
remaining intact for interactions with biological substrates.[46] The antiviral 
activity of HPA-23 within AIDS patients was observed by Rozenbaum et al.[47] 
and the agent was introduced into clinical trials in France and the US in the 
1980s. However, testing was subsequently abandoned due to the adverse, dosed-
related toxicity of the drug.[48] A comprehensive review of the antiviral 
properties of HPA-23, along with an extensive range of POMs, has been 
conducted by Hill and co-workers.[33]   
A study conducted by Inouye et al. in 1992 identified that POMs possessing the 
Keggin and Wells-Dawson type structures possessed enhanced antiviral 
activity.[49] Hill and co-workers subsequently examined the protease activity of 
a group of high molecular weight (ca. 4500 g mol-1), niobium-containing 
polyoxometalates based on the Wells-Dawson structural family (Table A.D.4, 
21-24).[21] Significantly, these agents were found to selectively inhibit HIV-1 
protease with IC50 values below 2.0 µM (Table A.D.4) and had no effects against 
pepsin when tested at a concentration of 100 µM. Significantly, these Nb-POMs 
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demonstrated potent anti-HIV-1 activity while being minimally toxic to 
peripheral blood mononuclear cells (PBMC). Molecular modelling experiments 
revealed that the α2-isomer, [P2W17NbO62]7- (24), does not occupy the active 
protease site but forms oxygen-to-hydrogen bonds at amino acids, Lys45, Lys43 
and Lys55 located in the hinge region behind the hair-pin flaps of the HIV 
protease (Figure A.D.5) with two POMs binding per protease homo-dimer. This 
work thus identified a new, selective mode of inhibition, potentially rendering 
these agents less sensitive to amino acid substitution mutations occurring within 
the active protease site.  
 
Table A.D.4	  HIV-1 protease inhibition, antiviral and cytotoxicity data for a range of Nb-POMs. 
Entry	   POM	   IC50	  (µM)	  	  
(HIV-­‐1P)	  
Anti-­‐HIV-­‐1	  Activity	  
PBMC	  EC50	  (µM)	  
Cytotoxicity	  
PBMC	  IC50	  (µM)	  
21	   K7[α1-­‐P2W17(NbO2)O61]	   2.0	   0.78	   66	  
22	   K7[α2-­‐P2W17(NbO2)O61]	   1.2	   0.81	   74	  
23	   K7[α1-­‐P2W17NbO62]	   1.5	   0.83	   >100	  
24	   K7[α2-­‐P2W17NbO62]	   1.8	   0.17	   50	  
 
	  
Figure A.D.72	   Crystal structure of a synthetic HIV-1 protease (PDB 3HVP) with lysine residues 
55, 43 and 41 shown (spacefill, coloured teal) along the hinge region behind the hair-pin flaps.  
 
In a recent, preliminary study by Patzke et al. an extensive range of POMs were 
examined for their ability to inhibit a mutant HIV-1 protease (Q7K) and were 
compared to Keggin- and Dawson-type POMs containing functionalised organic 
side chains.[40] In these experiments, where assay buffer composition was 
varied, it was generally found that POMs containing the Dawson-type 
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architecture were more effective in their protease inhibition. Additionally, butyl-
functionalised Sn-POMs were found to exert the strongest inhibitory effect 
among the DMSO-soluble agents regardless of the POM framework. Other 
potentially significant results were observed for propionic acid derivatised POM 
molecules.  
 
A.D.3.3 Gold Complexes 
In the late 19th century, Robert Koch discovered the bacteriostatic properties of 
gold cyanide against the tubercle bacillus.[50] This discovery resulted in the 
development of gold complexes such as aurothioglucose, sodium aurothiomalate 
and auranofin (Figure A.D.6) for the treatment of rheumatoid arthritis. Of the 
many gold thiolates originally approved for use for the treatment of rheumatoid 
arthritis, gold sodium thiomalate and gold thioglucose remain in use within the 
US, while sodium bis(thiosulfato)gold-(I) and sodium thiopropanolsulfonate-S-
gold(I) are in clinical use in Europe.[51] These compounds can also be employed 
in the treatment of bronchial asthma and investigations are currently underway 
for the use of both gold(I) and gold(III) complexes for the treatment of cancer, 
malaria and Chagas disease.[52]  
 
	  
Figure A.D.73	   Molecular structures of the HIV-1 PR active Au(I) phosphine complexes, 25 to 
29, the Au(III) tetrachloride anion in complex 5 and auranofin. 
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The anti-HIV activity of gold compounds have not been as thoroughly 
investigated in comparison to their anti-arthritic and antitumour properties. 
Although auranofin was the first documented metal phosphine complex to be 
used to treat rheumatoid arthritis,[3] observations made from the clinical data of 
a HIV patient recieving auranofin for psoriatic arthritis, spurred interest in 
chrysotherapy as a potential treatment of the viral disease, AIDS. It is interesting 
to note that, despite this patient refusing to accept antiviral HIV drugs, a 
significant increase in the CD4+ lymphocyte count was observed even though 
AIDS is associated with an irreversible decline in this cell type.[53] As 
chrysotherapy was known to produce [Au(CN)2]− metabolites, one theory linked 
the possible inhibitory effect of this complex to metallo-ligand exchange 
reactions, with gold binding to sulfhydryl groups in the active site of reverse 
transcriptase (RT), thus leading to a remission in the overall AIDS status of the 
patient.[54] These findings have prompted further studies of gold compounds as 
potentially novel anti-HIV therapeutics.  
Gold possesses two common oxidation states within biological environments, 
Au(I) ([Xe]4f145d10) and Au(III) ([Xe]4f145d8). Au(I) compounds are 
thermodynamically more stable than gold(III) and have considerably lower 
toxicity levels associated with their usage. Thus, the majority of gold compounds 
reported to have anti-HIV activity are those in the +1 oxidation state. 
Furthermore, Au(III) complexes are generally considered to be strong oxidizing 
agents which can be easily reduced to gold(I), and are therefore targets for 
naturally occurring biological reductants (e.g. glutathione). A recent study by 
Meyer et al. examined eleven Au(I) phosphine compounds, to determine their 
inhibitory effect on HIV RT and PR inhibition. Four of the complexes tested 
(Figure A.D.6, 25 to 28) were found to inhibit HIV-1 PR (≥50%) at 100 µM, 
while cross-inhibition for both HIV-1 RT and PR was noted for complex 25.[54] 
In comparison, many of this tested group exhibited EC50 values of 25 µM when 
examined against HIV reverse transcriptase (RT), with none being significantly 
cytotoxic toward peripheral blood mononuclear cells (PBMC). 
There are fewer examples in the literature of Au(III) HIV-1 PR inhibitor 
complexes, although the Au(III) tetrachloride anion, in the bis-pyrazole complex 
(tetrachloro-(bis-(3,5-dimethylpyrazolyl)methane)gold(III) chloride), has 
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recently shown inhibition at 100 µM (Figure A.D.6, 29).[55] In this study, the 
simple salt, H[AuCl4]⋅H2O, was a less effective HIV-1P inhibitor at this same 
concentration. Complex 29 also exhibited RT activity at 5 µM, suggesting that it 
may be more applicable toward RT inhibition rather than PR. The anti-HIV 
properties of gold complexes has recently been reviewed and a detailed 
discussion of potentially new HIV RT-active compounds can be found 
therein.[56] 
 
A.D.3.4 Copper Complexes 
The HIV-1P inhibitory effects of an extensive range metal ions was reported in 
1991 by Karlström and Levine.[57] Using an extensive range of metal cations 
these researchers demonstrated that Cu(II) and Hg(II) ions possessed potent 
inhibitory effects on wild-type HIV-1 protease (Table A.D.5). Through a series 
of elegant experiments, they demonstrated that cysteine residues in the wild-type 
protease were required for Cu(II) ion to directly inhibit the enzyme. Thus, a 
synthetic protease containing no cysteine residues was found to function 
normally in the presence of added cupric ions. Further analysis revealed that the 
inhibition was independent of O2 and that catalytic function could not be restored 
through the addition of the metal ion sequestering agent, EDTA, to the reaction. 
Binding analysis studies revealed that approximately two cupric ions were 
required per stoichiometric unit of PR and that the non-cysteine containing, 
synthetic, HIV-PR could be inhibited by cupric ions only in the presence of the 
reducing agent, dithiothreitol (DTT). 
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Table A.D.5	  Effect of metal cations on wild-type protease activity.[57] 
Metal	  ion	  
(25	  μM)	  
Activity	  
%	  Control	  
Al3+	   94	  
Ca2+	   100	  
Co2+	   92	  
Cr3+	   96	  
Cu2+	   <2	  
Fe2+	   94	  
Fe3+	   93	  
Hg2+	   <2	  
K+	   92	  
Mg2+	   91	  
Mn2+	   95	  
Ni2+	   94	  
Pb2+	   92	  
Zn2+	   99	  
 
Given that the activity of the non-cysteine protease could be repressed by Cu(II) 
ions in the presence of the chelating reducing agent, DTT, a subsequent study by 
Davis, Levine et al. tested this hypothesis by using the Cu(I) chelate, 
bathocuprione disulfonic acid (BCDS-Cu+) (Figure A.D.7, 30).[58] While 
BCDS-Cu+ complex was not quite as active at inhibiting the wild-type HIV-1P 
(IC50 = 4 µM) compared to free Cu(I) ions (IC50 = 1 µM), it was equally as 
effective against the synthetic PR (IC50 = 4 µM) which lacks the cysteine groups 
essential for cuprous (and cupric) ion inhibition. Interestingly, the study also 
revealed that neocuprione-Cu+ (Figure A.D.7, 31) did not inhibit wild-type PR 
and had only a limited inhibitory effect on the synthetic PR up to a tested 
maximum concentration of 25 µM. 
The HIV-1 protease activity of a family of boronated porphyrins was reported by 
DeCamp, Craik et al. and among the agents tested was the Cu(II) 
metalloporphyrin complex (Figure A.D.7, 32).[59] This complex displayed 
significant HIV-1P inhibition (0.975 µM) although its activity was much lower 
than that of the metal-free porphyrin (IC50 = 0.185 µM). The Cu(II) complex did, 
however, display lower lethality toward COS A6 cells (LD50 = 80 µM) compared 
to the parent porphyrin (LD50 = 25 µM). Further analysis of the metal-free 
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porphyrin revealed that it was highly specific toward HIV-1P and HIV-2P, with 
considerably lower inhibitory effects toward renin, cathepsin D and pepsin 
proteases.  
The de novo design of the Cu(II) complex, bis-(2-pyridylcarbonyI)-amido 
copper(II) nitrate (Figure A.D.7, 33),  as a protease inhibitor was reported after 
docking studies revealed the complex fitted the active protease site.[60] The 
agent was found to competitively inhibit HIV-1P (Ki = 480 ± 120 µM) and was 
non-active in the presence of added EDTA. A more efficient copper(II) HIV-1P 
inhibitor (Figure A.D.7, 34) was later reported which inhibited the wild-type 
HIV-1P at 1.1 µM.[61, 62] This agent also demonstrated >20% inhibition toward 
the synthetic, non-cysteine protease in the concentration range 1.7 to 2.0 µM. In 
contrast, complexes 35 and 36 (Figure VII.7) did not inhibit the synthetic 
protease enzyme and exhibited an identical inhibitory profile and value to that of 
the ‘free’ Cu(II) ion. Thus, it appeared likely these complexes readily dissociate 
their Cu(II) ions in solution.   
	  
Figure A.D.74	   Molecular structures and HIV-1P inhibitory properties of a range of copper(I) and 
copper(II) complexes. 
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A.D.4.1 Introduction 
Proteolytic enzymes are known to perform essential metabolic and regulatory 
roles within parasitic microorganisms.[5, 63] Serine-, cysteine-, and metallo-
proteases are found in many of these pathogens where they perform critical 
functions in colonisation and evasion of the host immune defence, acquisition of 
nutrients for growth and proliferation, and in damaging tissue during 
infection.[64, 65]  Important parasite proteases include cathepsin B and cathepsin 
L-like (family C1) and also calpain-like (family C2).[63] Cysteine proteases, 
which contain a thiol functional group within their active site, constitute a family 
of emerging parasitic targets that are divided into two main groups often referred 
to as clans CA and CD.[66] The proteolytic activity of these cysteine proteases 
arises from the presence of both Cys- and His- residues in the active site, with the 
crucial step in the catalytic process being the formation of a reactive 
imidazolium- thiolate ion pair (His-Im+ / Cys-S– ).[67]  
Infection by Plasmodium falciparum, the most virulent human malaria 
pathogen,[68-72] is now estimated to be responsible for between 500,000 and 
1,000,000 deaths annually.[68] Falcipain-2 (Fp2) belongs to the papain family of 
cysteine proteases and plays an important role in the malarial life cycle.[9, 73] 
Inhibition of Fp2 by either protein-based inhibitors, such as cystatin[74] (Figure 
A.D.8 a.) or small organic molecules, such as epoxysuccinate (E64) [72] (Figure 
A.D.8 b.) have revealed protease as a prime target for the development of 
effective anti-malarial agents.[75] Indeed, while the E64 inhibitor is an example 
is a non-specific inhibitor of cysteine proteases, it is a useful template for 
medicinal chemists looking to design specific inhibitors. Treatment of malaria 
and Trypanosoma cruzi infections with cysteine protease inhibitors have been 
demonstrated in mice and several other parasitic organisms with homologous 
proteases may now be potential targets.[76-78] Cysteine protease inhibitors have 
also been shown to reduce worm size and egg number in Schistosoma mansoni, 
confirming the importance of this class of protease to the parasite.[63] 
Furthermore, the enzymes have been found to play an integral role in parasitic 
life cycles of Plasmodia, Trypanosoma and Leishmania with functions in 
nutrition, host invasion, protein processing, and evasion of the host immune 
response.[79, 80] 
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Significant efforts have made in the design and therapeutic application of metal-
based chemotherapeutic agents directed against tropical diseases such as malaria, 
trypanosomiasis and leishmaniasis.[3, 66, 81] Metal complexes of the 
antimalarial quinolone-based drug chloroquine[82] (CQ) (Figure A.D.9), such as 
the ruthenium(II) complex, {[RuCl2(CQ)]}2 (RuQ),[83] the ferrocene-
functionalised compound, ferrochloroquine (FQ)[84] and the Au(I) complex, 
[Au(PPh3)(CQ)]PF6,[85]  have shown superior drug properties, both in terms of 
parasite growth inhibition and activity toward CQ-resistant strains, compared to 
the parent organic drug. Indeed FQ is currently one of the most advanced 
antimalarial candidate drugs being clinically trialled by Sanofi-Aventis.[86, 87] 
Reasons for the enhanced mode of action displayed by FQ remain unknown 
although a recent study by Christophe Biot et al. demonstrated the 
ferrochloroquine bioprobe, ruthenoquine, accumulated in the digestive vacuole 
of the parasite which is the same target organelle as the organic antimalarial 
drug, CQ.[88] For over half a century, the chemotherapeutic drugs of choice for 
the treatment of leishmaniasis have been the antimony(V) stibonic acid-derived 
complexes, sodium stibogluconate (Pentosam®) and meglumine antimoniate 
(Glucantime®).[81, 89, 90] In order to achieve clinical effectiveness, these 
compounds must be aged prior to administration and this process appears to give 
rise to a multitude of uncharacterized daughter compounds. Possible structures 
for some forms of these clinical antileishmanial Sb(V) compounds are shown in 
Figure VII.9. Their mode of inhibitory action also remains largely unknown 
although it is thought that various proteins, particularly those containing thiol 
groups, become inhibited by the agents which are also known to cause severe 
side effects in patients.  
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Figure A.D.75	   Crystal structures of, a. Plasmodium falciparum cysteine protease, Falcipain-2 
(coloured cream) bound to a cystatin inhibitor (coloured white) (PDB 1YVB),[74] and b. of 
Falcipain-2 with the small molecule cysteine protease inhibitor, epoxysuccinate E64 (coloured 
teal) (PDB 3BPF).[72] 
	  
 
	  
Figure A.D.76	   Molecular structures for the antimalarial drugs chloroquine (CQ), 
{[RuCl2(CQ)2]}2 (RQ), ferroquine (FQ), [Au(PPh3)(CQ)]PF6 and the antileishmaniasis Sb(V) 
complexes, Glucantime® and Pentosam®.   
 
Given the wide platform of metal-based compounds either in clinical use or 
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interest in the design of metallodrugs as effective agents toward protease 
inhibition. 
 
A.D 4.2 Gold(I) and gold(III) complexes  
Recently, Fricker et al. reported the activity of gold(III) cyclometallated 
complexes as cathepsin cysteine protease inhibitors.[7, 79] The group previously 
observed, through NMR studies, that the antitumour candidate complexes 37-39 
(Table A.D.6) had a preference for binding S-donor ligands and thus decided to 
examine the activity of compounds 37-42 as possible inhibitors of cathespin B. 
All six complexes were significantly active against the protease with the 
mercapto-benzoate bis-chelate complex, 42, being the most efficient. Further 
analysis of complex 41 using cysteine parasite proteases, Cruzain (T. cruzi) and 
cpB (L. major), revealed broadly similar inhibitory activity (IC50 Cruzain = 0.7 
µM; cpB = 1.7 µM) as cathepsin B. Complex 41 was also examined, in vivo, for 
its ability to increase the life cycle duration of T. cruzi infected macrophage cells, 
therefore measuring its effectiveness at preventing exogenous cell death and 
subsequent release of infectious parasites. However, at a concentration of 10 µM, 
the complex did not extend the life cycle of infected macrophage cells beyond 
that observed for the control (5 days).  
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Table A.D.6	   Molecular structures and cathepsin B inhibitory effects of cyctometallated Au(III) 
complexes.[79] 
Compound	   Molecular	  Structure	   IC50	  value	  (µM)	  
37	  
	  
1.36	  ±	  0.04	  
	  
38	  
	  
0.60	  ±	  0.04	  
	  
39	  
	  
0.61	  ±	  0.01	  
40	  
	  
0.85	  ±	  0.21	  
	  
41	  
	  
1.29	  ±	  0.09	  
	  
42	  
	  
0.18	  ±	  0.03	  
	  
 
The antimalarial activity of a selection of gold(I) complexes, 43-47 (Table 
A.D.7), along with the known Au(I) and Pt(II) therapeutics, auranofin and 
cisplatin, were assessed by Micale, Messori et al.[91] It was found that these 
structurally diverse chelator complexes induced pronounced but reversible 
inhibition of Fp2 with Ki values falling within the micromolar range. The gold 
compounds were subsequently tested for their ability to inhibit P. falciparum 
growth in vitro with activity also being observed in the micromolar range. 
Further analysis failed to establish any direct correlation between enzyme 
inhibition and reduction of P. falciparum growth suggesting that Fp2 inhibition, 
ascribed to the Au(I) complex binding to the cysteine active site, may represent 
just one of multiple mechanisms through which the complexes retard parasitic 
growth. Interestingly, in this study auranofin showed nearly complete inhibition 
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of P. falciparum growth (IC50 = 0.142 µM) with cisplatin being only moderately 
active by comparison (IC50 = 27.40 µM).  
 
Table A.D.7	   Inhibition of Fp2 and antiplasmodial activity of gold(I) and gold(III) 
complexes.[91] 
Compound	   Molecular	  Structure	   Fp2	  inhibition	  Ki	  
(µM)	  
IC50	  P.	  falciparum	  
(µM)	  
43	  
	  
11	  ±	  2.0	   1.33	  ±	  0.27	  
43	  
	  
1.8	  ±	  0.2	  
	  
4.51	  ±	  0.44	  
	  
44	  
	  
1.4	  ±	  0.2	  
	  
5.11	  ±	  0.46	  
	  
45	  
	  
1.5	  ±	  0.2	  
	  
2.30	  ±	  1.00	  
	  
46	  
	  
Not	  detected	  
5.16	  ±	  0.14	  
	  
47	  
	  
2.0	  ±	  0.3	   4.82	  ±	  0.26	  
Auranofin	  
	  
Not	  detected	   0.142	  ±	  0.00	  
Cisplatin	  
	  
Not	  detected	   27.40	  ±	  2.00	  
The Chibale group utilized a different structural approach in the development of 
gold(I) complexes as potential antimalarial drugs.[69] Through the use of 
coordinated thiosemicarbazone ligands (TSCs), which had received considerable 
attention due to their inhibiton of the T. cruzi protease enzyme cruzain,[92] the 
group rationally generated a series of Au(I) complexes. The hypothesis here was 
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that coordination of gold(I), itself having an affinity toward thiolated proteins, to 
the TSC ligand would result in an enhanced Fp2 inhibitory and antiplasmodial 
agent. A series of seven linear Au(I) complexes were generated (48-54, Table 
A.D.8), with complex 54 being further funcationalised with ferrocene. These 
complexes were examined along with the clinical antimalarial drug CQ and 
known Fp2 inhibitor E64 for their Fp2 enzyme inhibitory and CQ-sensitive and 
resistant antiplasmodial properties. With the exception of the methoxy-phenol 
complex (53), all tested complexes displayed low micromolar inhibition toward 
the CQ-resistant strain with favourable results to inhibitor E64. Complexes 48-52 
were also considerably active toward the CQ-sensitive strain while, interestingly, 
the ferrocene containing agent, 54, was 14-times less active when compared with 
the W2 strain. The organic drug CQ was clearly the most active antiplasmodial 
agent with IC50 values being 0.095 and 0.017 µM for the resistant (W2) and 
sensitive (D10) strains, respectively. The Fp2 inhibitory responses from the 
seven TSC Au(I) complexes produced a variety of Ki responses. The most active 
agents were the dichlorobenzene agent, 49, and the ferrocene-derived complex, 
54, which gave inhibitory responses at 0.87 and 8.89 µM, respectively. Overall, 
no correlation between Fp2 inhibition and antiplasmodial activity was identified 
which again raises the question of falcipain-2 protease being the primary target 
for these compounds.         
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 Table A.D.8	  FP-2 inhibition and antiplasmodial activity of gold(I) TSC complexes.[69]  
Compound	   Cationic	  Complex	  
/Organic	  Structure	  
Fp2	  
inhibition	  
IC50	  P.	  falciparum	  	  
CQ-­‐sensitive	  (D10)	  
IC50	  P.	  falciparum	  	  
CQ-­‐resistant	  (W2)	  
	   	   µM	  
48	  
	  
59.4	   2.02	   3.55	  
49	  
	  
0.87	   6.92	   2.74	  
50	  
	  
93.9	   6.26	   2.80	  
51	  
	  
46.5	   3.84	   2.81	  
52	  
	  
63.6	   4.76	   3.06	  
53	  
	  
Not	  
detected	  
>10	   >20	  
54	  
	  
8.89	   >20	   1.28	  
CQ	  
	  
Not	  
detected	  
0.017	   0.095	  
E64	  
	  
0.034	   ND	   3.00	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A.D 4.3 Palladium(II) and Oxorhenium(V) complexes  
As part of the Fricker group’s study into the development of cyclometallated 
complexes (37-42, Table A.D.6), a series of palladium(II) and oxorhenium(V) 
complexes (Figure A.D.10) were also examined for their ability to inhibit the 
protease, cathepsin B.[7] Of the bidendate Pd(II) aminomethyl-phenyl complexes 
developed (55 to 57), the pyridine complex, 55, displayed the greatest inhibitory 
activity (IC50 = 1.52 µM). Tridentate Pd(II) complexes of bis-thiomethyl-phenyl 
ligands (58-60) were also significantly active with further improvement in 
cathepsin B inhibition being noted for complex 59 (IC50 = 0.40 µM). The 
protease inhibitory properties for ‘3+1’ oxorhenium complexes (61-66) also 
yielded a series of interesting results within this study. The ReO(V) complexes 
incorporating bis-mercaptomethyl-pyridine tridentate ligands (61-63) displayed a 
variety of activities with an impressive IC50 value being observed for the 
pyridinethionato complex (63) (IC50 = 0.12 µM). The most active compound in 
the series was 64, which incorporated the bis-ethanethiolato-thiol tridentate 
ligand. This agent displayed excellent, low nano-molar inhibition of cathespin B 
(IC50 = 0.0088 µM).   
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Figure A.D.77	   Molecular structures and cathepsin B inhibitory properties of a range of gold(I) 
and oxo-rhenium(V) complexes. 
 
A comparative analysis of complexes 59, 62, 63, 64 and 66, using a panel of 
cysteine parasite proteases, Cruzain (T. cruzi) and cpB (L. major), along with the 
serine protease, chymotrypsin, was conducted (Table A.D.9). The 
oxorhenium(V) complexes, 63 and 64, were the most active agents, overall, 
against all proteases. It is also interesting to note that complex 64 appears to be 
highly specific toward cathespin B and is approximately 4.5 and 23 times less 
effective toward cruzain and cpB, respectively. In vivo analysis of the five 
complexes for their ability to increase the life cycle duration of T. cruzi infected 
macrophage cells (normally 5 days) was conducted at both 10 and 1 µM 
concentrations. The Pd(II) complex 59 induced toxicity toward the macrophage 
cells at 10 µM, however, at 1 µM it prevented infected macrophage cell death for 
the duration of the experiment (42 days). Other results of note from this 
particular experiment were the extension to the life cycle, to day 32, induced by 
10 µM of the ReO(V) complexes 62 and 66. The final aspect of this study 
involved the growth inhibition of Leishmania promastigoties, the extracellular 
form of the parasite’s life cycle, with the Pd(II) complex, 59, being the only 
active species.  
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Table A.D.9	   Comparative IC50 inhibitory values for selected complexes against parasite cysteine 
proteases and chymotrypsin.  
Compound	   Cat	  B	   Cruzain	   L.	  major	  cpB	   Chymotrypsin	  
	   µM	  
59	   0.40	   0.07	   2.1	   >25	  
62	   6.51	   0.35	   1.0	   >25	  
63	   0.12	   0.015	   0.07	   Not	  detected	  
64	   0.0088	   0.04	   0.2	   >25	  
66	   1.26	   5.0	   >10	   >25	  
 
 The chiral dinulcear cyclopalladated complex [{Pd(C2N-S-dmpa)Cl}2(µ-
dppf)] (C2N-S-dmpa = N,N-dimethyl-1-phenethylamine and dppf = bis-
(diphenylphosphine)-ferrocene) (67, Figure A.D.11), was reported by Caires et 
al. in 2005 as an effective antitumoural agent capable of reducing solid tumour 
mass in vivo.[93] The compound displayed significant inhibitory properties 
toward the cysteine proteases; papain (IC50 = 1.3 µM), cathepsin B (IC50 = 4.5 
µM) and cathepsin L (IC50 = 1.6 µM). This palladacycle was also found to bind 
free cathepsin B as well as to the enzyme-substrate complex with dissociation 
constants of KH = 12 µM and Kα = 12 µM, respectively. Although, in this case, 
complex 67 was not examined as an antiparasitic protease inhibitor, this study 
along with others,[94] stimulated further research into this class of compound for 
treating against parasitic diseases. Matsuo et al. subsequently investigated the in 
vivo antitumoural agent 68 (Figure A.D.11),[95] as a possible therapeutic against 
T. cruzi, the causative agent of Chagas disease.[96] These researchers found the 
dinuclear compound to; inhibit trypomastigote cell invasion, decrease 
intracellular amastigote proliferation, and to be effective in vivo, at very low 
doses, as a trypanocidal drug. Significantly, the agent was found to be 
approximately 340-fold more cytotoxic to parasites than mammalian cells and 
was more effective than benznidazole, one of the only clinical drugs available to 
treat Chagas disease. More recently, the mononuclear palladacycle complex, 69, 
which also contains the chiral C2N-S-dmpa ligand, was reported by Paladi, 
Barbiéri et al. as an effective in vitro and in vivo agent against Leishmania 
amazonensis.[80] Zymography assays, conducted along with the epoxysuccinate 
protease inhibitor E64 (Figure A.D.8 b.), revealed that 69 completely inhibited 
the cysteine protease activity of L. amazonesis amastigotes. The complex 
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displayed excellent in vitro inhibitory activity against the parasite (IC50 = 2.13 
nM), a result that compared favourably with the therapeutic agent, amphotericin 
B (IC50 = 15.58 nM). Treatment of L. amazonensis-infected macrophages with 
either complex 69 or the Sb(V) therapeutic, Glucantime® (Figure A.D.9), 
showed the complex to be vastly more effective agent (IC50 = 128.55 nM). In 
vivo treatment of mice infected with L. amazonesis with 320 µg/kg/QOD of 69 
for 1 month resulted in significantly smaller foot lesions in comparison to the 
untreated control and also compared favourably to a Glucantime® treated 
control. Furthermore, complex 69 and Glucantime® were found to reduce the in 
vivo parasite load by 97% and 99%, respectively.  
	  
Figure A.D.78	   Molecular structures of dinuclear (67 and 68) mononuclear (69) cyctometallated 
Pd(II) phosphine complexes. 
 
A.D.5. Conclusion 
With respect to the HIV-1 protease enzyme, a number of relatively non-toxic 
cobaltacarboranes have delivered EC50 values in the low nanomolar range and 
were selective towards the homodimer protein. In some instances, X-ray 
crystallographic analysis revealed unique binding modes of single- and dual-cage 
cobaltacarbollide clusters in the active site of the HIV wild-type enzyme. 
Polyoxometallates, which have demonstrated potent in vitro antiviral properties, 
represent exciting lead compounds as HIV-1 inhibitors. The high charge density 
anions can traverse cell membranes and remain intact for interactions with 
biological substrates. Molecular modelling studies conducted on a heterometallic 
polyoxotungstate identified a new, selective mode of inhibition based on 
hydrogen-bonding to specific amino acids on the periphery of the enzyme’s 
active site, a feature which suggests that the complex might be less sensitive to 
amino acid substitution mutations within the protease. Gold(I) phosphine 
complexes appear to be only moderately active against HIV-1 PR but, 
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importantly, there is evidence of cross-inhibition for both HIV-1 RT and HIV-1 
PR. A structurally diverse range of copper(II) complexes, and also ‘free’ 
copper(II) ions, display potent inhibitory effects and the activity of the latter 
species appears intimately linked to the presence of cysteine residues in the 
protease. Significant inroads have also been made in targeting the proteolytic 
enzymes of parasitic microorganisms, particularly those associated with malaria, 
trypanosomiasis and leishmaniasis. Ruthenium(II), iron(II) and gold(I) 
complexes incorporating the antimalarial quinolone-based drug, chloroquine, 
have activities exceeding that of metal-free chloroquine. The anti-arthritis, 
gold(I) prescription drug, auranofin, shows almost complete inhibition of 
Plasmodium falciparum growth at low micromolar concentrations. Additionally, 
a variety of gold(I) and gold(III) complexes are also active against prominent, 
thiolated proteins in Trypanosoma cruzi. Palladium(II) and oxorhenium(V) 
complexes constructed from tridentate ligands provide both activity and 
selectivity across a range of cysteine parasite proteases whilst being relatively 
silent against chymotrypsin. Furthermore, low micromolar concentrations of a 
palladium(II) complex can provide a lifeline to T. cruzi-infected macrophage 
cells. Dinuclear palladium(II) complexes, configured with a diphosphine and a 
chiral amine ligand, impress aginst cysteine proteases, discriminate positively 
between parasite and mammalian cells, and offer a better prognosis for the 
treatment of Chagas disease compared to the clinical drug, benznidazole. 
Leishmaniasis, in a mouse model, also responds well to treatment with an 
asymmetric, cyclopalladated complex, as evidenced by shrinkage of foot lesions 
and a dramatic reduction in parasite load.  
To progress the rational design of even more effective, metal-based, protease 
inhibitors it is essential that we address the shortages of both computer modelling 
studies and the X-ray crystallographic data available on metal-complex-protease 
interactions. Furthermore, an important example from literature we wish to 
highlight is the rational design of oxorhenium complexes by Baird et al.[97] 
where it has been proposed that ligand modification can give enzyme selectivity 
and an inhibition mechanism has been proposed based on experimental data. Our 
final comment on the design of effective bioinorganic protease inhibitors is that 
it is crucial for researchers to examine, and report, the effects of uncoordinated 
metal ions and metal-free ligands on PR before describing inhibitory properties 
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on the corresponding complexes. The inhibitory evidence from Cu2+, Hg2+ and 
Au3+ ions alone demonstrate that PR activity may not arise from a discrete 
complex being present in the reaction and therefore, it should not be taken for 
granted that simple metal ions and free ligands have negligible effects on PR.     
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